[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare cutaneous disorder that is typically associated with various types of cancer, including breast, lung, and gastrointestinal cancers. Here are some synonyms for Acrokeratosis paraneoplastica:\n1. Paraneoplastic acrokeratosis - This term is often used interchangeably with Acrokeratosis paraneoplastica, as it refers to a similar condition where there is a growth of keratinocytes in the skin in association with cancer.\n2. Acrokeratosis - This term refers to a general condition where there is an abnormal growth of keratinocytes in the skin, which can lead to the formation of scaly or crusty patches on the skin.\n3. Paraneoplastic skin lesion - This term refers to any type of skin lesion that occurs in association with cancer, including Acrokeratosis paraneoplastica.\n4. Cutaneous paraneoplastic syndrome - This term refers to a group of skin disorders that occur in association with various types of cancer, including Acrokeratosis paraneoplastica.\n5. Paraneoplastic pemphigus - This term refers to a specific type of skin disorder that occurs in association with cancer, including Acrokeratosis paraneoplastica.\nIt is important to note that each of these terms has a slightly different meaning, and they may be used interchangeably in different contexts. However, they all refer to conditions where there is an abnormal growth of keratinocytes in the skin in association with cancer.\nI hope this information is helpful! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is typically associated with various types of cancer, including breast, lung, and gastrointestinal cancers.\n2. Paraneoplastic acrokeratosis refers to a condition with abnormal growth of keratinocytes in the skin associated with cancer.\n3. Acrokeratosis refers to a condition with an abnormal growth of keratinocytes, leading to scaly or crusty skin patches.\n4. Paraneoplastic skin lesion refers to any type of skin lesion that occurs in association with cancer.\n5. Cutaneous paraneoplastic syndrome refers to a group of skin disorders associated with various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is typically associated with various types of cancer, including breast, lung, and gastrointestinal cancers.",
      "Paraneoplastic acrokeratosis refers to a condition with abnormal growth of keratinocytes in the skin associated with cancer.",
      "Acrokeratosis refers to a condition with an abnormal growth of keratinocytes, leading to scaly or crusty skin patches.",
      "Paraneoplastic skin lesion refers to any type of skin lesion that occurs in association with cancer.",
      "Cutaneous paraneoplastic syndrome refers to a group of skin disorders associated with various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause developmental delays, intellectual disability, and a range of physical abnormalities. While they share some similarities, they are distinct conditions with different genetic causes and clinical characteristics.\nWeaver syndrome, also known as contiguous gene syndrome or chromosome 7q11.23 duplication syndrome, is caused by a duplication of genetic material on chromosome 7, specifically at the q11.23 location. This duplication can result in the expression of a mixture of wild-type and mutant proteins, leading to a range of clinical features.\nThe primary features of Weaver syndrome include:\n1. Developmental delays and intellectual disability: Children with Weaver syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking, and may have intellectual disability.\n2. Dysmorphic features: Affected individuals may have distinct facial features, such as a long face, narrow eyes, and a small head. They may also have other physical abnormalities, such as short stature, skeletal deformities, and heart defects.\n3. Neurological problems: Weaver syndrome can cause a range of neurological problems, including seizures, autism, and difficulty with coordination and balance.\n4. Vision and hearing problems: Affected individuals may have vision and hearing problems, including cataracts, glaucoma, and hearing loss.\n5. Increased risk of infections: Weaver syndrome can impair the immune system, leading to an increased risk of infections.\nSotos syndrome, on the other hand, is caused by a mutation in the NSD1 gene on chromosome 5. This mutation results in the production of a faulty proteins that disrupts normal cellular function, leading to developmental delays, intellectual disability, and other clinical features.\nThe primary features of Sotos syndrome include:\n1. Developmental delays and intellectual disability: Children with Sotos syndrome typically experience significant delays in reaching developmental milestones, and may have intellectual disability.\n2. Growth delays: Affected individuals may have slower",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by a duplication of genetic material on chromosome 7 at the q11.23 location.\n2. Sotos syndrome is caused by a mutation in the NSD1 gene on chromosome 5.\n3. Both Weaver syndrome and Sotos syndrome can cause developmental delays and intellectual disability.\n4. Weaver syndrome can result in distinct facial features, skeletal deformities, and heart defects.\n5. Sotos syndrome can cause significant growth delays in affected individuals.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by a duplication of genetic material on chromosome 7 at the q11.23 location.",
      "Sotos syndrome is caused by a mutation in the NSD1 gene on chromosome 5.",
      "Both Weaver syndrome and Sotos syndrome can cause developmental delays and intellectual disability.",
      "Weaver syndrome can result in distinct facial features, skeletal deformities, and heart defects.",
      "Sotos syndrome can cause significant growth delays in affected individuals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by a mutation in the EZH2 gene on chromosome 7.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Sotos syndrome is characterized by overgrowth in childhood, not significant growth delays.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Jumping Angular Momentum Spectral Array in Physics and Reactor) is a widely used database of angular momentum couplings for electronic transitions in molecules. Here are the releases of the JASPAR database, along with their publication dates and key features:\n1. JASPAR Release 1 (1987):\n* Contained 30,000 molecules with 126,000 transitions.\n* Calculated the angular momentum couplings for transitions within each molecule using the Coupled-Cluster (CC) theory.\n* Provided both the harmonic and anharmonic coupling constants for each transition.\n2. JASPAR Release 2 (1991):\n* Increased the number of molecules to 80,000 and transitions to 480,000.\n* Introduced the use of the complete active space (CAS) method for calculating angular momentum couplings.\n* Improved the accuracy of the coupling constants by using smaller basis sets and higher level theory.\n3. JASPAR Release 3 (1995):\n* Increased the number of molecules to 250,000 and transitions to 1.5 million.\n* Introduced the use of the full configuration interaction (FCI) method for calculating angular momentum couplings.\n* Improved the accuracy of the coupling constants by using larger basis sets and higher level theory.\n4. JASPAR Release 4 (2000):\n* Increased the number of molecules to 400,000 and transitions to 3 million.\n* Introduced the use of the multireference男opsis (MR-CC) method for calculating angular momentum couplings.\n* Improved the accuracy of the coupling constants by using even larger basis sets and higher level theory.\n5. JASPAR Release 5 (2005):\n* Increased the number of molecules to 600,000 and transitions to 5 million.\n* Improved the accuracy of the coupling constants by using even larger basis sets and higher level theory.\n* Introduced the use of the quantum chemistry calculations.\n6. JASPAR Release 6 (2",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1 was published in 1987 and contained 30,000 molecules with 126,000 transitions.\n2. JASPAR Release 2 was published in 1991 and increased the number of molecules to 80,000 and transitions to 480,000.\n3. JASPAR Release 3 was published in 1995 and increased the number of molecules to 250,000 and transitions to 1.5 million.\n4. JASPAR Release 4 was published in 2000 and increased the number of molecules to 400,000 and transitions to 3 million.\n5. JASPAR Release 5 was published in 2005 and increased the number of molecules to 600,000 and transitions to 5 million.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1 was published in 1987 and contained 30,000 molecules with 126,000 transitions.",
      "JASPAR Release 2 was published in 1991 and increased the number of molecules to 80,000 and transitions to 480,000.",
      "JASPAR Release 3 was published in 1995 and increased the number of molecules to 250,000 and transitions to 1.5 million.",
      "JASPAR Release 4 was published in 2000 and increased the number of molecules to 400,000 and transitions to 3 million.",
      "JASPAR Release 5 was published in 2005 and increased the number of molecules to 600,000 and transitions to 5 million."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The statements provided are highly specific and would require access to historical records or databases related to JASPAR (which stands for \"JASmine PAth Remaining\") releases to verify their accuracy. Without such access or additional context, it is not possible to determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a viral protein that is encoded by the KP4 virus, which is a member of the Kp40-like viruses. These viruses are African lunate insect parasites that infect the haematopoeitic system of their hosts.\nThe KP4 protein has been shown to have a number of functions, including:\n1. Regulation of viral replication: The KP4 protein is involved in the regulation of viral replication, including the transcription and translation of viral genes. It is thought to act as a transcriptional activator of certain viral genes, and may also play a role in the initiation of viral DNA replication.\n2. Modulation of the host immune response: The KP4 protein has been shown to modulate the host immune response, suppressing the activation of immune cells and reducing the production of pro-inflammatory cytokines. This can help the virus to evade the host's immune system and establish a persistent infection.\n3. Induction of apoptosis: The KP4 protein has been shown to induce apoptosis (programmed cell death) in host cells, which can help the virus to eliminate host cells that are damaged or infected with viral particles.\n4. Inhibition of protein synthesis: The KP4 protein has been shown to inhibit protein synthesis in host cells, which can help the virus to reduce the host's ability to mount a immune response against it.\n5. Cell-to-cell transmission: The KP4 protein has been shown to be involved in the cell-to-cell transmission of the virus, allowing it to spread efficiently between host cells.\n6. Virulence factor: The KP4 protein has been identified as a virulence factor, meaning that it plays a direct role in the pathogenesis of the virus and its ability to cause disease in the host.\n7. Interaction with host cell membranes: The KP4 protein has been shown to interact with host cell membranes, which can help the virus to enter and exit host cells, and to evade the host's immune system.\n8. Inhibition of interferon response: The KP4 protein has been shown to inhibit the interferon response in",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 virus, which is a member of the Kp40-like viruses.\n2. Kp40-like viruses infect the haematopoeitic system of their hosts, which are African lunate insect parasites.\n3. The KP4 protein is involved in the regulation of viral replication.\n4. The KP4 protein can modulate the host immune response and suppress the activation of immune cells.\n5. The KP4 protein has been shown to induce apoptosis in host cells.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 virus, which is a member of the Kp40-like viruses.",
      "Kp40-like viruses infect the haematopoeitic system of their hosts, which are African lunate insect parasites.",
      "The KP4 protein is involved in the regulation of viral replication.",
      "The KP4 protein can modulate the host immune response and suppress the activation of immune cells.",
      "The KP4 protein has been shown to induce apoptosis in host cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (1,1-diethyl-2-methylpiperazine-4-hexanone) is a thyroid hormone analog that has been utilized in both experimental and clinical studies.\nDITPA is a synthetic compound that is structurally similar to the thyroid hormone thyroxine (T4). It has been shown to have similar regulatory effects on metabolism as T4, but it is more potent and has a longer half-life than T4 in animals. As such, DITPA has been used as a tool to study the physiological effects of thyroid hormones in various experimental models.\nOne of the primary ways in which DITPA has been used in research is to study thyroid hormone action in the brain. DITPA has been shown to cross the blood-brain barrier and accumulate in brain tissue, where it can modulate the activity of various neurotransmitters and neuronal circuits. For example, DITPA has been shown to increase the levels of the neurotransmitter acetylcholine in the brain, which is involved in a variety of cognitive and motor functions.\nIn addition to its effects on the brain, DITPA has also been studied for its potential therapeutic uses in various diseases. For example, DITPA has been shown to have anti-inflammatory effects in animal models of inflammation, and it has also been investigated as a potential treatment for hypothyroidism (an underactive thyroid gland).\nClinical studies of DITPA have been limited, but there are a few examples of its use in humans. For example, DITPA has been used in the treatment of thyroid cancer, where it can help to suppress the growth of cancer cells. DITPA has also been used in the treatment of certain neurological disorders, such as tremors and spasms, where it can help to modulate the activity of certain neuronal circuits.\nOverall, DITPA is a useful tool for studying the physiological effects of thyroid hormones in both animals and humans. While its clinical applications are still limited, it has the potential to be developed as a therapeutic agent for a variety of diseases, including thyroid disorders and neuro",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies.\n2. DITPA is structurally similar to the thyroid hormone thyroxine (T4) and has regulatory effects on metabolism.\n3. DITPA is more potent and has a longer half-life than T4 in animals.\n4. DITPA has been shown to cross the blood-brain barrier and affect neurotransmitter activity in the brain.\n5. DITPA has been investigated as a potential treatment for hypothyroidism and thyroid cancer.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies.",
      "DITPA is structurally similar to the thyroid hormone thyroxine (T4) and has regulatory effects on metabolism.",
      "DITPA is more potent and has a longer half-life than T4 in animals.",
      "DITPA has been shown to cross the blood-brain barrier and affect neurotransmitter activity in the brain.",
      "DITPA has been investigated as a potential treatment for hypothyroidism and thyroid cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: DITPA has been investigated as a potential treatment for hypothyroidism and heart failure, not thyroid cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Ah, a very interesting question, indeed!COUGER (Citation Optional Universal Google Engine Repository) is an open-source tool developed by Google to help researchers and scholarly authors working with various citation styles. It's a user-friendly platform that streamlines the citation process and allows users to easily import citations from Google Scholar and Google Books into their preferred citation style.\nCOUGER offers a unique advantage over traditional citation management tools by eliminating the need for manual formatting and ensuring accurate citations in any style. Here's a detailed explanation of how COUGER works and what it offers:\nHow COUGER Works:\n1. Importing Citations: COUGER allows you to import citations directly from Google Scholar and Google Books. You can simply enter the author's name, title of the book or article, or the publication date, and COUGER will import the relevant information.\n2. Citation Formatting: Once you've imported the citations, COUGER will format them according to your chosen citation style (e.g., MLA, APA, Chicago, etc.). You can select from over 7,000 citation styles available on COUGER, ensuring that your work meets the formatting requirements of your instructor or journal.\n3. Personal Database: COUGER creates a personal database of your imported citations, which you can access at any time. This feature allows you to easily locate and format citations for future use.\n4. Collaboration: COUGER also enables collaboration among researchers. You can share your personal database with others, and they can import your citations into their own COUGER accounts. This feature simplifies the citation process for group projects and allows for seamless collaboration.\nKey Features of COUGER:\n1. Automatic formatting: COUGER automatically formats your citations in your chosen citation style, saving you time and effort.\n2. Customizable: COUGER offers a wide range of customization options, allowing you to tailor the tool to meet your specific needs.\n3. Integration with Google Scholar and Google Books: COUGER integrates directly with Google Scholar and Google Books, making it easy to import citations directly from these sources.\n4. Multi-language support: COUGER supports various languages, allowing researchers worldwide to use the",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER (Citation Optional Universal Google Engine Repository) is an open-source tool developed by Google for researchers and authors.\n2. COUGER allows users to import citations from Google Scholar and Google Books.\n3. The platform can format citations according to over 7,000 different citation styles.\n4. Users can create a personal database of imported citations on COUGER.\n5. COUGER offers collaboration features that allow users to share their personal database with others.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER (Citation Optional Universal Google Engine Repository) is an open-source tool developed by Google for researchers and authors.",
      "COUGER allows users to import citations from Google Scholar and Google Books.",
      "The platform can format citations according to over 7,000 different citation styles.",
      "Users can create a personal database of imported citations on COUGER.",
      "COUGER offers collaboration features that allow users to share their personal database with others."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: There is no publicly available information or source confirming the existence or features of COUGER (Citation Optional Universal Google Engine Repository), so the validity of these statements cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of Tick-borne Encephalitis (TBE). TBE is a viral infection that is transmitted through the bite of an infected tick, typically found in wooded areas with heavy underbrush. The drugs used to treat TBE are primarily antiviral medications, which can help alleviate symptoms and reduce the risk of complications.\nHere are some of the commonly used drugs for the treatment of TBE:\n1. Ribavirin: This is an antiviral medication that is commonly used to treat TBE. It works by reducing the replication of the virus in the body and can help alleviate symptoms such as fever, headache, and muscle weakness. Ribavirin is usually given orally and can be effective in reducing the severity of TBE.\n2. Ceftriaxone and azithromycin: These are antibiotics that are sometimes used to treat TBE, particularly in cases where the infection has caused a secondary bacterial infection, such as meningitis or sepsis. Ceftriaxone is an intravenous antibiotic that is effective against a wide range of bacterial infections, while azithromycin is an oral antibiotic that is effective against a variety of bacterial infections, including those caused by Gram-positive and Gram-negative bacteria.\n3. Vaccines: There are also vaccines available for the prevention of TBE. These vaccines contain inactivated TBE virus particles and are usually given to individuals who are at high risk of contracting the infection, such as those who live in areas where TBE is common or who work outdoors. The vaccines can provide protection against TBE for several years and can help prevent the development of severe symptoms.\n4. Favipiravir: This is an antiviral medication that has been shown to be effective in treating TBE. It works by inhibiting the replication of the virus in the body and can help alleviate symptoms such as fever, headache, and muscle weakness. Favipiravir is usually given orally and can be effective in reducing the severity of TBE.\n5. Rizator",
    "llama-2-7b-chat-hf_fact_raw": "1. Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.\n2. Antiviral medications are primarily used to treat TBE.\n3. Ribavirin is an antiviral medication commonly used to treat TBE and is usually given orally.\n4. Ceftriaxone and azithromycin are antibiotics that are sometimes used to treat TBE when there is a secondary bacterial infection.\n5. Vaccines containing inactivated TBE virus particles are available for the prevention of TBE.",
    "llama-2-7b-chat-hf_fact": [
      "Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.",
      "Antiviral medications are primarily used to treat TBE.",
      "Ribavirin is an antiviral medication commonly used to treat TBE and is usually given orally.",
      "Ceftriaxone and azithromycin are antibiotics that are sometimes used to treat TBE when there is a secondary bacterial infection.",
      "Vaccines containing inactivated TBE virus particles are available for the prevention of TBE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no specific antiviral treatment for TBE; supportive therapy is the primary treatment approach.\n3. FALSE [correction]: Ribavirin is not commonly used to treat TBE as there is no specific antiviral treatment for TBE.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browser databases available for DNA shape annotations, each offering unique features and functionalities. Here are some of the most popular ones:\n1. UCSC Genome Browser: The UCSC Genome Browser is a widely used genome browser that provides DNA shape annotations, including nucleosome positioning, histone modification, and other chromatin-related features. It offers a comprehensive and updated database of gene expression, genetic variation, and epigenetic marks.\nWebsite: <https://genome.ucsc.edu/>\n2. Ensembl Genome Browser: Ensembl is another well-known genome browser that provides DNA shape annotations, including DNA sequence, variation, and expression data. It also offers tools for exploring genetic variations, gene function, and evolutionary relationships.\nWebsite: <https://ensembl.org/>\n3. Genome GraphDB: Genome GraphDB is a genome browser that focuses on the spatial annotation of genomic regions. It provides a graph-based representation of the genome, allowing users to explore the 3D structure of chromatin and the interactions between genomic regions.\nWebsite: <https://genomegraphdb.org/>\n4. 4D Nucleome Browser: The 4D Nucleome Browser is a genome browser that visualizes the 3D organization of chromatin in nucleosomes and higher-order structures. It provides a comprehensive view of chromatin dynamics and gene regulation, including the positions of nucleosomes, histone modifications, and other epigenetic marks.\nWebsite: <http://4dnucleome.org/>\n5. HiSeQ Browser: HiSeQ is a genome browser that specializes in the analysis of histone modification data. It provides detailed information on histone modification profiles and their spatial distribution in the genome, allowing researchers to identify regions of active or repressed chromatin.\nWebsite: <https://hiseq.uni-freiburg.de/>\n6. ChromHMM: ChromHMM is a genome browser that uses a hidden Markov model to predict the 3D structure of chromatin. It provides a detailed view of chromatin structure, including the positions of nucleosomes and higher-order chromatin structures, and can be used to identify regions of open or closed chromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UCSC Genome Browser provides DNA shape annotations, including nucleosome positioning, histone modification, and other chromatin-related features.\n2. Ensembl Genome Browser offers DNA shape annotations, including DNA sequence, variation, and expression data.\n3. Genome GraphDB focuses on the spatial annotation of genomic regions and provides a graph-based representation of the genome.\n4. The 4D Nucleome Browser visualizes the 3D organization of chromatin in nucleosomes and higher-order structures.\n5. HiSeQ specializes in the analysis of histone modification data and provides information on histone modification profiles and their spatial distribution in the genome.",
    "llama-2-7b-chat-hf_fact": [
      "The UCSC Genome Browser provides DNA shape annotations, including nucleosome positioning, histone modification, and other chromatin-related features.",
      "Ensembl Genome Browser offers DNA shape annotations, including DNA sequence, variation, and expression data.",
      "Genome GraphDB focuses on the spatial annotation of genomic regions and provides a graph-based representation of the genome.",
      "The 4D Nucleome Browser visualizes the 3D organization of chromatin in nucleosomes and higher-order structures.",
      "HiSeQ specializes in the analysis of histone modification data and provides information on histone modification profiles and their spatial distribution in the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser does not specifically provide DNA shape annotations, but it provides access to a wide range of genomic data, including sequence, gene annotations, and expression data.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: HiSeQ is a high-throughput sequencing technology, not a browser or software that specializes in the analysis of histone modification data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes for the enzyme enzyme epigenetic histone methyltransferase 2 (EHMT2), which playes a crucial role in the regulation of gene expression by modifying histones, the proteins that DNA wraps around to form chromatin. Mutations in the EZH2 gene have been associated with a variety of human diseases, including:\n1. Peutz-Jeghers syndrome (PJS): PJS is a rare autosomal dominant disorder characterized by pigmented macules on the skin, palmoplantar hyperkeratosis, and an increased risk of various cancers, including breast, ovarian, and pancreatic cancer. PJS is caused by mutations in the EZH2 gene and has been associated with more than 60% of EZH2-related disorders.\n2. Lhermitte-Duclos syndrome (LDS): LDS is a rare form of brain tumors that affects the cerebral white matter. It is characterized by slow-growing masses in the white matter of the brain, seizures, and cognitive decline. LDS has been linked to EZH2 mutations in approximately 20% of cases.\n3. Bannayan-Riley-Ruvalcaba syndrome (BRRS): BRR is a rare disorder that affects the skin, liver, and brain. It is characterized by Rothmund-Thomson syndrome (RTS)-like macules on the skin, neurological abnormalities, and an increased risk of cancer. Approximately 10% of BRRS cases have been linked to EZH2 mutations.\n4. Cowden syndrome (CS): CS is a rare genetic disorder characterized by multiple hamartomas throughout the body, particularly in the skin, breast, thyroid, and endometrium. CS is caused by mutations in the PTEN gene, which is located downstream of the EZH2 gene in the same signaling pathway. Approximately 5% of CS cases have been linked to EZH2 mutations.\n5. Cancer: EZH2 mutations have been found in various types of cancer, including breast, ovarian",
    "llama-2-7b-chat-hf_fact_raw": "1. EZH2 gene mutations have been associated with Peutz-Jeghers syndrome (PJS).\n2. Lhermitte-Duclos syndrome (LDS) has been linked to EZH2 mutations in about 20% of cases.\n3. Mutations in the EZH2 gene are linked to approximately 10% of Bannayan-Riley-Ruvalcaba syndrome (BRRS) cases.\n4. About 5% of Cowden syndrome (CS) cases have been associated with EZH2 gene mutations.\n5. Various types of cancer have been found to have EZH2 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "EZH2 gene mutations have been associated with Peutz-Jeghers syndrome (PJS).",
      "Lhermitte-Duclos syndrome (LDS) has been linked to EZH2 mutations in about 20% of cases.",
      "Mutations in the EZH2 gene are linked to approximately 10% of Bannayan-Riley-Ruvalcaba syndrome (BRRS) cases.",
      "About 5% of Cowden syndrome (CS) cases have been associated with EZH2 gene mutations.",
      "Various types of cancer have been found to have EZH2 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: EZH2 gene mutations have not been associated with Peutz-Jeghers syndrome (PJS), but rather STK11 gene mutations.\n2. FALSE [correction]: Lhermitte-Duclos syndrome (LDS) is associated with mutations in the PTEN gene, not EZH2.\n3. FALSE [correction]: Mutations in the EZH2 gene are not linked to Bannayan-Riley-Ruvalcaba syndrome (BRRS), which is also associated with PTEN gene mutations.\n4. FALSE [correction]: About 80-85% of Cowden syndrome (CS) cases have been associated with PTEN gene mutations, not EZH2.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with a list of human proteins that are known to undergo a dimer-to-tetramer transition. This type of transition is common in many proteins, especially those involved in signal transduction pathways. Here are some examples:\n1. Cyclin-dependent kinases (CDKs): CDKs are protein kinases that play a crucial role in regulating the cell cycle. They exist as monomers in their inactive state but can dimerize to form active enzymes that phosphorylate and activate various cell cycle regulators.\n2. MAPKs (mitogen-activated protein kinases): MAPKs are intracellular signaling proteins that are activated by various extracellular signals, including growth factors and hormones. They exist as monomers in their inactive state but can dimerize to form active enzymes that phosphorylate and activate various downstream targets.\n3. IκB (inhibitor of κB): IκB is a protein that inhibits the activation of NF-κB, a transcription factor involved in inflammation. IκB exists as a monomer in its unphosphorylated state but can be phosphorylated and dimerize to reveal its inhibitory activity.\n4. p53 (tumor suppressor protein 53): p53 is a tumor suppressor protein that plays a crucial role in regulating cell growth and preventing the formation of tumors. It exists as a monomer in its inactive state but can dimerize to form active protein that regulates the expression of various target genes.\n5. P debut (plectin): P debut is a protein that is involved in cell adhesion and signaling. It exists as monomers in its inactive state but can dimerize to form active protein that interacts with and regulates the activity of various downstream signaling proteins.\n6. Caspase 8 (apoptosis-related cysteine protease 8): Caspase 8 is an enzyme that is involved in the execution of apoptosis, or programmed cell death. It exists as monomers in its inactive state but can dimerize",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinases (CDKs) are known to undergo a dimer-to-tetramer transition and play a crucial role in cell cycle regulation.\n2. MAPKs (mitogen-activated protein kinases) dimerize to form active enzymes upon extracellular signal activation.\n3. IκB (inhibitor of κB) can dimerize when phosphorylated to exhibit its inhibitory activity on NF-κB.\n4. The tumor suppressor protein p53 can dimerize to form an active protein that regulates gene expression.\n5. Plectin, also referred to as P debut, dimerizes to form active protein involved in cell adhesion and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinases (CDKs) are known to undergo a dimer-to-tetramer transition and play a crucial role in cell cycle regulation.",
      "MAPKs (mitogen-activated protein kinases) dimerize to form active enzymes upon extracellular signal activation.",
      "IκB (inhibitor of κB) can dimerize when phosphorylated to exhibit its inhibitory activity on NF-κB.",
      "The tumor suppressor protein p53 can dimerize to form an active protein that regulates gene expression.",
      "Plectin, also referred to as P debut, dimerizes to form active protein involved in cell adhesion and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinases (CDKs) do not undergo a dimer-to-tetramer transition; they form complexes with cyclins to be active and play a crucial role in cell cycle regulation.\n2. TRUE\n3. FALSE [correction]: IκB (inhibitor of κB) does not dimerize when phosphorylated; rather it undergoes phosphorylation, which leads to its degradation and subsequent activation of NF-κB.\n4. TRUE\n5. FALSE [correction]: Plectin is not referred to as P debut, and it forms dimers and higher-order oligomers involved in maintaining cell integrity and cytoskeletal organization.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is a protein that plays a crucial role in regulating the activity of the sodium-potassium pump (Na+/K+-ATPase) in cells. PLN is known to interact with and inhibit the activity of the Na+/K+-ATPase, which is an important enzyme that maintains cellular ion homeostasis by pumping sodium ions out of cells and potassium ions into cells.\nSeveral proteins have been found to interact with PLN and are also anti-apoptotic proteins, which means they help protect cells from undergoing programmed cell death (apoptosis). Here are some examples:\n1. Bcl-2: Bcl-2 is a protein that belongs to the Bcl-2 family of proteins, which are involved in regulating apoptosis. Bcl-2 is known to directly interact with PLN and inhibit its ability to inhibit the Na+/K+-ATPase. Overexpression of Bcl-2 has been shown to protect cells from apoptosis induced by various stimuli, including oxidative stress and exposure to chemotherapeutic agents.\n2. Bcl-xL: Similar to Bcl-2, Bcl-xL is another anti-apoptotic protein that has been found to interact with PLN. Bcl-xL has been shown to inhibit the pro-apoptotic activity of PLN and protect cells from apoptosis.\n3. Mcl-1: Mcl-1 is another member of the Bcl-2 family of proteins that has been found to interact with PLN. Mcl-1 has been shown to inhibit the pro-apoptotic activity of PLN and protect cells from apoptosis.\n4.Surviving: Surviving is a protein that belongs to the Bcl-2 family of proteins and has been shown to interact with PLN. Surviving has been shown to inhibit the pro-apoptotic activity of PLN and protect cells from apoptosis.\n5.Apolipoprotein J: Apolipoprotein J (APJ) is a protein that has been found to interact with PLN and is involved in regulating lipid metabolism. APJ has been",
    "llama-2-7b-chat-hf_fact_raw": "1. Phospholamban (PLN) plays a role in regulating the activity of the sodium-potassium pump (Na+/K+-ATPase) in cells.\n2. Bcl-2 is an anti-apoptotic protein that interacts with PLN and inhibits its ability to inhibit the Na+/K+-ATPase.\n3. Bcl-xL is an anti-apoptotic protein that has been found to interact with PLN.\n4. Mcl-1 is a member of the Bcl-2 family of proteins that interacts with PLN and has anti-apoptotic properties.\n5. Surviving is a protein from the Bcl-2 family that interacts with PLN and inhibits its pro-apoptotic activity.",
    "llama-2-7b-chat-hf_fact": [
      "Phospholamban (PLN) plays a role in regulating the activity of the sodium-potassium pump (Na+/K+-ATPase) in cells.",
      "Bcl-2 is an anti-apoptotic protein that interacts with PLN and inhibits its ability to inhibit the Na+/K+-ATPase.",
      "Bcl-xL is an anti-apoptotic protein that has been found to interact with PLN.",
      "Mcl-1 is a member of the Bcl-2 family of proteins that interacts with PLN and has anti-apoptotic properties.",
      "Surviving is a protein from the Bcl-2 family that interacts with PLN and inhibits its pro-apoptotic activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Phospholamban (PLN) plays a role in regulating the activity of the sarcoplasmic reticulum Ca2+-ATPase (SERCA) in heart cells, not the sodium-potassium pump (Na+/K+-ATPase).\n2. FALSE [correction]: Bcl-2 is an anti-apoptotic protein, but there is no evidence that it interacts with PLN or inhibits the Na+/K+-ATPase.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Survivin is a protein from the inhibitor of apoptosis (IAP) family, not the Bcl-2 family, and there is no evidence of it interacting with PLN.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that vitamin D supplementation may reduce the incidence of falls in older people. Here are some key findings from clinical trials that have investigated the relationship between vitamin D and falls in older adults:\n1. A 2012 meta-analysis published in the Journal of the American Geriatrics Society combined data from 18 randomized controlled trials involving over 47,000 participants aged 65 years and older. The analysis found that vitamin D supplementation was associated with a significant reduction in the risk of falls (risk ratio 0.79, 95% CI 0.67-0.94).\n2. A 2013 Cochrane review included 13 randomized controlled trials with 26,295 participants aged 65 years and older. The review found that vitamin D supplementation reduced the risk of falls by 15% (risk ratio 0.85, 95% CI 0.74-0.97).\n3. A 2018 meta-analysis published in the Journal of Gerontology included 15 randomized controlled trials with 34,409 participants aged 65 years and older. The analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls (odds ratio 0.77, 95% CI 0.65-0.90).\n4. A 2020 systematic review and meta-analysis published in the journal Nutrients included 21 randomized controlled trials with 36,376 participants aged 65 years and older. The analysis found that vitamin D supplementation reduced the risk of falls by 31% (odds ratio 0.69, 95% CI 0.55-0.86).\nIt's worth noting that while these studies suggest a potential benefit of vitamin D supplementation in reducing the risk of falls, the evidence is not yet definitive. Some studies have found no association between vitamin D supplementation and falls, while others have suggested that the relationship may be complex and influenced by a variety of factors, such as age, sex, and underlying health conditions.\nIn",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2012 meta-analysis published in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in the risk of falls in participants aged 65 years and older.\n2. A 2013 Cochrane review found that vitamin D supplementation reduced the risk of falls by 15% in participants aged 65 years and older.\n3. A 2018 meta-analysis published in the Journal of Gerontology found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in participants aged 65 years and older.\n4. A 2020 systematic review and meta-analysis published in the journal Nutrients found that vitamin D supplementation reduced the risk of falls by 31% in participants aged 65 years and older.\n5. Some studies have found no association between vitamin D supplementation and falls.",
    "llama-2-7b-chat-hf_fact": [
      "A 2012 meta-analysis published in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in the risk of falls in participants aged 65 years and older.",
      "A 2013 Cochrane review found that vitamin D supplementation reduced the risk of falls by 15% in participants aged 65 years and older.",
      "A 2018 meta-analysis published in the Journal of Gerontology found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in participants aged 65 years and older.",
      "A 2020 systematic review and meta-analysis published in the journal Nutrients found that vitamin D supplementation reduced the risk of falls by 31% in participants aged 65 years and older.",
      "Some studies have found no association between vitamin D supplementation and falls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Thank you for your query! Jarid2 and miR-155 are indeed related in Th17 cells, and here's a detailed explanation:\nJarid2 (Jumonji-domain-containing protein 2) is a histone demethylase that specifically demethylates trimethylated lysine 4 on histone H3 (H3K4me3) and histone H4 (H4K4me3). H3K4me3 and H4K4me3 are epigenetic marks that play important roles in the regulation of gene expression, particularly during the process of T cell differentiation.\nmiR-155 (microRNA-155), on the other hand, is a small non-coding RNA molecule that regulates gene expression by binding to the 3' untranslated region (3' UTR) of target mRNAs and inhibiting their translation. miR-155 has been shown to play a crucial role in the regulation of Th17 cell differentiation and function.\nStudies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells. Jarid2 has been shown to demethylate the promoter region of miR-155, leading to its increased expression. miR-155, in turn, regulates the expression of Jarid2 by binding to its 3' UTR and inhibiting its translation.\nFurthermore, both Jarid2 and miR-155 have been shown to be involved in the regulation of Th17 cell function. Jarid2 has been shown to demethylate the promoter region of genes involved in Th17 cell differentiation, such as the transcription factor IRF4. miR-155, on the other hand, has been shown to regulates the expression of genes involved in Th17 cell function, such as the cytokine IL-17A.\nIn summary, there is a feedback loop between Jarid2 and miR-155 in Th17 cells, where Jarid2 demethylates the promoter region of miR-155, leading to its increased expression, which in turn regulates the expression of Jarid2. This loop",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone demethylase that specifically demethylates H3K4me3 and H4K4me3.\n2. miR-155 is a small non-coding RNA molecule that regulates gene expression by binding to the 3' untranslated region of target mRNAs.\n3. Studies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells.\n4. Jarid2 demethylates the promoter region of miR-155, leading to its increased expression.\n5. miR-155 regulates the expression of Jarid2 by binding to its 3' UTR and inhibiting its translation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone demethylase that specifically demethylates H3K4me3 and H4K4me3.",
      "miR-155 is a small non-coding RNA molecule that regulates gene expression by binding to the 3' untranslated region of target mRNAs.",
      "Studies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells.",
      "Jarid2 demethylates the promoter region of miR-155, leading to its increased expression.",
      "miR-155 regulates the expression of Jarid2 by binding to its 3' UTR and inhibiting its translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone demethylase, it is a member of the Jumonji family of proteins and is involved in the regulation of histone methylation, but it does not have demethylase activity itself.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Jarid2 does not demethylate the promoter region of miR-155 as it does not have demethylase activity. It may be involved in the regulation of miR-155 expression through other mechanisms.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster, also known as the HOXD complex, is a group of genes located on chromosome 2 and 12 that are involved in the development and organization of the along the anteroposterior (head-tail) axis in vertebrates.\nThe human HoxD cluster contains 8 genes, which are named Hoxd1-Hoxd8. These genes are highly conserved across different species and play crucial roles in the development of various tissues, including the brain, spinal cord, and limbs.\nHere are the functions of each HoxD gene in the human genome:\n1. Hoxd1: Encodes a transcription factor that regulates the expression of genes involved in the development of the anterior (head) end of the embryo.\n2. Hoxd2: Encodes a transcription factor that regulates the expression of genes involved in the development of the posterior (tail) end of the embryo.\n3. Hoxd3: Encodes a transcription factor that regulates the expression of genes involved in the development of the neural tube and the formation of the brain.\n4. Hoxd4: Encodes a transcription factor that regulates the expression of genes involved in the development of the limbs and the formation of the skeleton.\n5. Hoxd5: Encodes a transcription factor that regulates the expression of genes involved in the development of the gut and the establishment of the anterior-posterior axis.\n6. Hoxd6: Encodes a transcription factor that regulates the expression of genes involved in the development of the neural tube and the formation of the brain.\n7. Hoxd7: Encodes a transcription factor that regulates the expression of genes involved in the development of the limbs and the formation of the skeleton.\n8. Hoxd8: Encodes a transcription factor that regulates the expression of genes involved in the development of the anterior (head) end of the embryo.\nIt is important to note that the HoxD genes are not individual genes, but rather a group of genes that are arranged in a specific order on the chromosome and work together to regulate the development of the embryo. The HoxD genes are also part",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 8 genes named Hoxd1-Hoxd8.\n2. The HoxD genes are located on chromosome 2 and 12.\n3. HoxD genes are involved in the development and organization of the anteroposterior axis in vertebrates.\n4. Each HoxD gene encodes a transcription factor that regulates the expression of genes involved in the development of various body parts.\n5. HoxD genes play crucial roles in the development of the brain, spinal cord, and limbs.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 8 genes named Hoxd1-Hoxd8.",
      "The HoxD genes are located on chromosome 2 and 12.",
      "HoxD genes are involved in the development and organization of the anteroposterior axis in vertebrates.",
      "Each HoxD gene encodes a transcription factor that regulates the expression of genes involved in the development of various body parts.",
      "HoxD genes play crucial roles in the development of the brain, spinal cord, and limbs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes named HoxD1 to HoxD13, with some numbers skipped (e.g., HoxD12 is not present).\n2. FALSE [correction]: The HoxD genes are located on chromosome 2 only.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and genomic stability. Phosphorylation of CK1 by other kinases can modulate its activity and substrate specificity. Here are some common phosphorylation consensus motifs for CK1:\n1. The \"RPxF/X\" sequence: This is a conserved consensus motif found in many protein phosphorylation sites. The \"R\" stands for either arginine or lysine, and \"P\" is a proline or other non-basic amino acid. The \"x\" can be any amino acid, but the most common is a glutamate (\"E\"). The \"F\" is usually a phenylalanine or a non-basic amino acid, and the \"X\" can be any amino acid.\nExamples of CK1 phosphorylation sites with the \"RPxF/X\" sequence include:\n* Sites phosphorylated by CK1α in mammalian cells: RPxF/X-S/T (where \"S\" is serine, \"T\" is threonine, and \"x\" is any amino acid). Examples: S203/204 on the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (Liu et al., 2015), S187 on the protein kinase CK1α (yc023913806.1) (Chen et al., 2011).\n* Sites phosphorylated by CK1β in Drosophila melanogaster: RPxF/X-S/T (Liu et al., 2015). Examples: S120 on the forkhead box protein Dpf1 (Liu et al., 2015), S74 on the protein kinase CGK1 (Liu et al., 2015).\n2. The \"RRxxSR\" sequence: This is another common consensus motif for protein phosphorylation. The \"R\" is usually a basic amino",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine kinase involved in cell signaling, metabolism, and genomic stability.\n2. The \"RPxF/X\" is a conserved consensus motif found in protein phosphorylation sites for CK1.\n3. The \"RPxF/X\" sequence includes arginine or lysine (\"R\"), proline or other non-basic amino acid (\"P\"), and glutamate (\"E\") as the most common amino acid at the \"x\" position.\n4. The \"F\" in the \"RPxF/X\" sequence usually represents phenylalanine or a non-basic amino acid, and \"X\" can be any amino acid.\n5. The \"RRxxSR\" sequence is another common consensus motif for protein phosphorylation related to CK1.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine kinase involved in cell signaling, metabolism, and genomic stability.",
      "The \"RPxF/X\" is a conserved consensus motif found in protein phosphorylation sites for CK1.",
      "The \"RPxF/X\" sequence includes arginine or lysine (\"R\"), proline or other non-basic amino acid (\"P\"), and glutamate (\"E\") as the most common amino acid at the \"x\" position.",
      "The \"F\" in the \"RPxF/X\" sequence usually represents phenylalanine or a non-basic amino acid, and \"X\" can be any amino acid.",
      "The \"RRxxSR\" sequence is another common consensus motif for protein phosphorylation related to CK1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The \"RPxF/X\" sequence includes arginine (\"R\"), any amino acid (\"P\"), and any amino acid at the \"x\" position, not necessarily glutamate (\"E\").\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins and isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary protein product of the ASPH gene, which plays a key role in the synthesis of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) in the brain.\n2. Tyrpto-aspartate hydroxylase (TPAH): This protein is a variant of aspirate beta-hydroxylase that results from a missense mutation in the ASPH gene. TPAH has a different enzymatic activity compared to ASPH, and it is thought to play a role in the regulation of serotonin synthesis.\n3. Carboxy-terminal domain-containing protein (CTDP): This protein is a proteolytically processed form of ASPH that is generated by the action of proteases. CTDP contains the carboxy-terminal domain of ASPH and has been implicated in the regulation of serotonin metabolism.\n4. Calcium-binding protein (CABP): CABP is a splice variant of ASPH that contains a calcium-binding domain. It is thought to play a role in regulating the activity of ASPH and modifying the function of the protein.\n5. Neurotransmitter-glutamate S-amidase (GNMT): GNMT is a splice variant of ASPH that is specifically expressed in brain and regulates the degradation of glutamate, a neurotransmitter involved in synaptic transmission and plasticity.\n6. Pro-form of ASPH (pASPH): The pro-form of ASPH is the precursor form of the protein, which is generated by the alternative splicing of the ASPH gene. It contains the amino terminal domain of the mature protein and is involved in the regulation of ASPH expression.\n7. Disulfide-linked form of ASPH (dASPH): dASPH is a form of ASPH that is linked by disulfide bonds, which is generated by the oxidation of cysteine residues in the protein. It is thought",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes the primary protein product, aspartate beta-hydroxylase (ASPH).\n2. Tyrpto-aspartate hydroxylase (TPAH) is a variant protein resulting from a missense mutation in the ASPH gene.\n3. Carboxy-terminal domain-containing protein (CTDP) is a proteolytically processed form of ASPH.\n4. Calcium-binding protein (CABP) is a splice variant of ASPH with a calcium-binding domain.\n5. Neurotransmitter-glutamate S-amidase (GNMT) is a splice variant of ASPH, specifically expressed in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes the primary protein product, aspartate beta-hydroxylase (ASPH).",
      "Tyrpto-aspartate hydroxylase (TPAH) is a variant protein resulting from a missense mutation in the ASPH gene.",
      "Carboxy-terminal domain-containing protein (CTDP) is a proteolytically processed form of ASPH.",
      "Calcium-binding protein (CABP) is a splice variant of ASPH with a calcium-binding domain.",
      "Neurotransmitter-glutamate S-amidase (GNMT) is a splice variant of ASPH, specifically expressed in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin, a medication used to treat type 2 diabetes, was approved by the US Food and Drug Administration (FDA) in 2014. Specifically, the FDA approved empagliflozin on June 28, 2014, for the treatment of adults with type 2 diabetes to improve glycemic control.\nEmpagliflozin is marketed as the brand name drug \"Jardiance\" by Boehringer Ingelheim Pharmaceuticals, Inc. and is available in strengths of 10 mg and 25 mg tablets. It works by helping the kidneys remove excess sugar from the bloodstream, which can help lower blood sugar levels and improve glycemic control.\nThe FDA's approval of empagliflozin was based on results from a clinical trial program that involved more than 10,000 patients with type 2 diabetes. The trial program demonstrated that empagliflozin was effective in improving glycemic control, reducing the risk of major adverse cardiovascular events, and reducing the risk of cardiovascular death in people with type 2 diabetes.\nSince its approval in 2014, empagliflozin has become a widely used medication for the treatment of type 2 diabetes. It is important to note, however, that empagliflozin is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis, as it is not effective in these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was approved by the US Food and Drug Administration in 2014.\n2. The FDA approved empagliflozin specifically on June 28, 2014.\n3. Empagliflozin is marketed under the brand name \"Jardiance.\"\n4. Empagliflozin is available in strengths of 10 mg and 25 mg tablets.\n5. The clinical trial program for empagliflozin involved more than 10,000 patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was approved by the US Food and Drug Administration in 2014.",
      "The FDA approved empagliflozin specifically on June 28, 2014.",
      "Empagliflozin is marketed under the brand name \"Jardiance.\"",
      "Empagliflozin is available in strengths of 10 mg and 25 mg tablets.",
      "The clinical trial program for empagliflozin involved more than 10,000 patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The FDA approved empagliflozin on August 1, 2014.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Lon1 is a protein that plays a crucial role in regulating protein longevity and protein quality control in various organisms, including plants. In Arabidopsis, a small plant model organism, Lon1 has been shown to be a key regulator of protein degradation and protein homeostasis.\nMutations in the Lon1 gene in Arabidopsis have been found to result in a variety of phenotypes, including:\n1. Prolonged leaf longevity: Lon1 mutants exhibit longer-lived leaves compared to wild-type plants, suggesting that Lon1 regulates the turnover of leaves.\n2. Enhanced tolerance to abiotic stress: Lon1 mutants have been found to be more resistant to drought, heat, and salt stress, suggesting that Lon1 regulates stress tolerance pathways in Arabidopsis.\n3. Altered protein degradation pathways: Lon1 regulates the degradation of several key regulatory proteins in Arabidopsis, including transcription factors and signaling proteins. Mutations in the Lon1 gene can lead to changes in the levels and activity of these proteins, which can affect various cellular processes.\n4. Changes in protein localization: Lon1 can also regulate the subcellular localization of proteins, and mutations in the Lon1 gene can lead to changes in protein localization, which can affect protein function.\n5. Delayed senescence: Lon1 mutants have a delay in the onset of senescence, a process by which cells enter a state of permanent cell cycle arrest. This delay can be due to the longer lifespan of proteins, which can lead to the accumulation of proteins that inhibit the onset of senescence.\n6. Altered cell wall composition: Lon1 mutants have been found to have altered cell wall composition, including changes in the levels of cellulose and hemicellulose.\n7. Changes in hormone signaling: Lon1 can also regulate hormone signaling pathways in Arabidopsis, and mutations in the Lon1 gene can lead to changes in hormone levels and signaling, which can affect various cellular processes.\n8. Altered mitochondrial function: Lon1 can reg",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 mutants in Arabidopsis exhibit longer-lived leaves compared to wild-type plants.\n2. Lon1 mutants in Arabidopsis have been found to be more resistant to drought, heat, and salt stress.\n3. Mutations in the Lon1 gene can lead to changes in the degradation of regulatory proteins in Arabidopsis.\n4. Mutations in the Lon1 gene can lead to changes in subcellular localization of proteins in Arabidopsis.\n5. Lon1 mutants in Arabidopsis have a delay in the onset of senescence.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 mutants in Arabidopsis exhibit longer-lived leaves compared to wild-type plants.",
      "Lon1 mutants in Arabidopsis have been found to be more resistant to drought, heat, and salt stress.",
      "Mutations in the Lon1 gene can lead to changes in the degradation of regulatory proteins in Arabidopsis.",
      "Mutations in the Lon1 gene can lead to changes in subcellular localization of proteins in Arabidopsis.",
      "Lon1 mutants in Arabidopsis have a delay in the onset of senescence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, histones are present in the yeast genome, and they play a crucial role in the organization and structure of chromatin, the complex of DNA and proteins that make up the chromosomes in eukaryotic cells, including yeast. Histones are small, positively charged proteins that are highly conserved across different species and are known to be involved in a variety of cellular processes, including DNA replication, repair, and transcription.\nIn yeast, there are five histone proteins (H1, H2A, H2B, H3, and H4) that are present in the nucleosomes, which are the repeating units of the chromatin fiber. These histones are dynamically modified by a variety of enzymes, including histone-modifying enzymes, which add or remove various chemical groups to the histone proteins, such as acetyl, methyl, and phosphoryl groups. These modifications can alter the chromatin structure and accessibility to transcription factors and other regulatory proteins, leading to changes in gene expression.\nThe presence of histones in the yeast genome was first demonstrated in the early 1970s using biochemical and molecular biology techniques. Since then, numerous studies have focused on understanding the functional roles of histones in yeast, including their involvement in regulating gene expression, the response to stress, and the cell cycle.\nSome examples of histone-related processes in yeast include:\n1. Histone acetylation: Histone acetylation is known to play a role in the regulation of gene expression in yeast. For example, the histone H3 is acetylated at lysine 9 (H3K9) and is associated with active gene transcription.\n2. Histone methylation: Histone methylation is also known to play a role in the regulation of gene expression in yeast. For example, histone H3 is methylated at lysine 4 (H3K4) and is associated with constitutive gene expression.\n3. Histone ubiquitination: Histone ubiquitination is known to play a role in the regulation of histone turnover and chromatin remodeling in yeast. For example, the histone H2A is ubiquit",
    "llama-2-7b-chat-hf_fact_raw": "1. Histones are present in the yeast genome.\n2. There are five histone proteins in yeast: H1, H2A, H2B, H3, and H4.\n3. Histone modifications can alter chromatin structure and affect gene expression.\n4. The presence of histones in the yeast genome was first demonstrated in the early 1970s.\n5. Histone H3 is acetylated at lysine 9 (H3K9) and is associated with active gene transcription in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Histones are present in the yeast genome.",
      "There are five histone proteins in yeast: H1, H2A, H2B, H3, and H4.",
      "Histone modifications can alter chromatin structure and affect gene expression.",
      "The presence of histones in the yeast genome was first demonstrated in the early 1970s.",
      "Histone H3 is acetylated at lysine 9 (H3K9) and is associated with active gene transcription in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are four core histone proteins in yeast: H2A, H2B, H3, and H4. H1 is not considered a core histone protein in yeast.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that tomato juice may help lower cholesterol levels. Here are some key findings from studies that have investigated the potential cholesterol-lowering effects of tomato juice:\n1. A 2012 study published in the Journal of Functional Foods found that drinking tomato juice for 12 weeks lowered total cholesterol and LDL (\"bad\") cholesterol levels in healthy adults. The study involved 40 participants who were divided into two groups: one group drank tomato juice, while the other group did not. At the end of the 12-week period, the tomato juice group had lower total cholesterol and LDL cholesterol levels compared to the control group.\n2. A 2010 study published in the Journal of Nutrition found that consuming a beverage made from concentrated tomato juice and flaxseed oil lowered cholesterol levels in healthy adults. The study involved 20 participants who were given the beverage for 12 weeks and had their cholesterol levels measured at the beginning and end of the study. The results showed that the beverage significantly reduced total cholesterol and LDL cholesterol levels.\n3. A 2010 review of 10 clinical trials published in the British Journal of Cardiology found that tomato juice consumption was associated with significant reductions in total cholesterol and LDL cholesterol levels. The review included a total of 526 participants and found that the average reduction in total cholesterol levels was 7.2% and the average reduction in LDL cholesterol levels was 11.1%.\n4. A 2016 study published in the Journal of Food Science and Technology found that tomato juice modified cholesterol metabolism in rats by increasing the excretion of bile acids, which can help reduce cholesterol levels. The study involved 30 rats that were divided into two groups: one group was given a tomato juice diet, while the other group was not. The results showed that the tomato juice group had higher levels of bile acid excretion and lower levels of total cholesterol and L",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2012 study published in the Journal of Functional Foods found that drinking tomato juice for 12 weeks lowered total cholesterol and LDL cholesterol levels in healthy adults.\n2. A 2010 study published in the Journal of Nutrition found that consuming a beverage made from concentrated tomato juice and flaxseed oil lowered cholesterol levels in healthy adults.\n3. A 2010 review of 10 clinical trials published in the British Journal of Cardiology found tomato juice consumption was associated with significant reductions in total cholesterol and LDL cholesterol levels.\n4. A 2016 study published in the Journal of Food Science and Technology found that tomato juice modified cholesterol metabolism in rats by increasing the excretion of bile acids.",
    "llama-2-7b-chat-hf_fact": [
      "A 2012 study published in the Journal of Functional Foods found that drinking tomato juice for 12 weeks lowered total cholesterol and LDL cholesterol levels in healthy adults.",
      "A 2010 study published in the Journal of Nutrition found that consuming a beverage made from concentrated tomato juice and flaxseed oil lowered cholesterol levels in healthy adults.",
      "A 2010 review of 10 clinical trials published in the British Journal of Cardiology found tomato juice consumption was associated with significant reductions in total cholesterol and LDL cholesterol levels.",
      "A 2016 study published in the Journal of Food Science and Technology found that tomato juice modified cholesterol metabolism in rats by increasing the excretion of bile acids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\n[Note: The provided statements require access to specific scientific studies and their findings to verify their accuracy. Without access to these studies, it is not possible to determine the truthfulness of the statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are two proteins that play critical roles in regulating mRNA stability. These proteins are members of the heat shock protein (HSP) family, which are induced in cells under conditions of stress, including high temperatures, oxidative stress, and cellular stress response. Here's how Hsp70 and Hsp110 affect mRNA stability:\n1. Protection of mRNA from degradation: Hsp70 and Hsp110 can bind to mRNA and protect it from degradation by RNA-degrading enzymes, such as ribonucleases. This helps to maintain the stability of the mRNA and ensure that it is available for translation.\n2. Enhancing translation initiation: Hsp70 and Hsp110 can also interact with the ribosome and enhance translation initiation by recruiting ribosomal proteins and mRNA-bound factors. This can lead to increased protein synthesis and a stronger response to cellular stress.\n3. Modulation of mRNA splicing: Hsp70 and Hsp110 can also regulate mRNA splicing by interacting with splicing factors and modulating the splicing process. This can result in the production of alternative splice variants of proteins, which can play different roles in cellular stress response.\n4. mRNA localization: Hsp70 and Hsp110 can also influence mRNA localization in cells. For example, Hsp70 has been shown to promote the export of mRNA from the nucleus to the cytoplasm, where it can be translated.\n5. Regulation of mRNA transport: Hsp70 and Hsp110 can also regulate the transport of mRNA within the cell. For example, Hsp70 has been shown to interact with the mRNA-binding protein, Exportin-1, which is involved in the export of mRNA from the nucleus.\n6. Protection of mRNA from RNA-degrading enzymes: Hsp70 and Hsp110 can also protect mRNA from RNA-degrading enzymes, such as the ribonucleases, by blocking their access to the",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are proteins that regulate mRNA stability.\n2. Hsp70 and Hsp110 bind to mRNA to protect it from degradation by ribonucleases.\n3. These proteins can enhance translation initiation by interacting with the ribosome and recruiting ribosomal proteins.\n4. Hsp70 and Hsp110 can regulate mRNA splicing by interacting with splicing factors.\n5. Hsp70 promotes the export of mRNA from the nucleus to the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are proteins that regulate mRNA stability.",
      "Hsp70 and Hsp110 bind to mRNA to protect it from degradation by ribonucleases.",
      "These proteins can enhance translation initiation by interacting with the ribosome and recruiting ribosomal proteins.",
      "Hsp70 and Hsp110 can regulate mRNA splicing by interacting with splicing factors.",
      "Hsp70 promotes the export of mRNA from the nucleus to the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 and Hsp110 are proteins that function as molecular chaperones, not regulators of mRNA stability.\n2. FALSE [correction]: Hsp70 and Hsp110 do not directly bind to mRNA; they interact with other proteins that may influence mRNA stability.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Hsp70 does not directly promote the export of mRNA from the nucleus to the cytoplasm; it assists in the proper folding and assembly of proteins that may be involved in mRNA export.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism in various tissues throughout the body, including skeletal muscle. In skeletal muscle, there are three isoforms of deiodinases:\n1. Type 1 deiodinase (D1): This is the primary deiodinase isoform in skeletal muscle, and it is responsible for most of the deiodination reactions in this tissue. D1 isoenzyme is encoded by the TIID1 gene and is mostly found in slow-twitch red muscle fibers. D1 is involved in the conversions of T4 to T3 and T3 to T2 in the muscle, and it also participates in the regulation of T3 nuclear receptor activity.\n2. Type 2 deiodinase (D2): D2 is found in both fast-twitch and slow-twitch muscle fibers and is responsible for the conversion of T4 to T3 in skeletal muscle. D2 is encoded by the TIID2 gene.\n3. Type 3 deiodinase (D3): D3 is the least abundant deiodinase in skeletal muscle and is primarily found in brown adipose tissue. However, it can also be detected in small amounts in skeletal muscle. D3 is encoded by the TIID3 gene.\nIn summary, skeletal muscle contains three isoforms of deiodinases: D1 (primarily found in slow-twitch red muscle fibers), D2 (found in both fast-twitch and slow-twitch muscle fibers), and D3 (found primarily in brown adipose tissue). These deiodinases play important roles in regulating the metabolism of thyroid hormones in skeletal muscle.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are three isoforms of deiodinases present in skeletal muscle: Type 1 deiodinase (D1), Type 2 deiodinase (D2), and Type 3 deiodinase (D3).\n2. Type 1 deiodinase (D1) is the primary deiodinase isoform in skeletal muscle, encoded by the TIID1 gene.\n3. Type 2 deiodinase (D2) is found in both fast-twitch and slow-twitch muscle fibers and is responsible for the conversion of T4 to T3 in skeletal muscle.\n4. Type 3 deiodinase (D3) is the least abundant deiodinase in skeletal muscle, primarily found in brown adipose tissue, but also detectable in skeletal muscle.\n5. The D1 isoenzyme is mostly found in slow-twitch red muscle fibers and is involved in the conversions of T4 to T3 and T3 to T2 in the muscle.",
    "llama-2-7b-chat-hf_fact": [
      "There are three isoforms of deiodinases present in skeletal muscle: Type 1 deiodinase (D1), Type 2 deiodinase (D2), and Type 3 deiodinase (D3).",
      "Type 1 deiodinase (D1) is the primary deiodinase isoform in skeletal muscle, encoded by the TIID1 gene.",
      "Type 2 deiodinase (D2) is found in both fast-twitch and slow-twitch muscle fibers and is responsible for the conversion of T4 to T3 in skeletal muscle.",
      "Type 3 deiodinase (D3) is the least abundant deiodinase in skeletal muscle, primarily found in brown adipose tissue, but also detectable in skeletal muscle.",
      "The D1 isoenzyme is mostly found in slow-twitch red muscle fibers and is involved in the conversions of T4 to T3 and T3 to T2 in the muscle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Type 2 deiodinase (D2) is the primary deiodinase isoform in skeletal muscle, encoded by the DIO2 gene.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The D2 isoenzyme, not D1, is mostly found in both fast-twitch and slow-twitch muscle fibers and is involved in the conversion of T4 to T3 in the muscle.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Certainly! Inflammatory caspase proteins are a category of enzymes that play a crucial role in the regulation of inflammation in the body. Here are some of the key inflammatory caspase proteins:\n1. CASPASE-1 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE): Also known as caspase-1, this enzyme is a key regulator of inflammasomes, which are protein complexes that activate the release of protein substrates that trigger inflammation.\n2. CASPASE-6 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE 6): Similar to caspase-1, caspase-6 is another inflammatory caspase that is involved in the regulation of inflammasomes and the activation of inflammatory responses.\n3. CASPASE-8 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE 8): Caspase-8 is a pro-apoptotic caspase that is activated during the immune response and plays a role in the induction of apoptosis, or programmed cell death, in infected cells.\n4. CASPASE-9 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE 9): Caspase-9 is another pro-apoptotic caspase that plays a key role in the regulation of the immune response. It is involved in the activation of the immune response and the induction of apoptosis in infected cells.\n5. CASPASE-12 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE 12): Casase-12 is a pro-inflammatory caspase that is activated during the immune response and plays a role in the regulation of inflammation.\n6. CASPASE-13 (CYTOPLASMIC ASPHYTITE CYSTEINE PROTEASE 13): Caspase-13 is a",
    "llama-2-7b-chat-hf_fact_raw": "1. CASPASE-1 is a key regulator of inflammasomes and plays a crucial role in the regulation of inflammation.\n2. CASPASE-6 is involved in the regulation of inflammasomes and the activation of inflammatory responses.\n3. CASPASE-8 is a pro-apoptotic caspase activated during the immune response and induces apoptosis in infected cells.\n4. CASPASE-9 plays a key role in regulating the immune response and inducing apoptosis in infected cells.\n5. CASPASE-12 is a pro-inflammatory caspase activated during the immune response and regulates inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "CASPASE-1 is a key regulator of inflammasomes and plays a crucial role in the regulation of inflammation.",
      "CASPASE-6 is involved in the regulation of inflammasomes and the activation of inflammatory responses.",
      "CASPASE-8 is a pro-apoptotic caspase activated during the immune response and induces apoptosis in infected cells.",
      "CASPASE-9 plays a key role in regulating the immune response and inducing apoptosis in infected cells.",
      "CASPASE-12 is a pro-inflammatory caspase activated during the immune response and regulates inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CASPASE-6 is not primarily involved in the regulation of inflammasomes, it is mainly involved in neuronal apoptosis.\n3. TRUE\n4. FALSE [correction]: CASPASE-9 is involved in the intrinsic apoptosis pathway and is not primarily known for regulating the immune response.\n5. FALSE [correction]: CASPASE-12 is actually anti-inflammatory and its activity suppresses the inflammatory response.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a known link between Aurora B kinase and Polycomb protein Ring1B. Both of these proteins play important roles in regulating cellular processes, including cell division, differentiation, and development. While they have distinct functions, they have been found to interact and coordinate their actions in certain contexts.\nAurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis and cell division. It is essential for proper chromosome separation and cousin cleavage during M phase of the cell cycle. Aurora B kinase regulates the monastery of microtubules, which are essential for the formation of the spindle fibers that separate chromosomes during cell division.\nOn the other hand, Polycomb protein Ring1B is a transcriptional repressor that plays a crucial role in regulating gene expression during development and cell differentiation. Ring1B is part of the Polycomb repressive complex 2 (PRC2), which is responsible for maintaining the repressive chromatin state of gene silencing. PRC2 is known to be involved in the regulation of stem cell self-renewal, differentiation, and tumorigenesis.\nStudies have shown that Aurora B kinase and Ring1B interact in the regulation of mitosis and cell division. For example, Aurora B kinase has been shown to phosphorylate Ring1B, leading to its stabilization and accumulation in the nucleus. This interaction is thought to be important for the proper progression of mitosis and the maintenance of chromosome integrity.\nIn addition, Ring1B has been shown to play a role in the regulation of the G1/S checkpoint, which is crucial for ensuring that cells are ready to enter the S phase of the cell cycle. Ring1B has been shown to interact with the retinoblastoma protein (Rb), a tumor suppressor that is inactivated in many types of cancer. The interaction between Ring1B and Rb has been shown to regulate the G1/S checkpoint and ensure that cells progress through the cell cycle in an ordered manner.\nOverall, the link between Aurora B kinase and Ring1B is one of coordination and collaboration in the regulation of cellular processes. Both of these proteins play critical roles in",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Polycomb protein Ring1B interact and coordinate actions in certain cellular contexts.\n2. Aurora B kinase is a serine/threonine kinase involved in the regulation of mitosis and cell division.\n3. Polycomb protein Ring1B is a transcriptional repressor that is part of the Polycomb repressive complex 2 (PRC2).\n4. Aurora B kinase has been shown to phosphorylate Ring1B, leading to its stabilization and accumulation in the nucleus.\n5. Ring1B interacts with the retinoblastoma protein (Rb) to regulate the G1/S checkpoint of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Polycomb protein Ring1B interact and coordinate actions in certain cellular contexts.",
      "Aurora B kinase is a serine/threonine kinase involved in the regulation of mitosis and cell division.",
      "Polycomb protein Ring1B is a transcriptional repressor that is part of the Polycomb repressive complex 2 (PRC2).",
      "Aurora B kinase has been shown to phosphorylate Ring1B, leading to its stabilization and accumulation in the nucleus.",
      "Ring1B interacts with the retinoblastoma protein (Rb) to regulate the G1/S checkpoint of the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Polycomb protein Ring1B is part of the Polycomb repressive complex 1 (PRC1), not PRC2.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are sequences that are not typically found in the standard splice sites but can still be recognized by the spliceosome. These motifs can play important roles in the splicing process and can be associated with certain diseases or conditions.\nAt the donor splice site, the most frequent non-canonical sequence motifs in vertebrates include:\n1. GAG/GGA: These motifs are typically found in introns and are recognized by the SR protein SRp20. GAG/GGA motifs are often associated with the retention of intronic sequences, which can lead to the production of aberrant mRNAs.\n2. AAG/AAG: These motifs are recognized by the SR protein SRp55 and are often found in the splice sites of constitutive exons. AAG/AAG motifs can lead to the skipping of some exons, leading to altered mRNA processing.\n3. GU/GTG: These motifs are recognized by the SR protein SRp15 and are often found in the introns of gene clusters. GU/GTG motifs can lead to the retention of intronic sequences and the production of aberrant mRNAs.\nAt the acceptor splice site, the most frequent non-canonical sequence motifs in vertebrates include:\n1. UGA: This motif is recognized by the SR protein SRp18 and is often found in the terminal introns of gene clusters. UGA motifs can lead to the production of aberrant mRNAs, especially when the UGA motif is located in the last intron of a gene cluster.\n2. CAG/CGG: These motifs are recognized by the SR protein SRp30A and are often found in the acceptor splice sites of constitutive exons. CAG/CGG motifs can lead to the skipping of some exons, leading to altered mRNA processing.\n3. G/T-rich motifs: These motifs are recognized by the SR protein SRp24 and are often found in the acceptor splice sites of cryptic exons. G/T-rich motifs can lead to the inclusion of some exons and",
    "llama-2-7b-chat-hf_fact_raw": "1. GAG/GGA motifs at the donor splice site are recognized by the SR protein SRp20 and associated with intron retention.\n2. AAG/AAG motifs at the donor splice site are recognized by the SR protein SRp55 and can lead to exon skipping.\n3. GU/GTG motifs at the donor splice site are recognized by the SR protein SRp15 and associated with intron retention.\n4. UGA motifs at the acceptor splice site are recognized by the SR protein SRp18 and can lead to the production of aberrant mRNAs.\n5. CAG/CGG motifs at the acceptor splice site are recognized by the SR protein SRp30A and can lead to exon skipping.",
    "llama-2-7b-chat-hf_fact": [
      "GAG/GGA motifs at the donor splice site are recognized by the SR protein SRp20 and associated with intron retention.",
      "AAG/AAG motifs at the donor splice site are recognized by the SR protein SRp55 and can lead to exon skipping.",
      "GU/GTG motifs at the donor splice site are recognized by the SR protein SRp15 and associated with intron retention.",
      "UGA motifs at the acceptor splice site are recognized by the SR protein SRp18 and can lead to the production of aberrant mRNAs.",
      "CAG/CGG motifs at the acceptor splice site are recognized by the SR protein SRp30A and can lead to exon skipping."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The recognition of specific motifs by SR proteins and their functional consequences in splicing is a highly specialized topic in molecular biology. Without the proper context or additional information, it is not possible to determine the veracity of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (Serine/Threonine kinase 1) is a key regulator of protein synthesis and degradation, and its acetylation plays a crucial role in various cellular processes, including cell growth, proliferation, and survival. There are several events that can result in the acetylation of S6K1, including:\n1. Insulin signaling: Insulin receptor activation leads to the phosphorylation and subsequent acetylation of S6K1, which promotes protein synthesis and inhibits protein degradation. This event occurs downstream of the insulin receptor substrate (IRS) molecules, which are activated by insulin binding to their receptors.\n2. mTOR signaling: mTOR (mechanistic target of rapamycin) is a key regulator of cell growth and metabolism, and it also regulates S6K1 acetylation. mTOR signaling pathway activates S6K1 through phosphorylation and acetylation, leading to increased protein synthesis and decreased protein degradation. mTOR signaling is activated by growth factors, nutrient availability, and cellular energy status.\n3. NF-kB signaling: NF-kB (Nuclear Factor kappa B) is a transcription factor that regulates gene expression involved in various cellular processes, including inflammation, immune response, and cell survival. Activation of NF-kB signaling pathway can lead to the acetylation of S6K1, which promotes protein synthesis and inhibits protein degradation.\n4. Hypoxia: Hypoxia, or low oxygen availability, can lead to the acetylation of S6K1. This event occurs through the activation of hypoxia-inducible factor (HIF) signaling pathway, which regulates the expression of genes involved in cellular adaptation to hypoxia.\n5. AMP-activated protein kinase (AMPK) signaling: AMPK is a metabolic sensor that regulates energy metabolism and cellular homeostasis. Activation of AMPK signaling pathway can lead to the acet",
    "llama-2-7b-chat-hf_fact_raw": "1. Insulin signaling can result in the acetylation of S6K1, promoting protein synthesis and inhibiting protein degradation.\n2. mTOR signaling activates S6K1 through phosphorylation and acetylation, leading to increased protein synthesis and decreased protein degradation.\n3. NF-kB signaling activation can lead to the acetylation of S6K1, promoting protein synthesis and inhibiting protein degradation.\n4. Hypoxia can lead to the acetylation of S6K1 through the activation of hypoxia-inducible factor signaling pathway.\n5. Activation of AMP-activated protein kinase signaling pathway can lead to the acetylation of S6K1.",
    "llama-2-7b-chat-hf_fact": [
      "Insulin signaling can result in the acetylation of S6K1, promoting protein synthesis and inhibiting protein degradation.",
      "mTOR signaling activates S6K1 through phosphorylation and acetylation, leading to increased protein synthesis and decreased protein degradation.",
      "NF-kB signaling activation can lead to the acetylation of S6K1, promoting protein synthesis and inhibiting protein degradation.",
      "Hypoxia can lead to the acetylation of S6K1 through the activation of hypoxia-inducible factor signaling pathway.",
      "Activation of AMP-activated protein kinase signaling pathway can lead to the acetylation of S6K1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: NF-kB signaling activation does not directly lead to the acetylation of S6K1, but can impact other pathways that influence protein synthesis and degradation.\n4. UNKNOWN\n5. FALSE [correction]: Activation of AMP-activated protein kinase signaling pathway generally leads to the phosphorylation of S6K1 which can inhibit protein synthesis rather than promote it through acetylation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the PAF1 gene. The PAF1 gene provides instructions for making a protein called PAF1, which is involved in the regulation of gene expression and is important for the development and maintenance of several tissues in the body, including the nervous system.\nThe PAF1 protein plays a critical role in the regulation of gene expression by modulating the activity of transcription factors, which are proteins that control the expression of genes. The PAF1 protein is particularly important for the expression of genes involved in the development and maintenance of the nervous system.\nMutations in the PAF1 gene that cause EA6 lead to a deficiency of functional PAF1 protein, which disrupts the regulation of gene expression in the nervous system. This disruption can lead to a variety of symptoms, including:\n1. Ataxia: The term \"ataxia\" refers to a lack of coordination and balance, which can cause awkward movements and difficulty with walking, speaking, and performing other physical tasks.\n2. Epilepsy: Many people with EA6 experience seizures, which can range from mild to severe.\n3. Intellectual disability: Some individuals with EA6 may have mild to moderate intellectual disability, which can affect their ability to learn and function in daily life.\n4. Vision problems: Some people with EA6 may experience vision problems, including blurred vision, double vision, or loss of peripheral vision.\n5. Hearing loss: Some individuals with EA6 may experience hearing loss or impairment.\n6. Sleep disturbances: People with EA6 may experience difficulty falling asleep or staying asleep, which can lead to excessive daytime sleepiness and fatigue.\n7. Mood changes: Some individuals with EA6 may experience mood changes, including depression, anxiety, or irritability.\n8. Autism spectrum disorder: Some people with EA6 may have autism spectrum disorder (ASD), which can affect communication, social interaction, and behavior.\nThe symptoms of EA6 typically begin in childhood or adolescence and can vary in severity from person to person. The",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the PAF1 gene.\n2. The PAF1 gene provides instructions for making a protein that is involved in gene expression regulation.\n3. Mutations in the PAF1 gene result in a deficiency of functional PAF1 protein.\n4. Deficiency of functional PAF1 protein disrupts regulation of gene expression in the nervous system.\n5. Symptoms of EA6 typically begin in childhood or adolescence.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the PAF1 gene.",
      "The PAF1 gene provides instructions for making a protein that is involved in gene expression regulation.",
      "Mutations in the PAF1 gene result in a deficiency of functional PAF1 protein.",
      "Deficiency of functional PAF1 protein disrupts regulation of gene expression in the nervous system.",
      "Symptoms of EA6 typically begin in childhood or adolescence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 (EA6) is caused by mutations in the SLC1A3 gene.\n2. TRUE\n3. FALSE [correction]: Mutations in the SLC1A3 gene result in a deficiency of functional SLC1A3 protein.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding a methyl groups to specific residues on histones or other chromatin components. These enzymes play important roles in regulating gene expression, DNA repair, and chromatin remodeling in various organisms, including animals.\nIn animals, chromomethylases have been found to be involved in a variety of cellular processes, including:\n1. Gene silencing: Chromomethylases can modify histones to create repressive chromatin structures that silence gene expression. This is a common mechanism used by cells to regulate gene expression, especially for genes that are not actively being used.\n2. DNA repair: Chromomethylases can also modify histones involved in DNA repair processes, such as checkpoint activation and Dam-antoxin repair. This helps to ensure that damaged DNA is properly repaired and that genetic information is maintained.\n3. Chromatin remodeling: Chromomethylases can alter the chromatin structure to allow or block access to specific genes, thereby influencing gene expression. This is especially important in X chromosome inactivation, where the expression of X-linked genes is silenced through chromatin remodeling.\n4. Stem cell maintenance: Chromomethylases have been implicated in the regulation of stem cell self-renewal and differentiation. This is thought to be achieved through the modification of chromatin structures that are involved in stem cell maintenance and differentiation.\n5. Cancer: Chromomethylases have been linked to cancer development and progression. For example, some chromomethylases have been shown to be involved in the silencing of tumor suppressor genes, leading to the development of cancer. Others have been implicated in the regulation of oncogenes, leading to uncontrolled cell growth and division.\nExamples of chromomethylases found in animal genomes include:\n1. histone methyltransferases (HMTs): HMTs are the most common type of chromomethylase found in animals. They modify histone tails by adding methyl groups, leading to changes in chromatin structure and gene expression.\n2. lysine-specific dem",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes present in animal genomes.\n2. These enzymes play roles in regulating gene expression, DNA repair, and chromatin remodeling.\n3. Chromomethylases can modify histones to create repressive chromatin structures that silence gene expression.\n4. Histone methyltransferases (HMTs) are a common type of chromomethylase found in animals.\n5. Chromomethylases have been linked to cancer development and progression.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes present in animal genomes.",
      "These enzymes play roles in regulating gene expression, DNA repair, and chromatin remodeling.",
      "Chromomethylases can modify histones to create repressive chromatin structures that silence gene expression.",
      "Histone methyltransferases (HMTs) are a common type of chromomethylase found in animals.",
      "Chromomethylases have been linked to cancer development and progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes present in plant genomes, not animal genomes.\n2. TRUE\n3. FALSE [correction]: Chromomethylases modify DNA directly, not histones, to create repressive chromatin structures that silence gene expression.\n4. FALSE [correction]: Histone methyltransferases (HMTs) are not considered chromomethylases. Chromomethylases are specific to DNA methylation.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Certainly! There are several packages in R/Bioconductor that can be used for transcription factor binding site (TFBS) analysis. Here are some of the most popular ones:\n1. **TCGA**: The TCGA package is a collection of tools for the analysis of ChIP-seq and other genomic data. It includes functions for peak calling, motif discovery, and functional enrichment analysis.\n2. **HISAT2**: HISAT2 is a spliced aligner that can be used for ChIP-seq and RNA-seq data analysis. It can be used to identify TFBSs and predict their binding locations.\n3. **STAR**: STAR is another spliced aligner that can be used for ChIP-seq data analysis. It can also be used to identify TFBSs and predict their binding locations.\n4. **MACS**: The MACS package is a popular toolkit for ChIP-seq data analysis. It includes functions for peak calling, motif discovery, and pathway analysis.\n5. **PeakAnalyzer**: PeakAnalyzer is a R/Bioconductor package that provides a comprehensive framework for the analysis of ChIP-seq data. It includes functions for peak calling, motif discovery, and functional enrichment analysis.\n6. **ChIPseek**: ChIPseek is a tool for the identification of putative TFBSs in ChIP-seq data. It uses a profile-based approach and can be used to identify both known and novel TFBSs.\n7. **TFbinding**: TFbinding is a package for the analysis of TFBSs in ChIP-seq data. It includes functions for peak calling, motif discovery, and functional enrichment analysis.\n8. **ChIPExplorer**: ChIPExplorer is a package for the visualization and analysis of ChIP-seq data. It includes functions for peak calling, motif discovery, and functional enrichment analysis.\n9. **ENCODE**: The ENCODE package is a collection of tools for the analysis of ChIP-seq and other genomic data. It includes functions for peak calling, motif discovery, and functional enrichment analysis.\n10. **ChIPPe**: ChIPPe is a package for the analysis",
    "llama-2-7b-chat-hf_fact_raw": "1. TCGA is a package that provides tools for ChIP-seq and other genomic data analysis.\n2. HISAT2 is a spliced aligner for ChIP-seq and RNA-seq data analysis, used for identifying TFBSs.\n3. STAR is a spliced aligner for ChIP-seq data analysis used to identify TFBSs.\n4. MACS is a toolkit for ChIP-seq data analysis with functions for peak calling and motif discovery.\n5. PeakAnalyzer is an R/Bioconductor package for ChIP-seq data analysis, including peak calling and motif discovery functions.",
    "llama-2-7b-chat-hf_fact": [
      "TCGA is a package that provides tools for ChIP-seq and other genomic data analysis.",
      "HISAT2 is a spliced aligner for ChIP-seq and RNA-seq data analysis, used for identifying TFBSs.",
      "STAR is a spliced aligner for ChIP-seq data analysis used to identify TFBSs.",
      "MACS is a toolkit for ChIP-seq data analysis with functions for peak calling and motif discovery.",
      "PeakAnalyzer is an R/Bioconductor package for ChIP-seq data analysis, including peak calling and motif discovery functions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TCGA (The Cancer Genome Atlas) is a project that provides a collection of cancer-related genomic data, not a package for ChIP-seq data analysis.\n2. FALSE [correction]: HISAT2 is a fast and sensitive spliced aligner for RNA-seq data analysis, not specifically for identifying TFBSs (Transcription Factor Binding Sites).\n3. FALSE [correction]: STAR is a spliced aligner for RNA-seq data analysis, not for ChIP-seq data analysis or specifically for identifying TFBSs.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some ongoing and completed clinical trials related to the prevention of sarcopenia:\n1. Sarcopenia Prevention and Exercise Trial (SPaRET) - This is a randomized, controlled trial conducted in Australia that aims to determine the effectiveness of a supervised exercise program in preventing sarcopenia in older adults. The trial includes 400 participants aged 65-80 years and is scheduled to complete in 2023.\n2. PREVENT-SDKFU - This is a randomized, controlled trial conducted in the United States that aims to evaluate the effectiveness of a daily dose of omega-3 fatty acids in preventing sarcopenia in older adults. The trial includes 400 participants aged 65-80 years and is expected to complete in 2024.\n3. Fit and Strong in 30s (FS3) - This is a randomized, controlled trial conducted in the United States that aims to evaluate the effectiveness of a resistance training program in preventing sarcopenia in young adults aged 30-50 years. The trial includes 100 participants and is expected to complete in 2023.\n4. Effects of Resistance Training on Sarcopenia in Older Adults (ERT-SARC) - This is a randomized, controlled trial conducted in Canada that aims to evaluate the effectiveness of resistance training in preventing sarcopenia in older adults aged 65-80 years. The trial includes 100 participants and is expected to complete in 2023.\n5. Nutrient Timing and Protection against Sarcopenia (NUTRI-SARC) - This is a randomized, controlled trial conducted in the United States that aims to evaluate the effectiveness of nutrient timing strategies in preventing sarcopenia in older adults. The trial includes 100 participants and is expected to complete in 2023.\n6. Sarcopenia Prevention and Management Initiative (SPAMI) - This is a randomized, controlled trial conducted in the United Kingdom that aims to evaluate the effectiveness of a compreh",
    "llama-2-7b-chat-hf_fact_raw": "1. The Sarcopenia Prevention and Exercise Trial (SPaRET) is a randomized, controlled trial in Australia with 400 participants aged 65-80 years, scheduled to complete in 2023.\n2. The PREVENT-SDKFU trial in the United States evaluates the effectiveness of omega-3 fatty acids in preventing sarcopenia and includes 400 participants aged 65-80 years, expected to complete in 2024.\n3. The Fit and Strong in 30s (FS3) trial in the United States includes 100 participants aged 30-50 years and is a randomized, controlled trial expected to complete in 2023.\n4. The Effects of Resistance Training on Sarcopenia in Older Adults (ERT-SARC) trial in Canada includes 100 participants aged 65-80 years and is a randomized, controlled trial expected to complete in 2023.\n5. The Nutrient Timing and Protection against Sarcopenia (NUTRI-SARC) trial in the United States includes 100 participants and is set to complete in 2023.",
    "llama-2-7b-chat-hf_fact": [
      "The Sarcopenia Prevention and Exercise Trial (SPaRET) is a randomized, controlled trial in Australia with 400 participants aged 65-80 years, scheduled to complete in 2023.",
      "The PREVENT-SDKFU trial in the United States evaluates the effectiveness of omega-3 fatty acids in preventing sarcopenia and includes 400 participants aged 65-80 years, expected to complete in 2024.",
      "The Fit and Strong in 30s (FS3) trial in the United States includes 100 participants aged 30-50 years and is a randomized, controlled trial expected to complete in 2023.",
      "The Effects of Resistance Training on Sarcopenia in Older Adults (ERT-SARC) trial in Canada includes 100 participants aged 65-80 years and is a randomized, controlled trial expected to complete in 2023.",
      "The Nutrient Timing and Protection against Sarcopenia (NUTRI-SARC) trial in the United States includes 100 participants and is set to complete in 2023."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Due to the lack of context and specific details about these trials, it is not possible to determine the accuracy of the statements provided.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that can be used for querying and retrieving information on the structural elements and features of these proteins. Here are some of the most popular and widely used databases:\n1. MAMM (Membrane Protein Matrix): MAMM is a comprehensive database of membrane protein structures, including both synthetic and natural membrane proteins. The database contains over 100,000 protein entries, each of which contains detailed information on the protein's structure, sequence, and functional features.\n2. Membrane Protein Database (MPD): MPD is another large database of membrane protein structures, with over 100,000 entries. The database contains detailed information on the protein's structure, sequence, and functional features, as well as links to related databases and literature.\n3. Protein Data Bank (PDB): The PDB is a comprehensive database of three-dimensional structures of proteins, nucleic acids, and other biological molecules. While not exclusively focused on membrane proteins, the PDB does contain a significant number of membrane protein structures, including both transmembrane and peripheral membrane proteins.\n4. MEMBRANE: MEMBRANE is a database of membrane protein structure and function, with a focus on G protein-coupled receptors (GPCRs) and their ligands. The database contains detailed information on the structure and function of GPCRs, as well as tools for querying and analyzing the data.\n5. Membrane Protein Structural Database (MPSD): MPSD is a database of structural data on membrane proteins, including both X-ray crystallography and NMR structures. The database contains over 12,000 entries, with detailed information on the protein's structure and functional features.\n6. INTERACT: INTERACT is a database of protein-protein interactions, including information on the binding interactions of membrane proteins with other proteins or ligands. The database contains over 10,000 entries, with detailed information on the interaction partners and the binding affinities of the interactions.\n7. Membrane Protein - Mechanisms of Action (MPMA): MPMA is a database of information on the",
    "llama-2-7b-chat-hf_fact_raw": "1. MAMM (Membrane Protein Matrix) is a database containing over 100,000 entries of membrane protein structures.\n2. Membrane Protein Database (MPD) has over 100,000 entries of membrane protein structures.\n3. Protein Data Bank (PDB) is a comprehensive database of three-dimensional structures of proteins, nucleic acids, and other biological molecules, including membrane proteins.\n4. Membrane Protein Structural Database (MPSD) contains over 12,000 entries of structural data on membrane proteins.\n5. INTERACT is a database of protein-protein interactions with over 10,000 entries including information on membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "MAMM (Membrane Protein Matrix) is a database containing over 100,000 entries of membrane protein structures.",
      "Membrane Protein Database (MPD) has over 100,000 entries of membrane protein structures.",
      "Protein Data Bank (PDB) is a comprehensive database of three-dimensional structures of proteins, nucleic acids, and other biological molecules, including membrane proteins.",
      "Membrane Protein Structural Database (MPSD) contains over 12,000 entries of structural data on membrane proteins.",
      "INTERACT is a database of protein-protein interactions with over 10,000 entries including information on membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: Membrane Protein Structural Database (MPSD) contains over 9,000 entries of structural data on membrane proteins.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys to a limited extent. Rivaroxaban is a direct oral anticoagulant (DOAC) that is primarily eliminated through the kidneys, with approximately 70% of the drug recovered in the urine as the inactive metabolite, 6-O-desmethylrivaroxaban.\nThe kidneys play a critical role in the elimination of rivaroxaban, as they are responsible for removing most of the drug and its metabolites from the body. The liver also plays a role in the metabolism of rivaroxaban, as it metabolizes the drug to its active form through the CYP3A4 enzyme. However, the kidneys are the primary site of competition between the drug and its active metabolite, which is formed through the liver enzyme CYP2C8.\nReduced kidney function can lead to reduced elimination of rivaroxaban, which may result in increased concentrations of the drug in the body and an increased risk of bleeding. In particular, patients with creatinine clearance (CrCl) <30 mL/min may require closer monitoring and dose adjustment to avoid adverse events.\nOn the other hand, increased kidney function can also lead to increased elimination of rivaroxaban, which may reduce its efficacy. In patients with CrCl ≥60 mL/min, the drug may need to be adjusted to maintain efficacy and minimize the risk of bleeding.\nIn summary, rivaroxaban is metabolized in the kidneys, and the kidneys play a critical role in its elimination. The dose and frequency of the drug may need to be adjusted based on the patient's kidney function to ensure optimal efficacy and safety.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys to a limited extent.\n2. Approximately 70% of rivaroxaban is recovered in the urine as the inactive metabolite, 6-O-desmethylrivaroxaban.\n3. The liver metabolizes rivaroxaban to its active form through the CYP3A4 enzyme.\n4. Patients with creatinine clearance (CrCl) less than 30 mL/min may require dose adjustments for rivaroxaban due to reduced kidney function.\n5. In patients with CrCl greater than or equal to 60 mL/min, rivaroxaban dose may need adjustment to maintain efficacy.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys to a limited extent.",
      "Approximately 70% of rivaroxaban is recovered in the urine as the inactive metabolite, 6-O-desmethylrivaroxaban.",
      "The liver metabolizes rivaroxaban to its active form through the CYP3A4 enzyme.",
      "Patients with creatinine clearance (CrCl) less than 30 mL/min may require dose adjustments for rivaroxaban due to reduced kidney function.",
      "In patients with CrCl greater than or equal to 60 mL/min, rivaroxaban dose may need adjustment to maintain efficacy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Approximately 36% of rivaroxaban is recovered in the urine as the inactive metabolite, 6-O-desmethylrivaroxaban.\n3. FALSE [correction]: The liver metabolizes rivaroxaban to its active form through the CYP3A4 and CYP2J2 enzymes.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a transmembrane receptor that plays a crucial role in the regulation of cardiac function and remodeling in response to various physiological and pathological stimuli. The following are some of the genes that are known to be regulated by TRalpha2 in the heart:\n1. Atrial natriuretic factor (ANF): TRalpha2 regulates the expression of ANF, a peptide hormone that plays a key role in the regulation of cardiac function, blood pressure, and fluid balance.\n2. Brain natriuretic peptide (BNP): BNP is a hormone that is produced in the heart in response to cardiac stress and is secreted into the bloodstream. TRalpha2 regulates the expression of BNP, which acts on the brain to regulate cardiac function and blood pressure.\n3. Growth differentiation factor 11 (Gdf11): Gdf11 is a growth factor that plays a role in the regulation of cardiac development and function. TRalpha2 regulates the expression of Gdf11, which is important for the maintenance of cardiac contractility and relaxation.\n4. Transforming growth factor-beta 1 (Tgf-beta1): Tgf-beta1 is a potent growth factor that regulates a variety of cellular processes, including cell proliferation, differentiation, and extracellular matrix production. TRalpha2 regulates the expression of Tgf-beta1, which is important for the regulation of cardiac remodeling and fibrosis.\n5. connexin 43 (Cx43): Cx43 is a member of the connexin family of gap junction proteins that are important for direct cell-to-cell communication. TRalpha2 regulates the expression of Cx43, which plays a role in the regulation of cardiac excitability and contractility.\n6.Pyruvate dehydrogenase kinase isozyme 4 (PDK4): PDK4 is a key regulator of glucose metabolism in the heart. TRalpha2 regulates the expression of PDK4, which is important for the regulation of cardiac glucose metabolism and energy production.\n7. Carbohydrate",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the expression of Atrial natriuretic factor (ANF) in the heart.\n2. TRalpha2 regulates the expression of Brain natriuretic peptide (BNP) in the heart.\n3. TRalpha2 regulates the expression of Growth differentiation factor 11 (Gdf11) in the heart.\n4. TRalpha2 regulates the expression of Transforming growth factor-beta 1 (Tgf-beta1) in the heart.\n5. TRalpha2 regulates the expression of connexin 43 (Cx43) in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the expression of Atrial natriuretic factor (ANF) in the heart.",
      "TRalpha2 regulates the expression of Brain natriuretic peptide (BNP) in the heart.",
      "TRalpha2 regulates the expression of Growth differentiation factor 11 (Gdf11) in the heart.",
      "TRalpha2 regulates the expression of Transforming growth factor-beta 1 (Tgf-beta1) in the heart.",
      "TRalpha2 regulates the expression of connexin 43 (Cx43) in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The specific regulatory functions of TRalpha2 in the heart and its relationship to the mentioned factors would require specialized knowledge in molecular biology or access to scientific research on the subject. Without additional context or information, it's not possible to accurately confirm or correct these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I must inform you that there are several biomedical question answering systems available that can help you with your queries related to health, medicine, and biology. Here are some of the most popular and widely used biomedical question answering systems:\n1. PubMed Central (PMC): PMC is a free full-text database of biomedical literature provided by the National Library of Medicine (NLM). It contains over 4.5 million articles from the MEDLINE database, as well as other life science journals.\n2. Google Scholar (GS): Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers. It provides easy access to a wide range of biomedical literature and can be used to answer questions on various biomedical topics.\n3. PubMed: PubMed is a free database of biomedical literature provided by the National Library of Medicine (NLM). It contains over 28 million citations from the MEDLINE database, as well as other life science journals. It also provides access to full-text articles and other related resources.\n4. MetaMap: MetaMap is a biomedical natural language processing (NLP) system developed by the National Center for Biotechnology Information (NCBI). It can be used to extract biomedical concepts, relationships, and entities from text, and can answer questions on various biomedical topics.\n5. BioGrades: BioGrades is a biomedical question answering system that uses natural language processing (NLP) and machine learning techniques to answer questions on various biomedical topics. It can answer questions on topics such as genetics, molecular biology, biochemistry, and pharmacology.\n6. Biopython: Biopython is a freely available tool for integrating bioinformatics tools into Python programs. It provides a comprehensive set of tools for working with biological data, including sequence analysis, gene finding, and protein structure prediction.\n7. BioJava: BioJava is an open-source Java library for bioinformatics. It provides a wide range of tools for working with biological data, including sequence analysis, gene finding, and protein structure prediction.\n8. Bioplayer: Bioplayer is a biomedical question answering system that uses natural language processing (NLP) and",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central (PMC) is a free full-text database of biomedical literature provided by the National Library of Medicine (NLM) containing over 4.5 million articles.\n2. Google Scholar is a free search engine that indexes scholarly literature across many disciplines and provides access to biomedical literature.\n3. PubMed is a free database of biomedical literature provided by the National Library of Medicine (NLM) containing over 28 million citations.\n4. MetaMap is a biomedical natural language processing (NLP) system developed by the National Center for Biotechnology Information (NCBI).\n5. BioJava is an open-source Java library for bioinformatics providing tools for sequence analysis, gene finding, and protein structure prediction.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central (PMC) is a free full-text database of biomedical literature provided by the National Library of Medicine (NLM) containing over 4.5 million articles.",
      "Google Scholar is a free search engine that indexes scholarly literature across many disciplines and provides access to biomedical literature.",
      "PubMed is a free database of biomedical literature provided by the National Library of Medicine (NLM) containing over 28 million citations.",
      "MetaMap is a biomedical natural language processing (NLP) system developed by the National Center for Biotechnology Information (NCBI).",
      "BioJava is an open-source Java library for bioinformatics providing tools for sequence analysis, gene finding, and protein structure prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The betalain pathway is a complex metabolic pathway involved in the biosynthesis of a variety of secondary metabolites, including betalains, which are a class of natural pigments found in plants. There are several transcription factors that have been shown to regulate the expression of genes involved in the betalain pathway, depending on the specific plant species and environment. Here are some examples of transcription factors that have been implicated in the regulation of the betalain pathway:\n1. TCP (Trellis Cold-regulated) transcription factors: TCP transcription factors are a family of transcription regulators that are involved in the regulation of gene expression in response to environmental cues, such as light and temperature. In Arabidopsis thaliana, several TCP transcription factors (TCP1, TCP2, and TCP3) have been shown to regulate the expression of genes involved in the betalain pathway, particularly in response to high temperatures.\n2. WRKY transcription factors: WRKY transcription factors are a family of transcription regulators that are involved in the regulation of gene expression in response to abiotic stress, including high temperatures. In Arabidopsis thaliana, several WRKY transcription factors (WRKY1, WRKY2, and WRKY3) have been shown to regulate the expression of genes involved in the betalain pathway in response to heat stress.\n3. DREB (Dehydration-Regulated Element Binding) transcription factors: DREB transcription factors are a family of transcription regulators that are involved in the regulation of gene expression in response to drought and other abiotic stresses. In Arabidopsis thaliana, several DREB transcription factors (DREB1A, DREB2A, and DREB2B) have been shown to regulate the expression of genes involved in the betalain pathway in response to drought stress.\n4. HAT (Heat-Active Transcription) transcription factors: HAT transcription factors are a family of transcription regulators that are involved in the regulation of gene expression in response to high temperatures. In Arabidopsis thaliana, several HAT transcription factors (HAT1 and HAT",
    "llama-2-7b-chat-hf_fact_raw": "1. The betalain pathway involves the biosynthesis of secondary metabolites including betalains.\n2. TCP transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to high temperatures.\n3. WRKY transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to heat stress.\n4. DREB transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to drought stress.\n5. HAT transcription factors in Arabidopsis thaliana are involved in regulating gene expression in response to high temperatures.",
    "llama-2-7b-chat-hf_fact": [
      "The betalain pathway involves the biosynthesis of secondary metabolites including betalains.",
      "TCP transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to high temperatures.",
      "WRKY transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to heat stress.",
      "DREB transcription factors in Arabidopsis thaliana regulate gene expression in the betalain pathway in response to drought stress.",
      "HAT transcription factors in Arabidopsis thaliana are involved in regulating gene expression in response to high temperatures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses are indeed emerging as a powerful approach to study the dynamics of protein phosphorylation in various biological systems. The enrichment of phosphorylated peptides prior to mass spectrometry analysis is crucial to improve the sensitivity and accuracy of phosphoproteomics studies. Here are some of the most preferred technologies for phosphorylated peptide enrichment:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) as a solid phase to selectively bind phosphorylated peptides. The sample is first denatured, then mixed with TiO2, and the resulting mixture is centrifuged. The phosphorylated peptides are retained on the TiO2 surface while non-phosphorylated peptides are washed away.\n2. Antibody-based enrichment: This method using phosphorylation-specific antibodies to capture phosphorylated peptides. The sample is first incubated with the antibody, which binds to phosphorylated peptides, and then the complex is isolated using magnetic beads or other separation methods.\n3. IMAC (Immunomagnetic separation): This method uses a phosphorylation-specific antibody conjugated to magnetic beads, which can magnetically separate the phosphorylated peptides from the rest of the protein sample.\n4. RAfting: Is a method based on the difference in the density between phosphorylated and non-phosphorylated peptides, this method uses a hydrophobic interaction chromatography (HIC) column to separate the phosphorylated peptides.\n5. Metal-based enrichment: This method uses metal ions to selectively bind phosphorylated peptides. The most common metal used is copper, which interacts with phosphorylated peptides through metal-ion-dependent phosphorelay.\n6. Cation-exchange (CEX) chromatography: This method uses a cation-exchange resin to separate phosphorylated peptides based on their charge. Phosphorylated peptides have a positive charge due to",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment selectively binds phosphorylated peptides using titanium dioxide as a solid phase.\n2. Antibody-based enrichment captures phosphorylated peptides using phosphorylation-specific antibodies.\n3. Immunomagnetic separation (IMAC) utilizes a phosphorylation-specific antibody conjugated to magnetic beads.\n4. RAfting separates phosphorylated peptides using hydrophobic interaction chromatography based on density differences.\n5. Metal-based enrichment methods commonly use copper ions to bind phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment selectively binds phosphorylated peptides using titanium dioxide as a solid phase.",
      "Antibody-based enrichment captures phosphorylated peptides using phosphorylation-specific antibodies.",
      "Immunomagnetic separation (IMAC) utilizes a phosphorylation-specific antibody conjugated to magnetic beads.",
      "RAfting separates phosphorylated peptides using hydrophobic interaction chromatography based on density differences.",
      "Metal-based enrichment methods commonly use copper ions to bind phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Immunomagnetic separation (IMS) utilizes a phosphorylation-specific antibody conjugated to magnetic beads. IMAC uses metal ions such as Fe3+ or Ga3+ to bind phosphorylated peptides.\n4. UNKNOWN\n5. FALSE [correction]: Metal-based enrichment methods commonly use metal ions such as iron or gallium, not copper ions, to bind phosphorylated peptides.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini is a classification system used to categorize and organize mental disorders. The Palmini classification system is based on the World Health Organization's (WHO) International Classification of Diseases (ICD) and is widely used by mental health professionals.\nAccording to the Palmini classification, the following disorders are rated:\n1. Mood Disorders:\n* Major Depressive Disorder (F32.1)\n* Bipolar Disorder (F31.1, F31.2)\n* Cyclothymic Disorder (F30.3)\n* Dysthymic Disorder (F30.0)\n2. Anxiety Disorders:\n* Generalized Anxiety Disorder (F41.1)\n* Panic Disorder (F41.0)\n* Social Anxiety Disorder (F40.1)\n* Specific Phobia (F40.2)\n* Obsessive-Compulsive Disorder (F42.1)\n3. Personality Disorders:\n* Paranoid Personality Disorder (F60.3)\n* Schizoid Personality Disorder (F60.0)\n* Schizotypal Personality Disorder (F60.2)\n* Antisocial Personality Disorder (F60.4)\n* Borderline Personality Disorder (F60.5)\n* Histrionic Personality Disorder (F60.6)\n* Narcissistic Personality Disorder (F60.7)\n4. Psychotic Disorders:\n* Schizophrenia (F20.0)\n* Brief Psychotic Disorder (F29.0)\n* Postpartum Psychosis (F33.9)\n* Schizoaffective Disorder (F25.0)\n5. Neurodevelopmental Disorders:\n* Attention Deficit Hyperactivity Disorder (F90.2)\n* Autism Spectrum Disorder (F84.0)\n6. Dissociative Disorders:\n* Dissociative Amnesia (F22.0)\n* Depersonalization Disorder (F25.6)\n* Dissoci",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification system is used to categorize and organize mental disorders.\n2. The Palmini classification system is based on the WHO's International Classification of Diseases.\n3. Major Depressive Disorder is categorized under Mood Disorders in the Palmini classification with the code F32.1.\n4. Generalized Anxiety Disorder is categorized under Anxiety Disorders in the Palmini classification with the code F41.1.\n5. Schizophrenia is categorized under Psychotic Disorders in the Palmini classification with the code F20.0.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification system is used to categorize and organize mental disorders.",
      "The Palmini classification system is based on the WHO's International Classification of Diseases.",
      "Major Depressive Disorder is categorized under Mood Disorders in the Palmini classification with the code F32.1.",
      "Generalized Anxiety Disorder is categorized under Anxiety Disorders in the Palmini classification with the code F41.1.",
      "Schizophrenia is categorized under Psychotic Disorders in the Palmini classification with the code F20.0."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The DSM (Diagnostic and Statistical Manual of Mental Disorders) and ICD (International Classification of Diseases), not the Palmini classification system, are used to categorize and organize mental disorders.\n2. FALSE [correction]: The Palmini classification system is not based on the WHO's International Classification of Diseases, as there is no Palmini classification system for mental disorders.\n3. FALSE [correction]: Major Depressive Disorder is categorized under Mood Disorders in the ICD with the code F32.1, not the non-existent Palmini classification.\n4. FALSE [correction]: Generalized Anxiety Disorder is categorized under Anxiety Disorders in the ICD with the code F41.1, not the non-existent Palmini classification.\n5. FALSE [correction]: Schizophrenia is categorized under Psychotic Disorders in the ICD with the code F20.0, not the non-existent Palmini classification.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is a type of inflammatory thyroiditis that typically occurs in the setting of a viral infection. The virus is thought to triggers an immune response that leads to inflammation in the thyroid gland, causing symptoms such as pain in the neck, swelling, and difficulty swallowing.\nThere are several viruses that have been linked to the development of subacute thyroiditis, including:\n1. Respiratory viruses: Respiratory viruses, such as influenza, adenovirus, and parainfluenza, are the most commonly implicated viruses in the development of subacute thyroiditis. These viruses are thought to spread from person to person through the air, and may cause an inflammatory response in the thyroid gland.\n2. Enteroviruses: Enteroviruses, such as coxsackievirus and echovirus, are also commonly associated with subacute thyroiditis. These viruses are typically found in the gastrointestinal tract, but can also infect the thyroid gland.\n3. Herpesviruses: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been linked to subacute thyroiditis. HSV is more commonly associated with orofacial herpes, but can also cause central nervous system infections that may lead to thyroiditis. HHV-6 is more commonly associated with roseola infantum and exanthem subitum, but can also cause thyroiditis.\n4. Other viruses: Other viruses that have been implicated in the development of subacute thyroiditis include HIV, hepatitis viruses, and measles virus.\nThe exact mechanism by which viruses cause subacute thyroiditis is not fully understood. It is thought that the virus triggers an immune response in the thyroid gland, leading to inflammation and damage to the thyroid tissue. This inflammation can lead to the production of autoantibodies, which are antibodies that attack the thyroid gland and can cause damage to the thyroid tissue.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis typically occurs in the setting of a viral infection.\n2. Respiratory viruses such as influenza, adenovirus, and parainfluenza have been implicated in the development of subacute thyroiditis.\n3. Enteroviruses, including coxsackievirus and echovirus, are commonly associated with subacute thyroiditis.\n4. Herpesviruses like herpes simplex virus and human herpesvirus 6 have been linked to subacute thyroiditis.\n5. HIV, hepatitis viruses, and measles virus have also been implicated in the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis typically occurs in the setting of a viral infection.",
      "Respiratory viruses such as influenza, adenovirus, and parainfluenza have been implicated in the development of subacute thyroiditis.",
      "Enteroviruses, including coxsackievirus and echovirus, are commonly associated with subacute thyroiditis.",
      "Herpesviruses like herpes simplex virus and human herpesvirus 6 have been linked to subacute thyroiditis.",
      "HIV, hepatitis viruses, and measles virus have also been implicated in the development of subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: HIV, hepatitis viruses, and measles virus are not commonly associated with subacute thyroiditis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including inflammation, immune response, and cell survival. EIF2AK2 (Eukaryotic Translation Initiation Factor 2- Associated Kinase 2) is an enzyme that phosphorylates the alpha subunit of the eukaryotic translation initiation factor 2 (eIF2), leading to the inhibition of protein synthesis and the activation of autophagy. While the relationship between STAT3 and EIF2AK2 has not been fully characterized, recent studies suggest that STAT3 may be involved in EIF2AK2-dependent suppression of autophagy.\nOne study published in the journal Nature Communications in 2019 found that STAT3 regulates the expression of EIF2AK2 and promotes its phosphorylation and activity (1). The study found that inhibition of STAT3 led to a decrease in EIF2AK2 phosphorylation and an increase in autophagy, suggesting that STAT3 plays a negative regulatory role in EIF2AK2-mediated suppression of autophagy.\nAnother study published in the journal Cell Reports in 2020 found that STAT3 is required for EIF2AK2-mediated suppression of autophagy in response to DNA damage (2). The study found that inhibition of STAT3 led to a decrease in EIF2AK2-mediated autophagy and an increase in cell death, suggesting that STAT3 is essential for EIF2AK2 to suppress autophagy in response to DNA damage.\nFurthermore, a recent review article published in the journal Cellular and Molecular Life Sciences highlighted the potential of STAT3 as a therapeutic target in cancer, emphasizing its role in regulating autophagy and energy metabolism (3). The review suggested that inhibition of STAT3 may be a promising strategy for enhancing cancer therapy by promoting autophagy and inhibiting pro-survival signaling pathways.\nIn summary, while the exact mechanisms by which STAT3 regulates EIF2AK2-dependent suppression of autoph",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is a transcription factor involved in inflammation, immune response, and cell survival.\n2. EIF2AK2 is an enzyme that phosphorylates the alpha subunit of eIF2, leading to inhibition of protein synthesis and activation of autophagy.\n3. A study in Nature Communications in 2019 found that STAT3 regulates the expression and activity of EIF2AK2, negatively impacting autophagy.\n4. A study in Cell Reports in 2020 found that STAT3 is required for EIF2AK2-mediated suppression of autophagy in response to DNA damage.\n5. Inhibition of STAT3 could be a potential therapeutic strategy in cancer by promoting autophagy, as suggested by a review article in Cellular and Molecular Life Sciences.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is a transcription factor involved in inflammation, immune response, and cell survival.",
      "EIF2AK2 is an enzyme that phosphorylates the alpha subunit of eIF2, leading to inhibition of protein synthesis and activation of autophagy.",
      "A study in Nature Communications in 2019 found that STAT3 regulates the expression and activity of EIF2AK2, negatively impacting autophagy.",
      "A study in Cell Reports in 2020 found that STAT3 is required for EIF2AK2-mediated suppression of autophagy in response to DNA damage.",
      "Inhibition of STAT3 could be a potential therapeutic strategy in cancer by promoting autophagy, as suggested by a review article in Cellular and Molecular Life Sciences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre software tool is a powerful genomic analysis tool that can be used for a variety of purposes in the field of genomics. Here are some of the ways in which Theatre can be used for genomic analysis:\n1. Genome Visualization: Theatre can be used to visualize genome data in a 3D format. This can help researchers to better understand the structure and organization of the genome, and to identify patterns and relationships between different genetic elements.\n2. Genome Assembly: Theatre can be used to assemble genomes from sequencing data. This involves using computational algorithms to reconstruct the original DNA sequence of an organism from fragmented DNA sequencing data.\n3. Genome Annotation: Theatre can be used to annotate genomes by identifying and labeling various features within the genome, such as genes, regulatory elements, and repetitive sequences.\n4. Gene Prediction: Theatre can be used to predict the location and sequence of genes within a genome. This can help researchers to identify potential drug targets and to understand the function of genes involved in various biological processes.\n5. Mutation Analysis: Theatre can be used to identify and characterize mutations within a genome. This can help researchers to understand the genetic basis of diseases and to design drugs that target specific mutations.\n6. Genome Comparison: Theatre can be used to compare genomes between different organisms. This can help researchers to identify similarities and differences between organisms, and to understand how these similarities and differences relate to their evolutionary history.\n7. Genome Design: Theatre can be used to design genomes for organisms that do not yet have a fully understood genome. This can involve using computational algorithms to predict the locations and sequences of genes and other genetic elements, and to design a genome that meets specific functional requirements.\n8. Genome Editing: Theatre can be used to edit genomes by making targeted changes to the DNA sequence. This can involve using techniques such as CRISPR/Cas9 to introduce specific mutations or to delete or modify genes.\n9. Genome Engineering: Theatre can be used to engineer genomes by introducing specific genetic modifications. This can involve using techniques such as gene knockout or gene insertion to create organisms with specific functional genetic changes.\n10. Genome Safety: Theatre can be used",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre software tool can visualize genome data in a 3D format.\n2. Theatre can assemble genomes from sequencing data using computational algorithms.\n3. Genome annotation can be performed with Theatre by identifying and labeling features within the genome.\n4. Theatre software tool can predict the location and sequence of genes within a genome.\n5. Mutation analysis can be conducted using Theatre to identify and characterize mutations within a genome.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre software tool can visualize genome data in a 3D format.",
      "Theatre can assemble genomes from sequencing data using computational algorithms.",
      "Genome annotation can be performed with Theatre by identifying and labeling features within the genome.",
      "Theatre software tool can predict the location and sequence of genes within a genome.",
      "Mutation analysis can be conducted using Theatre to identify and characterize mutations within a genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The Smith-Waterman algorithm for the alignment of two sequences has an execution time of O(n^2), where n is the length of the shorter sequence.\nTo understand why, let's break down the algorithm's main steps:\n1. Compute the similarity matrix: The algorithm starts by computing a similarity matrix between the two sequences, where the similarity between two positions i and j is given by the dot product of the two sequences' values at those positions. This step takes O(n^2) time.\n2. Find the maximum value in the similarity matrix: After computing the similarity matrix, the algorithm finds the maximum similarity value among all positions in the matrix. This step takes O(n) time.\n3. Find the alignment: starting from the position with the maximum similarity value, the algorithm scans the shorter sequence and finds the first position where the similarity value is greater than or equal to a given threshold. This step takes O(n) time.\n4. Check for completeness: After finding the first position in the shorter sequence, the algorithm checks whether the alignment is complete by scanning the rest of the shorter sequence. This step takes O(n) time.\n5. Repeat the process: If the alignment is not complete, the algorithm repeats steps 3 and 4 until the alignment is complete.\nOverall, the execution time of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2 + n), where n is the length of the shorter sequence. However, in practice, the actual execution time may be faster due to optimizations and caching.\nIt's worth noting that there are more efficient algorithms for sequence alignment, such as the Needleman-Wunsch algorithm, which has an execution time of O(n log n).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm has an execution time of O(n^2).\n2. The length of the shorter sequence is used to determine the value of n in the execution time.\n3. The algorithm involves computing a similarity matrix, which takes O(n^2) time.\n4. Finding the maximum value in the similarity matrix takes O(n) time.\n5. The Needleman-Wunsch algorithm has an execution time of O(n log n).",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm has an execution time of O(n^2).",
      "The length of the shorter sequence is used to determine the value of n in the execution time.",
      "The algorithm involves computing a similarity matrix, which takes O(n^2) time.",
      "Finding the maximum value in the similarity matrix takes O(n) time.",
      "The Needleman-Wunsch algorithm has an execution time of O(n log n)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Finding the maximum value in the similarity matrix takes O(n^2) time as you have to check all elements in the matrix.\n5. FALSE [correction]: The Needleman-Wunsch algorithm has an execution time of O(n^2).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Flavocyclin Related Protein 1) is a member of the SLC (Solute Carrier) family of transmembrane proteins. Specifically, FLVCR1 is a member of the SLC12 (Sodium-Dependent Vitamin C Transporter) subfamily within the SLC family.\nThe SLC12 subfamily is responsible for the transport of vitamins, amino acids, and other nutrients across cellular membranes. FLVCR1 is one of the membrane proteins that mediate the transport of vitamin C (ascorbate) in cells. It is primarily expressed in the small intestine and plays a critical role in maintaining the proper concentration of vitamin C in the body.\nIn summary, FLVCR1 is a member of the SLC12 subfamily of the SLC family of proteins, specifically involved in the transport of vitamin C in cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 (Flavocyclin Related Protein 1) is a member of the SLC (Solute Carrier) family of transmembrane proteins.\n2. FLVCR1 is a member of the SLC12 (Sodium-Dependent Vitamin C Transporter) subfamily.\n3. The SLC12 subfamily is responsible for the transport of vitamins, amino acids, and other nutrients across cellular membranes.\n4. FLVCR1 mediates the transport of vitamin C (ascorbate) in cells.\n5. FLVCR1 is primarily expressed in the small intestine and plays a critical role in maintaining the proper concentration of vitamin C in the body.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 (Flavocyclin Related Protein 1) is a member of the SLC (Solute Carrier) family of transmembrane proteins.",
      "FLVCR1 is a member of the SLC12 (Sodium-Dependent Vitamin C Transporter) subfamily.",
      "The SLC12 subfamily is responsible for the transport of vitamins, amino acids, and other nutrients across cellular membranes.",
      "FLVCR1 mediates the transport of vitamin C (ascorbate) in cells.",
      "FLVCR1 is primarily expressed in the small intestine and plays a critical role in maintaining the proper concentration of vitamin C in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 (Feline Leukemia Virus subgroup C Receptor) is not a member of the SLC (Solute Carrier) family but rather the Major Facilitator Superfamily (MFS) of transporters.\n2. FALSE [correction]: FLVCR1 is not a member of the SLC12 (Sodium-Dependent Vitamin C Transporter) subfamily. It is a heme transporter.\n3. TRUE\n4. FALSE [correction]: FLVCR1 does not mediate the transport of vitamin C (ascorbate) in cells. It is involved in heme export from the cell.\n5. FALSE [correction]: FLVCR1 is primarily expressed in the intestine, liver, and macrophages but is not primarily responsible for maintaining the proper concentration of vitamin C in the body.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythroid differentiation. The biotinylation tagging approach has been widely used to identify GATA-1 interacting partners. Here are some of the key interacting partners of GATA-1 that have been identified using this approach:\n1. running box protein 1 (RBP1): RBP1 is a splicing factor that recognizes and binds to the introns of GATA-1 mRNA and enhances its stability. Biotinylation tagging studies have shown that RBP1 binds to GATA-1 with high affinity and promotes its stability and localization in the nucleus.\n2. hnRNP A1: hnRNP A1 is a heteronuclear ribonucleoprotein that recognizes and binds to the 3' untranslated region (UTR) of GATA-1 mRNA. Biotinylation tagging studies have shown that hnRNP A1 binds to GATA-1 with high affinity and regulates its translation by recruiting ribosomes.\n3. TAF3: TAF3 (TATA-box protein 3) is a general transcription factor that binds to the TATA box of promoter regions and helps to recruit RNA polymerase II. Biotinylation tagging studies have shown that TAF3 also binds to GATA-1 with high affinity and regulates its transcriptional activity.\n4. CBP80/90: CBP80/90 (CREB-binding protein) is a histone acetyltransferase that regulates chromatin structure and gene expression. Biotinylation tagging studies have shown that CBP80/90 binds to GATA-1 with high affinity and acetylates histones H3 and H4, leading to increased chromatin accessibility and GATA-1 transcriptional activity.\n5. p300: p300 is another histone acetyltransferase that regulates chromatin structure and gene expression. Biotinylation tagging studies have shown that p300 binds to GATA-1 with high affinity and acet",
    "llama-2-7b-chat-hf_fact_raw": "1. Running box protein 1 (RBP1) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n2. Heteronuclear ribonucleoprotein A1 (hnRNP A1) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n3. TATA-box protein 3 (TAF3) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n4. CREB-binding protein (CBP80/90) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n5. P300 has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_fact": [
      "Running box protein 1 (RBP1) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "Heteronuclear ribonucleoprotein A1 (hnRNP A1) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "TATA-box protein 3 (TAF3) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "CREB-binding protein (CBP80/90) has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "P300 has been identified as a GATA-1 interacting partner using the biotinylation tagging approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The determination of whether these statements are true or false requires specific knowledge of the subject matter and data obtained from the biotinylation tagging approach. Without access to this data, it is not possible to accurately determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-box binding protein 10) and GATA1 are two important transcription factors that play critical roles in regulating gene expression during various cellular processes. When these two proteins interact, they affect the activity of genes involved in different cellular functions, including cell proliferation, differentiation, and responses to stress. In this answer, we will discuss the outcome of TAF10 interacting with GATA1 and their joint impact on gene expression.\nTAF10 is a component of the basal transcriptional machinery of RNA polymerase II (RNAPII) and is involved in the initiation of transcription. It binds to the TATA box, a specific DNA sequence found upstream of the transcription start site, and helps recruit RNAPII to the promoter region. GATA1, on the other hand, is a zinc finger protein that recognizes and binds to specific DNA sequences, known as GATA boxes, which are located upstream of the transcription start site. GATA1 plays a crucial role in regulating the expression of genes involved in erythropoiesis, specifically during the development and maturation of red blood cells.\nInteraction between TAF10 and GATA1 has been observed in various cell types, including erythroid cells. When these two proteins interact, they cooperate to enhance the recruitment of RNAPII to the promoter region and activate the transcription of GATA1-regulated genes. This outcome is mediated by several mechanisms, including:\n1. Enhanced RNAPII recruitment: TAF10 binds to the TATA box and helps recruit RNAPII to the promoter region. When TAF10 interacts with GATA1, it augments the recruitment of RNAPII by providing additional bindings sites for the complex. This leads to a greater amount of RNAPII available for transcription initiation, resulting in increased gene expression.\n2. Concerted transcription initiation: TAF10 and GATA1 work together to facilitate the initiation of transcription by promoting the formation of transcription complexes. By interacting directly with RNAPII, TAF10 helps to establish the correct orientation of the transcription complex, while",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 is a component of the basal transcriptional machinery of RNA polymerase II (RNAPII).\n2. TAF10 binds to the TATA box, a specific DNA sequence found upstream of the transcription start site.\n3. GATA1 is a zinc finger protein that binds to GATA boxes, located upstream of the transcription start site.\n4. GATA1 plays a crucial role in regulating the expression of genes involved in erythropoiesis.\n5. When TAF10 interacts with GATA1, they cooperate to enhance the recruitment of RNAPII to the promoter region and activate the transcription of GATA1-regulated genes.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 is a component of the basal transcriptional machinery of RNA polymerase II (RNAPII).",
      "TAF10 binds to the TATA box, a specific DNA sequence found upstream of the transcription start site.",
      "GATA1 is a zinc finger protein that binds to GATA boxes, located upstream of the transcription start site.",
      "GATA1 plays a crucial role in regulating the expression of genes involved in erythropoiesis.",
      "When TAF10 interacts with GATA1, they cooperate to enhance the recruitment of RNAPII to the promoter region and activate the transcription of GATA1-regulated genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: It is TBP (TATA-binding protein), not TAF10, that binds to the TATA box.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare professionals with clinical decision-making support by analyzing patient data and providing evidence-based recommendations. Here are some examples of DSS for chronic pain management:\n1. Chronic Pain Guidelines (CPG): This DSS is designed to help primary care clinicians manage chronic pain by providing evidence-based guidelines and recommendations for pain evaluation, diagnosis, and treatment. CPG uses a logic-based decision support system to generate personalized treatment plans based on the patient's medical history, physical examination findings, and laboratory results.\n2. PainCare: This DSS is a comprehensive pain management system that provides a step-by-step approach to evaluating and managing chronic pain. PainCare includes a symptom checker, pain assessment tools, and a treatment planning module that helps clinicians develop personalized treatment plans.\n3. PAINSights: This DSS is a pain management software that uses advanced analytics and machine learning algorithms to help clinicians identify the underlying causes of chronic pain. PAINSights includes a clinical decision support module that provides recommendations for pain diagnosis, evaluation, and treatment.\n4. PainSense: This DSS is a point-of-care platform that helps clinicians diagnose and manage chronic pain through a series of clinical questions and algorithms. PainSense includes a decision support module that provides evidence-based recommendations for pain treatment and management.\n5. Pain Management Clinical Decision Support (PMC-CDS): This DSS is a web-based system that provides clinicians with decision support for chronic pain management. PMC-CDS includes a comprehensive library of clinical guidelines, decision support algorithms, and a patient education module.\n6. Chronic Pain Management System (CPMS): This DSS is designed to help clinicians manage chronic pain through a comprehensive evaluation and treatment plan. CPMS includes a clinical decision support module that provides recommendations for pain diagnosis, evaluation, and treatment based on the patient's medical history, physical examination findings, and laboratory results.\n7. Paingine: This DSS is a cloud-based platform that provides clinicians",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems for chronic pain management are computer-based systems that provide healthcare professionals with clinical decision-making support.\n2. Chronic Pain Guidelines (CPG) is a decision support system that offers evidence-based guidelines for pain evaluation, diagnosis, and treatment.\n3. PainCare is a comprehensive pain management system with a symptom checker, pain assessment tools, and a treatment planning module.\n4. PAINSights is a pain management software that uses advanced analytics and machine learning algorithms for pain diagnosis and treatment recommendations.\n5. Pain Management Clinical Decision Support (PMC-CDS) is a web-based system with a library of clinical guidelines and decision support algorithms.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems for chronic pain management are computer-based systems that provide healthcare professionals with clinical decision-making support.",
      "Chronic Pain Guidelines (CPG) is a decision support system that offers evidence-based guidelines for pain evaluation, diagnosis, and treatment.",
      "PainCare is a comprehensive pain management system with a symptom checker, pain assessment tools, and a treatment planning module.",
      "PAINSights is a pain management software that uses advanced analytics and machine learning algorithms for pain diagnosis and treatment recommendations.",
      "Pain Management Clinical Decision Support (PMC-CDS) is a web-based system with a library of clinical guidelines and decision support algorithms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that plays a crucial role in angiogenesis, the process of blood vessel formation. As an assistant, I must provide you with detailed information on the subcellular localization of angiogenin.\nAngiogenin is a secreted protein that is primarily localized to the cytoplasm of endothelial cells, which are the cells that line blood vessels. However, it can also be found in the nucleus of these cells, where it regulates gene expression and contributes to the pro-angiogenic phenotype of endothelial cells.\nIn addition, angiogenin has been shown to localize to the plasma membrane of endothelial cells, where it can interact with cell surface proteins and modulate signaling pathways involved in angiogenesis.\nStudies have also suggested that angiogenin may be localized to specific subcellular structures within endothelial cells, such as the Golgi apparatus and the endoplasmic reticulum. For example, one study found that angiogenin is concentrated in the Golgi apparatus of endothelial cells in the early stages of angiogenesis, where it regulates the expression of genes involved in blood vessel formation.\nFurthermore, angiogenin has been shown to be localized to the extracellular space, where it can interact with other proteins and modulate angiogenesis-related processes.\nIn summary, the subcellular localization of angiogenin is primarily in the cytoplasm of endothelial cells, but it can also be found in the nucleus, plasma membrane, Golgi apparatus, and endoplasmic reticulum. The precise subcellular localization of angiogenin may vary depending on the specific stage of angiogenesis and the cellular context in which it is expressed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that plays a role in angiogenesis, the formation of blood vessels.\n2. Angiogenin is primarily localized to the cytoplasm of endothelial cells.\n3. Angiogenin can also be found in the nucleus of endothelial cells.\n4. Angiogenin localizes to the plasma membrane, Golgi apparatus, and endoplasmic reticulum of endothelial cells.\n5. Studies suggest angiogenin regulates gene expression and contributes to the pro-angiogenic phenotype of endothelial cells.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that plays a role in angiogenesis, the formation of blood vessels.",
      "Angiogenin is primarily localized to the cytoplasm of endothelial cells.",
      "Angiogenin can also be found in the nucleus of endothelial cells.",
      "Angiogenin localizes to the plasma membrane, Golgi apparatus, and endoplasmic reticulum of endothelial cells.",
      "Studies suggest angiogenin regulates gene expression and contributes to the pro-angiogenic phenotype of endothelial cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Angiogenin does not localize to the plasma membrane, Golgi apparatus, and endoplasmic reticulum of endothelial cells.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is an anti-anginal medication that is primarily used to treat chronic angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. While its primary mechanism of action is to increase blood flow to the heart muscle, ranolazine has been shown to have secondary effects on kinase signaling activation in the heart.\nKinase signaling is a crucial pathway involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. In the heart, kinase signaling is involved in the regulation of contraction, relaxation, and excitation-contraction coupling. Dysregulation of kinase signaling has been implicated in various heart diseases, including cardiac hypertrophy, heart failure, and arrhythmias.\nRanolazine has been shown to activate the G-protein-coupled kinase (GPK) signaling pathway in the heart, which is involved in the regulation of ion channels and excitation-contraction coupling. Activation of GPK signaling by ranolazine leads to increased activity of the ion channels, resulting in enhanced excitation-contraction coupling and improved cardiac function.\nStudies have shown that ranolazine selectively activates the GPK signaling pathway without affecting other kinase signaling pathways, such as the protein kinase B (PKB) pathway, which is involved in the regulation of glucose metabolism and insulin signaling. This selectivity suggests that ranolazine may be a useful therapeutic agent for treating heart conditions that are associated with dysregulation of specific kinase signaling pathways.\nIn addition, ranolazine has been shown to reduce oxidative stress in the heart, which is a major contributor to the development of heart diseases. Oxidative stress leads to the activation of pro-inflammatory signaling pathways, which can further exacerbate cardiac dysfunction. By reducing oxidative stress, ranolazine may help to protect the heart against disease.\nOverall, the effects of ranolazine on kinase signaling activation in the heart are complex and involve the activation of multiple signaling pathways. While its primary mechanism of action is to increase blood flow to the",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is used to treat chronic angina pectoris, which is characterized by chest pain or discomfort due to reduced blood flow to the heart muscle.\n2. Kinase signaling in the heart is involved in the regulation of contraction, relaxation, and excitation-contraction coupling.\n3. Ranolazine has been shown to activate the G-protein-coupled kinase (GPK) signaling pathway in the heart.\n4. Ranolazine selectively activates the GPK signaling pathway without affecting other kinase signaling pathways such as the protein kinase B (PKB) pathway.\n5. Ranolazine has been shown to reduce oxidative stress in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is used to treat chronic angina pectoris, which is characterized by chest pain or discomfort due to reduced blood flow to the heart muscle.",
      "Kinase signaling in the heart is involved in the regulation of contraction, relaxation, and excitation-contraction coupling.",
      "Ranolazine has been shown to activate the G-protein-coupled kinase (GPK) signaling pathway in the heart.",
      "Ranolazine selectively activates the GPK signaling pathway without affecting other kinase signaling pathways such as the protein kinase B (PKB) pathway.",
      "Ranolazine has been shown to reduce oxidative stress in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Ranolazine has been shown to inhibit the late sodium current in the heart, not activate the G-protein-coupled kinase (GPK) signaling pathway.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Vsr endonuclease is aociated with the SOS response of E. coli and plays a distinct role in the repair of DNA damage for quick repair, independently of the growth phase. \nThe SOS response is a phenotype of bacteria that helps in dealing with DNA damage. It is a complex process that involves the activation of many repair genes to quickly repair DNA double-strand breaks or interstrand crosslinks. The Vsr endonuclease is distinctly activated in this process to specifically cleave a DNA strand at fixed intervals (16-18 nt) to generate 3' OH and 5' phosphate termini, thereby creating a cohort of 25-30 nt in length. \nThe regulation of Vсr endonuclease activity during DNA repair is complex and highly regulated by the cell. In E. coli, the Vсr endonuclease is primarily activated during DNA repair, particularly in the SOS response, and has been shown to be independent of the growth phase. However, studies have shown that during the stationary phase of growth, the ⍺ subunit of the Vсr endonuclease may undergo a conformational change that reduces its interaction with the VсrB subunit. This change in interactions decreases the catalytic activity of Vсr endonuclease during the later stationary phase.\nIn conclusion, the regulation of Vсr endonuclease during DNA repair is complex and highly regulated by cellular conditions. While the activity of Vсr endonuclease during DNA repair is independent of the growth phase in E. coli, there may be changes in the subunit interactions that can influence its catalytic activity during different growth phases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease is associated with the SOS response of E. coli and plays a role in the repair of DNA damage.\n2. The regulation of Vsr endonuclease activity during DNA repair is independent of the growth phase in E. coli.\n3. The Vsr endonuclease cleaves DNA strands at 16-18 nucleotide intervals to generate 3' OH and 5' phosphate termini.\n4. The SOS response involves activation of repair genes to address DNA double-strand breaks or interstrand crosslinks.\n5. The α subunit of the Vsr endonuclease may undergo a conformational change during the stationary phase, affecting its interaction with the VsrB subunit and catalytic activity.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease is associated with the SOS response of E. coli and plays a role in the repair of DNA damage.",
      "The regulation of Vsr endonuclease activity during DNA repair is independent of the growth phase in E. coli.",
      "The Vsr endonuclease cleaves DNA strands at 16-18 nucleotide intervals to generate 3' OH and 5' phosphate termini.",
      "The SOS response involves activation of repair genes to address DNA double-strand breaks or interstrand crosslinks.",
      "The α subunit of the Vsr endonuclease may undergo a conformational change during the stationary phase, affecting its interaction with the VsrB subunit and catalytic activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The regulation of Vsr endonuclease activity during DNA repair is dependent on the growth phase in E. coli.\n3. FALSE [correction]: The Vsr endonuclease cleaves DNA strands at mismatched deoxyribose-phosphate sites, not at specific nucleotide intervals.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Computational tools for the prediction of beta-barrel transmembrane proteins are software programs that use various algorithms and techniques to predict the structure and function of these proteins. Here are some commonly used computational tools for beta-barrel transmembrane protein prediction:\n1. TMRELIB: TMRELIB is a widely used tool for beta-barrel transmembrane protein prediction. It uses a combination of machine learning algorithms and structural bioinformatics tools to predict the transmembrane spanners and the topology of the protein. TMRELIB can predict the number of transmembrane helices, the type of transmembrane helices (β-barrel or non-β), and the subcellular localization of the protein.\n2. Promise: Promise is a tool that uses a combination of sequence analysis, molecular dynamics simulation, and machine learning to predict the structure and function of transmembrane proteins. It can predict the type of transmembrane helices, the number of transmembrane helices, and the subcellular localization of the protein. Promise also provides information on the protein's binding sites and the types of ligands it binds.\n3. Predict-Tm: Predict-Tm is a tool that uses a combination of sequence analysis and machine learning to predict the number and type of transmembrane helices in a protein. It can also predict the subcellular localization of the protein and provide information on the protein's structural constraints.\n4. TMHMM: TMHMM is a tool that uses a combination of sequence analysis and machine learning to predict the number and type of transmembrane helices in a protein. It can also predict the subcellular localization of the protein and provide information on the protein's structural constraints.\n5. Beta-□ Predictor: Beta-□ Predictor is a tool that uses a combination of sequence analysis and machine learning to predict the type of transmembrane helices in a protein. It can also predict the subcellular localization of the protein and provide information on the protein's structural constraints.\n6. Transmembrane Helix Predictor (THP): THP is a tool that uses a combination of sequence analysis and machine learning to predict the number and type of transmembrane helices in a protein. It can also predict the subcellular",
    "llama-2-7b-chat-hf_fact_raw": "1. TMRELIB is a computational tool used for beta-barrel transmembrane protein prediction.\n2. Promise is a computational tool that predicts the structure and function of transmembrane proteins using sequence analysis, molecular dynamics simulation, and machine learning.\n3. Predict-Tm is a computational tool that predicts the number and type of transmembrane helices in a protein.\n4. TMHMM is a computational tool that predicts the number and type of transmembrane helices in a protein.\n5. Beta-□ Predictor is a computational tool that predicts the type of transmembrane helices in a protein.",
    "llama-2-7b-chat-hf_fact": [
      "TMRELIB is a computational tool used for beta-barrel transmembrane protein prediction.",
      "Promise is a computational tool that predicts the structure and function of transmembrane proteins using sequence analysis, molecular dynamics simulation, and machine learning.",
      "Predict-Tm is a computational tool that predicts the number and type of transmembrane helices in a protein.",
      "TMHMM is a computational tool that predicts the number and type of transmembrane helices in a protein.",
      "Beta-□ Predictor is a computational tool that predicts the type of transmembrane helices in a protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Beta-□ Predictor is a computational tool that predicts the presence and location of beta-barrel transmembrane regions in a protein, not the type of transmembrane helices.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is a system used to classify mood disorders, specifically bipolar disorder. It was developed by Antonio Galassi in the 1920s and is based on the idea that bipolar disorder can be subdivided into several distinct subtypes based on the duration and severity of symptoms.\nThe Galassi classification system recognizes five subtypes of bipolar disorder:\n1. Type I: Bipolar I disorder - characterized by at least one manic episode, which can be acute or hypomanic.\n2. Type II: Bipolar II disorder - characterized by at least one major depressive episode and at least one hypomanic episode.\n3. Type III: Cyclothymic disorder - characterized by periods of hypomania and depression that last at least 2 years.\n4. Type IV: Mixed episodes - characterized by both manic and depressive symptoms occurring simultaneously.\n5. Type V: Other specified and unspecified bipolar and related disorders - includes subtypes that do not fit into the above categories, such as bipolar disorder not otherwise specified (NOS) or bipolar disorder with melancholic features.\nIt's important to note that while the Galassi classification system is widely used, it has been criticized for being overly complex and not completely reliable. Some researchers argue that the subtypes do not have clear-cut definitions and do not accurately reflect the heterogeneity of bipolar disorder. As a result, some mental health professionals prefer to use a simpler classification system, such as the World Health Organization's (WHO) International Classification of Diseases (ICD-10) or the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for bipolar disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is a system used to classify mood disorders, specifically bipolar disorder.\n2. It was developed by Antonio Galassi in the 1920s.\n3. The Galassi classification system recognizes five subtypes of bipolar disorder.\n4. Type I of the Galassi classification is characterized by at least one manic episode.\n5. Some mental health professionals prefer to use the WHO's ICD-10 or the DSM-5 criteria for bipolar disorder instead of the Galassi classification system.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is a system used to classify mood disorders, specifically bipolar disorder.",
      "It was developed by Antonio Galassi in the 1920s.",
      "The Galassi classification system recognizes five subtypes of bipolar disorder.",
      "Type I of the Galassi classification is characterized by at least one manic episode.",
      "Some mental health professionals prefer to use the WHO's ICD-10 or the DSM-5 criteria for bipolar disorder instead of the Galassi classification system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Galassi classification is a system used to classify fractures of the tibia plateau, not mood disorders.\n2. UNKNOWN\n3. FALSE [correction]: Galassi classification system recognizes three different types of fractures based on the extent of damage to the tibia plateau.\n4. FALSE [correction]: Type I of the Galassi classification refers to a split of the lateral tibial plateau without depression, not a manic episode.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Thye grenulomatosis, is a rare genetic disorder characterized by the accumulation of extra cellular deposits of a type of protein called granulin. Here are some common features of Shapiro syndrome:\n1. Hypopigmentation: In Shapiro syndrome, there is loss of pigmentation (hypopigmentation) in the skin, hair, and eyes. This can lead to a lightening of the skin, hair, and eye color.\n2. Slow growth and short stature: Children with Shapiro syndrome tend to grow slowly and are shorter than average.\n3. Skin thickening: The skin can become thick and leathery, particularly on the palms and soles.\n4. Nail abnormalities: Children with Shapiro syndrome may have thin, brittle nails that are prone to breaking.\n5. Eye abnormalities: Some people with Shapiro syndrome may have eye problems, including microphthalmia (small eyes), cataracts, and glaucoma.\n6. Intellectual disability: Many people with Shapiro syndrome have intellectual disability, which can range from mild to severe.\n7. Respiratory problems: People with Shapiro syndrome may experience respiratory problems, including chronic lung disease and respiratory infections.\n8. Orthopedic problems: Children with Shapiro syndrome may experience joint dislocations, contractures, and other orthopedic problems.\n9. Gastrointestinal problems: Some people with Shapiro syndrome may experience gastrointestinal problems, including constipation and gastroesophageal reflux disease.\n10. Hearing loss: Some people with Shapiro syndrome may experience hearing loss.\n11. Endocrine problems: People with Shapiro syndrome may experience endocrine problems, including growth hormone deficiency and thyroid problems.\n12. Increased risk of infections: People with Shapiro syndrome may have an increased risk of infections due to their impaired immune system.\n13. Cardiac problems: Some people with Shapiro syndrome may experience cardiac problems",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder characterized by the accumulation of extra cellular deposits of a type of protein called granulin.\n2. A common feature of Shapiro syndrome is hypopigmentation in the skin, hair, and eyes.\n3. Children with Shapiro syndrome tend to grow slowly and are shorter than average.\n4. Skin can become thick and leathery in individuals with Shapiro syndrome, particularly on the palms and soles.\n5. People with Shapiro syndrome may have intellectual disability, which can range from mild to severe.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder characterized by the accumulation of extra cellular deposits of a type of protein called granulin.",
      "A common feature of Shapiro syndrome is hypopigmentation in the skin, hair, and eyes.",
      "Children with Shapiro syndrome tend to grow slowly and are shorter than average.",
      "Skin can become thick and leathery in individuals with Shapiro syndrome, particularly on the palms and soles.",
      "People with Shapiro syndrome may have intellectual disability, which can range from mild to severe."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is a rare neurological disorder characterized by recurrent episodes of excessive sweating, hypothermia, and agenesis of the corpus callosum.\n2. FALSE [correction]: Hypopigmentation is not a common feature of Shapiro syndrome.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG-1 gene) is a gene that plays a crucial role in the maintenance of genomic stability and the regulation of mitotic progression in eukaryotic cells. Mutations in the BRAG1 gene have been implicated in various diseases, including:\n1. Cancer: Mutations in BRAG1 have been observed in various types of cancer, including breast, ovarian, lung, and colon cancer. These mutations can lead to the loss of BRAG1 protein function, which can contribute to the development and progression of cancer.\n2. familial adenomatous polyposis (FAP): FAP is a rare genetic disorder that causes the growth of numerous non-cancerous (benign) tumors in the colon and rectum. Mutations in the BRAG1 gene are a common cause of FAP, accounting for about 50% of cases.\n3. Hereditary breast and ovarian cancer (HBOC): BRAG1 mutations have also been found in individuals with HBOC, which is a rare inherited disorder that increases the risk of developing breast, ovarian, and other cancers.\n4. Cowden syndrome: Cowden syndrome is a rare genetic disorder that affects the growth and development of various organs, including the skin, mucous membranes, and internal organs. Mutations in the BRAG1 gene are a common cause of Cowden syndrome.\n5. Neurodegenerative diseases: Recent studies have suggested that BRAG1 mutations may also play a role in the development of certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\nIt's worth noting that BRAG1 mutations can also occur spontaneously in individuals without a family history of these diseases, and the likelihood of developing cancer or other diseases associated with BRAG1 mutations can vary depending on the specific mutation and the individual's genetic background.\nIn summary, mutations in the BRAG1 gene have been linked to various diseases, including cancer, FAP, HBOC, Cowden syndrome, and possibly neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the BRAG1 gene have been observed in various types of cancer, including breast, ovarian, lung, and colon cancer.\n2. Familial adenomatous polyposis (FAP) is commonly caused by mutations in the BRAG1 gene, accounting for about 50% of cases.\n3. Hereditary breast and ovarian cancer (HBOC) is associated with BRAG1 mutations.\n4. Cowden syndrome is commonly caused by mutations in the BRAG1 gene.\n5. BRAG1 mutations may play a role in the development of certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the BRAG1 gene have been observed in various types of cancer, including breast, ovarian, lung, and colon cancer.",
      "Familial adenomatous polyposis (FAP) is commonly caused by mutations in the BRAG1 gene, accounting for about 50% of cases.",
      "Hereditary breast and ovarian cancer (HBOC) is associated with BRAG1 mutations.",
      "Cowden syndrome is commonly caused by mutations in the BRAG1 gene.",
      "BRAG1 mutations may play a role in the development of certain neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Familial adenomatous polyposis (FAP) is commonly caused by mutations in the APC gene, not the BRAG1 gene.\n3. FALSE [correction]: Hereditary breast and ovarian cancer (HBOC) is associated with mutations in the BRCA1 gene, not BRAG1.\n4. FALSE [correction]: Cowden syndrome is commonly caused by mutations in the PTEN gene, not the BRAG1 gene.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Great! I'm here to help you with your question.\nProtein phosphatase 1 (PP1) is an enzyme that plays a crucial role in regulating various cellular processes, including metabolism, signaling pathways, and protein synthesis. PP1 is a serine/threonine protein phosphatase that dephosphorylates a variety of proteins, leading to changes in their activity or stability.\nThe main inhibitor of PP1 is the protein called procaspase-9. Procaspase-9 is a cysteine protease that is involved in the regulation of apoptosis (programmed cell death) and inflammation. It has been shown that procaspase-9 can bind to and inhibit the activity of PP1, thereby preventing PP1 from dephosphorylating and activating various pro-apoptotic proteins.\nOther proteins have also been identified as potential inhibitors of PP1, including protein tyrosine phosphatase 1B (PTP1B), protein tyrosine phosphatase 4 (PTP4), and protein tyrosine phosphatase 5 (PTP5). However, procaspase-9 is the most well-studied and well- characterized inhibitor of PP1.\nIt is worth noting that PP1 has also been shown to have regulatory interactions with other proteins, including protein kinases and phosphatases, which can affect its activity and function. Therefore, the regulation of PP1 is complex and involves multiple layers of regulation, including both positive and negative regulators.\nI hope this information helps you in your research on PP1 and its regulation! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein phosphatase 1 (PP1) is an enzyme that regulates various cellular processes, including metabolism, signaling pathways, and protein synthesis.\n2. PP1 is a serine/threonine protein phosphatase.\n3. The main inhibitor of PP1 is the protein procaspase-9.\n4. Procaspase-9 is a cysteine protease involved in regulating apoptosis and inflammation.\n5. Procaspase-9 binds to and inhibits the activity of PP1, preventing it from dephosphorylating and activating pro-apoptotic proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Protein phosphatase 1 (PP1) is an enzyme that regulates various cellular processes, including metabolism, signaling pathways, and protein synthesis.",
      "PP1 is a serine/threonine protein phosphatase.",
      "The main inhibitor of PP1 is the protein procaspase-9.",
      "Procaspase-9 is a cysteine protease involved in regulating apoptosis and inflammation.",
      "Procaspase-9 binds to and inhibits the activity of PP1, preventing it from dephosphorylating and activating pro-apoptotic proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The main inhibitor of PP1 is not procaspase-9, but inhibitor-1 (I-1) and inhibitor-2 (I-2) proteins.\n4. TRUE\n5. FALSE [correction]: Procaspase-9 does not bind to and inhibit the activity of PP1; it is cleaved and activated to caspase-9, which then executes the apoptosis process.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\nAdaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria produce mutations in their DNA to adapt to changes in their environment. This process is particularly important in the bacterium Bacillus subtilis, which is a common soil and foodborne pathogen.\nThere are several mechanisms that underlie adaptive mutagenesis in Bacillus subtilis. Here are some of the key ones:\n1. DNA repair pathways: Bacillus subtilis has several DNA repair pathways that can introduce mutations into its genome. One of the most well-studied pathways is the base excision repair (BER) pathway, which repairs damaged DNA bases through a multi-step process involving removal of the damaged base, its replacement with a correct base, and the synthesis of a new DNA strand. During this process, errors can occur, leading to mutations.\n2. Oxidative stress: Bacillus subtilis can undergo oxidative stress when exposed to certain environmental factors, such as antibiotics, bacteriophages, or even normal metabolic byproducts. Oxidative stress can lead to the formation of reactive oxygen species (ROS), which can damage DNA and lead to mutations.\n3. recombination and mutation: Recombination is the process by which DNA is exchanged between two genetic markers, leading to genetic variation. In stationary phase, when nutrient availability is low, recombination can occur more frequently, leading to an increased frequency of mutations.\n4. UV radiation: UV radiation can also cause mutations in the DNA of Bacillus subtilis. The DNA damage caused by UV radiation can lead to the formation of cytosine dimers, which can result in frame-shift mutations.\n5. DNA methylation and demethylation: DNA methylation is the process of adding a methyl group to the DNA molecule. In Bacillus subtilis, DNA methylation can play a role in mutation rates by either methylating or demethylating specific regions of the genome. When methylation is reduced, the frequency of mutations can increase.\n6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis is a common soil and foodborne pathogen.\n2. The base excision repair (BER) pathway in Bacillus subtilis repairs damaged DNA bases and can introduce mutations during this process.\n3. Oxidative stress in Bacillus subtilis can lead to the formation of reactive oxygen species (ROS) that damage DNA and cause mutations.\n4. Recombination in Bacillus subtilis can occur more frequently in stationary phase due to low nutrient availability, resulting in an increased frequency of mutations.\n5. UV radiation can cause mutations in the DNA of Bacillus subtilis by leading to the formation of cytosine dimers.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis is a common soil and foodborne pathogen.",
      "The base excision repair (BER) pathway in Bacillus subtilis repairs damaged DNA bases and can introduce mutations during this process.",
      "Oxidative stress in Bacillus subtilis can lead to the formation of reactive oxygen species (ROS) that damage DNA and cause mutations.",
      "Recombination in Bacillus subtilis can occur more frequently in stationary phase due to low nutrient availability, resulting in an increased frequency of mutations.",
      "UV radiation can cause mutations in the DNA of Bacillus subtilis by leading to the formation of cytosine dimers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Bacillus subtilis is commonly found in soil but it is generally regarded as non-pathogenic.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: UV radiation can cause mutations in the DNA of Bacillus subtilis by leading to the formation of thymine dimers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erythromelalgia, is a rare medical condition characterized by pain and discoloration of the hands and feet. The exact cause of erucism is not yet fully understood, but there are several theories that have been proposed. Here are some of the possible causes of erucism:\n1. Vascular abnormalities: One theory is that erucism is caused by abnormalities in the blood vessels of the hands and feet. This could include problems with the shape and size of the blood vessels, as well as issues with the way they regulate blood flow.\n2. Neurological factors: Another theory is that erucism is caused by problems in the nervous system, which could be related to conditions such as multiple sclerosis, peripheral neuropathy, or other neurological disorders.\n3. Infection: Some researchers believe that erucism may be caused by an infection, such as a virus or bacterium, that affects the blood vessels or nerves in the hands and feet.\n4. Genetic factors: Erucism may also be inherited, and certain genetic mutations may contribute to the development of the condition.\n5. Hormonal imbalances: Hormonal imbalances, such as an imbalance of thyroid hormones, have been linked to erucism in some cases.\n6. Autoimmune disorders: Some researchers believe that erucism may be caused by an autoimmune disorder, in which the body's immune system mistakenly attacks the blood vessels or nerves in the hands and feet.\n7. Trauma: In some cases, erucism may be caused by trauma to the hands or feet, such as a broken bone or nerve damage.\n8. Medications: Certain medications, such as chemotherapy drugs and anticonvulsants, have been linked to erucism in some cases.\n9. Nutrient deficiencies: Deficiencies in certain nutrients, such as vitamin B12 or folate, have been linked to erucism in some cases.\n10. Unknown causes: In some cases, the exact cause of erucism may not be able to be determined.\nIt is important to note that erucism is a rare",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism, also known as erythromelalgia, is characterized by pain and discoloration of the hands and feet.\n2. The exact cause of erucism is not yet fully understood.\n3. Vascular abnormalities are one proposed cause of erucism.\n4. Neurological factors have been theorized to cause erucism.\n5. Genetic factors may contribute to the development of erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism, also known as erythromelalgia, is characterized by pain and discoloration of the hands and feet.",
      "The exact cause of erucism is not yet fully understood.",
      "Vascular abnormalities are one proposed cause of erucism.",
      "Neurological factors have been theorized to cause erucism.",
      "Genetic factors may contribute to the development of erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is a condition caused by caterpillar hairs and is different from erythromelalgia which is characterized by pain and discoloration of the hands and feet.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a commonly used diuretic medication that is used to treat a variety of medical conditions. Some of the main indications for hydrochlorothiazide include:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is often used to treat mild to moderate hypertension, as it helps to reduce blood volume and blood pressure. It is commonly used in combination with other medications, such as beta blockers or ACE inhibitors, to achieve a greater reduction in blood pressure.\n2. Heart Failure: Hydrochlorothiazide can help to improve symptoms of heart failure, such as shortness of breath and swelling in the legs, by reducing fluid buildup in the body.\n3. edema (fluid retention): Hydrochlorothiazide is used to treat edema (fluid buildup) caused by a variety of conditions, including heart failure, liver disease, and kidney disease.\n4. Hyperlipidemia (elevated cholesterol and triglycerides): Hydrochlorothiazide can help to reduce elevated levels of cholesterol and triglycerides in the blood.\n5. Diabetes insipidus: Hydrochlorothiazide is used to treat diabetes insipidus, a rare condition that causes excessive thirst and urination.\n6. Renal disease: Hydrochlorothiazide can help to reduce the progression of renal disease by reducing fluid buildup in the body and improving blood pressure control.\n7. Post-myocardial infarction (heart attack): Hydrochlorothiazide can help to reduce the risk of heart failure and improve survival rates in people who have had a heart attack.\n8. Hypervolemia (elevated blood volume): Hydrochlorothiazide can help to reduce elevated blood volume in people with conditions such as liver cirrhosis.\n9. Kidney disease: Hydrochlorothiazide can help to reduce the workload on the kidneys and improve blood pressure control in people with kidney disease.\n10. systemic lupus erythematosus: Hydrochlorothiazide can",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat mild to moderate hypertension.\n2. It is used to improve symptoms of heart failure, such as shortness of breath and swelling in the legs.\n3. Hydrochlorothiazide is used to treat edema caused by conditions like heart failure, liver disease, and kidney disease.\n4. It is used to reduce elevated levels of cholesterol and triglycerides in the blood.\n5. Hydrochlorothiazide is prescribed for the treatment of diabetes insipidus.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat mild to moderate hypertension.",
      "It is used to improve symptoms of heart failure, such as shortness of breath and swelling in the legs.",
      "Hydrochlorothiazide is used to treat edema caused by conditions like heart failure, liver disease, and kidney disease.",
      "It is used to reduce elevated levels of cholesterol and triglycerides in the blood.",
      "Hydrochlorothiazide is prescribed for the treatment of diabetes insipidus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not used to reduce elevated levels of cholesterol and triglycerides in the blood.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been developed and used in various medical applications, including the treatment of urinary incontinence.\nSilicon is a biocompatible material that is non-toxic and non-irritating to the body. It is commonly used in medical devices, such as catheters, wound dressings, and implantable devices. In the case of incontinence, silicon-based materials can be used to create products that help manage and treat the condition.\nHere are some ways silicon is used in the treatment of incontinence:\n1. Incontinence diapers: Silicon is often used in the production of incontinence diapers. These diapers are designed to absorb and contain urine, and are typically made with a layer of silicon-coated fabric that helps to keep the diaper in place.\n2. Pelvic floor exercisers: Silicon-based pelvic floor exercisers are designed to help strengthen the muscles in the pelvic floor, which can help to treat incontinence. These exercisers are typically made with a silicon or silicone-coated surface that provides resistance and support to the muscles during exercise.\n3. Incontinence pessaries: Silicon-based pessaries are designed to help manage stress urinary incontinence (SUI), which is the most common type of incontinence. These pessaries are inserted into the vagina and provide support to the bladder and urethra, helping to prevent leakage.\n4. Urinary retention devices: Silicon-based urinary retention devices are used to treat urinary retention, which is the inability to fully empty the bladder. These devices are typically made with a silicon or silicone-coated catheter that is inserted into the urethra to help drain the bladder and prevent retention.\n5. Incontinence underwear: Silicon-based incontinence underwear is designed to provide discreet and comfortable protection against incontinence. These underwear are made with a silicon-coated layer that helps to absorb and contain urine, and are available in a range of styles and sizes.\nSilicon has",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon is biocompatible and non-toxic to the body.\n3. Silicon is commonly used in medical devices, such as catheters and implantable devices.\n4. Silicon-based incontinence diapers are designed to absorb and contain urine.\n5. Silicon-based pelvic floor exercisers are designed to help strengthen the muscles in the pelvic floor to treat incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon is biocompatible and non-toxic to the body.",
      "Silicon is commonly used in medical devices, such as catheters and implantable devices.",
      "Silicon-based incontinence diapers are designed to absorb and contain urine.",
      "Silicon-based pelvic floor exercisers are designed to help strengthen the muscles in the pelvic floor to treat incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Silicone-based incontinence products, not silicon-based, are designed to absorb and contain urine.\n5. FALSE [correction]: Silicone-based pelvic floor exercisers, not silicon-based, are designed to help strengthen the muscles in the pelvic floor to treat incontinence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Intracranial aneurysms are abnormal bulges or pouches that occur in the walls of blood vessels in the brain. These aneurysms can rupture, leading to bleeding in the brain and causing serious complications, including stroke, brain damage, and even death. While the exact cause of intracranial aneurysms is not fully understood, research has shown that there may be an association between the moon cycle and the risk of rupture for these aneurysms.\nStudies have suggested that the frequency of aneurysm rupture may vary depending on the phase of the moon. A study published in the Journal of Neurointerventional Surgery in 2019 analyzed data from over 2,300 patients who had undergone angiography, a test used to visualize the blood vessels in the brain, and found that the risk of aneurysm rupture was higher during the full moon than during other phases of the moon. Another study published in the journal Neurosurgery in 2018 found similar results, with the risk of aneurysm rupture highest during the full moon and lowest during the new moon.\nThe exact mechanism by which the moon cycle may affect the risk of aneurysm rupture is not fully understood, but several theories have been proposed. One theory is that the changes in ambient pressure and humidity during the full moon may influence the integrity of the blood vessels in the brain, increasing the risk of aneurysm rupture. Another theory is that the gravitational forces associated with the full moon may cause stretching of the blood vessels in the brain, leading to increased pressure and increased risk of rupture.\nIt is important to note that these findings are not conclusive and more research is needed to fully understand the association between the moon cycle and the risk of aneurysm rupture. Additionally, these studies only looked at the relationship between the moon cycle and aneurysm rupture in patients who had already experienced an aneurysm rupture, and more research is needed to determine if there is a similar association in patients who have not yet experienced an aneurysm rupture.\nIn summary, while the exact mechanism is not completely understood, some studies suggest that there may be an association between the moon cycle and the risk of rupture for intrac",
    "llama-2-7b-chat-hf_fact_raw": "1. Intracranial aneurysms are abnormal bulges or pouches in the walls of blood vessels in the brain.\n2. The risk of rupture for intracranial aneurysms may be associated with the moon cycle.\n3. A study in the Journal of Neurointerventional Surgery in 2019 found a higher risk of aneurysm rupture during the full moon.\n4. A study in the journal Neurosurgery in 2018 reported the highest risk of aneurysm rupture during the full moon and the lowest during the new moon.\n5. Theories suggest that changes in ambient pressure, humidity, or gravitational forces during the full moon might influence the risk of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact": [
      "Intracranial aneurysms are abnormal bulges or pouches in the walls of blood vessels in the brain.",
      "The risk of rupture for intracranial aneurysms may be associated with the moon cycle.",
      "A study in the Journal of Neurointerventional Surgery in 2019 found a higher risk of aneurysm rupture during the full moon.",
      "A study in the journal Neurosurgery in 2018 reported the highest risk of aneurysm rupture during the full moon and the lowest during the new moon.",
      "Theories suggest that changes in ambient pressure, humidity, or gravitational forces during the full moon might influence the risk of aneurysm rupture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The risk of rupture for intracranial aneurysms may be associated with various factors, but the moon cycle is not a scientifically established risk factor.\n3. FALSE [correction]: There is no scientific evidence to support the claim that the risk of aneurysm rupture is higher during the full moon.\n4. FALSE [correction]: There is no scientific evidence to support the claim that the risk of aneurysm rupture is highest during the full moon and lowest during the new moon.\n5. FALSE [correction]: Theories about changes in ambient pressure, humidity, or gravitational forces during the full moon influencing the risk of aneurysm rupture are speculative and not backed by scientific evidence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein (also known as E79 or KHDRBS1) plays a crucial role in regulating the splicing process in eukaryotic cells. HuR is a multi-functional protein that is involved in various cellular processes, including RNA metabolism, gene expression, and cell signaling.\nHuR is a splicing factor that is specifically involved in the regulation of pre-mRNA splicing, which is the process by which introns (non-coding regions) are removed and exons (coding regions) are joined together to form mature mRNA. HuR recognizes and binds to specific sequences in the pre-mRNA and helps to facilitate the splicing reaction by positioning the splicing machinery at the correct location.\nStudies have shown that HuR regulates the splicing of a wide range of pre-mRNAs, including those involved in cell proliferation, differentiation, and survival. For example, HuR has been shown to regulate the splicing of the bcl-2 pre-mRNA, which encodes a protein that inhibits apoptosis (programmed cell death). By regulating the splicing of this pre-mRNA, HuR can influence the expression of bcl-2 protein and impact cell survival.\nIn addition to its role in pre-mRNA splicing, HuR has been implicated in the regulation of mRNA stability and translation. HuR can bind to the 3' untranslated region (UTR) of mRNAs and stabilize them by inhibiting their degradation. HuR can also interact with the ribosome and regulate the translation of mRNAs into proteins.\nOverall, HuR is a critical regulator of the splicing process and plays a important role in the regulation of gene expression in eukaryotic cells. Its dysregulation has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein (also known as E79 or KHDRBS1) is involved in the regulation of the splicing process in eukaryotic cells.\n2. HuR is a splicing factor that regulates pre-mRNA splicing by removing introns and joining exons to form mature mRNA.\n3. HuR recognizes and binds to specific sequences in the pre-mRNA to facilitate the splicing reaction.\n4. HuR has been shown to regulate the splicing of bcl-2 pre-mRNA, which encodes a protein that inhibits apoptosis.\n5. Dysregulation of HuR has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein (also known as E79 or KHDRBS1) is involved in the regulation of the splicing process in eukaryotic cells.",
      "HuR is a splicing factor that regulates pre-mRNA splicing by removing introns and joining exons to form mature mRNA.",
      "HuR recognizes and binds to specific sequences in the pre-mRNA to facilitate the splicing reaction.",
      "HuR has been shown to regulate the splicing of bcl-2 pre-mRNA, which encodes a protein that inhibits apoptosis.",
      "Dysregulation of HuR has been implicated in a variety of diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: HuR is not a splicing factor but rather a RNA binding protein that influences the stability and translation of mRNAs.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (Pa) is a small protein that plays a crucial role in various cellular processes, including the regulation of protein synthesis, cell growth, and differentiation. The c-terminal peptide of Pa, also known as PaCT, is a 13-amino acid peptide that is derived from the C-terminal region of the full-length Pa protein.\nKnown functions of PaCT include:\n1. Regulation of protein synthesis: PaCT has been shown to inhibit the initiation of protein synthesis by disrupting the interaction between the initiation factors eIF4E and eIF4G. This suggests that PaCT may play a role in regulating the balance between protein synthesis and degradation.\n2. Cell growth and proliferation: PaCT has been shown to promote cell growth and proliferation by enhancing the expression of genes involved in these processes. This is thought to be achieved by PaCT's ability to bind to and activate transcription factors, such as c-Myc.\n3. Differentiation: PaCT has been implicated in the regulation of cellular differentiation, particularly in the context of neuronal differentiation. PaCT has been shown to promote the expression of genes involved in neural differentiation and to inhibit the expression of genes involved in non-neuronal cell types.\n4. Apoptosis: PaCT has been shown to inhibit apoptosis, or programmed cell death, in various cell types. This is thought to be achieved by PaCT's ability to bind to and inhibit the activity of pro-apoptotic proteins, such as Bax and caspase-3.\n5. Autophagy: PaCT has been shown to regulate autophagy, a process by which cells degrade and recycle damaged or excess membranes and organelles. PaCT has been shown to promote autophagy by inhibiting the activity of the pro-autophagic protein mTOR.\n6. DNA repair: PaCT has been shown to be involved in the regulation of DNA repair pathways. PaCT has been shown to promote the expression of genes involved in DNA repair and to inhibit the expression of genes involved in DNA damage response.\n7. Immune response:",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (PaCT) is a 13-amino acid peptide derived from the C-terminal region of the full-length Pa protein.\n2. PaCT has been shown to inhibit the initiation of protein synthesis by disrupting the interaction between eIF4E and eIF4G.\n3. PaCT can promote cell growth and proliferation by enhancing the expression of genes involved in these processes.\n4. PaCT has been implicated in the regulation of cellular differentiation, particularly in neuronal differentiation.\n5. PaCT has been shown to inhibit apoptosis in various cell types by binding to and inhibiting pro-apoptotic proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (PaCT) is a 13-amino acid peptide derived from the C-terminal region of the full-length Pa protein.",
      "PaCT has been shown to inhibit the initiation of protein synthesis by disrupting the interaction between eIF4E and eIF4G.",
      "PaCT can promote cell growth and proliferation by enhancing the expression of genes involved in these processes.",
      "PaCT has been implicated in the regulation of cellular differentiation, particularly in neuronal differentiation.",
      "PaCT has been shown to inhibit apoptosis in various cell types by binding to and inhibiting pro-apoptotic proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PaCT does not promote cell growth and proliferation, it inhibits it by disrupting protein synthesis.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that plays a crucial role in maintaining the balance of intracellular levels of certain ions, such as zinc and copper, in the human body. Cystatin C is also involved in various cellular processes, including protein degradation and cell signaling. Fibrillization of cystatin C is a process by which the protein aggregates and forms insoluble fibrils, which are thought to be associated with various neurodegenerative disorders, including Alzheimer's disease and amyotrophic lateral sclerosis.\nSeveral studies have shown that the peptide region of cystatin C between residues 13 and 24 plays a pivotal role in its fibrillization. This region is known as the \"fibrillation-prone\" region, and it is characterized by a high content of hydrophobic and charged amino acids. These structural features promote the formation of β-sheets and α-helices, which are hallmarks of amyloid fibrils.\nAdditionally, several studies have identified specific amino acid residues within this region that are critical for cystatin C fibrillization. For example, mutations at positions 16 and 20 have been shown to enhance the fibrillation of cystatin C, while mutations at position 14 have been shown to reduce its fibrillation. These findings suggest that the fibrillation-prone region of cystatin C is a hotspot for aggregation and that specific residues within this region play a critical role in its fibrillization.\nOverall, the pivotal role of the fibrillation-prone region of cystatin C in its fibrillization is consistent with the idea that protein misfolding and aggregation are key mechanisms underlying the pathogenesis of neurodegenerative disorders. Understanding the structural and chemical properties of cystatin C that contribute to its fibrillization may provide important insights into the development of new therapeutic strategies for these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C plays a crucial role in maintaining the balance of intracellular levels of ions like zinc and copper in the human body.\n2. Fibrillization of cystatin C involves the protein forming insoluble fibrils associated with neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis.\n3. The peptide region of cystatin C between residues 13 and 24 is pivotal in its fibrillization.\n4. Mutations at positions 16 and 20 of cystatin C enhance its fibrillation, while mutations at position 14 reduce fibrillation. \n5. The fibrillation-prone region of cystatin C contains a high content of hydrophobic and charged amino acids.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C plays a crucial role in maintaining the balance of intracellular levels of ions like zinc and copper in the human body.",
      "Fibrillization of cystatin C involves the protein forming insoluble fibrils associated with neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis.",
      "The peptide region of cystatin C between residues 13 and 24 is pivotal in its fibrillization.",
      "Mutations at positions 16 and 20 of cystatin C enhance its fibrillation, while mutations at position 14 reduce fibrillation.",
      "The fibrillation-prone region of cystatin C contains a high content of hydrophobic and charged amino acids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cystatin C plays a crucial role in inhibiting cysteine proteases and maintaining protease-antiprotease balance, not in maintaining the balance of intracellular levels of ions like zinc and copper.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! I'm here to help you understand the relationship between the cytoprotective prodrug \"amifostine\" (ethyol) and the concentration of protein HIF-1α.\nHIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that plays a crucial role in response to hypoxia, a condition of low oxygen levels in the body. HIF-1α is activated in response to hypoxia and promotes the expression of genes involved in adaptation to hypoxia, such as angiogenesis, metabolism, and cell survival.\nAmifostine, also known as ethyol, is a prodrug that is converted into the active compound ethylene diamine (EDA) in the body. EDA is known to have cytoprotective effects and has been shown to protect cells against oxidative stress, inflammation, and radiation damage.\nStudies have shown that the administration of amifostine can increase the concentration of HIF-1α in various tissues, including the heart, liver, and lungs. For example, a study published in the Journal of Pharmacology and Experimental Therapeutics found that administration of amifostine increased HIF-1α protein levels in the heart of rats exposed to hypoxia. Another study published in the European Journal of Pharmacology found that amifostine increased HIF-1α protein levels in the liver of mice exposed to oxidative stress.\nHowever, it is important to note that the concentration of HIF-1α can also be influenced by other factors, such as pH, temperature, and the presence of other cellular factors. Additionally, the mechanisms by which amifostine increases HIF-1α concentration may vary depending on the specific tissue or cell type.\nIn summary, while there is evidence to suggest that the administration of amifostine can increase the concentration of HIF-1α, the magnitude and duration of this effect may vary depending on the specific condition and tissue being studied. Further research is needed to fully understand the mechanisms by which amifostine affects HIF-1α concentration and its potential therapeutic applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor involved in the body's response to hypoxia, including angiogenesis, metabolism, and cell survival.\n2. Amifostine, also known as ethyol, is converted into the active compound ethylene diamine (EDA) in the body.\n3. Ethylene diamine (EDA) has cytoprotective effects and protects cells against oxidative stress, inflammation, and radiation damage.\n4. Administration of amifostine has been shown to increase HIF-1α concentration in heart, liver, and lung tissues.\n5. Studies regarding the increase of HIF-1α concentration after amifostine administration have been published in the Journal of Pharmacology and Experimental Therapeutics and the European Journal of Pharmacology.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor involved in the body's response to hypoxia, including angiogenesis, metabolism, and cell survival.",
      "Amifostine, also known as ethyol, is converted into the active compound ethylene diamine (EDA) in the body.",
      "Ethylene diamine (EDA) has cytoprotective effects and protects cells against oxidative stress, inflammation, and radiation damage.",
      "Administration of amifostine has been shown to increase HIF-1α concentration in heart, liver, and lung tissues.",
      "Studies regarding the increase of HIF-1α concentration after amifostine administration have been published in the Journal of Pharmacology and Experimental Therapeutics and the European Journal of Pharmacology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Amifostine is converted into the active compound WR-1065 in the body.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase enzyme that is involved in the manipulation of histone tails, particularly the lysine 7 (K7) residue. Set7 is known to deposit the following histone marks:\n1. Histone H3 K7 trimethylation (H3K7me3): Set7 is the primary enzyme responsible for the monomethylation of histone H3 at lysine 7 (H3K7me1), as well as the dimethylation of histone H3 at lysine 7 (H3K7me2) and trimethylation of histone H3 at lysine 7 (H3K7me3). H3K7me3 is a mark of active gene expression and is involved in the regulation of various cellular processes, including transcriptional elongation, chromatin remodeling, and DNA repair.\n2. Histone H3 K27 trimethylation (H3K27me3): Set7 has also been shown to deposit histone H3 lysine 27 trimethylation (H3K27me3), which is a mark of gene silencing and chromatin repression. H3K27me3 is established during embryonic development and is important for the maintenance of stem cell self-renewal and pluripotency.\n3. Histone H4 K8 trimethylation (H4K8me3): Set7 has been reported to trimethylate histone H4 at lysine 8 (H4K8me3), which is involved in the regulation of chromatin structure and gene expression. H4K8me3 is known to be involved in the formation of condensed chromatin structures and is associated with the regulation of cellular processes, including cell division and differentiation.\n4. Histone H3 K4 trimethylation (H3K4me3): Set7 has also been reported to trimethylate histone H3 at lysine 4 (H3K4me3), which is involved in the regulation of gene expression and chromatin structure. H3K4me3 is known to be involved in the activation of gene transcription and is associated with the regulation of various cellular processes, including cell",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase enzyme.\n2. Set7 is responsible for the monomethylation of histone H3 at lysine 7 (H3K7me1).\n3. Set7 deposits dimethylation of histone H3 at lysine 7 (H3K7me2) and trimethylation of histone H3 at lysine 7 (H3K7me3).\n4. Histone H3 lysine 27 trimethylation (H3K27me3) deposited by Set7 is a mark of gene silencing and chromatin repression.\n5. Set7 is reported to trimethylate histone H4 at lysine 8 (H4K8me3) and histone H3 at lysine 4 (H3K4me3).",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase enzyme.",
      "Set7 is responsible for the monomethylation of histone H3 at lysine 7 (H3K7me1).",
      "Set7 deposits dimethylation of histone H3 at lysine 7 (H3K7me2) and trimethylation of histone H3 at lysine 7 (H3K7me3).",
      "Histone H3 lysine 27 trimethylation (H3K27me3) deposited by Set7 is a mark of gene silencing and chromatin repression.",
      "Set7 is reported to trimethylate histone H4 at lysine 8 (H4K8me3) and histone H3 at lysine 4 (H3K4me3)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 is responsible for the monomethylation of histone H3 at lysine 4 (H3K4me1).\n3. FALSE [correction]: Set7 does not deposit dimethylation or trimethylation at lysine 7; it only catalyzes the monomethylation at lysine 4.\n4. FALSE [correction]: Histone H3 lysine 27 trimethylation (H3K27me3) is not deposited by Set7; it is deposited by the Polycomb Repressive Complex 2 (PRC2) enzymes such as EZH2.\n5. FALSE [correction]: Set7 does not trimethylate histone H4 at lysine 8 (H4K8me3) nor histone H3 at lysine 4 (H3K4me3); it only catalyzes the monomethylation at lysine 4 (H3K4me1).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that plays a crucial role in the regulation of iron metabolism in the body. It is a small peptide hormone that is produced in the liver and secreted into the bloodstream, where it binds to iron-regulatory proteins (IRPs) and ferric iron-binding proteins (FEPs) to regulate iron availability and transport.\nHepcidin contains 6 cysteine residues, which form disulfide bonds with each other. These disulfide bonds are important for the proper folding and stability of the protein, and they also play a role in the regulation of hepcidin function.\nThere are 3 disulfide bridges in hepcidin:\n1. Cys-25-Cys-107: This bridge is formed between the C-terminal cysteine residue (Cys-25) and the N-terminal cysteine residue (Cys-107) of hepcidin.\n2. Cys-58-Cys-107: This bridge is formed between the internal cysteine residue (Cys-58) and the N-terminal cysteine residue (Cys-107) of hepcidin.\n3. Cys-84-Cys-107: This bridge is formed between the C-terminal cysteine residue (Cys-84) and the N-terminal cysteine residue (Cys-107) of hepcidin.\nThese disulfide bridges are important for the proper folding and stability of hepcidin, and they also play a role in the regulation of hepcidin function. They can affect the binding of hepcidin to its receptors, and they can also influence the stability and secretion of the protein.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin contains 6 cysteine residues that form disulfide bonds.\n2. Hepcidin has 3 disulfide bridges.\n3. The Cys-25-Cys-107 bridge is formed between the C-terminal and N-terminal cysteine residues of hepcidin.\n4. The Cys-58-Cys-107 bridge is formed between an internal cysteine residue and the N-terminal cysteine residue of hepcidin.\n5. The Cys-84-Cys-107 bridge is formed between the C-terminal and N-terminal cysteine residues of hepcidin.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin contains 6 cysteine residues that form disulfide bonds.",
      "Hepcidin has 3 disulfide bridges.",
      "The Cys-25-Cys-107 bridge is formed between the C-terminal and N-terminal cysteine residues of hepcidin.",
      "The Cys-58-Cys-107 bridge is formed between an internal cysteine residue and the N-terminal cysteine residue of hepcidin.",
      "The Cys-84-Cys-107 bridge is formed between the C-terminal and N-terminal cysteine residues of hepcidin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Cys-25-Cys-107 bridge is not formed between the C-terminal and N-terminal cysteine residues of hepcidin; Cys-25 and Cys-107 are not terminal residues.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a member of the DJ-1 protein family, which is involved in various cellular processes, including antioxidant defense, protein synthesis, and mitochondrial function.\nDNAJC11 is specifically localized to the mitochondria, where it plays a role in maintaining the proper functioning of the organelle. The protein is synthesized in the cytoplasm and then targeted to the mitochondria through a process called \"targeting sequence-mediated protein localization.\" This involves the use of specific amino acid sequences within the protein that are recognized by mitochondrial targeting sequences, which direct the protein to the mitochondria for proper folding and localization.\nOnce localized to the mitochondria, DNAJC11 plays a role in protecting the organelle from oxidative stress by scavenging reactive oxygen species (ROS) and maintaining the proper redox state of the mitochondrial matrix. It has been shown to interact with various mitochondrial proteins, including the electron transport chain, and play a role in regulating the proper functioning of the mitochondrial respiratory chain.\nIn addition to its role in mitochondrial function, DNAJC11 has also been implicated in the regulation of protein synthesis and degradation, as well as the maintenance of cellular homeostasis. Dysregulation of DNAJC11 has been linked to various diseases, including cancer, neurodegenerative disorders, and metabolic disorders, highlighting the importance of this protein in maintaining proper cellular function.\nIn summary, the localization of the protein encoded by the gene DNAJC11 is specifically to the mitochondria, where it plays a critical role in maintaining the proper functioning of the organelle through the scavenging of ROS and regulation of mitochondrial respiratory chain function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the mitochondria.\n2. DNAJC11 is synthesized in the cytoplasm before being targeted to the mitochondria.\n3. DNAJC11 plays a role in protecting the mitochondria from oxidative stress by scavenging reactive oxygen species.\n4. The protein DNAJC11 interacts with various mitochondrial proteins, including the electron transport chain.\n5. Dysregulation of DNAJC11 has been linked to diseases such as cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the mitochondria.",
      "DNAJC11 is synthesized in the cytoplasm before being targeted to the mitochondria.",
      "DNAJC11 plays a role in protecting the mitochondria from oxidative stress by scavenging reactive oxygen species.",
      "The protein DNAJC11 interacts with various mitochondrial proteins, including the electron transport chain.",
      "Dysregulation of DNAJC11 has been linked to diseases such as cancer, neurodegenerative disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DNAJC11 plays a role in mitochondrial protein import and folding, not in scavenging reactive oxygen species.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Ultraconserved elements (UCEs) are short sequences of DNA that are conserved across species and are thought to play important roles in regulating gene expression and other cellular processes. Copy number variants (CNVs) are genetic changes that involve an alteration in the number of copies of a particular DNA sequence. In the context of CNVs, the question of whether UCEs are depleted is an important one, as it can provide insights into the potential functional effects of these genetic changes.\nTo answer this question, it is first important to define what is meant by \"ultraconserved elements.\" UCEs are regions of DNA that are conserved across species, meaning that they are present in the same sequence and same location in different species. These regions are typically short, ranging in length from a few hundred to a few thousand base pairs, and are often found in non-coding regions of the genome.\nNow, to determine whether UCEs are depleted among CNVs, we need to examine the literature and see what studies have found.\nSeveral studies have investigated the relationship between UCEs and CNVs. For example, a study published in the journal Nature in 2010 found that UCEs areoverrepresented among CNVs in the human genome. The authors of this study used a combination of computational and experimental approaches to identify UCEs and CNVs in the human genome, and found that 65% of CNVs overlap with UCEs.\nAnother study published in the journal Genetics in 2017 found similar results. This study analyzed CNVs in a sample of individuals from the Haplotype Reference Consortium and found that 57% of CNVs overlap with UCEs.\nHowever, it is important to note that not all studies have found an association between UCEs and CNVs. For example, a study published in the journal PLOS Genetics in 2019 found no significant association between UCEs and CNVs in a sample of individuals with schizophrenia.\nThe reason for the discrepancy in these findings may be due to the differences in the populations studied, the methods used to identify UCEs and CNVs, or the specific gen",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are short sequences of DNA conserved across species.\n2. Copy number variants (CNVs) involve an alteration in the number of copies of a DNA sequence.\n3. A study published in the journal Nature in 2010 found that UCEs are overrepresented among CNVs in the human genome.\n4. According to the 2010 study, 65% of CNVs overlap with UCEs.\n5. A different study published in PLOS Genetics in 2019 found no significant association between UCEs and CNVs in individuals with schizophrenia.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are short sequences of DNA conserved across species.",
      "Copy number variants (CNVs) involve an alteration in the number of copies of a DNA sequence.",
      "A study published in the journal Nature in 2010 found that UCEs are overrepresented among CNVs in the human genome.",
      "According to the 2010 study, 65% of CNVs overlap with UCEs.",
      "A different study published in PLOS Genetics in 2019 found no significant association between UCEs and CNVs in individuals with schizophrenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The study published in the journal Nature in 2010 found that UCEs are underrepresented among CNVs in the human genome.\n4. FALSE [correction]: The 2010 study did not specify that 65% of CNVs overlap with UCEs, the true percentage was not mentioned in the statement provided.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) molecule. Haspin is a protein kinase that plays a critical role in regulating the progression of mitosis by phosphorylating and activating the protein kinase CK2 (Casein Kinase 2). CK2 is a key regulator of mitotic progression, and Haspin serves as a downstream effector of CK2, amplifying its signaling activity.\nDuring mitosis, Haspin is highly phosphorylated and activated by CK2, which enables it to phosphorylate and activate additional downstream targets involved in mitotic progression. One of these downstream targets is the PI(3,4,5)P3 molecule, which is a key player in regulating the assembly and organization of the cytoskeleton during mitosis.\nPI(3,4,5)P3 is generated by the action of the enzyme PI3K (Phosphatidylinositol 3-kinase) and is primarily localized to the plasma membrane and cytoskeletal components. During mitosis, PI(3,4,5)P3 is involved in the recruitment and activation of proteins that are essential for the transition from interphase to mitosis, such as the polo-like kinase 1 (PLK1) and the aurora kinase A (AURKA).\nHaspin phosphorylation and activation of PI(3,4,5)P3 are crucial for the proper progression of mitosis. Haspin puts PI(3,4,5)P3 in a stable kinase-active conformation that can efficiently activate downstream targets, including PLK1 and AURKA. This leads to the proper assembly and organization of the cytoskeleton and the nuclear envelope, which are critical for the proper separation of chromosomes and the completion of mitosis.\nIn summary, the substrate of the Haspin kinase during mitosis is the PI(3,4,5)P3 molecule, which is ph",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is the phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) molecule.\n2. Haspin is a protein kinase that regulates the progression of mitosis by phosphorylating and activating CK2.\n3. CK2 is a key regulator of mitotic progression.\n4. PI(3,4,5)P3 is involved in regulating the assembly and organization of the cytoskeleton during mitosis.\n5. Haspin phosphorylation and activation of PI(3,4,5)P3 are crucial for the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is the phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) molecule.",
      "Haspin is a protein kinase that regulates the progression of mitosis by phosphorylating and activating CK2.",
      "CK2 is a key regulator of mitotic progression.",
      "PI(3,4,5)P3 is involved in regulating the assembly and organization of the cytoskeleton during mitosis.",
      "Haspin phosphorylation and activation of PI(3,4,5)P3 are crucial for the proper progression of mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The substrate of Haspin kinase during mitosis is histone H3 at threonine 3 (H3T3ph), not the PI(3,4,5)P3 molecule.\n2. FALSE [correction]: Haspin is a protein kinase that regulates the progression of mitosis by phosphorylating histone H3, not by activating CK2.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Haspin phosphorylation of histone H3, not PI(3,4,5)P3, is crucial for the proper progression of mitosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are a type of small, single-stranded RNA molecule that replicate through a unique mechanism that does not involve the traditional DNA-based replication process. Here's a detailed explanation of the mechanism of viroid replication:\n1. Attachment to host cells: Viroids are capable of attaching themselves to the cell membranes of host plants through hydrophobic interactions. This attachment allows the viroids to enter the host cell and begin the replication process.\n2. Release of the viroid genome: Once inside the host cell, the viroid releases its genome, which is a single-stranded RNA molecule, into the cytoplasm. The genome is quite small, typically around 250-300 nucleotides in length.\n3. Initiation of RNA synthesis: The viroid genome acts as a template for the host cell's RNA polymerase enzyme, which begins synthesizing complementary RNA (cRNA) strands. The cRNA strands are complementary to the viroid genome, and they are used as a template for the synthesis of more viroid genome RNA.\n4. Expanding the infectious cycle: The newly synthesized cRNA strands are then exported from the host cell through a process called RNA export. These exported RNA strands can then attach to other host cells and initiate the replication process again. This creates an exponential increase in the number of viroids in the infected plant, leading to a rapid decline in plant health and productivity.\n5. Incorporation of new RNA into the viroid structure: As the replication process continues, the new RNA strands are incorporated into theviroid structure, which becomes larger and more complex. This results in the formation of multiple copies of the viroid genome and the expansion of the infectious cycle.\n6. Production of new viroid particles: Once the replication process is complete, the newly synthesized viroid particles are released from the host cell through a process called lysis, and they can then infect other host cells.\nIt's important to note that viroids do not have a cellular machinery to support their replication, so they must rely on the host cell'",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are a type of small, single-stranded RNA molecule.\n2. Viroids replicate through a mechanism that does not involve traditional DNA-based replication.\n3. The viroid genome is typically around 250-300 nucleotides in length.\n4. Viroids attach themselves to host plant cells through hydrophobic interactions.\n5. Viroid replication involves the RNA polymerase enzyme of the host cell synthesizing complementary RNA strands.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are a type of small, single-stranded RNA molecule.",
      "Viroids replicate through a mechanism that does not involve traditional DNA-based replication.",
      "The viroid genome is typically around 250-300 nucleotides in length.",
      "Viroids attach themselves to host plant cells through hydrophobic interactions.",
      "Viroid replication involves the RNA polymerase enzyme of the host cell synthesizing complementary RNA strands."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Viroids do not attach themselves to host plant cells through hydrophobic interactions; they instead enter cells through wounds or via vectors like insects.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that plays a crucial role in the structure and function of muscles, and it has been investigated as a potential biomarker for Duchenne muscular dystrophy (DMD). Here is a detailed answer to your question:\nDuchenne muscular dystrophy (DMD) is a severe genetic disorder that affects approximately 1 in 3600 males, causing progressive muscle weakness and wasting. Currently, there is no cure for DMD, and diagnosis is based on a combination of clinical evaluation, molecular genetic testing, and imaging studies.\nFibronectin is a type of extracellular matrix protein that is involved in cell adhesion, migration, and differentiation. It is also a crucial component of the basement membrane, a specialized extracellular matrix that separates muscle fibers from the underlying connective tissue. In muscles, fibronectin helps to maintain muscle architecture and regulate muscle function.\nStudies have shown that levels of fibronectin are significantly reduced in the serum of children with DMD, especially during the early stages of the disease. This reduction in fibronectin levels can be detected as early as 6-12 months of age, before the onset of muscle symptoms. The reduction in fibronectin levels is more pronounced in the skeletal muscles than in the cardiac muscle.\nThe reduction in fibronectin levels in DMD can be used as a biomarker for the diagnosis and monitoring of the disease. Measurement of fibronectin levels in the serum or plasma of children with DMD can help to:\n1. Diagnose DMD: The reduction in fibronectin levels can be used as a biomarker for the diagnosis of DMD, especially in the early stages of the disease.\n2. Monitor disease progression: Measurement of fibronectin levels in the serum or plasma of children with DMD can help to monitor the progression of the disease over time.\n3. Evaluate drug effectiveness: The levels of fibronectin in the serum or plasma can be used to evaluate the effectiveness of drugs that target the dystrophin-glycoprote",
    "llama-2-7b-chat-hf_fact_raw": "1. Duchenne muscular dystrophy affects approximately 1 in 3600 males.\n2. Diagnosis of Duchenne muscular dystrophy is based on clinical evaluation, molecular genetic testing, and imaging studies.\n3. Fibronectin is involved in cell adhesion, migration, and differentiation, as well as maintaining muscle architecture and regulating muscle function.\n4. Levels of fibronectin are significantly reduced in the serum of children with DMD, particularly during the early stages of the disease.\n5. The reduction in fibronectin levels in the serum or plasma of children with DMD can be detected as early as 6-12 months of age.",
    "llama-2-7b-chat-hf_fact": [
      "Duchenne muscular dystrophy affects approximately 1 in 3600 males.",
      "Diagnosis of Duchenne muscular dystrophy is based on clinical evaluation, molecular genetic testing, and imaging studies.",
      "Fibronectin is involved in cell adhesion, migration, and differentiation, as well as maintaining muscle architecture and regulating muscle function.",
      "Levels of fibronectin are significantly reduced in the serum of children with DMD, particularly during the early stages of the disease.",
      "The reduction in fibronectin levels in the serum or plasma of children with DMD can be detected as early as 6-12 months of age."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Duchenne muscular dystrophy affects approximately 1 in 3500 to 1 in 5000 males.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is a comprehensive epigenomic data server that houses a vast collection of epigenetic data from various projects. The following are some of the major epigenome projects whose data are contained in the DeepBlue data server:\n1. ENCODE (ENCyclopedia Of DNA Elements): The ENCODE project is a large-scale effort to map all of the functional elements in the human genome. The project has generated a wealth of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles, for a wide range of cell types and tissues.\n2. Roadmap Epigenomics Consortium: The Roadmap Epigenomics Consortium is a collaborative effort to coordinate and advance the field of epigenomics. The consortium has generated a large-scale epigenetic map of the human genome, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles, for a variety of human cell types.\n3. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to catalogue the genomic changes underlying various cancer types. The project includes epigenetic data for a range of cancer types, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles.\n4. The Encyclopedia of DNA Elements (ENCODE): ENCODE is a comprehensive effort to map all of the functional elements in the human genome. The project has generated a wealth of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles, for a wide range of cell types and tissues.\n5. The Genotype-Tissue Expression (GTEx) Project: The GTEx project is a large-scale effort to understand how genetic variants affect gene expression in different human tissues. The project includes epigenetic data for a range of tissues, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles.\n6. The NIH Human Brain Atlas (NHBA): The NHBA is a collaborative effort to generate a comprehensive map of the human brain's epigenetic landscape. The project includes epigenetic data for a range",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.\n2. Data from the Roadmap Epigenomics Consortium is housed in the DeepBlue data server.\n3. The Cancer Genome Atlas (TCGA) project's epigenetic data is included in the DeepBlue data server.\n4. The Genotype-Tissue Expression (GTEx) Project's data is contained in the DeepBlue data server.\n5. DeepBlue data server includes epigenetic data from the NIH Human Brain Atlas (NHBA).",
    "llama-2-7b-chat-hf_fact": [
      "DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.",
      "Data from the Roadmap Epigenomics Consortium is housed in the DeepBlue data server.",
      "The Cancer Genome Atlas (TCGA) project's epigenetic data is included in the DeepBlue data server.",
      "The Genotype-Tissue Expression (GTEx) Project's data is contained in the DeepBlue data server.",
      "DeepBlue data server includes epigenetic data from the NIH Human Brain Atlas (NHBA)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Cancer Genome Atlas (TCGA) project's genomic data, including epigenetic data, is housed in the Genomic Data Commons (GDC) data server.\n4. FALSE [correction]: The Genotype-Tissue Expression (GTEx) Project's data is housed in the GTEx Portal, not in the DeepBlue data server.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "There are several tools that employ self-organizing maps (SOMs) for analyzing synonymous codon usage. Here are a few examples:\n1. CodonOpt: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n2. Muscle: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n3. GenePro: This tool uses a SOM to predict the effects of synonymous codon usage on gene expression and protein function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n4. CodonDiversity: This tool uses a SOM to identify patterns of synonymous codon usage in a given gene, and to predict the effects of codon usage on protein function.\n5. Transcodon: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n6. COGUM: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n7. Cascleo: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\n8. COnsensus codon usage predictor: This tool uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function. It can be used to identify optimal codons for a given gene, based on their ability to direct the synthesis of a functional protein.\nThese are just a few examples of the many tools that use SOMs for analyzing synonymous codon usage. Each tool has its",
    "llama-2-7b-chat-hf_fact_raw": "1. CodonOpt uses a self-organizing map (SOM) to predict the effects of synonymous codon substitutions on protein structure and function.\n2. Muscle uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function.\n3. GenePro uses a SOM to predict the effects of synonymous codon usage on gene expression and protein function.\n4. CodonDiversity uses a SOM to identify patterns of synonymous codon usage in a given gene.\n5. Transcodon uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function.",
    "llama-2-7b-chat-hf_fact": [
      "CodonOpt uses a self-organizing map (SOM) to predict the effects of synonymous codon substitutions on protein structure and function.",
      "Muscle uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function.",
      "GenePro uses a SOM to predict the effects of synonymous codon usage on gene expression and protein function.",
      "CodonDiversity uses a SOM to identify patterns of synonymous codon usage in a given gene.",
      "Transcodon uses a SOM to predict the effects of synonymous codon substitutions on protein structure and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about the specific functions of CodonOpt, Muscle, GenePro, CodonDiversity, and Transcodon, it is not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 is a cutting-edge AI language model developed by the Meta AI team. It is a deep learning model that is trained on a large corpus of text data to generate human-like language outputs. MINDY-1 is capable of answering a wide range of questions, from simple queries to more complex conversations.\nHere are some key features of MINDY-1:\n1. Text-to-Text Translation: MINDY-1 can translate text from one language to another with high accuracy. It has been trained on a large dataset of text from the internet, which allows it to generate translations that are both accurate and fluent.\n2. Question Answering: MINDY-1 can answer a wide range of questions, from simple queries to more complex conversations. It uses a combination of natural language processing (NLP) and machine learning algorithms to understand the context of a question and generate an appropriate response.\n3. Writing Assistance: MINDY-1 can assist with writing tasks such as summarizing articles, writing short stories, and even generating entire books. It can also help with writing tasks such as proofreading and editing.\n4. Conversational Dialogue: MINDY-1 can engage in natural-sounding conversations with humans, using a combination of NLP and machine learning algorithms to understand the context of a conversation and generate appropriate responses.\n5. Generative Text: MINDY-1 can generate text on a given topic or subject, using a combination of NLP and machine learning algorithms to understand the context of the topic and generate relevant text.\n6. Sentiment Analysis: MINDY-1 can analyze the sentiment of text, such as determining whether a piece of text is positive, negative, or neutral.\n7. Named Entity Recognition: MINDY-1 can identify and classify named entities in text, such as people, organizations, and locations.\n8. Question Generation: MINDY-1 can generate new questions based on a given prompt or topic, using a combination of NLP and machine learning algorithms to understand the context of the prompt and generate appropriate questions.\n9. Summarization: MINDY-1 can summarize long pieces of text, such as articles or documents, using a combination of NLP and machine learning algorithms to identify the most important information and generate a concise summary.\n10. Creative Writing: M",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is an AI language model developed by the Meta AI team.\n2. MINDY-1 is trained on a large corpus of text data to generate human-like language outputs.\n3. The model is capable of text-to-text translation with high accuracy.\n4. MINDY-1 can assist with writing tasks such as summarizing articles and generating text on given topics.\n5. The model can analyze sentiment and identify named entities in text.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is an AI language model developed by the Meta AI team.",
      "MINDY-1 is trained on a large corpus of text data to generate human-like language outputs.",
      "The model is capable of text-to-text translation with high accuracy.",
      "MINDY-1 can assist with writing tasks such as summarizing articles and generating text on given topics.",
      "The model can analyze sentiment and identify named entities in text."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, each with their own strengths and limitations. Here are some of the most popular and widely-used tools in this field:\n1. ClastAr: ClastAr is a standalone software tool for the analysis of conserved genomic regions. It can identify clusters of orthologous genes (COGs) and estimate their evolutionary age. ClastAr can also identify conserved non-coding regions (CNCs) and predict their functional importance.\n2. PhastCons: PhastCons is a widely used tool for the analysis of conserved genomic regions. It can estimate the degree of conservation across multiple alignments of protein sequences from different species, and identifyconstraints on evolutionary changes in these regions. PhastCons can also output a variety of statistics and analysis results, including the distribution of amino acid substitution rates and the identification of positively selected genes.\n3. Prolos: Prolos is a tool for the analysis of highly conserved regions in multiple protein alignments. It can identify clusters of conserved residues and estimate their degree of conservation, and can also predict the functional significance of these regions. Prolos can output a variety of results, including a multiple sequence alignment of the conserved regions and a set of prediction rules for functional sites.\n4. C povera: Cpovera is a tool for the analysis of conserved genomic regions in multiple alignments of nucleotide sequences. It can identify clusters of orthologous genes and estimate their degree of conservation, and can also predict the functional significance of these regions. Cpovera can output a variety of results, including a multiple sequence alignment of the conserved regions and a set of prediction rules for functional sites.\n5. PhyloBLAST: PhyloBLAST is a tool for the analysis of conserved genomic regions in multiple alignments of protein sequences. It can identify clusters of orthologous genes and estimate their degree of conservation, and can also predict the functional significance of these regions. PhyloBLAST can output a variety of results, including a multiple sequence alignment of the conserved regions and a set of prediction rules for functional sites.\n6. Dali: Dali is a tool for the analysis of conserved genomic regions in multiple alignments of protein sequences. It can identify clusters of orthologous genes and",
    "llama-2-7b-chat-hf_fact_raw": "1. ClastAr is a software tool used for analyzing conserved genomic regions and identifying clusters of orthologous genes and conserved non-coding regions.\n2. PhastCons can estimate conservation across multiple alignments of protein sequences from various species and identify constraints on evolutionary changes.\n3. Prolos is designed to analyze highly conserved regions in multiple protein alignments and predict the functional significance of these regions.\n4. Cpovera analyzes conserved genomic regions in multiple alignments of nucleotide sequences and can predict functional significance of these regions.\n5. PhyloBLAST identifies clusters of orthologous genes in multiple alignments of protein sequences and estimates their degree of conservation.",
    "llama-2-7b-chat-hf_fact": [
      "ClastAr is a software tool used for analyzing conserved genomic regions and identifying clusters of orthologous genes and conserved non-coding regions.",
      "PhastCons can estimate conservation across multiple alignments of protein sequences from various species and identify constraints on evolutionary changes.",
      "Prolos is designed to analyze highly conserved regions in multiple protein alignments and predict the functional significance of these regions.",
      "Cpovera analyzes conserved genomic regions in multiple alignments of nucleotide sequences and can predict functional significance of these regions.",
      "PhyloBLAST identifies clusters of orthologous genes in multiple alignments of protein sequences and estimates their degree of conservation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PhastCons can estimate conservation across multiple alignments of nucleotide sequences from various species and identify constraints on evolutionary changes.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: PhyloBLAST compares protein sequences to a database of known sequences to identify homologous genes and does not directly estimate their degree of conservation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! The PIEZO2 gene is associated with several diseases, including:\n1. Ciliopathies: The PIEZO2 gene codes for a protein called PIEZO2, which is involved in the structure and function of cilia, small hair-like structures on the surface of cells that play a critical role in cellular signaling and movement. Mutations in the PIEZO2 gene have been linked to a group of rare genetic disorders known as ciliopathies, which can cause a range of symptoms including respiratory problems, polycystic kidney disease, and other organ system defects.\n2. Primary ciliary dyskinesia (PCD): PIEZO2 mutations are a common cause of primary ciliary dyskinesia (PCD), a rare genetic disorder that affects the structure and function of cilia. PCD is characterized by difficulties breathing, nasal congestion, and recurrent respiratory infections.\n3. Polycystic kidney disease (PKD): Some mutations in the PIEZO2 gene have been linked to an increased risk of developing polycystic kidney disease (PKD), a genetic disorder that causes cysts to grow on the kidneys. PKD can lead to kidney failure and other complications if left untreated.\nIt's important to note that not all PIEZO2 variants are pathogenic, and the specific disease association of a given variant depends on the context of the individual. Genetic counseling and testing can help determine whether a specific PIEZO2 variant is likely to cause disease.\nI hope this information helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been linked to ciliopathies, which can cause respiratory problems and polycystic kidney disease.\n2. PIEZO2 mutations are a common cause of primary ciliary dyskinesia (PCD).\n3. Some mutations in the PIEZO2 gene have been linked to an increased risk of developing polycystic kidney disease (PKD).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been linked to ciliopathies, which can cause respiratory problems and polycystic kidney disease.",
      "PIEZO2 mutations are a common cause of primary ciliary dyskinesia (PCD).",
      "Some mutations in the PIEZO2 gene have been linked to an increased risk of developing polycystic kidney disease (PKD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene have not been linked to ciliopathies, they are linked to conditions related to mechanosensation such as distal arthrogryposis and Gordon syndrome.\n2. FALSE [correction]: PIEZO2 mutations are not a common cause of primary ciliary dyskinesia (PCD), which is usually caused by mutations in genes responsible for the structure and function of cilia.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization is the formation of a protein complex between two proteins, ERAP1 and ERAP2. This dimerization promotes several cellular processes, including:\n1. mRNA degradation: ERAP1 and ERAP2 are involved in the degradation of specific messenger RNAs (mRNAs) that are involved in the regulation of gene expression. Dimerization of ERAP1 and ERAP2 enhances the degradation of these mRNAs, leading to changes in gene expression.\n2. Nuclear export: ERAP1 and ERAP2 also play a role in the export of proteins and mRNAs from the nucleus to the cytoplasm. Dimerization of these proteins helps to facilitate this process by mediating the interaction between export factors and their substrates.\n3. Transcriptional regulation: ERAP1 and ERAP2 can also interact with transcription factors and modulate their activity. Dimerization of these proteins helps to recruit transcription factors to specific genomic locations, enhancing their ability to interact with DNA and modulate gene expression.\n4. Splicing regulation: ERAP1 and ERAP2 are also involved in the regulation of pre-mRNA splicing, the process by which introns are removed from the pre-mRNA and exons are joined together to form mature RNA. Dimerization of these proteins helps to recruit splicing factors to specific genomic locations, enhancing the efficiency of pre-mRNA splicing.\n5. miRNA biogenesis: ERAP1 and ERAP2 are also involved in the biogenesis of microRNAs (miRNAs), which are small non-coding RNAs that play a key role in post-transcriptional gene regulation. Dimerization of these proteins helps to recruit miRNA biogenesis factors to specific genomic locations, enhancing the efficiency of miRNA processing.\nIn summary, ERAP1-ERAP2 dimerization is a complex process that plays a multifaceted role in cellular processes including mRNA degradation, nuclear export, transcriptional regulation, splicing regulation, and miRNA biogenesis. The exact mechan",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1 and ERAP2 are involved in the degradation of specific messenger RNAs (mRNAs).\n2. ERAP1 and ERAP2 play a role in the export of proteins and mRNAs from the nucleus to the cytoplasm.\n3. ERAP1 and ERAP2 can interact with transcription factors to modulate their activity.\n4. ERAP1 and ERAP2 are involved in the regulation of pre-mRNA splicing.\n5. ERAP1 and ERAP2 are involved in the biogenesis of microRNAs (miRNAs).",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1 and ERAP2 are involved in the degradation of specific messenger RNAs (mRNAs).",
      "ERAP1 and ERAP2 play a role in the export of proteins and mRNAs from the nucleus to the cytoplasm.",
      "ERAP1 and ERAP2 can interact with transcription factors to modulate their activity.",
      "ERAP1 and ERAP2 are involved in the regulation of pre-mRNA splicing.",
      "ERAP1 and ERAP2 are involved in the biogenesis of microRNAs (miRNAs)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are involved in the trimming of peptide antigens for presentation by MHC class I molecules, not the degradation of mRNAs.\n2. FALSE [correction]: ERAP1 and ERAP2 are not known to be involved in the export of proteins and mRNAs from the nucleus to the cytoplasm; they are aminopeptidases located in the cytoplasm and involved in antigen processing.\n3. UNKNOWN\n4. FALSE [correction]: ERAP1 and ERAP2 are not involved in the regulation of pre-mRNA splicing; they function in the trimming of peptide antigens.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two important proteins involved in the regulation of stem cell maintenance and differentiation in non-damaged gallbladders. Here is a detailed explanation of their functions:\n1. R-spondin 1:\nR-spondin 1 is a secreted protein that belongs to the R-spondin family, which is a group of secreted proteins that play critical roles in the regulation of stem cell maintenance and differentiation in various tissues, including the gallbladder. R-spondin 1 is expressed in the biliary epithelial cells of the gallbladder and plays a key role in maintaining the stem cell-like properties of these cells.\nStudies have shown that R-spondin 1 regulates the expression of genes involved in stem cell maintenance and differentiation in the gallbladder. For example, R-spondin 1 inhibits the expression of genes involved in the differentiated cell fate, such as the expression of the cell adhesion molecule E-cadherin, and promotes the expression of genes involved in stem cell maintenance, such as the expression of the stem cell marker, CD44.\nAdditionally, R-spondin 1 has been shown to modulate the activity of the transforming growth factor-beta (TGF-β) signaling pathway, which is important for regulating stem cell maintenance and differentiation in the gallbladder. R-spondin 1 inhibits the activity of TGF-β, which induces the expression of genes involved in differentiation and suppresses the expression of genes involved in stem cell maintenance.\n2. Noggin:\nNoggin is a secreted protein that belongs to the Bone Morphogenetic Protein (BMP) family. BMPs are a group of proteins that play critical roles in the regulation of stem cell maintenance and differentiation in various tissues, including the gallbladder. Noggin is specifically a BMP inhibitor, which means it binds to and inhibits the activity of BMPs.\nIn the gallbladder, Noggin regulates the expression of genes involved in stem cell maintenance and differentiation by binding to and inhibiting the activity of BMP",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein that is part of the R-spondin family.\n2. R-spondin 1 is expressed in the biliary epithelial cells of the gallbladder.\n3. R-spondin 1 plays a role in regulating the expression of genes involved in stem cell maintenance and differentiation in the gallbladder.\n4. Noggin is a secreted protein that is part of the Bone Morphogenetic Protein (BMP) family.\n5. Noggin functions as a BMP inhibitor in the gallbladder.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein that is part of the R-spondin family.",
      "R-spondin 1 is expressed in the biliary epithelial cells of the gallbladder.",
      "R-spondin 1 plays a role in regulating the expression of genes involved in stem cell maintenance and differentiation in the gallbladder.",
      "Noggin is a secreted protein that is part of the Bone Morphogenetic Protein (BMP) family.",
      "Noggin functions as a BMP inhibitor in the gallbladder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Noggin functions as a BMP inhibitor; however, whether it specifically acts in the gallbladder is unclear without more context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a complex enzyme that contains multiple subunits and requires the presence of certain subunits for its proper functioning.\nNOX5 is composed of four subunits: NOX5A, NOX5B, NOX5C, and NOX5D. These subunits work together to catalyze the transfer of electrons from NADPH to oxygen, resulting in the production of superoxide (O2-). The precise function of each subunit is as follows:\n1. NOX5A: This subunit is the catalytic core of the enzyme and is responsible for the transfer of electrons from NADPH to oxygen. It contains a conserved flavin prosthetic group that is involved in the electron transfer reaction.\n2. NOX5B: This subunit is involved in the regulation of the enzyme's activity and is responsible for the binding of cytosolic factors that modulate the enzyme's activity.\n3. NOX5C: This subunit is involved in the binding of the enzyme to the plasma membrane and plays a role in the targeting of the enzyme to specific subcellular locations.\n4. NOX5D: This subunit is involved in the anchoring of the enzyme to the plasma membrane and plays a role in the stability of the enzyme.\nThe precise function of each subunit in the catalytic cycle of NOX5 is as follows:\na. NOX5A: This subunit is responsible for the transfer of electrons from NADPH to the oxygen molecule, resulting in the production of superoxide (O2-).\nb. NOX5B: This subunit is involved in the transfer of electrons from the superoxide (O2-) to another electron acceptor, resulting in the conversion of oxidized NOX5 to an intermediate state.\nc. NOX5C: This subunit is involved in the transfer of electrons from the intermediate state of NOX5 to another electron acceptor, resulting in the final reduction of the enzyme.\nd. NOX5D: This subunit is involved in the stabilization of the enzyme and plays a role in the inhibition of the enzyme's",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a complex enzyme that requires the presence of certain subunits for its proper functioning.\n2. NOX5 is composed of four subunits: NOX5A, NOX5B, NOX5C, and NOX5D.\n3. NOX5A is the catalytic core of the enzyme, responsible for transferring electrons from NADPH to oxygen.\n4. NOX5B is involved in regulating the enzyme's activity and binds cytosolic factors that modulate the enzyme's activity.\n5. NOX5C is involved in binding the enzyme to the plasma membrane and plays a role in targeting the enzyme to specific subcellular locations.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a complex enzyme that requires the presence of certain subunits for its proper functioning.",
      "NOX5 is composed of four subunits: NOX5A, NOX5B, NOX5C, and NOX5D.",
      "NOX5A is the catalytic core of the enzyme, responsible for transferring electrons from NADPH to oxygen.",
      "NOX5B is involved in regulating the enzyme's activity and binds cytosolic factors that modulate the enzyme's activity.",
      "NOX5C is involved in binding the enzyme to the plasma membrane and plays a role in targeting the enzyme to specific subcellular locations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: NOX5 does not have subunits named NOX5A, NOX5B, NOX5C, or NOX5D. NOX5 is a single polypeptide enzyme.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are involved in the regulation of iron metabolism in the body. While they have some similar functions, they are not directly connected in terms of their structure or function. However, they do interact in some way to regulate iron homeostasis in the body.\nFurin is a protease enzyme that is produced in the liver and is responsible for activating a number of other proteins by catalyzing the removal of their inactive proforms. One of the proteins that furin activates is hepcidin, which is a hormone that regulates iron metabolism in the body. Hepcidin is produced in the liver and acts as a negative regulator of iron absorption in the duodenum and jejunum, and it also induces the degradation of ferroportin, a protein involved in iron efflux from cells.\nHepcidin is a key regulator of iron homeostasis in the body, and its activity is tightly linked to the availability of iron in the body. When iron levels are low, hepcidin expression is induced, leading to a reduction in iron absorption and an increase in iron recycling from old red blood cells. Conversely, when iron levels are high, hepcidin expression is reduced, leading to an increase in iron absorption and a decrease in iron recycling.\nFurin plays a role in this regulation of hepcidin expression by activating the proform of hepcidin, which is produced in the liver and is inactive until it is cleaved by furin. Once activated, hepcidin can enter the circulation and bind to its receptor on the surface of enterocytes, where it inhibits iron absorption.\nIn summary, furin and hepcidin are two proteins that are involved in the regulation of iron metabolism in the body. Furin activates hepcidin by cleaving its proform, which then enters the circulation and regulates iron absorption in the gut. This tight regulation of iron homeostasis is important for maintaining appropriate iron levels in the body and preventing iron overload or deficiency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme that activates other proteins by removing their inactive proforms.\n2. Hepcidin is a hormone produced in the liver that regulates iron metabolism.\n3. Hepcidin acts as a negative regulator of iron absorption in the duodenum and jejunum.\n4. The activity of hepcidin is linked to the availability of iron in the body.\n5. Furin activates the proform of hepcidin, allowing it to enter circulation and regulate iron absorption.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme that activates other proteins by removing their inactive proforms.",
      "Hepcidin is a hormone produced in the liver that regulates iron metabolism.",
      "Hepcidin acts as a negative regulator of iron absorption in the duodenum and jejunum.",
      "The activity of hepcidin is linked to the availability of iron in the body.",
      "Furin activates the proform of hepcidin, allowing it to enter circulation and regulate iron absorption."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Furin does not directly activate the proform of hepcidin. The activation of hepcidin is regulated by various factors including iron levels, inflammation, and erythropoiesis, not directly by Furin.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the Fermentation Gene Cluster (FGC). The FGC is responsible for the production of ethanol and other compounds during fermentation, a metabolic process in which sugars are converted into alcohol and carbon dioxide.\nThe FGC contains a total of 22 genes, which are organized into four functional modules:\n1. Stop Gene Module: Encodes proteins that regulate the fermentation process by inhibiting the activity of enzymes involved in glycolysis and the Pentose Phosphate Pathway (PPP).\n2. Alcoholic Fermentation Module: Encodes proteins involved in the alcoholic fermentation process, including the enzymes ADH1, ADH2, and ADH3. These enzymes catalyze the conversion of sugars into ethanol.\n3. Sugar Transport Module: Encodes proteins that facilitate the transport of sugars across the plasma membrane.\n4. Pentose Phosphate Pathway Module: Encodes proteins involved in the PPP, which is a metabolic pathway that generates NADPH and ribose-5-phosphate, important for the production of nucleotides and other metabolites.\nThe FGC is highly redundant, meaning that several genes within the cluster are involved in different steps of the fermentation process. This redundancy allows the yeast to maintain the fermentation process even when some genes are inactivated, providing flexibility and robustness to the cell.\nIn addition to the FGC, there are other metabolic gene clusters in yeast involved in other metabolic processes such as amino acid, lipid, and nucleotide metabolism. However, the FGC is the largest and most well-studied metabolic gene cluster in yeast and plays a critical role in the production of ethanol and other compounds during fermentation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the Fermentation Gene Cluster (FGC).\n2. The FGC is responsible for the production of ethanol and other compounds during fermentation.\n3. The Fermentation Gene Cluster contains a total of 22 genes.\n4. The FGC is organized into four functional modules: Stop Gene Module, Alcoholic Fermentation Module, Sugar Transport Module, and Pentose Phosphate Pathway Module.\n5. The Fermentation Gene Cluster has redundancy, allowing yeast to maintain fermentation even when some genes are inactivated.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the Fermentation Gene Cluster (FGC).",
      "The FGC is responsible for the production of ethanol and other compounds during fermentation.",
      "The Fermentation Gene Cluster contains a total of 22 genes.",
      "The FGC is organized into four functional modules: Stop Gene Module, Alcoholic Fermentation Module, Sugar Transport Module, and Pentose Phosphate Pathway Module.",
      "The Fermentation Gene Cluster has redundancy, allowing yeast to maintain fermentation even when some genes are inactivated."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The Fermentation Gene Cluster contains a total of 25 genes.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT lncRNA (Long Non-Coding RNA) is a type of non-coding RNA that plays a crucial role in regulating gene expression by acting as a negative regulator of transcription. Here are some key aspects of the role of LIMT lncRNA:\n1. Transcriptional regulation: LIMT lncRNA functions by binding to specific DNA sequences and preventing the recruitment of RNA polymerase, the enzyme responsible for transcribing DNA into RNA, to these sequences. By doing so, LIMT lncRNA can suppress the expression of target genes, leading to changes in gene expression profiles.\n2. Tissue-specific expression: LIMT lncRNA is expressed in specific tissues, such as the brain, heart, and liver, and its expression levels vary in these tissues. This specific tissue-wide expression profile enables LIMT lncRNA to regulate gene expression in a tissue-specific manner.\n3. Cellular differentiation: During cellular differentiation, the expression levels of LIMT lncRNA change, and it plays an essential role in regulating cell fate decisions by controlling the expression of genes involved in cell fate determination.\n4. Cancer progression: Limited expression of LIMT lncRNA has been observed in various types of cancer, including breast, lung, and colon cancer. It has been postulated that the loss of LIMT lncRNA expression may contribute to cancer progression by altering the expression of genes involved in cell growth, proliferation, and apoptosis (programmed cell death).\n5. Stem cell regulation: LIMT lncRNA also plays a role in regulating stem cell self-renewal and differentiation. It regulates the expression of genes involved in stem cell maintenance and differentiation, and its dysregulation may lead to stem cell-related disorders.\n6. Energy metabolism: LIMT lncRNA has been shown to regulate genes involved in energy metabolism, particularly in the context of cancer. The downregulation of LIMT lncRNA has been linked to increased glucose uptake, glycolysis, and oxidative phosphorylation, all of which are critical for cancer cell survival and proliferation.\n7",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA acts as a negative regulator of transcription by binding to DNA sequences and preventing RNA polymerase recruitment.\n2. LIMT lncRNA is expressed in specific tissues such as the brain, heart, and liver.\n3. The expression levels of LIMT lncRNA change during cellular differentiation, influencing cell fate decisions.\n4. A limited expression of LIMT lncRNA has been observed in various types of cancer.\n5. LIMT lncRNA plays a role in stem cell self-renewal and differentiation regulation.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA acts as a negative regulator of transcription by binding to DNA sequences and preventing RNA polymerase recruitment.",
      "LIMT lncRNA is expressed in specific tissues such as the brain, heart, and liver.",
      "The expression levels of LIMT lncRNA change during cellular differentiation, influencing cell fate decisions.",
      "A limited expression of LIMT lncRNA has been observed in various types of cancer.",
      "LIMT lncRNA plays a role in stem cell self-renewal and differentiation regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help!\nThere are several R packages that can be used for SNP (Single Nucleotide Polymorphism) enrichment analysis, but some of the most popular and widely used packages are:\n1. `exonder`: This package provides a flexible framework for performing enrichment analysis of genomic intervals. It allows users to perform both nominal and reviewed (i.e., corrected for multiple testing) enrichment analysis using a variety of test statistics, including Fisher's exact test, chi-square test, and the hypergeometric test.\n2. `GSEA`: This package is designed for gene set enrichment analysis (GSEA) and can be used to perform pathway-level enrichment analysis of genomic intervals. It uses areacted frame approach to calculate the enrichment score and can handle large-scale genomic data sets.\n3. `SNPaes`: This package provides a comprehensive framework for genome-wide association study (GWAS) analysis, including enrichment analysis for SNPs. It can perform both nominal and corrected (using the Benjamini-Hochberg procedure) enrichment analysis and allows users to filter and select genes based on multiple criteria.\n4. `enrichr`: This package provides a flexible framework for performing enrichment analysis of genomic intervals. It allows users to perform both nominal and corrected (using the Benjamini-Hochberg procedure) enrichment analysis using a variety of test statistics, including Fisher's exact test, chi-square test, and the hypergeometric test.\n5. `circleplot`: This package provides a graphical interface for performing enrichment analysis of genomic intervals using the GSEA algorithm. It allows users to visualize the results of the enrichment analysis using a circular plot and can be used to identify pathways that are enriched in the studied genomic interval.\nAll of these packages have been widely used and are reliable for performing SNP enrichment analysis, but it is important to keep in mind that the results of the enrichment analysis may change depending on the specific methods used and the data sets used for analysis. It is recommended to use multiple packages and methods to validate the results of the enrichment analysis.\nI hope this helps! Let me know if you have any further",
    "llama-2-7b-chat-hf_fact_raw": "1. The `exonder` R package provides a framework for performing SNP enrichment analysis with various test statistics.\n2. `GSEA` is an R package used for pathway-level enrichment analysis of genomic intervals.\n3. `SNPaes` is an R package designed for GWAS analysis, including SNP enrichment analysis, with options for nominal and corrected analysis.\n4. The `enrichr` R package allows for enrichment analysis of genomic intervals with nominal and corrected analysis using multiple test statistics.\n5. `circleplot` is an R package that visualizes the results of enrichment analysis using the GSEA algorithm through a circular plot.",
    "llama-2-7b-chat-hf_fact": [
      "The `exonder` R package provides a framework for performing SNP enrichment analysis with various test statistics.",
      "`GSEA` is an R package used for pathway-level enrichment analysis of genomic intervals.",
      "`SNPaes` is an R package designed for GWAS analysis, including SNP enrichment analysis, with options for nominal and corrected analysis.",
      "The `enrichr` R package allows for enrichment analysis of genomic intervals with nominal and corrected analysis using multiple test statistics.",
      "`circleplot` is an R package that visualizes the results of enrichment analysis using the GSEA algorithm through a circular plot."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge of the content and functionality of these R packages, it is not possible to accurately determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are critical for the proper development and maintenance of the central nervous system (CNS), particularly in the context of ependymal cell formation. Ependymal cells are a type of glial cell that lines the ventricles in the brain and spinal cord, and play a crucial role in the production and circulation of cerebrospinal fluid (CSF). The process of radial glial specification to ependymal cells is complex and involves multiple key players. Here are some of the key players involved in this process:\n1. Notch signaling pathway: The Notch signaling pathway is a crucial regulator of radial glial fate specification and differentiation. Notch is a transmembrane receptor that is activated by the binding of its ligands, Jagged1 and Delta-like 1, which are expressed on the surface of nearby cells. Activation of Notch signaling leads to the expression of genes involved in radial glial fate specification and the suppression of genes involved in other fates, such as neuronal differentiation.\n2. Sox2: Sox2 is a transcription factor that is essential for the maintenance of radial glial cells and their fate specification. Sox2 is expressed in radial glial cells and is required for their proliferation, survival, and differentiation. Sox2 also regulates the expression of genes involved in the Notch signaling pathway, thereby modulating the switch from radial glial to ependymal cell fate.\n3. Klf2: Krüppel-like factor 2 (Klf2) is a transcription factor that is involved in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells. Klf2 is expressed in radial glial cells and regulates the expression of genes involved in the Notch signaling pathway and the maintenance of radial glial cell fate.\n4. Pax7: Paired box protein 7 (Pax7) is a transcription factor that is expressed in radial glial cells and plays a crucial role in their differentiation to ependymal cells. Pax7 regulates the expression of genes involved in the Notch signaling pathway and the maintenance of radial glial cell fate, and is required for the proper formation of the ependymal cell",
    "llama-2-7b-chat-hf_fact_raw": "1. The Notch signaling pathway is a key regulator of radial glial cell fate specification and differentiation.\n2. Sox2 is a necessary transcription factor for the maintenance and fate specification of radial glial cells.\n3. Krüppel-like factor 2 (Klf2) is involved in regulating cell fate decisions of radial glial cells to ependymal cells.\n4. Paired box protein 7 (Pax7) plays a crucial role in the differentiation of radial glial cells to ependymal cells.\n5. Ependymal cells line the ventricles in the brain and spinal cord and are involved in the production and circulation of cerebrospinal fluid (CSF).",
    "llama-2-7b-chat-hf_fact": [
      "The Notch signaling pathway is a key regulator of radial glial cell fate specification and differentiation.",
      "Sox2 is a necessary transcription factor for the maintenance and fate specification of radial glial cells.",
      "Krüppel-like factor 2 (Klf2) is involved in regulating cell fate decisions of radial glial cells to ependymal cells.",
      "Paired box protein 7 (Pax7) plays a crucial role in the differentiation of radial glial cells to ependymal cells.",
      "Ependymal cells line the ventricles in the brain and spinal cord and are involved in the production and circulation of cerebrospinal fluid (CSF)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of brain tumor that is characterized by the lack of expression of certain biomarkers, including the following:\n1. Tumor suppressor proteins: Triple negative gliomas do not express enough of the tumor suppressor proteins, TP53, PTEN, or PML. These proteins help to regulate cell growth and prevent cells from becoming cancerous.\n2. Receptor proteins: Triple negative gliomas do not express enough of the receptor proteins, ERBB2 or EGFR. These proteins help to regulate cell growth and division.\n3. Markers of differentiation: Triple negative gliomas do not express enough of the markers of differentiation, GFAP or AQP4. These markers help to identify the type of cell that the tumor originated from.\n4. Neurofilaments: Triple negative gliomas do not express enough of the neurofilaments, NF-L or NF-H. These proteins help to regulate the structure and function of neurons.\n5. Mitochondrial proteins: Triple negative gliomas do not express enough of the mitochondrial proteins, COX6A1 or COX6B1. These proteins help to regulate the function of the mitochondria, which are the powerhouses of the cell.\nSymptoms of triple negative gliomas can include:\n* Seizures\n* Headaches\n* Weakness or numbness in the arms or legs\n* Confusion or difficulty with speech\n* Vision problems\n* Difficulty with coordination and balance\n* Fatigue\n* Weight loss\nTriple negative gliomas are often aggressive and tend to grow quickly. They can spread to other parts of the brain and are more likely to recur than other types of gliomas.\nTreatment options for triple negative gliomas can include:\n* Surgery: To remove as much of the tumor as possible.\n* Radiation therapy: To kill any remaining cancer cells.\n* Chemotherapy: To kill cancer cells throughout the body.\n* Targeted therapy: To attack specific molecules on the cancer cells that are involved in their growth and division.\nThe progn",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the lack of expression of tumor suppressor proteins, including TP53, PTEN, or PML.\n2. Triple negative gliomas do not express enough of the receptor proteins, ERBB2 or EGFR.\n3. Triple negative gliomas do not express enough of the markers of differentiation, GFAP or AQP4.\n4. Triple negative gliomas do not express enough of the neurofilaments, NF-L or NF-H.\n5. Triple negative gliomas do not express enough of the mitochondrial proteins, COX6A1 or COX6B1.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the lack of expression of tumor suppressor proteins, including TP53, PTEN, or PML.",
      "Triple negative gliomas do not express enough of the receptor proteins, ERBB2 or EGFR.",
      "Triple negative gliomas do not express enough of the markers of differentiation, GFAP or AQP4.",
      "Triple negative gliomas do not express enough of the neurofilaments, NF-L or NF-H.",
      "Triple negative gliomas do not express enough of the mitochondrial proteins, COX6A1 or COX6B1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Topaz1 is a software framework developed by the United States National Security Agency (NSA) for cryptographic key management. It is designed to provide a standardized and secure way of managing cryptographic keys in a distributed environment, and it is widely used in various applications, including government agencies, defense departments, and financial institutions.\nTopaz1 provides a comprehensive set of tools and protocols for key generation, distribution, revocation, and management. It supports a wide range of cryptographic algorithms, including symmetric encryption algorithms like AES and DES, and asymmetric encryption algorithms like RSA and elliptic curve cryptography. Topaz1 also provides support for key exchange protocols like TLS and SSL, and it can be used to manage keys in a variety of environments, including local machines, networked systems, and cloud-based infrastructures.\nSome of the key features of Topaz1 include:\n1. Key generation: Topaz1 provides a range of key management capabilities, including key generation, key recreation, and key updating. It also supports the generation of derived keys, such as initialization vectors (IVs) and nonces.\n2. Key distribution: Topaz1 provides secure mechanisms for distributing cryptographic keys to authorized users and systems. It supports a variety of key distribution protocols, including secure email, secure File Transfer protocol (FTP), and secure shell (SSH).\n3. Key revocation: Topaz1 includes tools for revoking and removing cryptographic keys from use. It provides mechanisms for tracking key usage and monitoring for unauthorized access, and it can automatically revoke keys that have been compromised or Otherwise become untrusted.\n4. Key management: Topaz1 provides a comprehensive set of tools for managing cryptographic keys, including key rotation, key backup, and key recovery. It also supports the integration of other key management systems and protocols.\n5. Security: Topaz1 is designed to provide a high level of security against unauthorized access and tampering. It uses advanced cryptographic techniques, such as digital signatures and message authentication codes (MACs), to ensure the integrity and authenticity of keys and other sensitive information.\n6. Scalability: Topaz1 is designed to be highly scalable, allowing it to support large-scale key management applications with thousands of users and systems.\n7. Flexibility: Topaz1 is highly flexible",
    "llama-2-7b-chat-hf_fact_raw": "1. Topaz1 is a software framework developed by the United States National Security Agency for cryptographic key management.\n2. Topaz1 is used in government agencies, defense departments, and financial institutions.\n3. Topaz1 supports symmetric encryption algorithms like AES and DES, and asymmetric encryption algorithms like RSA and elliptic curve cryptography.\n4. Topaz1 provides support for key exchange protocols like TLS and SSL.\n5. Topaz1 can manage keys in local machines, networked systems, and cloud-based infrastructures.",
    "llama-2-7b-chat-hf_fact": [
      "Topaz1 is a software framework developed by the United States National Security Agency for cryptographic key management.",
      "Topaz1 is used in government agencies, defense departments, and financial institutions.",
      "Topaz1 supports symmetric encryption algorithms like AES and DES, and asymmetric encryption algorithms like RSA and elliptic curve cryptography.",
      "Topaz1 provides support for key exchange protocols like TLS and SSL.",
      "Topaz1 can manage keys in local machines, networked systems, and cloud-based infrastructures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in the development and function of hematopoietic cells, including red blood cells, white blood cells, and platelets. The expression of GATA-1 isoforms is tightly regulated during hematopoiesis, and several genes have been identified that control the expression of these isoforms. Here are some of the genes that have been shown to regulate the expression of GATA-1 isoforms:\n1. GATA2: GATA2 is another transcription factor that plays a critical role in regulating the expression of GATA-1 isoforms. GATA2 binds to specific DNA sequences in the promoter region of the GATA-1 gene and triggers its transcription. Studies have shown that GATA2 and GATA-1 are co-regulated during hematopoiesis, and that alterations in GATA2 expression can lead to changes in GATA-1 isoform expression.\n2. KLF1: Krüppel-like factor 1 (KLF1) is a transcriptional repressor that has been shown to regulate the expression of GATA-1 isoforms. KLF1 binds to specific DNA sequences in the promoter region of the GATA-1 gene and represses its transcription. Studies have shown that KLF1 is expressed at low levels during early stages of hematopoiesis, but its expression increases as hematopoiesis progresses. KLF1 has been shown to regulates the expression of GATA-1 isoforms, particularly the GATA-1a isoform.\n3. NF-E2: Nuclear factor (erythroid-specific 2) (NF-E2) is a transcription factor that regulates the expression of GATA-1 isoforms in erythroid cells. Studies have shown that NF-E2 binds to specific DNA sequences in the promoter region of the GATA-1 gene and enhances its transcription. NF-E2 is essential for the proper development of red blood cells, and changes in its expression have been linked to red blood cell disorders.\n4. HIF1A:Hypoxia-inducible factor 1-alpha (HIF1A) is a transcription factor that plays a critical role in",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA2 is a transcription factor that regulates the expression of GATA-1 isoforms by binding to DNA sequences in the promoter region of the GATA-1 gene.\n2. Krüppel-like factor 1 (KLF1) is a transcriptional repressor that regulates the expression of GATA-1 isoforms by repressing transcription of the GATA-1 gene.\n3. Nuclear factor (erythroid-specific 2) (NF-E2) is a transcription factor that enhances the transcription of the GATA-1 gene in erythroid cells.\n4. Alterations in GATA2 expression can lead to changes in GATA-1 isoform expression.\n5. Hypoxia-inducible factor 1-alpha (HIF1A) is a transcription factor involved in the regulation of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "GATA2 is a transcription factor that regulates the expression of GATA-1 isoforms by binding to DNA sequences in the promoter region of the GATA-1 gene.",
      "Krüppel-like factor 1 (KLF1) is a transcriptional repressor that regulates the expression of GATA-1 isoforms by repressing transcription of the GATA-1 gene.",
      "Nuclear factor (erythroid-specific 2) (NF-E2) is a transcription factor that enhances the transcription of the GATA-1 gene in erythroid cells.",
      "Alterations in GATA2 expression can lead to changes in GATA-1 isoform expression.",
      "Hypoxia-inducible factor 1-alpha (HIF1A) is a transcription factor involved in the regulation of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GATA2 is a transcription factor that regulates the expression of GATA-1 by binding to DNA sequences in the promoter region of the GATA-1 gene, but it does not regulate GATA-1 isoforms.\n2. FALSE [correction]: Krüppel-like factor 1 (KLF1) is a transcriptional activator, not a repressor, that regulates the expression of GATA-1 by promoting transcription of the GATA-1 gene.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a powerful epigenetic profiling technique that allows researchers to simultaneously measure the expression levels of thousands of genes across their entire transcriptome, as well as their epigenetic marks (such as DNA methylation and histone modifications) at a single-nucleosome resolution.\nHere's a detailed explanation of what MIRA-seq is and how it works:\nWhat is MIRA-seq?:\nMIRA-seq stands for \"Methylation-sensitive reverse-transcription sequencing,\" and it is a relatively new technique that was developed to overcome the limitations of traditional epigenetic profiling methods. Traditional methods, such as bisulfite sequencing and methylation-specific PCR (MSP), can only provide information on a limited number of genes or regions of the genome at a time. In contrast, MIRA-seq can simultaneously profiling the epigenetic marks of an entire transcriptome, allowing researchers to identify patterns and changes in the epigenetic landscape across the genome.\nHow does MIRA-seq work?:\nThe MIRA-seq protocol involves three main steps:\n1. Sample preparation:\nIn this step, the sample (e.g., cells or tissues) is first treated with a methylation-sensitive reverse transcriptase (MST) enzyme that can only recognize actively transcribed mRNA. This step is essential because MST only recognizes mRNA with intact 5' caps and poly(A) tail, which are necessary for reverse transcription. Once the sample is treated with MST, the mRNA is then captured using a special probematerial (called a \"probe\") that is complementary to the mRNA.\n2. Library preparation:\nIn this step, the captured mRNA is then subjected to a library preparation protocol that involves fragmentation, end repair, and adapter ligation. The resulting libraries are then size-selected to isolate only the 100-200 base pair (bp) fragments that correspond to the size of the nucleosomes.\n3. Sequencing:\nIn this final step, the size-selected libraries are then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for \"Methylation-sensitive reverse-transcription sequencing.\"\n2. MIRA-seq is an epigenetic profiling technique that allows simultaneous measurement of gene expression levels and epigenetic marks.\n3. Traditional epigenetic profiling methods are limited to a small number of genes or genome regions at a time.\n4. The sample preparation step of MIRA-seq involves treating the sample with a methylation-sensitive reverse transcriptase enzyme.\n5. The library preparation step of MIRA-seq includes fragmentation, end repair, and adapter ligation of captured mRNA.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for \"Methylation-sensitive reverse-transcription sequencing.\"",
      "MIRA-seq is an epigenetic profiling technique that allows simultaneous measurement of gene expression levels and epigenetic marks.",
      "Traditional epigenetic profiling methods are limited to a small number of genes or genome regions at a time.",
      "The sample preparation step of MIRA-seq involves treating the sample with a methylation-sensitive reverse transcriptase enzyme.",
      "The library preparation step of MIRA-seq includes fragmentation, end repair, and adapter ligation of captured mRNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"Methylated CpG Island Recovery Assay sequencing.\"\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The sample preparation step of MIRA-seq involves treating the sample with a methylation-sensitive restriction enzyme.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST is a sterile, preservative-free, non-pyrogenic solution for intravenous (IV) injection. It is used for the treatment of acute pain in adults. The active ingredient in ARCALYST is ketorolac, which is a nonsteroidal anti-inflammatory drug (NSAID).\nThe indication for ARCALYST is as follows:\n* Management of moderate to severe pain in the short-term (up to 5 days) in adults.\nARCALYST is not indicated for the management of mild pain, as it may not be effective in providing adequate pain relief for these patients. Additionally, ARCALYST is not recommended for use in pediatric patients, as there are not enough data to establish its safety and effectiveness in this age group.\nIt is important to note that ketorolac, the active ingredient in ARCALYST, can cause gastrointestinal ulcers and bleeding, especially when used at high doses or for prolonged periods. Therefore, it is important to carefully evaluate the patient's medical history and perform regular monitoring of the patient's gastrointestinal system while using ARCALYST.\nIn summary, the primary indication for ARCALYST is the management of moderate to severe pain in adults for up to 5 days. However, it is important to carefully evaluate the patient's medical history and monitor their gastrointestinal system while using this medication to minimize the risk of adverse effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is used for the treatment of acute pain in adults.\n2. The active ingredient in ARCALYST is ketorolac, a nonsteroidal anti-inflammatory drug (NSAID).\n3. ARCALYST is indicated for the management of moderate to severe pain in adults for up to 5 days.\n4. ARCALYST is not indicated for the management of mild pain.\n5. ARCALYST is not recommended for use in pediatric patients due to insufficient data on safety and effectiveness.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is used for the treatment of acute pain in adults.",
      "The active ingredient in ARCALYST is ketorolac, a nonsteroidal anti-inflammatory drug (NSAID).",
      "ARCALYST is indicated for the management of moderate to severe pain in adults for up to 5 days.",
      "ARCALYST is not indicated for the management of mild pain.",
      "ARCALYST is not recommended for use in pediatric patients due to insufficient data on safety and effectiveness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ARCALYST is used for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, not acute pain.\n2. FALSE [correction]: The active ingredient in ARCALYST is rilonacept, not ketorolac.\n3. FALSE [correction]: ARCALYST is not indicated for the management of pain; it is used to treat inflammatory conditions.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'll do my best to provide a detailed answer.\nRobertsonian translocations are a type of chromosomal abnormality that involves the transfer of a portion of one acrocentric chromosome to another acrocentric chromosome. Acrocentric chromosomes are characterized by their terminal centromere, which is located near the ends of the chromosome.\nOf the 22 pairs of autosomal chromosomes in humans, there are six acrocentric chromosomes that are typically involved in Robertsonian translocations:\n1. Chromosome 13: This is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all translocations.\n2. Chromosome 14: Chromosome 14 is the second most common chromosome involved in Robertsonian translocations, accounting for approximately 20% of all translocations.\n3. Chromosome 15: Chromosome 15 is involved in approximately 5-7% of all Robertsonian translocations.\n4. Chromosome 17: Chromosome 17 is involved in approximately 3-5% of all Robertsonian translocations.\n5. Chromosome 21: Chromosome 21 is involved in approximately 1-2% of all Robertsonian translocations.\n6. Chromosome 22: Chromosome 22 is involved in approximately 1-2% of all Robertsonian translocations.\nIt's important to note that the specific chromosomes involved in a Robertsonian translocation can vary from one individual to another, and the arrangement of the genetic material on the translocated chromosome can also vary. In some cases, the translocated chromosome may contain a part of another chromosome, while in other cases, it may contain a part of the same chromosome.\nI hope this information helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are six acrocentric chromosomes typically involved in Robertsonian translocations.\n2. Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all translocations.\n3. Chromosome 14 is the second most common, accounting for approximately 20% of all Robertsonian translocations.\n4. Chromosome 15 is involved in approximately 5-7% of all Robertsonian translocations.\n5. Chromosomes 17, 21, and 22 are each involved in approximately 1-5% of all Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "There are six acrocentric chromosomes typically involved in Robertsonian translocations.",
      "Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all translocations.",
      "Chromosome 14 is the second most common, accounting for approximately 20% of all Robertsonian translocations.",
      "Chromosome 15 is involved in approximately 5-7% of all Robertsonian translocations.",
      "Chromosomes 17, 21, and 22 are each involved in approximately 1-5% of all Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromosome 14 is the most common chromosome involved in Robertsonian translocations, accounting for approximately 75% of all translocations.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the type of analysis and the data available. Here are a few packages that could be useful:\n1. `brain_tumor_classifier`: This package is specifically designed for the classification of brain tumors, including pediatric brain tumors. It uses a combination of machine learning algorithms and feature engineering techniques to classify tumors based on their histopathological characteristics. The package includes modules for data preprocessing, feature extraction, and classification, and can be used to classify tumors into different subtypes, such as gliomas, astrocytomas, and medulloblastomas.\n2. `rstan`: This package is a Bayesian linear mixed effects modeling framework that can be used for the analysis of pediatric brain tumor data. It allows for the estimation of fixed and random effects parameters, and can be used to model the variability in tumor measurements between different individuals and sites. The package includes a variety of models for binary and count data, as well as models for continuous data with various distributions.\n3. `MMGB charges`: This package is designed for the analysis of gene expression data, including data from pediatric brain tumors. It allows for the estimation of gene expression levels and the identification of differentially expressed genes between different groups, such as tumor and control tissues. The package includes methods for statistical analysis and visualization of gene expression data, as well as tools for clustering and pathway analysis.\n4. `pediatric_brain_tumor`: This package is a comprehensive resource for the analysis of pediatric brain tumor data. It includes a variety of tools and functions for preprocessing and analyzing tumor data, including functions for filtering, normalization, and feature engineering. The package also includes models for binary and count data, as well as tools for survival analysis and time-series analysis.\n5. `pediatric_tumor_segments`: This package is specifically designed for the segmentation of pediatric brain tumors. It includes a variety of algorithms and methods for segmenting tumors based on magnetic resonance imaging (MRI) data, including techniques for automated segmentation and image-based segmentation. The package also includes tools for visualizing and analyzing the segmented tumors, as well as functions for",
    "llama-2-7b-chat-hf_fact_raw": "1. The `brain_tumor_classifier` R package is designed for the classification of brain tumors, including pediatric brain tumors.\n2. `rstan` is an R package used for Bayesian linear mixed effects modeling of pediatric brain tumor data.\n3. `MMGB charges` is an R package used for analyzing gene expression data from pediatric brain tumors.\n4. The `pediatric_brain_tumor` R package is a resource for analyzing pediatric brain tumor data, including preprocessing and feature engineering functions.\n5. `pediatric_tumor_segments` is an R package used for the segmentation of pediatric brain tumors using MRI data.",
    "llama-2-7b-chat-hf_fact": [
      "The `brain_tumor_classifier` R package is designed for the classification of brain tumors, including pediatric brain tumors.",
      "`rstan` is an R package used for Bayesian linear mixed effects modeling of pediatric brain tumor data.",
      "`MMGB charges` is an R package used for analyzing gene expression data from pediatric brain tumors.",
      "The `pediatric_brain_tumor` R package is a resource for analyzing pediatric brain tumor data, including preprocessing and feature engineering functions.",
      "`pediatric_tumor_segments` is an R package used for the segmentation of pediatric brain tumors using MRI data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or references to these R packages, it's not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "NEMO (Nuclear Envelope-Associated Membranous Organization) is a protein that plays a crucial role in the immune system and is involved in various cellular processes, including innate immunity, inflammation, and cancer. While NEMO is not a zinc finger protein, it does contain zinc finger-like domains, which are responsible for its protein-DNA binding activity.\nZinc finger proteins are a class of transcription factors that are characterized by the presence of one or more zinc ions coordinately bound to cysteine residues in their structure. These proteins are involved in regulating gene expression by recognizing and binding to specific DNA sequences. Zinc finger proteins can either repress or activate transcription, depending on their specific DNA-binding pattern and the presence of other co-factors.\nNEMO, on the other hand, is a transmembrane protein that primarily localizes to the endoplasmic reticulum (ER) and the nuclear envelope. It contains multiple protein-protein interaction domains, including a coiled-coil domain, a proline-rich domain, and several SH3 (src homology 3) domains. These domains allow NEMO to interact with a variety of proteins and play a role in the regulation of signaling pathways involved in innate immunity, inflammation, and cancer.\nWhile NEMO does contain zinc finger-like domains, these domains are not responsible for its protein-DNA binding activity. Instead, NEMO uses its transmembrane domain to interact with the nuclear envelope, where it can regulate the activity of various transcription factors and other proteins involved in gene expression.\nIn summary, NEMO is not a zinc finger protein, but it contains zinc finger-like domains that are involved in its protein-protein interactions. While it does not directly bind to DNA, NEMO plays a critical role in regulating gene expression by interacting with other transcription factors and proteins involved in the regulation of inflammation and immune responses.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (Nuclear Envelope-Associated Membranous Organization) is not a zinc finger protein but contains zinc finger-like domains.\n2. Zinc finger proteins are characterized by the presence of zinc ions bound to cysteine residues in their structure.\n3. Zinc finger proteins regulate gene expression by recognizing and binding to specific DNA sequences.\n4. NEMO primarily localizes to the endoplasmic reticulum (ER) and the nuclear envelope.\n5. NEMO contains multiple protein-protein interaction domains, including a coiled-coil domain, a proline-rich domain, and SH3 domains.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (Nuclear Envelope-Associated Membranous Organization) is not a zinc finger protein but contains zinc finger-like domains.",
      "Zinc finger proteins are characterized by the presence of zinc ions bound to cysteine residues in their structure.",
      "Zinc finger proteins regulate gene expression by recognizing and binding to specific DNA sequences.",
      "NEMO primarily localizes to the endoplasmic reticulum (ER) and the nuclear envelope.",
      "NEMO contains multiple protein-protein interaction domains, including a coiled-coil domain, a proline-rich domain, and SH3 domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO contains multiple protein-protein interaction domains, including a coiled-coil domain and a leucine zipper domain, but it does not contain SH3 domains.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "TFIIS (Transcription Factor IIIs) is a transcriptional regulatory protein that plays a crucial role in the initiation of transcription in eukaryotic cells. While TFIIS does not directly affect nucleosome positioning, it can influence the process of nucleosome formation and remodeling, which in turn can impact the positioning of nucleosomes along the DNA molecule.\nNucleosome positioning refers to the spatial organization of nucleosomes along the DNA molecule, which can have significant consequences for gene expression. Nucleosomes are formed through the interaction of histone proteins and DNA, and their positioning can be influenced by various factors, including transcriptional activators and repressors, architectural proteins, and chromatin-modifying enzymes.\nTFIIS can affect nucleosome positioning in several ways:\n1. Nucleosome remodeling: TFIIS can stimulate the remodeling of nucleosomes through its interaction with the histone chaperone complex FACT (FACT is a Complex of Fellow Travelers and Chromatin-modifying factors). This remodeling can result in changes to the positioning of nucleosomes along the DNA molecule.\n2. Histone modifications: TFIIS can also induce histone modifications, such as histone H3 lysine 9 trimethylation (H3K9me3), which can affect nucleosome positioning. H3K9me3 is a repressive mark that can lead to the compactization of chromatin, making it more difficult for RNA polymerase to access the DNA template during transcription initiation.\n3. Chromatin looping: TFIIS can also influence chromatin looping events, which are important for the regulation of gene expression. Chromatin looping refers to the interaction between distant regulatory elements and gene promoters, which can lead to the activation or repression of gene transcription. TFIIS can facilitate these looping events by interacting with other transcription factors and chromatin-modifying enzymes.\n4. Transcriptional pausing: During transcription elongation, RNA polymerase can pause at specific DNA sequences, a process known as transcriptional pausing. TFIIS",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIIs) is a transcriptional regulatory protein that plays a role in the initiation of transcription in eukaryotic cells.\n2. TFIIS can stimulate the remodeling of nucleosomes through its interaction with the histone chaperone complex FACT.\n3. TFIIS can induce histone modifications, such as histone H3 lysine 9 trimethylation (H3K9me3).\n4. TFIIS can influence chromatin looping events, which are important for the regulation of gene expression.\n5. TFIIS can facilitate transcriptional pausing by interacting with RNA polymerase during transcription elongation.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIIs) is a transcriptional regulatory protein that plays a role in the initiation of transcription in eukaryotic cells.",
      "TFIIS can stimulate the remodeling of nucleosomes through its interaction with the histone chaperone complex FACT.",
      "TFIIS can induce histone modifications, such as histone H3 lysine 9 trimethylation (H3K9me3).",
      "TFIIS can influence chromatin looping events, which are important for the regulation of gene expression.",
      "TFIIS can facilitate transcriptional pausing by interacting with RNA polymerase during transcription elongation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS (Transcription Factor II S) is a transcriptional regulatory protein that plays a role in the elongation phase of transcription in eukaryotic cells.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Great question! The timing of origin firing near yeast centromeres is a fascinating topic. In budding yeast (Saccharomyces cerevisiae), the origins of replication are typically located near the centromeres, which are the regions where the repetitive DNA sequences known as satellite III are found.\nStudies have shown that the timing of origin firing near yeast centromeres can vary, depending on the specific location of the origin and the conditions under which the cells are grown. In general, however, it appears that origins located near the distal end of the centromere tend to fire later than those located near the proximal end.\nOne study published in the journal Nature in 2006 found that the distance between the origin and the centromere was a key factor in determining the timing of origin firing. The study found that origins located closer to the centromere fired later than those located farther away, suggesting that the centromere plays a role in regulating the timing of origin firing.\nAnother study published in the journal Cell in 2015 found that the timing of origin firing can be influenced by the presence of specific transcription factors. The study found that the transcription factor R presente (RNA polymerase I-specific binding protein eRP30) is required for the proper timing of origin firing near the centromere, and that eRP30 binds to specific DNA sequences near the origin to regulate its firing.\nAdditionally, a recent study published in the journal Genetics in 2020 found that the timing of origin firing near the centromere can be influenced by the presence of nearby heterochromatin, which is a type of repetitive DNA that is often found in the centromere region. The study found that the presence of heterochromatin can repress the activity of the nearby origin, leading to its firing later than origins located in less repressive locations.\nOverall, the timing of origin firing near yeast centromeres appears to be complex and influenced by a variety of factors, including the location of the origin relative to the centromere, the presence of transcription factors, and the presence of nearby heterochromatin. Further research is needed to fully understand the mechanisms that govern the timing of origin firing in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication in budding yeast (Saccharomyces cerevisiae) are typically located near the centromeres.\n2. The timing of origin firing near yeast centromeres varies depending on the location of the origin and the conditions under which the cells are grown.\n3. Origins located near the distal end of the centromere tend to fire later than those located near the proximal end.\n4. A study published in the journal Nature in 2006 found that the distance between the origin and the centromere affects the timing of origin firing.\n5. A study published in the journal Genetics in 2020 found that the presence of nearby heterochromatin can influence the timing of origin firing near the centromere.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication in budding yeast (Saccharomyces cerevisiae) are typically located near the centromeres.",
      "The timing of origin firing near yeast centromeres varies depending on the location of the origin and the conditions under which the cells are grown.",
      "Origins located near the distal end of the centromere tend to fire later than those located near the proximal end.",
      "A study published in the journal Nature in 2006 found that the distance between the origin and the centromere affects the timing of origin firing.",
      "A study published in the journal Genetics in 2020 found that the presence of nearby heterochromatin can influence the timing of origin firing near the centromere."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication in budding yeast (Saccharomyces cerevisiae) are not typically located near the centromeres; they are usually found at autonomous replicating sequences (ARS).\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as transfer RNA (tRNA) sequences, are a type of RNA molecule that plays a crucial role in the synthesis of proteins in mammalian cells. tRNAs are responsible for carrying the appropriate amino acids to the ribosome, where they are incorporated into the growing protein chain during protein synthesis.\nThe properties of mammalian GA-sequences can be broadly categorized into several areas:\n1. Sequence Composition: tRNAs are composed of several regions, including the coding region, the dolphin region, the D-arm, and the anticodon region. The coding region contains the codons that specify the amino acid to be incorporated into the protein. The dolphin region is a short sequence that helps to stabilize the tRNA structure. The D-arm is a variable region that is involved in the recognition of the tRNA by the ribosome. The anticodon region is responsible for recognizing the codon on the mRNA and aligning with the corresponding amino acid.\n2. tRNA Gene Structure: tRNA genes are located throughout the genome, with each gene contains a coding region, a promoter, and a terminator. The promoter region is responsible for recruiting RNA polymerase, the enzyme that transcribes the gene into RNA. The terminator region is responsible for signaling the end of the gene.\n3. tRNA Synthesis: tRNAs are synthesized through a process called transcription, which involves the following steps:\na. Initiation: The enzyme RNA polymerase binds to the promoter region of the tRNA gene and initiates transcription.\nb. Unfolding: The enzyme RNase III unwinds the DNA helix, and the RNA polymerase moves along the template strand, reading the nucleotides in the DNA code.\nc. Synthesis: The RNA polymerase reads the DNA code and adds nucleotides to the growing RNA chain.\nd. Termination: When the transcription terminates, the RNA polymerase releases the RNA transcript, and the process is complete.\n4. tRNA Modification: tR",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences, or tRNA sequences, play a crucial role in protein synthesis in mammalian cells.\n2. tRNAs carry amino acids to the ribosome where they are incorporated into the growing protein chain.\n3. tRNA sequences are composed of several regions including the coding region, the dolphin region, the D-arm, and the anticodon region.\n4. tRNA genes contain a coding region, a promoter, and a terminator.\n5. tRNAs are synthesized through a process called transcription which involves initiation, unfolding, synthesis, and termination.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences, or tRNA sequences, play a crucial role in protein synthesis in mammalian cells.",
      "tRNAs carry amino acids to the ribosome where they are incorporated into the growing protein chain.",
      "tRNA sequences are composed of several regions including the coding region, the dolphin region, the D-arm, and the anticodon region.",
      "tRNA genes contain a coding region, a promoter, and a terminator.",
      "tRNAs are synthesized through a process called transcription which involves initiation, unfolding, synthesis, and termination."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mammalian tRNA sequences, not GA-sequences, play a crucial role in protein synthesis in mammalian cells.\n2. TRUE\n3. FALSE [correction]: tRNA sequences are composed of several regions including the coding region, the D-arm, the TψC arm, and the anticodon region. There is no such thing as a dolphin region.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! To provide an accurate answer, I must inform you that the concept of \"Groucho-related genes\" (GRG) is not a recognized scientific term or gene category. Groucho is a comedic character from the Marx Brothers' films, and there are no genes in the mouse genome or any other organism that are specifically named after him.\nHowever, I can provide some information on the genetics of mice and their relationship to the Marx Brothers. Mice are common model organisms used in scientific research, particularly in the fields of genetics, physiology, and behavioral science. The laboratory mouse (Mus musculus) has been extensively studied and has a well-characterized genome that has been sequenced.\nWhile there are no genes specifically named \"Groucho,\" there are several genes in the mouse genome that are related to the development and function of the nervous system, which is the organ system that Groucho is most associated with. These genes include:\n1. Grin1 and Grin2: These genes encode for subunits of the N-methyl-D-aspartate (NMDA) receptor, which is a type of glutamate receptor involved in synaptic plasticity and learning.\n2. Grin3: This gene also encodes for a subunit of the NMDA receptor.\n3. Grm1: This gene encodes for a metabotropic glutamate receptor, which is a type of glutamate receptor that is involved in synaptic plasticity and learning.\n4. Grm3: This gene encodes for a metabotropic glutamate receptor that is involved in learning and memory.\n5. Grin4: This gene encodes for a subunit of the AMPA receptor, which is a type of glutamate receptor involved in fast synaptic transmission.\nThese genes are important for the proper functioning of the nervous system, and mutations in these genes have been implicated in various neurological disorders, including epilepsy, schizophrenia, and Alzheimer's disease.\nIn conclusion, while there are no genes specifically named \"Groucho,\" the mouse genome does contain",
    "llama-2-7b-chat-hf_fact_raw": "1. \"Groucho-related genes\" (GRG) is not a recognized scientific term or gene category.\n2. Mice are common model organisms used in scientific research.\n3. The laboratory mouse (Mus musculus) genome has been sequenced.\n4. Genes Grin1 and Grin2 encode for subunits of the NMDA receptor involved in synaptic plasticity and learning.\n5. Gene Grm3 encodes for a metabotropic glutamate receptor involved in learning and memory.",
    "llama-2-7b-chat-hf_fact": [
      "\"Groucho-related genes\" (GRG) is not a recognized scientific term or gene category.",
      "Mice are common model organisms used in scientific research.",
      "The laboratory mouse (Mus musculus) genome has been sequenced.",
      "Genes Grin1 and Grin2 encode for subunits of the NMDA receptor involved in synaptic plasticity and learning.",
      "Gene Grm3 encodes for a metabotropic glutamate receptor involved in learning and memory."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! RNA polymerase II (RNAPII) is a complex enzyme that plays a crucial role in transcribing DNA into RNA in eukaryotic cells. There are three subunits of RNAPII: RPB1 (large subunit), RPB2 (medium subunit), and RPB3 (small subunit). Of these subunits, RPB1 carries the RNA cleavage activity.\nRPB1 is the largest subunit of RNAPII and contains the active site where the enzymatic reaction takes place. It is responsible for positioning the RNA template and facilitating the movement of the transcription complex along the DNA template. RPB1 also contains a conserved RNA cleavage domain called the \"Ncke\" motif, which is responsible for cleaving the RNA transcript after transcription. This cleavage is essential for the maturation of the RNA transcript and its transport out of the nucleus.\nIn summary, RNA polymerase II subunit RPB1 carries the RNA cleavage activity, playing a crucial role in the maturation of RNA transcripts during transcription in eukaryotic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) transcribes DNA into RNA in eukaryotic cells.\n2. RNAPII has three subunits: RPB1, RPB2, and RPB3.\n3. The RPB1 subunit of RNAPII carries the RNA cleavage activity.\n4. RPB1 is the largest subunit of RNAPII and contains the active site for the enzymatic reaction.\n5. The \"Ncke\" motif within RPB1 is responsible for cleaving the RNA transcript after transcription.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) transcribes DNA into RNA in eukaryotic cells.",
      "RNAPII has three subunits: RPB1, RPB2, and RPB3.",
      "The RPB1 subunit of RNAPII carries the RNA cleavage activity.",
      "RPB1 is the largest subunit of RNAPII and contains the active site for the enzymatic reaction.",
      "The \"Ncke\" motif within RPB1 is responsible for cleaving the RNA transcript after transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNA polymerase II has 12 subunits, not just three.\n3. FALSE [correction]: The RPB1 subunit does not carry the RNA cleavage activity, it is involved in the synthesis of RNA.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the PERIOD (P Race is not a bonus). \"/>\nThe genetic basis of Ohdo syndrome is caused by mutations in the PERIOD (P Race is not a bonus). The protein encoded by the PERIOD gene is involved in the regulation of circadian rhythms, which are the internal biological processes that follow a daily cycle. PERIOD is a transcription factor that plays a key role in the regulation of the expression of clock genes, which are responsible for generating the circadian rhythm in living organisms.\nOhdo syndrome is characterized by a variety of symptoms, including sleep disorders, cognitive impairment, seizures, and cardiovascular problems. The disorder is caused by mutations in the PERIOD gene, which can result in the loss of function of the protein or the production of a faulty protein. These mutations can occur spontaneously or be inherited from one's parents.\nThe genetic mutations that cause Ohdo syndrome can affect any of the three exons in the PERIOD gene, which are the regions of the gene that contain the instructions for making the protein. These exons are numbered 1, 2, and 3, and mutations in any of these regions can result in the loss of function or the production of a faulty protein.\nThere are several known mutations in the PERIOD gene that have been linked to Ohdo syndrome. These include missense mutations, which result in a change in the amino acid sequence of the protein, and nonsense mutations, which result in the premature termination of protein synthesis. Other mutations may affect the splicing of the PERIOD mRNA, which can also disrupt the function of the protein.\nOhdo syndrome is a complex disorder that is still not fully understood. Researchers are continuing to study the genetic basis of the disorder and the mechanisms by which mutations in the PERIOD gene lead to the development of the disorder. In the future, genetic testing may be available to identify individuals who are at risk of developing Ohdo syndrome. However, at this time, there is no cure for the disorder, and treatment",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the PERIOD gene.\n2. The PERIOD gene encodes a protein involved in the regulation of circadian rhythms.\n3. Ohdo syndrome can involve symptoms such as sleep disorders, cognitive impairment, seizures, and cardiovascular problems.\n4. Mutations in any of the three exons of the PERIOD gene can result in Ohdo syndrome.\n5. Known mutations linked to Ohdo syndrome include missense mutations and nonsense mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the PERIOD gene.",
      "The PERIOD gene encodes a protein involved in the regulation of circadian rhythms.",
      "Ohdo syndrome can involve symptoms such as sleep disorders, cognitive impairment, seizures, and cardiovascular problems.",
      "Mutations in any of the three exons of the PERIOD gene can result in Ohdo syndrome.",
      "Known mutations linked to Ohdo syndrome include missense mutations and nonsense mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is not caused by mutations in the PERIOD gene; instead, it is caused by mutations in several genes, including KAT6B and MED12.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Ohdo syndrome is not solely caused by mutations in the PERIOD gene, and the number of exons involved in the responsible genes may vary.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! There are several R packages available for the analysis of psychiatric disease genes. Some of the popular ones include:\n1. PsychGen: This package provides functions for the analysis of genetic association studies in psychiatric disorders. It offers tools for statistical analysis, data visualization, and meta-analysis of genetic data.\n2. PsychAnal: This package offers a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for quality control, genotyping, imputation, and association studies.\n3. GAPP: The Genetic Analysis of Psychiatric Disorders Package is another popular package for the analysis of psychiatric disease genes. It includes functions for genetic association studies, gene-gene interaction analysis, and provides tools for visualizing and summarizing the results.\n4. PsychGWASamenta: This package provides functions for genome-wide association studies (GWAS) of psychiatric disorders. It includes tools for quality control, genotyping, and statistical analysis of genetic data.\n5. PSYCHEE: This package offers functions for the analysis of genetic data in psychiatric disorders, including GWAS, imputation, and gene-gene interaction analysis.\n6.Psyma: This package provides functions for the analysis of genetic data in psychiatric disorders, including association studies, regression analysis, and provides tools for visualizing and summarizing the results.\n7.PsychGenius: This package offers a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for quality control, genotyping, imputation, and association studies.\nThese packages are widely used in the field of psychiatric genetics and can be used to analyze genetic data from various psychiatric disorders such as autism, schizophrenia, bipolar disorder, and major depressive disorder.\nIt's worth noting that these packages are constantly evolving and new packages are being developed, so it's always a good idea to check the latest documentation and updates on the package website.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. PsychGen is an R package for the analysis of genetic association studies in psychiatric disorders.\n2. PsychAnal is an R package that offers tools for quality control, genotyping, imputation, and association studies in psychiatric disorders.\n3. GAPP is an R package that includes functions for genetic association studies and gene-gene interaction analysis in psychiatric disorders.\n4. PsychGWASamenta is an R package for genome-wide association studies of psychiatric disorders.\n5. PSYCHEE is an R package that provides functions for GWAS, imputation, and gene-gene interaction analysis in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "PsychGen is an R package for the analysis of genetic association studies in psychiatric disorders.",
      "PsychAnal is an R package that offers tools for quality control, genotyping, imputation, and association studies in psychiatric disorders.",
      "GAPP is an R package that includes functions for genetic association studies and gene-gene interaction analysis in psychiatric disorders.",
      "PsychGWASamenta is an R package for genome-wide association studies of psychiatric disorders.",
      "PSYCHEE is an R package that provides functions for GWAS, imputation, and gene-gene interaction analysis in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a clinical sign that is often observed in patients with intracerebral hemorrhage (ICH), which is bleeding that occurs inside the skull. It is characterized by a swirling or spiral motion of the hemorrhage within the brain, and can be seen on a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain.\nThe swirl sign is thought to occur due to the movement of blood within the bleed, which can result in a spiral-like pattern of the hemorrhage. This movement can be caused by various factors, including the flow of blood through blood vessels, the movement of the brain itself, or the pressure of the surrounding brain tissue.\nThe swirl sign can provide valuable information for clinicians in the assessment and management of ICH. For example, the size and location of the hemorrhage can be estimated based on the swirl pattern, which can help guide treatment decisions. Additionally, the swirl sign may be associated with certain clinical features, such as the presence of hydrocephalus or the risk of further bleeding.\nOn a CT scan, the swirl sign may appear as a bright, irregular pattern within the bleed, which can resemble a spiral or swirling motion. On an MRI scan, the sign may appear as a dark, irregular area within the bleed, which can also have a swirling pattern.\nIt is important to note that the swirl sign is not a diagnostic criterion for ICH, and its presence does not rule out other causes of intracerebral bleeding. A definitive diagnosis of ICH typically requires a combination of clinical, imaging, and laboratory findings.\nIn summary, the swirl sign is a clinical sign that can be observed on imaging studies in patients with intracerebral hemorrhage. It is characterized by a swirling or spiral motion of the hemorrhage within the brain, and can provide valuable information for clinicians in the assessment and management of ICH.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a clinical sign observed in patients with intracerebral hemorrhage (ICH).\n2. Intracerebral hemorrhage is bleeding that occurs inside the skull.\n3. The swirl sign can be seen on a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain.\n4. The swirl sign may be associated with clinical features such as the presence of hydrocephalus or the risk of further bleeding.\n5. A definitive diagnosis of ICH requires a combination of clinical, imaging, and laboratory findings.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a clinical sign observed in patients with intracerebral hemorrhage (ICH).",
      "Intracerebral hemorrhage is bleeding that occurs inside the skull.",
      "The swirl sign can be seen on a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain.",
      "The swirl sign may be associated with clinical features such as the presence of hydrocephalus or the risk of further bleeding.",
      "A definitive diagnosis of ICH requires a combination of clinical, imaging, and laboratory findings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Intracerebral hemorrhage is bleeding that occurs within the brain tissue itself, not inside the skull.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II factor 1) is a transcriptional elongation factor that plays a crucial role in regulating gene expression in response to various environmental and developmental cues. ROF1 is a Racing Involved in Flower Formation 1 gene product, which is named after the race track-like pattern of gene expression observed in rof1 mutants.\nROF1 expression is known to be induced by several different stimuli, including:\n1. Light: Light plays a crucial role in regulating gene expression in Arabidopsis, and ROF1 is no exception. ROF1 expression is induced by long-wavelength blue light (LW-B), but not by red light, suggesting that LW-B may act as a signal for flowering in Arabidopsis (Liu et al., 2010).\n2. Temperature: ROF1 expression is also temperature-sensitive, with higher expression observed at higher temperatures. For example, an increase in ROF1 expression was observed in rof1 mutants when they were exposed to 25°C, compared to 15°C (Chen et al., 2009).\n3. Water availability: ROF1 expression is also affected by water availability, with higher expression observed in plants exposed to drought conditions (Shook et al., 2010).\n4. Hormone signaling: ROF1 expression is influenced by hormone signaling, particularly by ethylene and auxin. For example, an ethylene treatment led to increased ROF1 expression in Arabidopsis seedlings, while an auxin treatment resulted in decreased ROF1 expression (Khang et al., 2012).\n5. Genetic interactive: ROF1 expression can also be influenced by genetic interactions, such as interactions between the ROF1 gene and other genes involved in flowering time regulation. For example, a study found that the rof1 mutation reduced the expression of the FLOWERING LOCUS C (FLC) gene, which is also involved in flowering time regulation (Chen et al., 2009).\n6. Transcription factor signaling: ROF1 expression can also be influenced by transcription factors, such as the MYB transcription factor",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by long-wavelength blue light (LW-B).\n2. ROF1 expression increases at higher temperatures, with higher expression observed at 25°C compared to 15°C.\n3. Water availability affects ROF1 expression, with higher expression observed in plants exposed to drought conditions.\n4. Ethylene and auxin hormone signaling influence ROF1 expression, with ethylene increasing and auxin decreasing its expression.\n5. Genetic interactions, such as the interaction between the ROF1 gene and the FLOWERING LOCUS C (FLC) gene, can influence ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by long-wavelength blue light (LW-B).",
      "ROF1 expression increases at higher temperatures, with higher expression observed at 25°C compared to 15°C.",
      "Water availability affects ROF1 expression, with higher expression observed in plants exposed to drought conditions.",
      "Ethylene and auxin hormone signaling influence ROF1 expression, with ethylene increasing and auxin decreasing its expression.",
      "Genetic interactions, such as the interaction between the ROF1 gene and the FLOWERING LOCUS C (FLC) gene, can influence ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or specific scientific research data, it is not possible to determine the truth of these statements about Arabidopsis ROF1 gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Hereditary renal amyloidosis, also known as familial amyloid nephropathy (FAN), is a rare genetic disorder that affects the kidneys and is caused by the accumulation of amyloid fibrils, which are composed of abnormal protein aggregates. The most common cause of hereditary renal amyloidosis is the mutation of the transthyretin (TTR) gene, which encodes the TTR protein.\nTTR is a multifunctional protein that is synthesized in the liver and secreted into the bloodstream. It plays a crucial role in the transport of thyroxine (T4) and retinol-binding protein (RBP) in the blood. However, in some individuals, mutations in the TTR gene can lead to the production of abnormally folded TTR proteins that are toxic to the kidneys and other organs. These abnormally folded proteins can aggregate and form amyloid fibrils, which accumulate in the kidneys and disrupt their normal function.\nThe mutations that cause hereditary renal amyloidosis usually occur in the TTR gene on chromosome 16. These mutations can lead to the formation of abnormally folded TTR proteins that are toxic to the kidneys and other organs. The most common mutations that cause hereditary renal amyloidosis are found in codons 60, 61, 63, and 70 of the TTR gene.\nHereditary renal amyloidosis is a rare disease, and the prevalence of TTR-related amyloidosis is estimated to be around 1 per 100,000 individuals worldwide. However, the incidence of TTR-related amyloidosis is increasing due to the aging population and the greater awareness of the disease. The disorder typically affects individuals in their 50s or 60s, although it can occur at any age.\nSymptoms of hereditary renal amyloidosis can include proteinuria (excess protein in the urine), hematuria (blood in the urine), kidney failure, and edema",
    "llama-2-7b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is caused by the accumulation of amyloid fibrils composed of abnormal protein aggregates.\n2. The mutation of the transthyretin (TTR) gene is the most common cause of hereditary renal amyloidosis.\n3. TTR is a protein that plays a crucial role in the transport of thyroxine (T4) and retinol-binding protein (RBP) in the blood.\n4. The most common mutations that cause hereditary renal amyloidosis are found in codons 60, 61, 63, and 70 of the TTR gene.\n5. The prevalence of TTR-related amyloidosis is estimated to be around 1 per 100,000 individuals worldwide.",
    "llama-2-7b-chat-hf_fact": [
      "Hereditary renal amyloidosis is caused by the accumulation of amyloid fibrils composed of abnormal protein aggregates.",
      "The mutation of the transthyretin (TTR) gene is the most common cause of hereditary renal amyloidosis.",
      "TTR is a protein that plays a crucial role in the transport of thyroxine (T4) and retinol-binding protein (RBP) in the blood.",
      "The most common mutations that cause hereditary renal amyloidosis are found in codons 60, 61, 63, and 70 of the TTR gene.",
      "The prevalence of TTR-related amyloidosis is estimated to be around 1 per 100,000 individuals worldwide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The mutation of the transthyretin (TTR) gene is one of the causes of hereditary amyloidosis, but not specifically limited to renal amyloidosis.\n3. TRUE\n4. FALSE [correction]: The most common mutations that cause hereditary TTR-related amyloidosis are found in codons 30, 58, 89, and 122 of the TTR gene.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed through various Mass Spectrometry (MS) based proteomics approaches. Here's a brief overview of some of the key studies and findings:\n1. Traditional protein separation techniques: One of the earliest studies on mouse hippocampus protein analysis was conducted by Oh et al. (1999) using gel-based separation techniques, such as SDS-PAGE and two-dimensional gel electrophoresis (2DGE). They identified and characterized around 50 proteins in the hippocampus, including structural and functional proteins, such as actins, tubulins, and synaptic proteins.\n2. Mass spectrometry-based proteomics: More recent studies have employed MS-based proteomics techniques, such as matrix-assisted laser desorption/ionization (MALDI) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), to identify and quantify a large number of proteins in the mouse hippocampus. For example, a study by Shan et al. (2013) identified over 1,000 proteins in the mouse hippocampus using a combination of MALDI-TOF and LC-MS/MS.\n3. Proteome analysis of the hippocampus in various diseases: The proteome of the mouse hippocampus has also been studied in various disease models, such as Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy. For example, a study by Gregoriou et al. (2015) found significant alterations in the hippocampal proteome of AD transgenic mice compared to wild-type mice, including upregulation of inflammatory and oxidative stress-related proteins and downregulation of synaptic proteins.\n4. Protein-protein interaction analysis: Protein-protein interaction analysis has also been conducted on the mouse hippocampus to identify protein complexes and networks. For example, a study by Li et al. (2012) used a combination of MS-based techniques and protein-protein interaction data to identify hippocampal protein complex",
    "llama-2-7b-chat-hf_fact_raw": "1. Oh et al. (1999) conducted one of the earliest studies on mouse hippocampus protein analysis using gel-based separation techniques and identified around 50 proteins.\n2. Shan et al. (2013) identified over 1,000 proteins in the mouse hippocampus using a combination of MALDI-TOF and LC-MS/MS.\n3. Gregoriou et al. (2015) found significant alterations in the hippocampal proteome of Alzheimer's disease transgenic mice compared to wild-type mice.\n4. The proteome of the mouse hippocampus has been analyzed in various disease models, including Alzheimer's disease, Parkinson's disease, and epilepsy.\n5. Li et al. (2012) conducted a protein-protein interaction analysis on the mouse hippocampus using MS-based techniques.",
    "llama-2-7b-chat-hf_fact": [
      "Oh et al. (1999) conducted one of the earliest studies on mouse hippocampus protein analysis using gel-based separation techniques and identified around 50 proteins.",
      "Shan et al. (2013) identified over 1,000 proteins in the mouse hippocampus using a combination of MALDI-TOF and LC-MS/MS.",
      "Gregoriou et al. (2015) found significant alterations in the hippocampal proteome of Alzheimer's disease transgenic mice compared to wild-type mice.",
      "The proteome of the mouse hippocampus has been analyzed in various disease models, including Alzheimer's disease, Parkinson's disease, and epilepsy.",
      "Li et al. (2012) conducted a protein-protein interaction analysis on the mouse hippocampus using MS-based techniques."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Great question! In mammals, including mice, chromosomes are classified based on their shape and size. Acrocentric chromosomes are those that have a distinct centromere region, which is the point where the chromosome is most condensed during cell division.\nIn mice, all 20 chromosomes are acrocentric. This means that the centromere region of each mouse chromosome is clearly defined and easily visible under a microscope. The acrocentric nature of mouse chromosomes is one of the reasons why mice are commonly used as model organisms in genetics and molecular biology research.\nIt's worth noting that the term \"acrocentric\" refers specifically to chromosomes that have a short arm (p) and a long arm (q), and is also used to describe chromosomes that are similar in shape to the letter \"A\" (acro-meaning \"top\" or \"peak\"). Other types of chromosomes include metacentric (which have a roughly equal-sized short and long arm), submetacentric (which have a slightly longer short arm than long arm), and satellite (which are smaller and have a more complex structure).",
    "llama-2-7b-chat-hf_fact_raw": "1. In mammals, including mice, chromosomes are classified based on their shape and size.\n2. Acrocentric chromosomes have a distinct centromere region.\n3. Mice have all 20 chromosomes that are acrocentric.\n4. The centromere region of each mouse chromosome is clearly defined and easily visible under a microscope.\n5. Acrocentric chromosomes have a short arm (p) and a long arm (q).",
    "llama-2-7b-chat-hf_fact": [
      "In mammals, including mice, chromosomes are classified based on their shape and size.",
      "Acrocentric chromosomes have a distinct centromere region.",
      "Mice have all 20 chromosomes that are acrocentric.",
      "The centromere region of each mouse chromosome is clearly defined and easily visible under a microscope.",
      "Acrocentric chromosomes have a short arm (p) and a long arm (q)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Mice have 19 pairs of acrocentric chromosomes and one pair of submetacentric chromosomes.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Here are a few examples:\n1. Vitrakvi (larotrectinib): Vitrakvi is an oral TRK inhibitor that is currently being investigated in clinical trials for the treatment of various solid tumors, including pancreatic cancer. TRK (tropomyosin receptor kinase) is a protein that is overexpressed in many pancreatic cancers, and Vitrakvi has shown promise in early-stage clinical trials as a potential treatment for this disease.\n2. BAX 751: BAX 751 is an investigational siRNA drug that is designed to target and inhibit the expression of multiple cancer-related genes, including the p53 gene. p53 is a tumor suppressor protein that is frequently mutated in pancreatic cancer, and BAX 751 has shown antitumor activity in preclinical studies of pancreatic cancer.\n3. GDC-0980: GDC-0980 is an oral siRNA drug that is being investigated in clinical trials for the treatment of various solid tumors, including pancreatic cancer. GDC-0980 works by targeting and inhibiting the expression of the stem cell factor receptor (SCF), which is overexpressed in many pancreatic cancers.\n4. RX-0201: RX-0201 is an investigational siRNA drug that is designed to target and inhibit the expression of the Bcl-2 family of genes, which are involved in the regulation of apoptosis (programmed cell death). Bcl-2 is overexpressed in many pancreatic cancers, and RX-0201 has shown antitumor activity in preclinical studies of this disease.\n5. ALX106: ALX106 is an oral siRNA drug that is being investigated in clinical trials for the treatment of various solid tumors, including pancreatic cancer. ALX106 works by targeting and inhibiting the expression of the FOXA2 gene, which is overexpressed in many pancreatic",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitrakvi (larotrectinib) is being investigated in clinical trials for the treatment of pancreatic cancer.\n2. BAX 751 is an investigational siRNA drug designed to target the p53 gene, which is frequently mutated in pancreatic cancer.\n3. GDC-0980 is an oral siRNA drug being investigated for the treatment of pancreatic cancer, targeting the stem cell factor receptor.\n4. RX-0201 is an investigational siRNA drug targeting the Bcl-2 family of genes, with antitumor activity in preclinical studies of pancreatic cancer.\n5. ALX106 is an oral siRNA drug in clinical trials for the treatment of pancreatic cancer, targeting the FOXA2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Vitrakvi (larotrectinib) is being investigated in clinical trials for the treatment of pancreatic cancer.",
      "BAX 751 is an investigational siRNA drug designed to target the p53 gene, which is frequently mutated in pancreatic cancer.",
      "GDC-0980 is an oral siRNA drug being investigated for the treatment of pancreatic cancer, targeting the stem cell factor receptor.",
      "RX-0201 is an investigational siRNA drug targeting the Bcl-2 family of genes, with antitumor activity in preclinical studies of pancreatic cancer.",
      "ALX106 is an oral siRNA drug in clinical trials for the treatment of pancreatic cancer, targeting the FOXA2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GDC-0980 is a small molecule, not an siRNA drug, and it targets the PI3K and mTOR pathways, not the stem cell factor receptor.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore, also known as the hemoglobin-polymerized gykylate pore, is a unique protein structure found in the red blood cell membrane of some animals, including humans. It is a small, hydrophobic pore that spans the red blood cell membrane and is formed by the protein hemoglobin.\nThe HPG pore plays a crucial role in the regulation of ion and small molecule transport across the red blood cell membrane. It is permeable to protons, potassium ions, and some smaller molecules such as oxygen and carbon dioxide. The HPG pore is thought to be involved in the regulation of blood pH, as it allows for the exchange of protons and bicarbonate ions across the red blood cell membrane.\nThe HPG pore is also thought to play a role in the regulation of red blood cell shapeshifting, a process by which red blood cells change their shape in response to changes in oxygen levels. The HPG pore is involved in the regulation of the cytoskeleton of the red blood cell, which is responsible for maintaining the cell's shape.\nResearch on the HPG pore has led to a greater understanding of the regulation of red blood cell function and its role in various diseases, including anemia and red blood cell disorders. Understanding the HPG pore and its role in red blood cell function may lead to the development of new treatments and therapies for these diseases.\nIn summary, the HPG pore is a unique protein structure found in the red blood cell membrane that plays a crucial role in the regulation of ion and small molecule transport and red blood cell shapeshifting. Further research on the HPG pore may lead to a greater understanding of the regulation of red blood cell function and the development of new treatments for red blood cell disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is also known as the hemoglobin-polymerized gykylate pore.\n2. The HPG pore is found in the red blood cell membrane of some animals, including humans.\n3. The HPG pore is permeable to protons, potassium ions, oxygen, and carbon dioxide.\n4. The HPG pore is thought to be involved in the regulation of blood pH and red blood cell shapeshifting.\n5. Research on the HPG pore may lead to the development of new treatments for diseases like anemia and red blood cell disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is also known as the hemoglobin-polymerized gykylate pore.",
      "The HPG pore is found in the red blood cell membrane of some animals, including humans.",
      "The HPG pore is permeable to protons, potassium ions, oxygen, and carbon dioxide.",
      "The HPG pore is thought to be involved in the regulation of blood pH and red blood cell shapeshifting.",
      "Research on the HPG pore may lead to the development of new treatments for diseases like anemia and red blood cell disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore is also known as the hemoglobin-polymerized glycolate pore.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing the genomes of 959 species of nematodes, a group of worms that includes parasitic and non-parasitic species. Nematodes are found in a wide range of environments, including soil, plants, and animals, and they play important roles in ecosystems as decomposers, symbionts, and pathogens.\nThe 959 Nematode Genomes initiative is a collaborative effort between scientists from around the world, led by the University of California, Davis. The goal of the project is to generate high-quality genomes for as many nematode species as possible, with the ultimate goal of improving our understanding of nematode biology and developing new tools for controlling nematode-based plant diseases.\nThe project began in 2017 and is expected to take several years to complete. To date, the project has sequenced the genomes of over 300 nematode species, with over 500 additional species currently in the pipeline. The genomes are being sequenced using a variety of techniques, including whole-genome shotgun sequencing, long-read sequencing, and assembly.\nOne of the key goals of the project is to develop better tools for identifying and characterizing nematode species. Traditionally, nematode species have been identified using morphological characteristics, such as the shape and size of their bodies. However, these methods are often incomplete and can be difficult to apply to large numbers of species. The 959 Nematode Genomes initiative is working to develop DNA-based methods for identifying and characterizing nematode species, which will provide a more accurate and comprehensive understanding of nematode diversity.\nIn addition to improving our understanding of nematode diversity, the 959 Nematode Genomes initiative is also focused on identifying genes that are specific to particular nematode species. Many nematode species have evolved unique genes that allow them to interact with their hosts or environments in specialized ways. By sequencing the genomes of multiple nematode species, researchers hope to identify genes that are responsible for these specialized interactions, which could lead to new strategies for controlling nemat",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. The initiative is led by the University of California, Davis.\n3. The project began in 2017 and is expected to take several years to complete.\n4. Over 300 nematode species' genomes have been sequenced, with over 500 additional species currently in the pipeline.\n5. The initiative is developing DNA-based methods for identifying and characterizing nematode species.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "The initiative is led by the University of California, Davis.",
      "The project began in 2017 and is expected to take several years to complete.",
      "Over 300 nematode species' genomes have been sequenced, with over 500 additional species currently in the pipeline.",
      "The initiative is developing DNA-based methods for identifying and characterizing nematode species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Here are some of the popular ones:\n1. `nip tempt` - This package provides a set of tools for analyzing NIPT data, including quality control, data cleaning, and statistical analysis. It can be used to analyze both Maria and Veritas NIPT data.\n2. `niftype` - This package provides a set of functions for working with NIPT data in R, including data cleaning, filtering, and statistical analysis. It can be used to analyze data from a variety of NIPT platforms, including those provided by Sequenom and Invitae.\n3. `niftystats` - This package provides a set of statistical functions for analyzing NIPT data, including tests for trisomy 21, 18, and 13, as well as other genetic disorders. It can be used to analyze data from a variety of NIPT platforms.\n4. `prenatals` - This package provides a comprehensive set of functions for working with NIPT data in R, including data cleaning, filtering, and statistical analysis. It can be used to analyze data from a variety of NIPT platforms, including those provided by Sequenom and Invitae.\n5. `ppkg` - This package provides a set of functions for working with NIPT data in R, including data cleaning, filtering, and statistical analysis. It can be used to analyze data from a variety of NIPT platforms, including those provided by Sequenom and Invitae.\n6. `niftym firefox` - This package provides a set of functions for working with NIPT data in R, including data cleaning, filtering, and statistical analysis. It can be used to analyze data from a variety of NIPT platforms, including those provided by Sequenom and Invitae.\n7. `niftym Info` - This package provides a set of functions for working with NIPT data in R, including data cleaning, filtering, and statistical analysis. It can be used to analyze data from a variety of NIPT platforms, including those provided by Sequenom and Invitae.\n8. `niftym package` - This package provides a set of functions for working",
    "llama-2-7b-chat-hf_fact_raw": "1. The `nip tempt` R package is designed for analyzing NIPT data including quality control, data cleaning, and statistical analysis.\n2. The `niftype` R package allows analysis of NIPT data from various platforms, like those provided by Sequenom and Invitae.\n3. The `niftystats` R package includes statistical functions for tests related to trisomy 21, 18, and 13, as well as other genetic disorders.\n4. The `prenatals` R package can be used to analyze NIPT data from different platforms, including those provided by Sequenom and Invitae.\n5. The `niftym firefox` R package aids in working with NIPT data from various platforms for analysis, including those provided by Sequenom and Invitae.",
    "llama-2-7b-chat-hf_fact": [
      "The `nip tempt` R package is designed for analyzing NIPT data including quality control, data cleaning, and statistical analysis.",
      "The `niftype` R package allows analysis of NIPT data from various platforms, like those provided by Sequenom and Invitae.",
      "The `niftystats` R package includes statistical functions for tests related to trisomy 21, 18, and 13, as well as other genetic disorders.",
      "The `prenatals` R package can be used to analyze NIPT data from different platforms, including those provided by Sequenom and Invitae.",
      "The `niftym firefox` R package aids in working with NIPT data from various platforms for analysis, including those provided by Sequenom and Invitae."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The correct package name is likely `niphy`, not `niftype`.\n3. UNKNOWN\n4. FALSE [correction]: The correct package name is likely `niphy`, not `prenatals`.\n5. FALSE [correction]: The correct package name is likely `niphy`, not `niftym firefox`.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach syndrome, is a rare genetic disorder characterized by several distinctive physical and behavioral features. It is named after Dr. Edwin Achenbach, an American pediatrician who first described the condition in 1978.\nThe primary symptoms of Achenbach's syndrome include:\n1. Distinctive facial features: Individuals with Achenbach's syndrome typically have a distinctive facial appearance, including a small head, narrow eyes, a long, narrow nose, and a thin upper lip.\n2. Growth delays: Children with Achenbach's syndrome often experience growth delays, both in terms of height and weight. They may also have a shorter stature than their peers.\n3. Intellectual disability: Individuals with Achenbach's syndrome may have mild to moderate intellectual disability, which can range from mild to moderate.\n4. Speech and language difficulties: Many individuals with Achenbach's syndrome experience difficulty with speech and language development, including slurred speech, difficulty with word retrieval, and a limited vocabulary.\n5. Motor skills delays: Achenbach's syndrome can also cause delays in motor skills development, including difficulties with coordination, balance, and fine motor skills.\n6. Behavioral issues: Some individuals with Achenbach's syndrome may experience behavioral issues, such as anxiety, hyperactivity, and impulsivity.\n7. Cerebellar hypoplasia: Achenbach's syndrome is often associated with cerebellar hypoplasia, which is a condition where the cerebellum is underdeveloped or malformed. The cerebellum is responsible for coordination, balance, and movement.\n8. Other features: Achenbach's syndrome can also cause a range of other symptoms, including delayed development of the nervous system, heart defects, and vision problems.\nThe exact cause of Achenbach's syndrome is not fully understood, but it is thought to be related to genetic mutations. It is usually diagnosed through a combination of physical examination, medical history, and genetic testing. There is no cure for Achenbach's syndrome, but",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare genetic disorder.\n2. Dr. Edwin Achenbach, an American pediatrician, first described Achenbach's syndrome in 1978.\n3. Primary symptoms include distinctive facial features, growth delays, and intellectual disability.\n4. Achenbach's syndrome is often associated with cerebellar hypoplasia.\n5. The condition is thought to be related to genetic mutations and is diagnosed through physical examination, medical history, and genetic testing.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is a rare genetic disorder.",
      "Dr. Edwin Achenbach, an American pediatrician, first described Achenbach's syndrome in 1978.",
      "Primary symptoms include distinctive facial features, growth delays, and intellectual disability.",
      "Achenbach's syndrome is often associated with cerebellar hypoplasia.",
      "The condition is thought to be related to genetic mutations and is diagnosed through physical examination, medical history, and genetic testing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder, it is a condition characterized by spontaneous bruising of the hands or fingers.\n2. UNKNOWN\n3. FALSE [correction]: The primary symptom of Achenbach's syndrome is the sudden appearance of a bruise, typically on the hands or fingers, without any known trauma or injury.\n4. FALSE [correction]: Achenbach's syndrome is not associated with cerebellar hypoplasia.\n5. FALSE [correction]: Achenbach's syndrome is not related to genetic mutations but is rather a benign self-limiting condition, diagnosed through physical examination and patient history.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Long repeat expansions are a type of genomic variation that can arise due to repeat sequences in the DNA. These expansions can lead to a range of genetic disorders, including those associated with neurodegenerative diseases, developmental delays, and intellectual disability. To detect long repeat expansions, researchers and clinicians use various algorithms, including:\n1. RepeatMasker: RepeatMasker is a widely used algorithm for detecting repetitive DNA sequences in a genome. It uses a combination of algorithms, including a profile-based approach, which compares the query sequence to a database of known repeat elements, and a hidden Markov model-based approach, which models the probability of a sequence being a repeat element. RepeatMasker can detect both short and long repeat expansions, but it is particularly useful for identifying short repeats (less than 100 base pairs).\n2. MACS (Multiple Alignment of Collapsed Sequences): MACS is a software package for genome-wide DNA sequence analysis that includes tools for repeat detection. The repeat detection module uses a probabilistic model to identify long repeat expansions, based on the alignment of multiple collapsed sequences from the query sequence. This approach is particularly useful for identifying large, complex repeats.\n3. LINE-SAT: LINE-SAT is a software package for identifying and characterizing the repetitive elements in a genome. It uses a combination of algorithms, including a de novo assembler, a repeat finder, and a gene predictor. The repeat finder module uses a probabilistic model to identify long repeat expansions, based on the similarity of the query sequence to known repeat elements.\n4. RT-LongRepeats: RT-LongRepeats is a tool for detecting long repeat expansions in RNA-seq data. It uses a combination of algorithms, including a de novo transcriptome assembly, a repeat finder, and a Comparative Genomics tool. The repeat finder module uses a probabilistic model to identify long repeat expansions, based on the similarity of the query sequence to known repeat elements.\n5. Long Repeat Finder (LRF): LRF is a tool for detecting long repeat expansions in a genome. It uses a combination of algorithms, including a probabilistic model and a hidden",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used for detecting repetitive DNA sequences, including long repeat expansions.\n2. RepeatMasker uses a profile-based approach and a hidden Markov model-based approach in its detection process.\n3. MACS includes a repeat detection module that uses a probabilistic model to identify long repeat expansions.\n4. LINE-SAT is a software package that uses several algorithms, including a de novo assembler and a repeat finder module, to identify long repeat expansions.\n5. RT-LongRepeats is a tool designed to detect long repeat expansions in RNA-seq data using a repeat finder module and comparative genomics.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used for detecting repetitive DNA sequences, including long repeat expansions.",
      "RepeatMasker uses a profile-based approach and a hidden Markov model-based approach in its detection process.",
      "MACS includes a repeat detection module that uses a probabilistic model to identify long repeat expansions.",
      "LINE-SAT is a software package that uses several algorithms, including a de novo assembler and a repeat finder module, to identify long repeat expansions.",
      "RT-LongRepeats is a tool designed to detect long repeat expansions in RNA-seq data using a repeat finder module and comparative genomics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "I must inform you that the information you are seeking is complex and requires careful consideration before providing a definitive answer. Neuroligin-3 is a protein that has been implicated in the development and progression of certain brain tumors, including:\n1. Glioblastoma: Also known as glioblastoma multiforme (GBM), this is the most common and aggressive form of brain cancer. Neuroligin-3 has been shown to be overexpressed in a significant proportion of glioblastomas, and its overexpression has been linked to poorer prognosis and treatment response.\n2. Medulloblastoma: This is a type of pediatric brain cancer that affects the cerebral hemispheres of children, typically under the age of 10. Neuroligin-3 has been found to be overexpressed in a subset of medulloblastomas, and its expression is correlated with the aggressive molecular subtype of the disease.\n3. Astrocytoma: This is a type of brain cancer that originates from star-shaped glial cells called astrocytes. Neuroligin-3 has been shown to be overexpressed in some subtypes of astrocytoma, including those with a worse prognosis.\n4. Meningioma: This is a benign tumor that arises from the meninges, the protective coverings of the brain and spinal cord. While meningioma is generally not as aggressive as other brain tumors, some subtypes have been found to overexpress neuroligin-3, which may be associated with increased growth and invasion.\nIt is important to note that the expression of neuroligin-3 in brain tumors can be complex and context-dependent, and the protein's role in tumorigenesis is still being elucidated. Further research is needed to fully understand the relationship between neuroligin-3 and the development and progression of different types of brain tumors.\nIn summary, neuroligin-3 has been implicated in the progression of various types of brain tumors, including glioblastoma, medulloblastoma, astrocytoma, and meningioma. However, the exact mechanisms by which neuroligin-3 promotes tumor growth and progression are still being investigated and require further research",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is a protein linked to the development and progression of some brain tumors.\n2. Glioblastoma, or glioblastoma multiforme (GBM), is the most common and aggressive form of brain cancer, and neuroligin-3 overexpression has been observed in a significant proportion of these tumors.\n3. Medulloblastoma is a pediatric brain cancer affecting children under the age of 10, with neuroligin-3 overexpressed in a subset correlating with an aggressive molecular subtype.\n4. Astrocytoma originates from astrocytes and has subtypes with neuroligin-3 overexpression, often linked to a worse prognosis.\n5. Meningioma arises from the meninges and may overexpress neuroligin-3 in subtypes that exhibit increased growth and invasion.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is a protein linked to the development and progression of some brain tumors.",
      "Glioblastoma, or glioblastoma multiforme (GBM), is the most common and aggressive form of brain cancer, and neuroligin-3 overexpression has been observed in a significant proportion of these tumors.",
      "Medulloblastoma is a pediatric brain cancer affecting children under the age of 10, with neuroligin-3 overexpressed in a subset correlating with an aggressive molecular subtype.",
      "Astrocytoma originates from astrocytes and has subtypes with neuroligin-3 overexpression, often linked to a worse prognosis.",
      "Meningioma arises from the meninges and may overexpress neuroligin-3 in subtypes that exhibit increased growth and invasion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are membrane-bound organelles found in some bacteria and archaea that are used for buoyancy and motility. The size of gas vesicles can vary depending on the species of organism and their function, but here are some approximate sizes:\n* In Escherichia coli (E. coli), gas vesicles are typically around 20-50 nanometers (nm) in diameter.\n* In Pseudomonas aeruginosa, gas vesicles can range in size from 50 nm to 100 nm in diameter.\n* In Halobacterium salinarum, gas vesicles are larger, typically ranging from 100 nm to 200 nm in diameter.\n* In some species of Cyanobacteria, gas vesicles can reach sizes of up to 500 nm in diameter.\nIt's worth noting that these sizes are approximate and can vary depending on the specific conditions in which the organism is growing, as well as the type of gas vesicle being measured. Additionally, some organisms may have multiple gas vesicles of different sizes, and the sizes of the gas vesicles can be highly variable within an individual organism.\nIn general, gas vesicles are much smaller than other organelles in a cell, such as chloroplasts or mitochondria, which can be several micrometers in diameter. The small size of gas vesicles allows them to be highly efficient at trapping and releasing gas, making them important for buoyancy and motility in many organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are membrane-bound organelles found in some bacteria and archaea.\n2. In Escherichia coli, gas vesicles are approximately 20-50 nanometers in diameter.\n3. In Pseudomonas aeruginosa, gas vesicles range in size from approximately 50 nm to 100 nm in diameter.\n4. In Halobacterium salinarum, gas vesicles typically range from 100 nm to 200 nm in diameter.\n5. Some species of Cyanobacteria can have gas vesicles that reach up to 500 nm in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are membrane-bound organelles found in some bacteria and archaea.",
      "In Escherichia coli, gas vesicles are approximately 20-50 nanometers in diameter.",
      "In Pseudomonas aeruginosa, gas vesicles range in size from approximately 50 nm to 100 nm in diameter.",
      "In Halobacterium salinarum, gas vesicles typically range from 100 nm to 200 nm in diameter.",
      "Some species of Cyanobacteria can have gas vesicles that reach up to 500 nm in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: In Escherichia coli, gas vesicles are not found as E. coli does not produce gas vesicles.\n3. FALSE [correction]: Pseudomonas aeruginosa does not produce gas vesicles.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (bromodomain and extra-terminal) proteins are a family of structurally related proteins that are involved in regulating chromatin dynamics and playing a crucial role in various cellular processes, including transcriptional activation, repression, and cellular differentiation. Here are some of the known BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is a key regulator of cellular differentiation and development. It is involved in the activation of lineage-specific genes during T cell differentiation and the maintenance of pluripotency in embryonic stem cells.\n2. BET2 (Bromodomain-Containing Protein 2): This protein is involved in the regulation of gene expression, particularly in the context of cancer. It is overexpressed in various types of cancer, including breast, lung, and colon cancer, and its overexpression has been linked to increased cancer aggressiveness and poor prognosis.\n3. BET3 (Bromodomain-Containing Protein 3): BRD3 is primarily involved in the regulation of gene expression during cellular differentiation and development. It is required for the maintenance of pluripotency in embryonic stem cells and plays a role in the differentiation of hematopoietic cells.\n4. BET4 (Bromodomain-Containing Protein 4): This protein is a key regulator of chromatin structure and gene expression. It is involved in the activation of lineage-specific genes during T cell differentiation and the maintenance of pluripotency in embryonic stem cells.\n5. BET5 (Bromodomain-Containing Protein 5): This protein is a member of the BET family that has been implicated in the regulation of gene expression in various cell types, including immune cells and cancer cells. It is involved in the activation of immune response genes and plays a role in the regulation of inflammation.\n6. BET6 (Bromodomain-Containing Protein 6): This protein is primarily involved in the regulation of gene expression during cellular differentiation and development. It is required for the maintenance of pluripotency in embryonic stem cells and plays",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are involved in regulating chromatin dynamics and play a role in various cellular processes.\n2. BET1, also known as BRD1, is involved in the activation of lineage-specific genes and the maintenance of pluripotency in embryonic stem cells.\n3. BET2 is overexpressed in various types of cancer, including breast, lung, and colon cancer.\n4. BET3, or BRD3, is required for the maintenance of pluripotency in embryonic stem cells.\n5. BET4 is a key regulator of chromatin structure and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are involved in regulating chromatin dynamics and play a role in various cellular processes.",
      "BET1, also known as BRD1, is involved in the activation of lineage-specific genes and the maintenance of pluripotency in embryonic stem cells.",
      "BET2 is overexpressed in various types of cancer, including breast, lung, and colon cancer.",
      "BET3, or BRD3, is required for the maintenance of pluripotency in embryonic stem cells.",
      "BET4 is a key regulator of chromatin structure and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: BET1 is not the same as BRD1. BRD1 is involved in the activation of lineage-specific genes and the maintenance of pluripotency in embryonic stem cells.\n3. UNKNOWN\n4. FALSE [correction]: BRD3, not BET3, is required for the maintenance of pluripotency in embryonic stem cells.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There have been several deep learning algorithms developed for protein subcellular localization prediction. Here are some of the most notable ones:\n1. DeepLoc: Developed by the lab of Dr. tombur et al. in 2017, DeepLoc is a deep learning-based method for predicting protein subcellular localization. It uses a convolutional neural network (CNN) to learn features from protein sequences and classifies them into different subcellular locations based on their recurrent features. DeepLoc has been shown to outperform traditional machine learning methods in predicting protein localization.\n2. LocNet: LocNet is another deep learning-based method for protein subcellular localization prediction. Developed by the lab of Dr. Cheng et al. in 2018, LocNet uses a hierarchical CNN to learn the representation of protein sequences and their associated subcellular locations. LocNet has been shown to achieve state-of-the-art performance on several protein localization datasets.\n3. PALS: PALS (Predicting Localization of Proteins by Semantic Search) is a deep learning-based method developed by the lab of Dr. Li et al. in 2017. PALS uses a sequence-to-sequence model with a CNN to learn the representation of protein sequences and predict their subcellular localization. PALS has been shown to outperform traditional machine learning methods in predicting protein localization.\n4. ANN-LSTM: Developed by the lab of Dr. Zhou et al. in 2018, ANN-LSTM is a deep learning-based method that combines both convolutional and recurrent neural networks to predict protein subcellular localization. ANN-LSTM uses a combination of sequence-based and structure-based features to improve the accuracy of protein localization prediction.\n5. DL-Star: DL-Star is a deep learning-based method developed by the lab of Dr. Wang et al. in 2020. DL-Star uses a two-stage approach, consisting of a feature extraction stage and a classification stage, to predict protein subcellular localization. DL-Star has been shown to achieve state-of-the-art performance on several protein localization datasets.\nThese are some of the most notable deep learning-based methods for",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc was developed by Dr. tombur et al. in 2017 and uses a convolutional neural network for predicting protein subcellular localization.\n2. LocNet was developed by Dr. Cheng et al. in 2018 and uses a hierarchical CNN for protein subcellular localization prediction.\n3. PALS was developed by Dr. Li et al. in 2017 and uses a sequence-to-sequence model with a CNN to predict subcellular localization of proteins.\n4. ANN-LSTM was developed by Dr. Zhou et al. in 2018 and combines convolutional and recurrent neural networks for protein subcellular localization prediction.\n5. DL-Star was developed by Dr. Wang et al. in 2020 and uses a two-stage approach for predicting protein subcellular localization.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc was developed by Dr. tombur et al. in 2017 and uses a convolutional neural network for predicting protein subcellular localization.",
      "LocNet was developed by Dr. Cheng et al. in 2018 and uses a hierarchical CNN for protein subcellular localization prediction.",
      "PALS was developed by Dr. Li et al. in 2017 and uses a sequence-to-sequence model with a CNN to predict subcellular localization of proteins.",
      "ANN-LSTM was developed by Dr. Zhou et al. in 2018 and combines convolutional and recurrent neural networks for protein subcellular localization prediction.",
      "DL-Star was developed by Dr. Wang et al. in 2020 and uses a two-stage approach for predicting protein subcellular localization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Great, I'm glad you asked! MULTOVL is a term that is used in various fields, including mathematics, computer science, and cryptography. It has multiple meanings depending on the context, but I'll provide an overview of the most common ones:\n1. Multivot Length: In cryptography, MULTOVL refers to the length of a multivot, which is a data structure used to speed up computations involving permutations. A multivot is a vector of bits where each element represents the position of a bit in a permutation. The length of a multivot refers to the number of bits in the vector.\n2. Multi-Volume Algorithm: MULTOVL can also be interpreted as an algorithm for solving a problem related to multivariate polynomials. In this context, the algorithm is called \"Multi-Volume\" because it involves computing the coefficients of a polynomial in multiple variables at once. The algorithm is used in computer algebra systems and has applications in cryptography, coding theory, and other areas of computer science.\n3. Multivariate Optimal Volume Lossless Compression: In computer science, MULTOVL is a method for compressing data using a combination of volume lossless compression techniques. The method is designed to achieve better compression ratios than any single technique by selecting the most appropriate compression algorithm for each data volume based on its statistical properties.\n4. Multi-Level Optimization Using Vector Lemmatization: In the field of natural language processing, MULTOVL is a method for optimizing word embeddings using a combination of vector lemmatization and multi-level optimization. Vector lemmatization is a technique for reducing the dimensionality of high-dimensional word embeddings by mapping words to their inflectional forms. The method is designed to improve the accuracy of text classification and other natural language processing tasks.\nIn summary, MULTOVL is a term with multiple meanings depending on the context. It can refer to a data structure used in cryptography, an algorithm for solving a problem related to multivariate polynomials, a method for compressing data, or a technique for optimizing word embeddings in natural language processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. In cryptography, MULTOVL refers to the length of a multivot, a data structure used to speed up computations involving permutations.\n2. MULTOVL stands for Multi-Volume Algorithm, used for solving problems related to multivariate polynomials.\n3. In computer science, MULTOVL is a method for compressing data using volume lossless compression techniques.\n4. MULTOVL is used in natural language processing as a method for optimizing word embeddings using vector lemmatization.",
    "llama-2-7b-chat-hf_fact": [
      "In cryptography, MULTOVL refers to the length of a multivot, a data structure used to speed up computations involving permutations.",
      "MULTOVL stands for Multi-Volume Algorithm, used for solving problems related to multivariate polynomials.",
      "In computer science, MULTOVL is a method for compressing data using volume lossless compression techniques.",
      "MULTOVL is used in natural language processing as a method for optimizing word embeddings using vector lemmatization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In cryptography, MULTOVL does not refer to the length of a multivot, it is not a recognized term in the context provided.\n2. FALSE [correction]: MULTOVL is not a recognized abbreviation for Multi-Volume Algorithm in the context of multivariate polynomials.\n3. FALSE [correction]: MULTOVL is not a method for compressing data using volume lossless compression techniques in computer science.\n4. FALSE [correction]: MULTOVL is not used in natural language processing for optimizing word embeddings using vector lemmatization.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "GDF15 (Growth Differentiation Factor 15) has been proposed as a potential biomarker for monitoring metformin treatment in various diseases, including type 2 diabetes, cancer, and cardiovascular disease. Here are some details on why GDF15 may be a useful biomarker for metformin treatment:\n1. Metformin stimulates GDF15 expression: Studies have shown that metformin can upregulate GDF15 expression in various cell types, including adipocytes, myocytes, and hepatocytes. This suggests that GDF15 levels may increase in response to metformin treatment, which could make it a useful biomarker for monitoring metformin therapy.\n2. GDF15 has anti-inflammatory and anti-oxidant properties: GDF15 has been shown to have anti-inflammatory and anti-oxidant properties, which may be relevant to the anti-diabetic effects of metformin. Metformin has been shown to reduce inflammation and oxidative stress in various tissues, including the pancreas, liver, and skeletal muscle.\n3. GDF15 may be a predictor of metformin response: Some studies have suggested that GDF15 levels may be associated with the response to metformin treatment. For example, one study found that GDF15 levels were higher in individuals who responded well to metformin therapy compared to those who did not respond as well.\n4. GDF15 may be a useful biomarker for diagnosis and monitoring of metformin side effects: Metformin is commonly associated with gastrointestinal side effects, such as diarrhea, nausea, and vomiting. GDF15 levels may be elevated in response to these side effects, and could potentially be used as a biomarker for monitoring metformin-related gastrointestinal toxicity.\n5. GDF15 may be a useful biomarker for monitoring drug interactions: Metformin can interact with other medications, including other anti-diabetic drugs, and GDF15 levels may be affected by these interactions. Monitoring GDF15 levels in response to drug interactions could",
    "llama-2-7b-chat-hf_fact_raw": "1. Studies have shown that metformin can upregulate GDF15 expression in various cell types.\n2. GDF15 has anti-inflammatory and anti-oxidant properties.\n3. GDF15 levels may be associated with the response to metformin treatment.\n4. GDF15 levels may be elevated in response to metformin-related gastrointestinal side effects.\n5. Metformin can interact with other medications, and GDF15 levels may be affected by these interactions.",
    "llama-2-7b-chat-hf_fact": [
      "Studies have shown that metformin can upregulate GDF15 expression in various cell types.",
      "GDF15 has anti-inflammatory and anti-oxidant properties.",
      "GDF15 levels may be associated with the response to metformin treatment.",
      "GDF15 levels may be elevated in response to metformin-related gastrointestinal side effects.",
      "Metformin can interact with other medications, and GDF15 levels may be affected by these interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Recursive splicing is a type of splicing event in which a portion of the RNA molecule is spliced back into its own molecule, creating a loop or a stem. This type of splicing is relatively rare in eukaryotic cells, but it is more common in short introns.\nIntrons are the regions of non-coding DNA within a gene that are removed during the splicing process, leaving behind a exon that contains the coding sequence. Short introns are those that are less than 100 nucleotides in length, while long introns are those that are longer than 100 nucleotides.\nRecursive splicing is more common in short introns for several reasons:\n1. Loop formation: Short introns are more likely to form loops with other regions of the RNA molecule, which can facilitate recursive splicing.\n2. Lower splicing efficiency: Recursive splicing requires the presence of a splicing enzyme called SR proteins, which bind to the intron-exon junction and facilitate the splicing reaction. However, the presence of a loop or stem in the RNA molecule can make it more difficult for the SR proteins to access the intron-exon junction, leading to lower splicing efficiency.\n3. Increased stem formation: Short introns are more likely to form stems with other regions of the RNA molecule, which can increase the likelihood of recursive splicing.\n4. Higher intron length : The shorter the intron, the less likely it is to form a loop or stem, making it less likely to undergo recursive splicing.\n5. Dependence on splicing factors : Recursive splicing requires the presence of specific splicing factors that are recruited to the intron-exon junction. The presence of a loop or stem in the RNA molecule can affect the recruitment of these factors, leading to lower splicing efficiency.\n6. RNA folding : Short introns are more likely to fold back on themselves, creating a loop or stem that can facilitate recursive splicing.\n7. Computational prediction: Some computational models have predicted that recursive splicing is more common in short introns, based on the prediction of RNA",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is a type of splicing event in which a portion of the RNA molecule is spliced back into its own molecule.\n2. Short introns are those that are less than 100 nucleotides in length.\n3. Recursive splicing is relatively rare in eukaryotic cells.\n4. Recursive splicing requires the presence of a splicing enzyme called SR proteins.\n5. Computational models have predicted that recursive splicing is more common in short introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is a type of splicing event in which a portion of the RNA molecule is spliced back into its own molecule.",
      "Short introns are those that are less than 100 nucleotides in length.",
      "Recursive splicing is relatively rare in eukaryotic cells.",
      "Recursive splicing requires the presence of a splicing enzyme called SR proteins.",
      "Computational models have predicted that recursive splicing is more common in short introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Recursive splicing requires the presence of a splicing enzyme called the spliceosome, not SR proteins.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "The TALE-iD method is a machine learning approach used for identifying novel transcriptional enhancers in the human genome. Transcriptional enhancers are specific DNA sequences that can increase the recruitment of RNA polymerase, the enzyme responsible for transcribing DNA into RNA, to specific gene promoters. Enhancers play a crucial role in regulating gene expression by modulating the strength and timing of transcription.\nThe TALE-iD method, which stands for \"TAL effector-induced DNA detection,\" is a computational approach that uses the CRISPR-Cas13 system, a type of RNA-guided DNA endonuclease, to detect and functionalize putative enhancers in the human genome. The basic workflow of the TALE-iD method involves the following steps:\n1. Identification of putative enhancer sequences: The TALE-iD method starts by identifying potential enhancer sequences in the human genome using computational methods such as SELEX (Systematic Evolution of Ligands by Exponential Enrichment) or other machine learning approaches. These sequences are often located far away from their target genes and have low Rouquier scores, which indicate their potential to function as enhancers.\n2. Design of TALENs: The next step is to design TALENs (TAL effector nucleases) that can bind to the identified putative enhancer sequences. TALENs are composed of two subunits, a target-specific DNA-binding domain (called the TAL effector) and a cleavage domain (called the CRISPR scissors). The TAL effector is responsible for recognizing and binding to the specific DNA sequence, while the CRISPR scissors are responsible for cleaving the DNA.\n3. Construction of TALE-iD library: The TALENs designed in step 2 are then cloned into a plasmid, along with a functionalizer (usually a sequence that can recruit the Cas13 enzyme) and a selectable marker (such as antibiotic resistance gene). This plasmid is then introduced into host cells, which are then selected using antibiotics to isolate those that have taken up the plasmid.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for identifying novel transcriptional enhancers in the human genome.\n2. Transcriptional enhancers increase the recruitment of RNA polymerase to specific gene promoters.\n3. The TALE-iD method uses the CRISPR-Cas13 system to detect and functionalize putative enhancers.\n4. TALENs, which are used in the TALE-iD method, consist of a DNA-binding domain and a cleavage domain.\n5. Putative enhancer sequences identified by the TALE-iD method often have low Rouquier scores.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for identifying novel transcriptional enhancers in the human genome.",
      "Transcriptional enhancers increase the recruitment of RNA polymerase to specific gene promoters.",
      "The TALE-iD method uses the CRISPR-Cas13 system to detect and functionalize putative enhancers.",
      "TALENs, which are used in the TALE-iD method, consist of a DNA-binding domain and a cleavage domain.",
      "Putative enhancer sequences identified by the TALE-iD method often have low Rouquier scores."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The TALE-iD method does not use the CRISPR-Cas13 system, but rather utilizes transcription activator-like effectors (TALEs) for the detection and functionalization of enhancers.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Φ (pronounced \"klyta\") - CL-Φ is a lightweight, pure Lisp image processing framework that provides a comprehensive set of image processing functions, including image manipulation, filtering, and analysis. It is designed to be fast and efficient, making it suitable for real-time image processing applications.\n2. ImageCBS - ImageCBS (Image Components Based System) is a Lisp framework for image processing that provides a modular, hierarchical structure for image processing components. It includes pre-built components for common image processing tasks, such as resizing, cropping, and filtering, and allows users to easily extend and modify these components.\n3. LispMIC - LispMIC (Lisp Micro Imaging Component) is a Lisp framework for image processing that provides a set of reusable, modular imaging components. It includes components for image manipulation, filtering, and analysis, and allows users to easily combine and customize these components to meet their needs.\n4. LISP-IE - LISP-IE (Lisp Image Processing Environment) is a Lisp framework for image processing that provides a comprehensive set of image processing functions, including image manipulation, filtering, and analysis. It is designed to be flexible and extensible, allowing users to easily add new functions and components to the framework.\n5. DisCiL - DisCiL (Discrete Component Lisp) is a Lisp framework for image processing that provides a modular, hierarchical structure for image processing components. It includes pre-built components for common image processing tasks, such as resizing, cropping, and filtering, and allows users to easily extend and modify these components.\n6. LispAP - LispAP (Lisp Algorithmic Processing) is a Lisp framework for image processing that provides a set of reusable, modular imaging components. It includes components for image manipulation, filtering, and analysis, and allows users to easily combine and customize these components to meet their needs.\n7. LP-M (Lisp Processing of Multidimensional Images) is a Lisp framework for image processing that provides a comprehensive set of image processing functions, including image manipulation, filtering, and analysis. It is designed to be flexible and extensible, allowing",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Φ is a Lisp framework developed for image processing that includes functions like image manipulation, filtering, and analysis.\n2. ImageCBS is a Lisp framework that offers a modular, hierarchical structure for image processing with pre-built components.\n3. LispMIC is a Lisp framework for image processing that provides reusable, modular imaging components.\n4. LISP-IE is a Lisp framework for image processing with a comprehensive set of functions and designed to be flexible and extensible.\n5. DisCiL is a Lisp framework for image processing that provides a modular structure and pre-built components for common tasks.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Φ is a Lisp framework developed for image processing that includes functions like image manipulation, filtering, and analysis.",
      "ImageCBS is a Lisp framework that offers a modular, hierarchical structure for image processing with pre-built components.",
      "LispMIC is a Lisp framework for image processing that provides reusable, modular imaging components.",
      "LISP-IE is a Lisp framework for image processing with a comprehensive set of functions and designed to be flexible and extensible.",
      "DisCiL is a Lisp framework for image processing that provides a modular structure and pre-built components for common tasks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific context or sources confirming the existence and features of these Lisp frameworks, it is not possible to accurately determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\nAncient whole genome duplication refers to a process where an entire genome is duplicated, resulting in two identical copies of the genome. This process has occurred multiple times in the evolutionary history of eukaryotes, including in the budding yeast Saccharomyces cerevisiae (S. cerevisiae).\nS. cerevisiae has experienced two whole genome duplications (WGDs) in its evolutionary history. The first WGD, referred to as the \"ancient duplication,\" occurred around 1,000-2,000 million years ago and resulted in the duplication of approximately 1,000-1,500 genes. The second WGD, referred to as the \"more recent duplication,\" occurred around 100-200 million years ago and resulted in the duplication of approximately 300-400 genes.\nTo estimate the number of genes in S. cerevisiae that are the result of these ancient WGDs, we can use a few different approaches:\n1. Gene density: One way to estimate the number of genes that are the result of WGDs is to look at the density of genes in different regions of the genome. Studies have shown that the density of genes in S. cerevisiae is higher in regions that are likely to have been affected by WGDs, such as gene-rich regions near the centromere and telomeres. Using this approach, one study estimated that around 1,200 genes in S. cerevisiae are the result of the ancient WGD.\n2. synteny analysis: Another approach to estimating the number of genes that are the result of WGDs is to look at the synteny (similarity in gene order) between the S. cerevisiae genome and other eukaryotic genomes. Studies have shown that genes that are the result of WGDs tend to be conserved across domains, but are more easily lost on the non- Duplicated (ND) chromosomes. Using this approach, one study estimated that around 1,100 genes in S. cerevisiae are the result of the ancient WGD.\n3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ancient whole genome duplication is a process where an entire genome is duplicated, resulting in two identical copies of the genome.\n2. The budding yeast Saccharomyces cerevisiae (S. cerevisiae) has experienced two whole genome duplications in its evolutionary history.\n3. The first whole genome duplication in S. cerevisiae occurred around 1,000-2,000 million years ago.\n4. The ancient whole genome duplication in S. cerevisiae resulted in the duplication of approximately 1,000-1,500 genes.\n5. One study estimated that around 1,200 genes in S. cerevisiae are the result of the ancient whole genome duplication.",
    "llama-2-7b-chat-hf_fact": [
      "Ancient whole genome duplication is a process where an entire genome is duplicated, resulting in two identical copies of the genome.",
      "The budding yeast Saccharomyces cerevisiae (S. cerevisiae) has experienced two whole genome duplications in its evolutionary history.",
      "The first whole genome duplication in S. cerevisiae occurred around 1,000-2,000 million years ago.",
      "The ancient whole genome duplication in S. cerevisiae resulted in the duplication of approximately 1,000-1,500 genes.",
      "One study estimated that around 1,200 genes in S. cerevisiae are the result of the ancient whole genome duplication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The budding yeast Saccharomyces cerevisiae (S. cerevisiae) has experienced one whole genome duplication in its evolutionary history.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor beta (ESRRB) is a nuclear receptor that plays a crucial role in regulating various physiological processes, including reproduction, metabolism, and cell signaling. ESRRB is activated by estrogen and modulates gene expression by binding to specific DNA sequences called estrogen response elements (EREs).\nSeveral complexes have been identified that are bound by ESRRB in various cell types. Here are some examples:\n1. Coactivator complex: ESRRB forms a complex with other coactivators, including p300 and CBP (CREB-binding protein), which enhance its transcriptional activity. This complex is involved in the regulation of gene expression in various tissues, including the uterus, breast, and bone.\n2. Corepressor complex: ESRRB can also form a complex with corepressors, such as N-CoR (nuclear receptor corepressor) and histone deacetylases (HDACs), which can repress transcription of target genes. This complex is involved in the regulation of genes involved in cell growth, differentiation, and apoptosis.\n3. Chromatin remodeling complex: ESRRB can interact with chromatin remodeling complexes, such as SWI/SNF and CHD (chromodomain-helicase-DNA-binding) complexes, which are involved in altering the structure of chromatin to access and activate transcriptional activators or repressors. This complex is important for the regulation of gene expression in various tissues, including the brain and skeletal muscle.\n4. Signal transducer and activator of transcription (STAT) complex: ESRRB can interact with STAT proteins, such as STAT3 and STAT5, which are involved in signaling pathways that regulate transcription of target genes involved in innate immunity and inflammation.\n5. β-Catenin complex: ESRRB can interact with β-catenin, a key component of the Wnt signaling pathway, which regulates embryonic development and tissue homeostasis. This complex is involved in regulating the expression of genes involved in stem cell maintenance and",
    "llama-2-7b-chat-hf_fact_raw": "1. ESRRB forms a coactivator complex with p300 and CBP, enhancing its transcriptional activity in tissues like the uterus, breast, and bone.\n2. ESRRB can form a corepressor complex with N-CoR and HDACs, which represses transcription of genes related to cell growth, differentiation, and apoptosis.\n3. ESRRB interacts with chromatin remodeling complexes, such as SWI/SNF and CHD, to regulate gene expression in tissues like the brain and skeletal muscle.\n4. ESRRB can interact with signal transducer and activator of transcription (STAT) proteins like STAT3 and STAT5, to regulate genes involved in innate immunity and inflammation.\n5. ESRRB can interact with β-catenin, a component of the Wnt signaling pathway, to regulate genes in stem cell maintenance and embryonic development.",
    "llama-2-7b-chat-hf_fact": [
      "ESRRB forms a coactivator complex with p300 and CBP, enhancing its transcriptional activity in tissues like the uterus, breast, and bone.",
      "ESRRB can form a corepressor complex with N-CoR and HDACs, which represses transcription of genes related to cell growth, differentiation, and apoptosis.",
      "ESRRB interacts with chromatin remodeling complexes, such as SWI/SNF and CHD, to regulate gene expression in tissues like the brain and skeletal muscle.",
      "ESRRB can interact with signal transducer and activator of transcription (STAT) proteins like STAT3 and STAT5, to regulate genes involved in innate immunity and inflammation.",
      "ESRRB can interact with β-catenin, a component of the Wnt signaling pathway, to regulate genes in stem cell maintenance and embryonic development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The statements provided are specific to molecular biology and would require specialized knowledge or research to verify their accuracy. Without additional context or sources, it is not possible to determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 (Zinc finger CCHC-type histone methyltransferase 17) is a protein that plays a crucial role in regulating various cellular processes, including gene expression, cell division, and the development of certain diseases. Here are some key aspects of the role of ZCCHC17:\n1. Histone methylation: ZCCHC17 is a histone methyltransferase, which means it adds a methyl group to histone proteins. Histones are the main structural proteins of DNA in eukaryotic cells, and histone methylation can alter chromatin structure and accessibility to transcription factors, leading to changes in gene expression. ZCCHC17 specifically methylates histone H3 on lysine 27 (H3K27me3), a mark that is known to repress gene transcription.\n2. Chromatin remodeling: ZCCHC17 can also interact with chromatin remodeling complexes, such as the SWI/SNF complex, to alter chromatin structure and accessibility. This can lead to changes in gene expression and chromatin dynamics, and is thought to play a role in cell fate determination and differentiation.\n3. Cell cycle regulation: ZCCHC17 is involved in regulating the cell cycle, particularly during the G1/S checkpoint. It interacts with and regulates the activity of key cell cycle regulators, such as CDKN1A (p21) and CDC25A (Cdc25A), to control progression from the G1 phase to the S phase.\n4. Cancer: ZCCHC17 has been implicated in various types of cancer, including breast, lung, and prostate cancer. It is thought to play a role in tumor suppressor gene silencing and in the development of chemotherapy resistance. For example, ZCCHC17 has been shown to methylate the promoter of the tumor suppressor gene p53, leading to its repression and contributing to tumorigenesis.\n5. Stem cell maintenance: ZCCHC17 has also been shown to be involved in the regulation of stem cell maintenance and differentiation. It regulates the expression of gen",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a histone methyltransferase that methylates histone H3 on lysine 27 (H3K27me3).\n2. ZCCHC17 interacts with the SWI/SNF chromatin remodeling complex to alter chromatin structure and gene expression.\n3. ZCCHC17 is involved in regulating the cell cycle, particularly during the G1/S checkpoint.\n4. ZCCHC17 has been implicated in various types of cancer, including breast, lung, and prostate cancer.\n5. ZCCHC17 has a role in the regulation of stem cell maintenance and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a histone methyltransferase that methylates histone H3 on lysine 27 (H3K27me3).",
      "ZCCHC17 interacts with the SWI/SNF chromatin remodeling complex to alter chromatin structure and gene expression.",
      "ZCCHC17 is involved in regulating the cell cycle, particularly during the G1/S checkpoint.",
      "ZCCHC17 has been implicated in various types of cancer, including breast, lung, and prostate cancer.",
      "ZCCHC17 has a role in the regulation of stem cell maintenance and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: EZH2 is a histone methyltransferase that methylates histone H3 on lysine 27 (H3K27me3), not ZCCHC17.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear porin complex, is a group of proteins that form the structure through which nuclear membranes interact and allow for the transport of molecules between the nucleus and cytoplasm in eukaryotic cells, including human cells. The nuclear pore basket is composed of several proteins that work together to form a complex structure that spans the nuclear envelope and regulates the movement of molecules across it.\nThe main proteins that form the nuclear pore basket in human cells are:\n1. Nucleoporin 1 (Nup1): This protein is one of the most abundant proteins in the nuclear pore basket and plays a key role in the transport of molecules across the nuclear envelope. Nup1 is a large protein with multiple transmembrane domains and a cytoplasmic domain that interacts with other nuclear pore complex proteins.\n2. Nucleoporin 2 (Nup2): Nup2 is another abundant protein in the nuclear pore basket and plays a critical role in the transport of large molecules, such as proteins and nucleic acids, across the nuclear envelope. Nup2 has multiple transmembrane domains and a cytoplasmic domain that interacts with other nuclear pore complex proteins.\n3. Nucleoporin 3 (Nup3): Nup3 is a protein that is involved in the transport of small molecules, such as ions and small metabolites, across the nuclear envelope. Nup3 has a single transmembrane domain and a cytoplasmic domain that interacts with other nuclear pore complex proteins.\n4. Nucleoporin 5 (Nup5): Nup5 is a protein that is involved in the transport of large molecules, such as proteins and nucleic acids, across the nuclear envelope. Nup5 has multiple transmembrane domains and a cytoplasmic domain that interacts with other nuclear pore complex proteins.\n5. Nucleoporin 6 (Nup6): Nup6 is a protein that is involved in the transport of small molecules, such as ions and small metabolites, across the nuclear envelope. Nup6 has a single transmembrane domain and a cytoplasmic domain that interacts with other nuclear p",
    "llama-2-7b-chat-hf_fact_raw": "1. Nucleoporin 1 (Nup1) forms part of the nuclear pore basket in human cells and plays a key role in the transport of molecules across the nuclear envelope.\n2. Nucleoporin 2 (Nup2) is a protein in the nuclear pore basket that plays a critical role in the transport of large molecules across the nuclear envelope.\n3. Nucleoporin 3 (Nup3) is involved in the transport of small molecules across the nuclear envelope in human cells.\n4. Nucleoporin 5 (Nup5) is a protein that assists in transporting large molecules across the nuclear envelope in human cells.\n5. Nucleoporin 6 (Nup6) is part of the nuclear pore basket and helps transport small molecules across the nuclear envelope in human cells.",
    "llama-2-7b-chat-hf_fact": [
      "Nucleoporin 1 (Nup1) forms part of the nuclear pore basket in human cells and plays a key role in the transport of molecules across the nuclear envelope.",
      "Nucleoporin 2 (Nup2) is a protein in the nuclear pore basket that plays a critical role in the transport of large molecules across the nuclear envelope.",
      "Nucleoporin 3 (Nup3) is involved in the transport of small molecules across the nuclear envelope in human cells.",
      "Nucleoporin 5 (Nup5) is a protein that assists in transporting large molecules across the nuclear envelope in human cells.",
      "Nucleoporin 6 (Nup6) is part of the nuclear pore basket and helps transport small molecules across the nuclear envelope in human cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a novel small molecule that was identified through a high-throughput screening assay as a potential topoisomerase inhibitor. Topoisomerase inhibitors are a class of compounds that bind to and alter the activity of topoisomerases, which are enzymes that regulate the relaxation of DNA during replication, transcription, and repair.\nGepotidacin is a small molecule that acts as a topoisomerase II (Topo II) inhibitor, specifically targeting the type II topoisomerase, Topo IIα. Topo IIα is a ubiquitous enzyme that is involved in a wide range of cellular processes, including DNA replication, transcription, and repair. Gepotidacin binds to the active site of Topo IIα, interfering with the enzyme's ability to relax DNA and leading to a buildup of supercoiled DNA.\nInhibition of Topo IIα by gepotidacin has been shown to have anticancer activity, particularly against certain types of leukemia and solid tumors. Gepotidacin treatment has been shown to cause DNA damage and activation of the DNA damage response, leading to cell death in cancer cells. In addition, gepotidacin has been shown to inhibit the activity of other topoisomerases, including Topo IIβ and Topo III, suggesting that it may have broader anticancer effects beyond its specific inhibition of Topo IIα.\nWhile the exact mechanism of action of gepotidacin is not fully understood, it is thought to be related to its ability to cause DNA damage and activate the DNA damage response. Gepotidacin has also been shown to inhibit the activity of certain cancer-associated proteins, such as the histone methyltransferase EZH2, which is involved in the regulation of gene expression and is overexpressed in many cancers.\nOverall, gepotidacin is a promising new topoisomerase inhibitor that is being investigated as a potential anticancer drug. While more research is needed to fully understand its mechanism of action and to determine its safety and efficacy in humans, early studies suggest that it may have clinical utility in the treatment of",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a small molecule that acts as a topoisomerase II (Topo II) inhibitor.\n2. Gepotidacin specifically targets the type II topoisomerase, Topo IIα.\n3. Topo IIα is involved in DNA replication, transcription, and repair.\n4. Inhibition of Topo IIα by gepotidacin has been shown to have anticancer activity against certain types of leukemia and solid tumors.\n5. Gepotidacin has also been shown to inhibit the activity of other topoisomerases, including Topo IIβ and Topo III.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a small molecule that acts as a topoisomerase II (Topo II) inhibitor.",
      "Gepotidacin specifically targets the type II topoisomerase, Topo IIα.",
      "Topo IIα is involved in DNA replication, transcription, and repair.",
      "Inhibition of Topo IIα by gepotidacin has been shown to have anticancer activity against certain types of leukemia and solid tumors.",
      "Gepotidacin has also been shown to inhibit the activity of other topoisomerases, including Topo IIβ and Topo III."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a small molecule that acts as a topoisomerase II (Topo II) inhibitor, but it specifically targets bacterial type II topoisomerases, not human Topo IIα.\n2. FALSE [correction]: Gepotidacin does not specifically target Topo IIα, it targets bacterial topoisomerases.\n3. TRUE\n4. FALSE [correction]: Inhibition of human Topo IIα may have anticancer activity, but gepotidacin targets bacterial topoisomerases, so this statement does not apply to gepotidacin.\n5. FALSE [correction]: Gepotidacin is specifically designed to target bacterial topoisomerases, not human topoisomerases such as Topo IIβ and Topo III.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Student Premium Workspace) is a powerful tool offered by Canvas, a popular learning management system (LMS) used by educators and students worldwide. As an online learning platform, Canvas SPW provides a range of features and functionalities that enable teachers to create an engaging and interactive learning environment for their students. Here's a detailed answer to your question, describing the core components and benefits of Canvas SPW:\n1. Personalized Learning Environment:\nCanvas SPW allows teachers to create a personalized learning environment for each student, based on their individual needs and learning styles. Teachers can customize course content, assignments, and rubrics to meet the unique requirements of each student. This ensures that every student receives a tailored learning experience that fosters their academic growth and success.\n2. Dedicated Workspace:\nCanvas SPW provides each student with a dedicated workspace, where they can access course materials, submit assignments, and communicate with their teachers and peers. This workspace is designed to enhance student engagement and motivation, as students can organize their work and track their progress in a single, user-friendly platform.\n3. Enhanced Collaboration Tools:\nCanvas SPW offers a range of collaboration tools that enable students to work together on group projects, share ideas, and provide feedback. These tools include discussion forums, joint document editing, and real-time collaboration on assignments. This fosters a sense of community and shared ownership among students, promoting deeper learning and more effective collaboration.\n4. Access to Premium Features:\nAs a premium workspace, Canvas SPW offers additional features and functionalities that enhance the learning experience. These include:\n* Enhanced analytics and reporting: Teachers can track student progress, identify areas of improvement, and make Data-driven decisions to improve instruction.\n* Learning paths and paths: Teachers can create customized learning paths for individual students or groups, based on their skill levels, goals, and interests. This helps students stay on track and achieve their academic objectives.\n* Pairing and grouping: Teachers can pair or group students based on their needs, interests, or learning styles. This fosters a sense of community and promotes deeper learning and more effective collaboration.\n* Automated grading and feedback: Teachers can use Canvas SPW to",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a tool offered by Canvas, a learning management system.\n2. Canvas SPW enables teachers to create personalized learning environments for individual students.\n3. Students are provided with a dedicated workspace in Canvas SPW to access course materials and submit assignments.\n4. Canvas SPW includes collaboration tools such as discussion forums, joint document editing, and real-time collaboration on assignments.\n5. Canvas SPW offers premium features like enhanced analytics and reporting, customized learning paths, and automated grading and feedback.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a tool offered by Canvas, a learning management system.",
      "Canvas SPW enables teachers to create personalized learning environments for individual students.",
      "Students are provided with a dedicated workspace in Canvas SPW to access course materials and submit assignments.",
      "Canvas SPW includes collaboration tools such as discussion forums, joint document editing, and real-time collaboration on assignments.",
      "Canvas SPW offers premium features like enhanced analytics and reporting, customized learning paths, and automated grading and feedback."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'd be happy to provide you with a list of STING agonists!\nSTING (Stimulator of Interferon Genes) is a protein found on the surface of cells that plays a crucial role in the immune system. STING agonists are compounds that bind to STING and activate it, triggering an immune response. Here are some examples of STING agonists:\n1. Pam3Cys: Pam3Cys is a synthetic lipid molecule that functions as a STING agonist. It has been shown to activate STING and trigger the production of interferon-alpha (IFN-alpha) and interferon-beta (IFN-beta), which are important cytokines in the immune response.\n2. Poly IC: Poly IC is a synthetic polymer that can bind to STING and activate it. Like Pam3Cys, it has been shown to induce the production of IFN-alpha and IFN-beta.\n3. Alexa Fluor 488: Alexa Fluor 488 is a fluorescent dye that has been shown to activate STING and trigger an immune response. Although it is not a traditional STING agonist, it has been used as a tool to study STING function and activation.\n4. Imiquimod: Imiquimod is a topical immunomodulator that functions as a STING agonist. It activates STING and triggers the production of pro-inflammatory cytokines, such as interleukin-12 (IL-12), which help to fight off infections.\n5. R848: R848 is a synthetic agonist of STING that has been shown to activate STING and trigger an immune response. It has been used to study STING function and activation, as well as to treat a variety of immune-related disorders.\n6. Toll-like receptor (TLR) agonists: TLRs are a family of pattern recognition receptors that can recognize pathogen-associated molecular patterns (PAMPs) and trigger an immune response. Some TLR agonists, such as Pam3Cys, can also activate STING",
    "llama-2-7b-chat-hf_fact_raw": "1. Pam3Cys is a synthetic lipid molecule that functions as a STING agonist.\n2. Poly IC is a synthetic polymer that can bind to and activate STING.\n3. Alexa Fluor 488 is a fluorescent dye that has been shown to activate STING.\n4. Imiquimod is a topical immunomodulator that functions as a STING agonist.\n5. R848 is a synthetic agonist of STING.",
    "llama-2-7b-chat-hf_fact": [
      "Pam3Cys is a synthetic lipid molecule that functions as a STING agonist.",
      "Poly IC is a synthetic polymer that can bind to and activate STING.",
      "Alexa Fluor 488 is a fluorescent dye that has been shown to activate STING.",
      "Imiquimod is a topical immunomodulator that functions as a STING agonist.",
      "R848 is a synthetic agonist of STING."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Poly IC is a synthetic polymer that can bind to and activate TLR3, not STING.\n3. FALSE [correction]: Alexa Fluor 488 is a fluorescent dye used in bioconjugation and not known to activate STING.\n4. TRUE\n5. FALSE [correction]: R848 is a synthetic agonist of TLR7/8, not STING.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SlIC-CAGE is a clinical assessment tool used to evaluate cognitive function in older adults. The acronym SLIC-CAGE stands for \"Severity of Life Events - Cognitive Assessment for Geriatric Emergencies.\" It is a brief, easily administered screening tool that assesses an older adult's cognitive function in five key areas:\n1. Cognitive performance: This area of the SLIC-CAGE assessment evaluates an older adult's ability to perform daily tasks that require cognitive function, such as managing medications, paying bills, and preparing meals.\n2. Confusion: This area of the assessment assesses an older adult's level of confusion, disorientation, and difficulty with orientation to person, place, and time.\n3. Level of consciousness: This area of the assessment evaluates an older adult's level of consciousness, including their level of arousal, responsiveness, and ability to react to stimuli.\n4. Memory: This area of the assessment assesses an older adult's memory loss, including their ability to recall recent events, learn new information, and remember important details.\n5. Behavioral disturbance: This area of the assessment evaluates an older adult's behavioral symptoms, including agitation, aggression, and hallucinations.\nThe SLIC-CAGE assessment is based on a clinical interview with the older adult and/or their caregiver, and it can be completed in as little as 5-10 minutes. The tool is designed to be used in emergency department settings, such as when an older adult is brought to the hospital with acute cognitive decline or after a stroke.\nThe SLIC-CAGE assessment tool is used to identify older adults who are at risk of cognitive decline or dementia, and it can help healthcare providers prioritize treatment and referrals for further evaluation and management. The tool can also be used to monitor changes in cognitive function over time and to evaluate the effectiveness of interventions aimed at improving cognitive function in older adults.\nIn summary, SLIC-CAGE is a brief and useful tool for assessing cognitive function in older adults, particularly in emergency department settings. It can help healthcare providers",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a clinical assessment tool used to evaluate cognitive function in older adults.\n2. The acronym SLIC-CAGE stands for \"Severity of Life Events - Cognitive Assessment for Geriatric Emergencies.\"\n3. The SLIC-CAGE assessment evaluates cognitive function in five key areas: cognitive performance, confusion, level of consciousness, memory, and behavioral disturbance.\n4. The SLIC-CAGE assessment can be completed in 5-10 minutes.\n5. The tool is designed to be used in emergency department settings to identify older adults at risk of cognitive decline or dementia.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a clinical assessment tool used to evaluate cognitive function in older adults.",
      "The acronym SLIC-CAGE stands for \"Severity of Life Events - Cognitive Assessment for Geriatric Emergencies.\"",
      "The SLIC-CAGE assessment evaluates cognitive function in five key areas: cognitive performance, confusion, level of consciousness, memory, and behavioral disturbance.",
      "The SLIC-CAGE assessment can be completed in 5-10 minutes.",
      "The tool is designed to be used in emergency department settings to identify older adults at risk of cognitive decline or dementia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SLIC-CAGE is not a recognized clinical assessment tool for cognitive function in older adults.\n2. FALSE [correction]: Since SLIC-CAGE is not a recognized assessment tool, the acronym does not stand for \"Severity of Life Events - Cognitive Assessment for Geriatric Emergencies.\"\n3. FALSE [correction]: Since SLIC-CAGE is not a recognized assessment tool, it does not evaluate cognitive function in five key areas.\n4. FALSE [correction]: Since SLIC-CAGE is not a recognized assessment tool, it cannot be completed in 5-10 minutes.\n5. FALSE [correction]: Since SLIC-CAGE is not a recognized assessment tool, it is not designed for use in emergency department settings.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Linear Energy Density Matrixial-3) is a protein that plays a crucial role in various cellular processes, including cell cycle progression, DNA damage response, and cancer development. Here are some of the key roles of LEM-3:\n1. Cell cycle regulation: LEM-3 is involved in the regulation of the G1/S checkpoint, a critical control point in the cell cycle that ensures cells are ready to enter the S phase of the cell cycle. LEM-3 interacts with the retinoblastoma protein (Rb), a tumor suppressor that inhibits the E2F transcription factor, to regulate the G1/S checkpoint.\n2. DNA damage response: LEM-3 is also involved in the DNA damage response, particularly in the repair of double-strand breaks (DSBs). LEM-3 interacts with the DNA damage response protein 53BP1 and helps to recruit 53BP1 to sites of DNA damage, where it plays a critical role in the repair of DSBs.\n3. Cancer development: LEM-3 has been implicated in cancer development and progression. Studies have shown that LEM-3 is overexpressed in various types of cancer, including breast, ovarian, and colon cancer. Overexpression of LEM-3 has been linked to increased cancer cell proliferation, migration, and invasiveness, as well as poor prognosis.\n4. Epigenetic regulation: LEM-3 has been shown to play a role in epigenetic regulation, particularly in the regulation of histone modifications. LEM-3 interacts with histone-modifying enzymes and helps to regulate the deposition of histone acetylations and methylations, which can impact gene expression.\n5. Nuclear organization: LEM-3 is also involved in the organization of the nucleus, particularly in the formation of nuclear speckles, which are clusters of RNA polymerase II (RNAPII) and other regulatory proteins that are involved in transcriptional elongation. LEM-3 helps to recruit RNAPII to nuclear speckles and regulate its activity.\nOverall, LEM-3 is a multifunctional protein that plays a critical role in",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the regulation of the G1/S checkpoint in the cell cycle.\n2. LEM-3 interacts with the retinoblastoma protein to regulate the G1/S checkpoint.\n3. LEM-3 is involved in the repair of double-strand breaks in DNA damage response.\n4. LEM-3 interacts with the DNA damage response protein 53BP1 to recruit it to sites of DNA damage.\n5. LEM-3 is implicated in the development and progression of various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the regulation of the G1/S checkpoint in the cell cycle.",
      "LEM-3 interacts with the retinoblastoma protein to regulate the G1/S checkpoint.",
      "LEM-3 is involved in the repair of double-strand breaks in DNA damage response.",
      "LEM-3 interacts with the DNA damage response protein 53BP1 to recruit it to sites of DNA damage.",
      "LEM-3 is implicated in the development and progression of various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "tmVar is a time series analysis toolkit that provides a flexible and efficient platform for time series forecasting, anomaly detection, and other time series-related tasks. Here are the releases of tmVar:\ntmVar was first released in 2017 with version 0.1. Since then, there have been several updates and releases, including:\ntmVar 0.2 (2018): This release introduced several new features, including improved support for multivariate time series analysis, enhanced visualization capabilities, and better integration with other R packages.\ntmVar 0.3 (2019): This version added new functionality for time series filtering and feature engineering, as well as improved documentation and an easier-to-use interface.\ntmVar 0.4 (2020): This release included several major updates, such as improved support for scrapying data from web pages, better handling of unevenly spaced time series data, and new methods for identifying seasonal patterns in time series data.\nAs of April 2023, the latest version of tm Var is 0.5, which includes several new features and improvements over previous versions. Some of the changes include a new built-in function for selecting the optimal prior distribution for the forecast model, improved support for non-linear time series models, and easier integration with other R packages.\nOverall, tmVar has been continuously updated and improved since its initial release, with a focus on adding new features and improving existing ones to make it a more powerful and user-friendly tool for time series analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar was first released in 2017 with version 0.1.\n2. tmVar 0.2 was released in 2018 and included improved support for multivariate time series analysis.\n3. tmVar 0.3 was released in 2019 and added functionality for time series filtering and feature engineering.\n4. tmVar 0.4 was released in 2020 with updates like improved support for scraping data from web pages.\n5. As of April 2023, the latest version of tmVar is 0.5, which includes a new function for selecting the optimal prior distribution for forecast models.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar was first released in 2017 with version 0.1.",
      "tmVar 0.2 was released in 2018 and included improved support for multivariate time series analysis.",
      "tmVar 0.3 was released in 2019 and added functionality for time series filtering and feature engineering.",
      "tmVar 0.4 was released in 2020 with updates like improved support for scraping data from web pages.",
      "As of April 2023, the latest version of tmVar is 0.5, which includes a new function for selecting the optimal prior distribution for forecast models."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without additional context or information about the specific release dates and features of the tmVar software, it is not possible to verify the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out! There are several databases of somatic mutations in normal cells, which are important for understanding the genetic changes that occur in cells as we age and develop diseases. Here are some of the most notable databases:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While TCGA primarily focuses on cancer genomics, it also includes a large collection of normal tissue samples that have been sequenced and analyzed for somatic mutations.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale effort to sequence the genomes of over 1,000 individuals from around the world. The project includes a component called the \"normal\" dataset, which includes sequencing data from a variety of non-cancerous tissues, including blood, saliva, and skin.\n3. The Genome Aggregation Database (gnomAD): gnomAD is a collation of genomic data from a variety of sources, including TCGA and the 1000 Genomes Project. gnomAD includes both exonic and whole-genome sequencing data, as well as detailed annotations of somatic mutations in normal tissues.\n4. The Ensembl Variant Effect Predictor (VEP): Ensembl VEP is a web-based tool that uses a combination of computational methods and curated data to predict the functional effects of somatic mutations. While the primary focus of Ensembl VEP is on cancer genomics, it also includes a database of normal tissue samples and their associated mutational profiles.\n5. The Mutational Dynamics of Human Tissues (MuTaH): MuTaH is a database of somatic mutations in a wide range of human tissues, including normal tissues. The database includes both exonic and whole-genome sequencing data, as well as detailed annotations of the functional impact of each mutation.\nThese are just a few examples of the many databases available for studying somatic mutations in normal cells. It's worth noting that each database has its own strengths and limitations, and the choice of",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project aims to sequence the genomes of over 1,000 individuals from around the world and includes a \"normal\" dataset.\n3. The Genome Aggregation Database (gnomAD) collates genomic data from various sources, including TCGA and the 1000 Genomes Project.\n4. The Ensembl Variant Effect Predictor (VEP) predicts the functional effects of somatic mutations and includes a database of normal tissue samples.\n5. The Mutational Dynamics of Human Tissues (MuTaH) is a database that includes exonic and whole-genome sequencing data of somatic mutations in human tissues.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project aims to sequence the genomes of over 1,000 individuals from around the world and includes a \"normal\" dataset.",
      "The Genome Aggregation Database (gnomAD) collates genomic data from various sources, including TCGA and the 1000 Genomes Project.",
      "The Ensembl Variant Effect Predictor (VEP) predicts the functional effects of somatic mutations and includes a database of normal tissue samples.",
      "The Mutational Dynamics of Human Tissues (MuTaH) is a database that includes exonic and whole-genome sequencing data of somatic mutations in human tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Ensembl Variant Effect Predictor (VEP) predicts the functional effects of genetic variants primarily in human, but also for some other species. It does not include a database of normal tissue samples.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are some of them:\n1. Jarnabench: Jarnabench is a library for Java that provides a graph kernel interface (GKI) implementation of graph algorithms. It includes a wide range of graph algorithms and data structures, such as Breadth-First Search (BFS), Depth-First Search (DFS), Dijkstra's algorithm, Bellman-Ford algorithm, and more. Jarnabench also provides a simple and efficient API for graph data structures and algorithms.\n2. Graph-Explorer: Graph-Explorer is a Java library for graph-based algorithms and data structures. It provides a simple and intuitive API for graph traversal, graph algorithms, and data structures such as adjacency matrices, adjacency lists, and graph graphs. Graph-Explorer also includes a range of graph algorithms, including BFS, DFS, Shortest Paths, and more.\n3. GraphCrumbs: GraphCrumbs is a Java library for graph exploration and manipulation. It provides a simple and efficient API for traversing and querying graphs, as well as a range of graph algorithms such as BFS, DFS, and network flow. GraphCrumbs also includes data structures such as adjacency matrices and graphs, and supports multiple graph formats such as CSV, JSON, and more.\n4. GraphDesigner: GraphDesigner is a Java library for graph data structures and algorithms. It provides a simple and intuitive API for creating, manipulating, and querying graphs, as well as a range of graph algorithms such as BFS, DFS, Shortest Paths, and more. GraphDesigner also includes data structures such as adjacency matrices and graphs, and supports multiple graph formats such as CSV, JSON, and more.\n5. igraph-j: igraph-j is a Java implementation of the igraph library, which is a widely-used library for graph theory and network analysis. igraph-j provides a range of graph algorithms, data structures, and visualization tools, including graph traversal, clustering, shortest paths, and more. igraph-j also supports multiple graph formats and can be easily integrated into other Java applications.\n6. Vade: Vade is a lightweight Java library for graph algorithms and data structures. It provides a simple and efficient API for graph travers",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarnabench is a Java library that includes graph algorithms and data structures, such as BFS, DFS, Dijkstra's algorithm, and Bellman-Ford algorithm.\n2. Graph-Explorer is a Java library that provides an API for graph traversal and includes algorithms like BFS, DFS, and Shortest Paths.\n3. GraphCrumbs is a Java library that allows for graph exploration and manipulation and supports multiple graph formats such as CSV and JSON.\n4. GraphDesigner is a Java library that includes data structures and algorithms for creating and querying graphs.\n5. igraph-j is a Java implementation of the igraph library for graph theory and network analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Jarnabench is a Java library that includes graph algorithms and data structures, such as BFS, DFS, Dijkstra's algorithm, and Bellman-Ford algorithm.",
      "Graph-Explorer is a Java library that provides an API for graph traversal and includes algorithms like BFS, DFS, and Shortest Paths.",
      "GraphCrumbs is a Java library that allows for graph exploration and manipulation and supports multiple graph formats such as CSV and JSON.",
      "GraphDesigner is a Java library that includes data structures and algorithms for creating and querying graphs.",
      "igraph-j is a Java implementation of the igraph library for graph theory and network analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without additional context or information about these specific Java libraries, it is not possible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'd be happy to provide you with information on the four advances integrated into the SHERLOCKv2 platform.\nSHERLOCKv2 is a next-generation digital PCR (dPCR) platform that has been designed to provide higher throughput, faster analysis times, and improved accuracy compared to its predecessor, SHERLOCK. Here are the four advances integrated into the SHERLOCKv2 platform:\n1. Droplet-based microfluidics: SHERLOCKv2 uses a droplet-based microfluidic technology that enables the simultaneous analysis of thousands of samples in a single run. This technology allows for the efficient and compact design of the platform, which is essential for high-throughput applications.\n2. Advanced thermal control: SHERLOCKv2 features advanced thermal control that enables faster and more precise temperature control. This is particularly useful for applications that require temperature-sensitive reactions, such as qRT-PCR. The platform's thermal control system allows for accurate temperature control and maintenance, which is essential for efficient and consistent results.\n3. Parallel Multiproc es: SHERLOCKv2 includes a parallel multiprocessing architecture that allows for the simultaneous analysis of multiple samples. This architecture enables faster analysis times and higher throughput, making the platform ideal for high-throughput applications such as drug discovery and biotechnology.\n4. Modular design: SHERLOCKv2 has a modular design, which makes it easy to upgrade and expand the platform. The modular design enables users to add new functions and features as needed, which is essential for keeping up with the rapidly evolving field of life sciences.\nIn conclusion, the four advances integrated into the SHERLOCKv2 platform are droplet-based microfluidics, advanced thermal control, parallel multiprocessing, and a modular design. These advances enable the platform to perform high-throughput and fast analysis, making it an ideal tool for a wide range of applications in the life sciences field.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses droplet-based microfluidic technology for simultaneous analysis of thousands of samples.\n2. The platform features advanced thermal control for faster and more precise temperature control.\n3. SHERLOCKv2 includes a parallel multiprocessing architecture for simultaneous multiple sample analysis.\n4. It has a modular design allowing for easy upgrades and expansion.\n5. The SHERLOCKv2 platform is designed for high-throughput applications such as drug discovery and biotechnology.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses droplet-based microfluidic technology for simultaneous analysis of thousands of samples.",
      "The platform features advanced thermal control for faster and more precise temperature control.",
      "SHERLOCKv2 includes a parallel multiprocessing architecture for simultaneous multiple sample analysis.",
      "It has a modular design allowing for easy upgrades and expansion.",
      "The SHERLOCKv2 platform is designed for high-throughput applications such as drug discovery and biotechnology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender Algorithm is a problem-solving algorithm that was first introduced in 1995 by Christopher C. Brinton and Michael A. Kearns. It is a linear-time algorithm that can determine, given a set of drinks and a bar, whether there exists a non-empty subset of the drinks that sums to a given target total. In other words, the algorithm tries to find a \"bartender\" mix of drinks that adds up to a specified target total.\nThe Bartender Algorithm works by maintaining a set of \"ingredients\" or \"drinks\" that are available at the bar, as well as a \"recommendation\" or \"mixed drink\" that the algorithm is currently trying to create. The algorithm starts by selecting a base drink (e.g., a whiskey or a beer) and then iteratively adds additional drinks to the recommendation, one at a time, based on the following rules:\n1. Select a drink that has not yet been added to the recommendation: If the current recommendation is already made up of n drinks, the algorithm selects the next drink in the order in which it appears in the available drinks set.\n2. Check if the total cost of the recommendation is less than or equal to the target total: The algorithm checks if the total cost of the current recommendation is less than or equal to the target total. If it is not, the algorithm skips the current drink and moves on to the next one.\n3. Add the selected drink to the recommendation: If the drink is not already in the recommendation, the algorithm adds it to the recommendation.\n4. Update the target total: The algorithm updates the target total to reflect the cost of the drink that was just added to the recommendation.\n5. Repeat steps 1-4 until the target total is reached: The algorithm repeats steps 1-4 until the target total is reached, or until there are no more drinks available at the bar.\nThe Bartender Algorithm terminates when it finds a valid recommendation that sums to the target total, or when there are no more drinks available at the bar. If there are no valid recommendations that sum to the target total, the algorithm reports failure.\nHere is an example of how the Bartender Algorithm would work for a simple case:\nSuppose we have a bar with three drinks: whiskey, beer, and cola. The target",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender Algorithm was introduced in 1995 by Christopher C. Brinton and Michael A. Kearns.\n2. It is a linear-time algorithm designed to find a non-empty subset of drinks that sums to a given target total.\n3. The algorithm maintains a set of drinks available at the bar and a recommendation it is trying to create.\n4. The Bartender Algorithm adds drinks to the recommendation iteratively based on a set of rules.\n5. The algorithm terminates when it finds a valid recommendation that sums to the target total or when there are no more drinks available.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender Algorithm was introduced in 1995 by Christopher C. Brinton and Michael A. Kearns.",
      "It is a linear-time algorithm designed to find a non-empty subset of drinks that sums to a given target total.",
      "The algorithm maintains a set of drinks available at the bar and a recommendation it is trying to create.",
      "The Bartender Algorithm adds drinks to the recommendation iteratively based on a set of rules.",
      "The algorithm terminates when it finds a valid recommendation that sums to the target total or when there are no more drinks available."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender Algorithm was introduced by Donald Knuth in 1971.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad you asked! There are several web-based pedigree editors available that can help you create and manage your family tree. Here are some of the most popular options:\n1. Ancestry.com: Ancestry.com is one of the most popular genealogy websites, and it offers a web-based pedigree editor called \"Ancestry Tree.\" With this tool, you can create and edit your family tree, add photos and documents, and connect with other users who share your ancestors.\n2. FamilySearch: FamilySearch is a non-profit organization dedicated to helping people learn about their family history. Their web-based pedigree editor, called \"Family Tree,\" allows you to create and manage your family tree, and connect with other users who are researching the same ancestors.\n3. MyHeritage: MyHeritage is another popular genealogy website that offers a web-based pedigree editor. Their tool, called \"Family Tree Builder,\" allows you to create and edit your family tree, and also offers a DNA testing service to help you discover your ancestral origins.\n4. Living pedigree: Living pedigree is a web-based tool that allows you to create and manage your family tree, and also offers a feature called \"Living Pedigree,\" which allows you to add living relatives to your tree and track their relationships.\n5. GenoPro: GenoPro is a professional genealogy software that allows you to create and manage your family tree, and also offers a web-based platform for access your tree from anywhere.\n6. Legacy Family Tree: Legacy Family Tree is a powerful genealogy software that offers a web-based platform for accessing and managing your family tree, as well as a mobile app for on-the-go access.\n7. Family Cham: Family Cham is a web-based family tree creator that allows you to create and manage your family tree, and also offers features like collaboration tools and DNA testing integration.\n8. Gramps: Gramps is a free and open-source genealogy software that offers a web-based platform for creating and managing your family tree.\nPlease note that this is not an exhaustive list and there are many more web-based pedigree editors available. Each one has its own unique features and pricing plans, so be sure to explore them and choose",
    "llama-2-7b-chat-hf_fact_raw": "1. Ancestry.com offers a web-based pedigree editor called \"Ancestry Tree.\"\n2. FamilySearch is a non-profit organization that provides a web-based pedigree editor called \"Family Tree.\"\n3. MyHeritage offers a web-based pedigree editor known as \"Family Tree Builder.\"\n4. GenoPro provides professional genealogy software with a web-based platform for family tree management.\n5. Gramps is a free and open-source genealogy software with a web-based platform for managing family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Ancestry.com offers a web-based pedigree editor called \"Ancestry Tree.\"",
      "FamilySearch is a non-profit organization that provides a web-based pedigree editor called \"Family Tree.\"",
      "MyHeritage offers a web-based pedigree editor known as \"Family Tree Builder.\"",
      "GenoPro provides professional genealogy software with a web-based platform for family tree management.",
      "Gramps is a free and open-source genealogy software with a web-based platform for managing family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro provides professional genealogy software but does not have a web-based platform. It requires installation on a computer.\n5. FALSE [correction]: Gramps is a free and open-source genealogy software but is not web-based. It requires installation on a user's computer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins that can provide valuable information on the structural and functional properties of these compounds. Here are some of the most well-known and widely used databases for spider-venom toxins:\n1. The Spider Silk database (SSdb): This is a comprehensive database of spider-venom peptides and proteins, including their sequences, structures, and functional properties. SSdb contains information on over 100 species of spiders, with more than 500 unique venom proteins and peptides listed.\n2. The University of Arizona's Spider Toxin Database (UA-STD): This database contains a collection of spider toxins, including their sequences, structures, and functional information. The database currently contains over 100 different spider species, with a focus on Southwestern United States species.\n3. The Venom-DB: This is a comprehensive database of venom peptides and proteins from various sources, including spiders, snakes, and scorpions. Venom-DB contains information on the structural and functional properties of these compounds, as well as their distribution and evolutionary history.\n4. The Toxinology Database (ToxinDB): This database is focused on toxins from various sources, including animals, plants, and microorganisms. ToxinDB contains information on the structure, function, and biological activities of toxins, including spider-venom toxins.\n5. The Natural Products Database (NatPaD): This database contains information on natural products, including their structural and functional properties, as well as their distribution and bioactivity. Although not exclusively focused on spider-venom toxins, NatPaD does contain a section dedicated to venom peptides and proteins.\nThese curated databases can provide valuable insights into the properties and functions of spider-venom toxins, and can be useful tools for researchers studying the evolution and function of venomous organisms. However, it is worth noting that the structure, function, and distribution of spider-venom toxins can vary widely between species and even within the venom of a single species, so further study is needed to fully understand the complexities of these compounds",
    "llama-2-7b-chat-hf_fact_raw": "1. The Spider Silk database (SSdb) is a comprehensive database that includes information on over 100 species of spiders and has more than 500 unique venom proteins and peptides listed.\n2. The University of Arizona's Spider Toxin Database (UA-STD) contains information on over 100 different spider species and focuses on species from the Southwestern United States.\n3. The Venom-DB is a comprehensive database of venom peptides and proteins from various sources including spiders, snakes, and scorpions.\n4. The Toxinology Database (ToxinDB) includes information on spider-venom toxins as well as toxins from animals, plants, and microorganisms.\n5. The Natural Products Database (NatPaD) has a section dedicated to venom peptides and proteins, though it covers natural products in general.",
    "llama-2-7b-chat-hf_fact": [
      "The Spider Silk database (SSdb) is a comprehensive database that includes information on over 100 species of spiders and has more than 500 unique venom proteins and peptides listed.",
      "The University of Arizona's Spider Toxin Database (UA-STD) contains information on over 100 different spider species and focuses on species from the Southwestern United States.",
      "The Venom-DB is a comprehensive database of venom peptides and proteins from various sources including spiders, snakes, and scorpions.",
      "The Toxinology Database (ToxinDB) includes information on spider-venom toxins as well as toxins from animals, plants, and microorganisms.",
      "The Natural Products Database (NatPaD) has a section dedicated to venom peptides and proteins, though it covers natural products in general."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has shown promise in the treatment of various types of cancer, including pancreatic cancer. While there is limited research specifically on the use of Axitinib in pancreatic cancer, here is what the available evidence suggests:\nProlongation of Survival:\nCurrently, there are no established treatments for pancreatic cancer that have been proven to significantly prolong survival. The 5-year survival rate for pancreatic cancer is less than 10%, and the majority of patients with metastatic disease (cancer that has spread beyond the pancreas) have a poor prognosis.\nThat being said, there are some studies that suggest Axitinib may have a role in treating pancreatic cancer, particularly in patients with having certain genetic mutations.\nA study published in the Journal of Clinical Oncology in 2019 found that Axitinib improved overall survival in patients with advanced pancreatic cancer who had a specific genetic mutation called KRAS G12C. The study found that patients with this mutation who received Axitinib had a median overall survival of 13.6 months, compared to 9.4 months for those who received chemotherapy.\nAnother study published in the Lancet Oncology in 2020 found that Axitinib was effective in treating pancreatic cancer in patients who had previously been treated with chemotherapy. The study found that 24% of patients who received Axitinib experienced a response to the treatment, defined as a reduction in the size of the tumor.\nIt's important to note that these studies were small and more research is needed to confirm these findings and establish the long-term safety and efficacy of Axitinib in pancreatic cancer. Additionally, Axitinib is not yet approved by the FDA for the treatment of pancreatic cancer.\nIt's also important to note that the current standard of care for pancreatic cancer is gemcitabine-based chemotherapy, which has been shown to improve survival in patients with metastatic pancreatic cancer.\nIn summary, while there is some evidence to suggest that Axitinib may have a role in treating pancreatic cancer, particularly in patients with certain genetic",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor used in the treatment of various types of cancer, including pancreatic cancer.\n2. The 5-year survival rate for pancreatic cancer is less than 10%.\n3. A study published in the Journal of Clinical Oncology in 2019 found that Axitinib improved overall survival in patients with advanced pancreatic cancer who had the KRAS G12C genetic mutation.\n4. Another study published in the Lancet Oncology in 2020 found that 24% of pancreatic cancer patients treated with Axitinib experienced a response to the treatment.\n5. Axitinib is not yet approved by the FDA for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor used in the treatment of various types of cancer, including pancreatic cancer.",
      "The 5-year survival rate for pancreatic cancer is less than 10%.",
      "A study published in the Journal of Clinical Oncology in 2019 found that Axitinib improved overall survival in patients with advanced pancreatic cancer who had the KRAS G12C genetic mutation.",
      "Another study published in the Lancet Oncology in 2020 found that 24% of pancreatic cancer patients treated with Axitinib experienced a response to the treatment.",
      "Axitinib is not yet approved by the FDA for the treatment of pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Axitinib is a tyrosine kinase inhibitor used in the treatment of various types of cancer, including renal cell carcinoma, not specifically pancreatic cancer.\n2. TRUE\n3. FALSE [correction]: There is no evidence provided that supports the existence of this study; therefore, its findings cannot be confirmed.\n4. FALSE [correction]: There is no evidence provided that supports the existence of this study or its findings; therefore, the statement cannot be confirmed.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Mixed Lineage Kinase Protein) regulates F-actin dynamics through several protein interactions, including:\n1. Interaction with MLKL (Mixed Lineage Kinase Domain-Like Protein): MLP and MLKL are closely related proteins that share a similar kinase domain structure. MLP has been shown to interact with MLKL and regulate its activity, leading to changes in F-actin dynamics.\n2. Interaction with CASK (Cerebral Actin-Associated Protein): CASK is a protein that is involved in the regulation of F-actin dynamics by interacting with actin filaments and modulating their dynamics. MLP has been shown to interact with CASK and regulate its activity, leading to changes in F-actin dynamics.\n3. Interaction with ACTB (Alpha-Tubulin): ACTB is a protein that is involved in the formation and regulation of microtubules. MLP has been shown to interact with ACTB and regulate its activity, leading to changes in F-actin dynamics.\n4. Interaction with EB1 (Electron Microscopy Study 1 Protein): EB1 is a protein that is involved in the regulation of F-actin dynamics by interacting with actin filaments and modulating their dynamics. MLP has been shown to interact with EB1 and regulate its activity, leading to changes in F-actin dynamics.\nAdditionally, MLP has been shown to regulate F-actin dynamics through its ability to phosphorylate and activate MLKL, which leads to changes in actin dynamics. MLP also regulates F-actin dynamics by interacting with other proteins, such as CASK and ACTB, and modulating their activity.\nIn summary, MLP regulates F-actin dynamics through multiple protein interactions, including those with MLKL, CASK, ACTB, and EB1, as well as through its ability to phosphorylate and activate MLKL.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Mixed Lineage Kinase Protein) interacts with MLKL (Mixed Lineage Kinase Domain-Like Protein) and regulates its activity.\n2. MLP has been shown to interact with CASK (Cerebral Actin-Associated Protein) and modulate its dynamics.\n3. MLP interacts with ACTB (Alpha-Tubulin) to regulate its activity.\n4. MLP engages in interaction with EB1 (Electron Microscopy Study 1 Protein) to regulate F-actin dynamics.\n5. MLP can phosphorylate and activate MLKL, leading to changes in actin dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Mixed Lineage Kinase Protein) interacts with MLKL (Mixed Lineage Kinase Domain-Like Protein) and regulates its activity.",
      "MLP has been shown to interact with CASK (Cerebral Actin-Associated Protein) and modulate its dynamics.",
      "MLP interacts with ACTB (Alpha-Tubulin) to regulate its activity.",
      "MLP engages in interaction with EB1 (Electron Microscopy Study 1 Protein) to regulate F-actin dynamics.",
      "MLP can phosphorylate and activate MLKL, leading to changes in actin dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific context or reference to a scientific study, it is difficult to determine the accuracy of these statements about protein interactions and functions.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out! The term \"pseudokinase\" refers to a protein that has some characteristics of kinases, but does not have the ability to transfer phosphate groups to other proteins. In the human kinome, there are 14 pseudokinases identified to date. These proteins are typically involved in various cellular processes, including signal transduction, cytoskeleton organization, and gene regulation.\nHere are the 14 human pseudokinases, along with their approximate functions and notable features:\n1. ACK1 (A suppressor of cytokines kinase 1): ACK1 is involved in the regulation of signaling pathways downstream of growth factors and cytokines. It phosphorylates and activates several downstream targets, including the protein kinase A (PKA) and the small GTPase Cdc42.\n2. CK2 (Casein kinase 2): CK2 is a constitutively active kinase that phosphorylates various substrates involved in cellular processes such as transcriptional regulation, protein synthesis, and cell signaling.\n3. Dacks (DACKS, Dendritic molecule-associated protein kinase substrate): Dacks is a pseudokinase that is involved in the regulation of synaptic plasticity and neuronal survival. It phosphorylates and modifies several downstream targets, including the N-methyl-D-aspartate (NMDA) receptor.\n4. DOK (Dishevelled-associated activating kinase): DOK is a pseudokinase that is involved in the regulation of Wnt/β-catenin signaling. It phosphorylates and activates β-catenin, leading to the transcription of Wnt target genes.\n5. Fyn: Fyn is a pseudokinase that is involved in the regulation of various cellular processes, including cell adhesion, migration, and signaling. It phosphorylates and activates several downstream targets, including the small GTPase Rac1.\n6. GCK (Glycogen synthase kinase 3β): GCK is a pseudokinase that is involved in the regulation of glyc",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 14 pseudokinases identified in the human kinome.\n2. Pseudokinases have characteristics of kinases but cannot transfer phosphate groups to other proteins.\n3. Pseudokinases are involved in cellular processes like signal transduction, cytoskeleton organization, and gene regulation.\n4. ACK1 is a pseudokinase involved in regulating signaling pathways downstream of growth factors and cytokines.\n5. CK2 is a constitutively active kinase that phosphorylates various substrates involved in transcriptional regulation, protein synthesis, and cell signaling.",
    "llama-2-7b-chat-hf_fact": [
      "There are 14 pseudokinases identified in the human kinome.",
      "Pseudokinases have characteristics of kinases but cannot transfer phosphate groups to other proteins.",
      "Pseudokinases are involved in cellular processes like signal transduction, cytoskeleton organization, and gene regulation.",
      "ACK1 is a pseudokinase involved in regulating signaling pathways downstream of growth factors and cytokines.",
      "CK2 is a constitutively active kinase that phosphorylates various substrates involved in transcriptional regulation, protein synthesis, and cell signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ACK1 is not a pseudokinase; it is an active tyrosine kinase involved in regulating signaling pathways downstream of growth factors and cytokines.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! Apolipoprotein mimetics are a class of compounds that mimic the structure and function of apolipoproteins, which are proteins that play a key role in lipid metabolism and transport. Here are three examples of apoE mimetics:\n1. Chenodeoxycholate: Chenodeoxycholate is a naturally occurring apoE mimetic that is found in very high levels in the plasma of patients with familial hypercholesterolemia. It has been shown to inhibit the uptake of cholesterol by the liver and promote its excretion in the bile, leading to a reduction in plasma cholesterol levels.\n2. Duodenal bioadhesin: Duodenal bioadhesin is a synthetic apoE mimetic that has been shown to reduce cholesterol absorption in the small intestine, leading to a decrease in plasma cholesterol levels. It has been shown to bind to apoE receptors on the surface of enterocytes in the small intestine, where it inhibits the uptake of cholesterol and other lipids.\n3. ApoC-III mimetic: ApoC-III mimetic is a synthetic compound that mimics the structure and function of apolipoprotein C-III (apoC-III). ApoC-III is a key player in the regulation of lipid metabolism and transport, and it has been shown to play a critical role in the transport of cholesterol from the bloodstream to the liver for excretion. The apoC-III mimetic has been shown to reduce plasma cholesterol levels by inhibiting the uptake of cholesterol by the liver.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chenodeoxycholate is a naturally occurring apoE mimetic found in high levels in the plasma of patients with familial hypercholesterolemia.\n2. Chenodeoxycholate inhibits the uptake of cholesterol by the liver and promotes its excretion in the bile.\n3. Duodenal bioadhesin is a synthetic apoE mimetic that reduces cholesterol absorption in the small intestine.\n4. Duodenal bioadhesin binds to apoE receptors on the surface of enterocytes in the small intestine.\n5. ApoC-III mimetic is a synthetic compound that mimics apolipoprotein C-III and reduces plasma cholesterol levels by inhibiting cholesterol uptake by the liver.",
    "llama-2-7b-chat-hf_fact": [
      "Chenodeoxycholate is a naturally occurring apoE mimetic found in high levels in the plasma of patients with familial hypercholesterolemia.",
      "Chenodeoxycholate inhibits the uptake of cholesterol by the liver and promotes its excretion in the bile.",
      "Duodenal bioadhesin is a synthetic apoE mimetic that reduces cholesterol absorption in the small intestine.",
      "Duodenal bioadhesin binds to apoE receptors on the surface of enterocytes in the small intestine.",
      "ApoC-III mimetic is a synthetic compound that mimics apolipoprotein C-III and reduces plasma cholesterol levels by inhibiting cholesterol uptake by the liver."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chenodeoxycholic acid is a naturally occurring bile acid not an apoE mimetic, and it is not specifically found in high levels in the plasma of patients with familial hypercholesterolemia.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Samhd1) is a protein that plays a critical role in regulating innate immune responses, particularly in the context of viral infections. There are several sex differences in SAMHD1 activity that have been observed in various studies. Here are some of the key findings:\n1. Expression levels: SAMHD1 expression levels have been found to be higher in males than in females in various tissues, including the brain, liver, and spleen (Li et al., 2013).\n2. Activity: SAMHD1 activity has been shown to be higher in males than in females in response to certain viral infections, such as HIV and HCV (Kim et al., 2014; Song et al., 2015). However, SAMHD1 activity is generally lower in male mice than in female mice, which can make them more susceptible to viral infections (Wang et al., 2013).\n3. Ligand binding: SAMHD1 has been found to bind to the ligand histone H3 lysine 9 (H3K9) in a sex-specific manner. H3K9 is a histone modification that is known to play a role in regulating gene expression, and SAMHD1 has been shown to bind to H3K9 in a way that is dependent on the sex of the cell (Liu et al., 2013).\n4. Cellular localization: SAMHD1 has been shown to localize differently in male and female cells. For example, SAMHD1 has been found to localize to the cytoplasm in male cells, while it localizes to the nucleus in female cells (Chen et al., 2014).\n5. Regulation by estrogen: Estrogen has been shown to play a role in regulating SAMHD1 activity. Estrogen can induce the expression of SAMHD1 in female cells, and it can also inhibit the activity of SAMHD1 in male cells (Yoon et al., 2013).\n6. Viral infection: SAMHD1 has been shown to play a role in regulating the replication of certain viruses, such as HIV and HCV, in a sex",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 expression levels are higher in males than in females in various tissues.\n2. SAMHD1 activity is higher in males in response to certain viral infections like HIV and HCV.\n3. SAMHD1 binds to histone H3 lysine 9 (H3K9) in a sex-specific manner.\n4. The cellular localization of SAMHD1 differs between male and female cells.\n5. Estrogen regulates SAMHD1 activity by inducing expression in female cells and inhibiting activity in male cells.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 expression levels are higher in males than in females in various tissues.",
      "SAMHD1 activity is higher in males in response to certain viral infections like HIV and HCV.",
      "SAMHD1 binds to histone H3 lysine 9 (H3K9) in a sex-specific manner.",
      "The cellular localization of SAMHD1 differs between male and female cells.",
      "Estrogen regulates SAMHD1 activity by inducing expression in female cells and inhibiting activity in male cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! RUNX2 is a transcription factor that has been shown to play a crucial role in the differentiation and maturation of astrocytes. While the exact mechanism of RUNX2 inhibition on astrocyte differentiation is complex and context-dependent, there is evidence to suggest that it can inhibit astrocyte differentiation to some extent.\nFirstly, RUNX2 has been shown to regulate the expression of genes involved in astrocyte differentiation, such as GFAP and SOX10. Studies have shown that depletion of RUNX2 leads to a decrease in the expression of these genes, which can inhibit astrocyte differentiation (1,2).\nSecondly, RUNX2 has been shown to regulate the expression of genes involved in the maintenance of astrocyte identity, such as AQP4 and VGluT1. Studies have shown that inhibition of RUNX2 leads to a decrease in the expression of these genes, which can result in the loss of astrocyte identity (3,4).\nLastly, recent studies have shown that RUNX2 can also regulate the balance between glial cell fate decisions, including astrocyte differentiation. For example, one study found that RUNX2 regulates the expression of the transcription factor BRN2, which is a key regulator of astrocyte differentiation (5).\nIn summary, while the inhibition of RUNX2 on astrocyte differentiation is not complete, there is evidence to suggest that it can inhibit astrocyte differentiation to some extent by regulating the expression of genes involved in astrocyte differentiation and maintenance of astrocyte identity.\nReferences:\n1. Koo et al. (2015). Depletion of Runx2 leads to reduced expression of GFAP and SOX10 in the developing brain. Developmental Dynamics, 244(8), 1051-1062.\n2. Kim et al. (2012). Runx2 regulates the expression of genes involved in astrocyte differentiation and maturation. Journal of Neuroscience Research, 90(8), 1178-11",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is a transcription factor that plays a role in astrocyte differentiation and maturation.\n2. Depletion of RUNX2 leads to decreased expression of genes involved in astrocyte differentiation such as GFAP and SOX10.\n3. Inhibition of RUNX2 also leads to a decrease in the expression of genes important for maintaining astrocyte identity, such as AQP4 and VGluT1.\n4. RUNX2 can regulate the balance between glial cell fate decisions, including astrocyte differentiation.\n5. The transcription factor BRN2, which is regulated by RUNX2, is a key regulator of astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is a transcription factor that plays a role in astrocyte differentiation and maturation.",
      "Depletion of RUNX2 leads to decreased expression of genes involved in astrocyte differentiation such as GFAP and SOX10.",
      "Inhibition of RUNX2 also leads to a decrease in the expression of genes important for maintaining astrocyte identity, such as AQP4 and VGluT1.",
      "RUNX2 can regulate the balance between glial cell fate decisions, including astrocyte differentiation.",
      "The transcription factor BRN2, which is regulated by RUNX2, is a key regulator of astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 is a transcription factor that plays a role in bone development and osteoblast differentiation, not astrocyte differentiation.\n2. FALSE [correction]: Depletion of RUNX2 would not lead to decreased expression of genes involved in astrocyte differentiation as RUNX2 is not involved in astrocyte differentiation.\n3. FALSE [correction]: Inhibition of RUNX2 would not lead to a decrease in the expression of genes important for maintaining astrocyte identity as RUNX2 is not involved in astrocyte identity.\n4. FALSE [correction]: RUNX2 regulates the balance between osteoblast and chondrocyte differentiation, not glial cell fate decisions, including astrocyte differentiation.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat a condition called psoriatic arthritis, which is a type of inflammatory arthritis that affects people with psoriasis. The procedure involves removing the inflamed joint space and replacing it with an artificial joint, called a prosthesis.\nThe Cobb-Stainsby excision arthroplasty is typically performed on the hand or foot, as these are the areas most commonly affected by psoriatic arthritis. The procedure is usually performed under general anesthesia, which means the patient will be asleep during the surgery.\nThe specific steps of the Cobb-Stainsby excision arthroplasty will depend on the patient's individual case and the extent of the disease in the affected joint. However, the general steps of the procedure can be summarized as follows:\n1. Preparation: The patient will be given general anesthesia and will be positioned on an operating table.\n2. Incision: The surgeon will make an incision on the affected joint, usually on the top or side of the joint. The incision will be about 1-2 inches long and will be deep enough to expose the inflamed joint space.\n3. Removal of the inflamed tissue: The surgeon will carefully remove the inflamed tissue and cartilage from the joint space. This may involve cutting through the ligaments and tendons that surround the joint, as well as removing any bone spurs or other bone abnormalities.\n4. Prosthesis insertion: After the inflamed tissue has been removed, the surgeon will insert an artificial joint prosthesis into the joint space. This prosthesis is designed to mimic the natural movement of the joint and will be secured in place with capsular tissue and/or bone grafts.\n5. Closure: The incision will be closed with sutures or staples, and the hand or foot will be immobilized in a splint or cast to allow the joint to heal.\nIt is important to note that the Cobb-Stainsby excision arthroplasty is a major surgical procedure and will require several weeks of recovery time. Patients will typically need to avoid",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat psoriatic arthritis.\n2. This procedure is typically performed on the hand or foot.\n3. The surgery involves removing the inflamed joint space and replacing it with an artificial joint, called a prosthesis.\n4. The Cobb-Stainsby excision arthroplasty is typically performed under general anesthesia.\n5. The procedure includes steps such as making an incision, removing inflamed tissue, inserting a prosthesis, and closing the incision.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat psoriatic arthritis.",
      "This procedure is typically performed on the hand or foot.",
      "The surgery involves removing the inflamed joint space and replacing it with an artificial joint, called a prosthesis.",
      "The Cobb-Stainsby excision arthroplasty is typically performed under general anesthesia.",
      "The procedure includes steps such as making an incision, removing inflamed tissue, inserting a prosthesis, and closing the incision."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis or rheumatoid arthritis in the metatarsophalangeal joint (usually of the big toe), not specifically psoriatic arthritis.\n2. TRUE\n3. FALSE [correction]: The surgery involves removing the metatarsal head and then creating a soft tissue interposition arthroplasty to maintain joint stability and motion, not replacing it with an artificial joint.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 (Growth factor Redirected Hypoxia-inducible Factor-Like 2) is a transcription factor that has been implicated in various cellular processes, including cell proliferation, differentiation, and survival. Over-expression of GRHL2 has been reported to have both prometastatic and pro-invasive effects in various cancer types, suggesting that it may play a role in cancer progression.\nRecent studies have also suggested that GRHL2 may be involved in the process of Epithelial-to-Mesenchymal Transition (EMT), which is a critical step in cancer progression. EMT is a process where epithelial cells lose their cell-cell adhesion and acquire mesenchymal properties, such as increased migration and invasion, and the ability to differentiate into fibroblastic or migratory cells.\nSeveral studies have shown that GRHL2 over-expression is associated with EMT in various cancer types, including breast, lung, and colon cancer. For example, one study found that GRHL2 over-expression led to the down-regulation of the epithelial marker E-cadherin and the up-regulation of the mesenchymal markers N-cadherin and vimentin in breast cancer cells (1). Another study found that GRHL2 over-expression promoted the acquisition of mesenchymal characteristics in lung cancer cells (2).\nThe mechanisms by which GRHL2 over-expression leads to EMT are not fully understood, but several studies have suggested that GRHL2 may regulate the expression of key transcription factors involved in EMT, such as Snail and Slug. GRHL2 has been shown to bind to the promoter regions of these genes and enhance their transcription, leading to the down-regulation of epithelial markers and the up-regulation of mesenchymal markers (3).\nIn addition, GRHL2 has been shown to regulate the activity of other transcription factors, such as β-catenin, which is a key player in the Wnt/β-catenin signaling pathway. GRHL2 over-expression has been shown to increase the stability and activity of β-catenin, leading to the up-regulation of mesenchym",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression is reported to have prometastatic and pro-invasive effects in various cancer types.\n2. GRHL2 over-expression is associated with the process of Epithelial-to-Mesenchymal Transition (EMT) in various cancer types.\n3. One study found that GRHL2 over-expression led to the down-regulation of E-cadherin and the up-regulation of N-cadherin and vimentin in breast cancer cells.\n4. Another study found that GRHL2 over-expression promoted the acquisition of mesenchymal characteristics in lung cancer cells.\n5. GRHL2 over-expression may regulate the expression of key transcription factors involved in EMT, such as Snail and Slug.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression is reported to have prometastatic and pro-invasive effects in various cancer types.",
      "GRHL2 over-expression is associated with the process of Epithelial-to-Mesenchymal Transition (EMT) in various cancer types.",
      "One study found that GRHL2 over-expression led to the down-regulation of E-cadherin and the up-regulation of N-cadherin and vimentin in breast cancer cells.",
      "Another study found that GRHL2 over-expression promoted the acquisition of mesenchymal characteristics in lung cancer cells.",
      "GRHL2 over-expression may regulate the expression of key transcription factors involved in EMT, such as Snail and Slug."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Lung cancer is a complex and Multifactorial disease, and various Transcriptional Up-regulated Connexins (T-UCRs) have been found to be implicated in its development and progression. Here are some of the T-UCRs that have been linked to lung cancer:\n1. Connectin 2 (Cx43): Cx43 is a critical regulator of cell adhesion, migration, and signaling. Studies have shown that Cx43 is downregulated in lung cancer tissues, leading to increased cancer cell migration and invasiveness. Cx43 has been suggested as a potential therapeutic target for lung cancer treatment.\n2. Connectin 17 (Cx17): Cx17 is a recently discovered T-UCR that has been shown to play a crucial role in lung cancer progression. Cx17 has been found to be overexpressed in various types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma. Overexpression of Cx17 has been linked to increased cancer cell migration, invasion, and metastasis.\n3. Connectin 40 (Cx40): Cx40 is another T-UCR that has been implicated in lung cancer. Studies have shown that Cx40 is overexpressed in lung cancer tissues, particularly in the more aggressive and malignant subtypes of lung cancer. Overexpression of Cx40 has been linked to increased cancer cell migration, invasion, and proliferation.\n4. Connectin 42 (Cx42): Cx42 is a T-UCR that has been implicated in the regulation of lung cancer cell adhesion and signaling. Studies have shown that Cx42 is downregulated in lung cancer tissues, leading to decreased cancer cell adhesion and increased cancer cell migration.\n5. Connectin 45 (Cx45): Cx45 is a recently identified T-UCR that has been shown to play a crucial role in lung cancer progression. Cx45 has been found to be overexpressed in various types of lung cancer, including NSCLC and squamous cell carcinoma. Overexpression of Cx45 has been linked to increased cancer cell",
    "llama-2-7b-chat-hf_fact_raw": "1. Connectin 2 (Cx43) is downregulated in lung cancer tissues, leading to increased cancer cell migration and invasiveness.\n2. Connectin 17 (Cx17) is overexpressed in various types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma.\n3. Connectin 40 (Cx40) is overexpressed in lung cancer tissues, particularly in aggressive and malignant subtypes of lung cancer.\n4. Connectin 42 (Cx42) is downregulated in lung cancer tissues, leading to decreased cancer cell adhesion and increased cancer cell migration.\n5. Connectin 45 (Cx45) is overexpressed in various types of lung cancer, including NSCLC and squamous cell carcinoma.",
    "llama-2-7b-chat-hf_fact": [
      "Connectin 2 (Cx43) is downregulated in lung cancer tissues, leading to increased cancer cell migration and invasiveness.",
      "Connectin 17 (Cx17) is overexpressed in various types of lung cancer, including non-small cell lung cancer (NSCLC) and adenocarcinoma.",
      "Connectin 40 (Cx40) is overexpressed in lung cancer tissues, particularly in aggressive and malignant subtypes of lung cancer.",
      "Connectin 42 (Cx42) is downregulated in lung cancer tissues, leading to decreased cancer cell adhesion and increased cancer cell migration.",
      "Connectin 45 (Cx45) is overexpressed in various types of lung cancer, including NSCLC and squamous cell carcinoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n(Note: The statements provided involve specific medical information that would require knowledge of current research on the topic. Without the context of the passage or access to relevant medical research, it is not possible to determine the truthfulness of these statements.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan G protein-coupled receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. The gene encoding GPR151 was first identified in the early 1990s, and since then, it has been the subject of extensive research due to its unique properties and potential therapeutic applications. Here is a summary of what is currently known about GPR151:\n1. Structure: GPR151 is a member of the G protein-coupled receptor (GPCR) superfamily, which consists of seven transmembrane domain proteins with an extracellular N-terminal domain, one or two transmembrane domains, and an intracellular C-terminal domain. GPR151 is particularly interesting due to its unique structure, which includes a long N-terminal tail and a C-terminal cytoplasmic loop.\n2. Expression and distribution: GPR151 is expressed in a wide range of tissues, including the brain, heart, liver, and pancreas. It is also expressed in certain immune cells, such as T cells and macrophages. The expression of GPR151 varies among individuals and can be influenced by genetic and environmental factors.\n3. Function: Despite being an orphan receptor, GPR151 has been shown to play a role in various physiological processes, including;\n* Neurotransmission: GPR151 is involved in the regulation of synaptic plasticity and neuronal survival in the brain. It modulates the activity of ion channels, neurotransmitters, and neurotrophic factors.\n* Inflammation: GPR151 is involved in the immune response, particularly in the regulation of inflammation. It modulates the activity of immune cells, including T cells and macrophages, and can reduce inflammation in various models of disease.\n* Cardiovascular system: GPR151 is expressed in the heart and can regulate cardiac function, including heart rate and contractility. It also plays a role in the regulation of blood pressure.\n* Metabolism:",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.\n2. The gene encoding GPR151 was first identified in the early 1990s.\n3. GPR151 is a member of the GPCR superfamily with seven transmembrane domain proteins.\n4. GPR151 is expressed in various tissues including the brain, heart, liver, pancreas, and certain immune cells.\n5. GPR151 plays a role in synaptic plasticity and neuronal survival in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.",
      "The gene encoding GPR151 was first identified in the early 1990s.",
      "GPR151 is a member of the GPCR superfamily with seven transmembrane domain proteins.",
      "GPR151 is expressed in various tissues including the brain, heart, liver, pancreas, and certain immune cells.",
      "GPR151 plays a role in synaptic plasticity and neuronal survival in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The gene encoding GPR151 was first identified in the early 2000s.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Certainly! The Fluzone Intradermal Quadrivalent vaccine contains four strains of attenuated live viruses:\n1. FluB (H1N1): This strain is based on the A/Massachusetts/21/2007 (H1N1) strain, which is a strain of the H1N1 subtype. The virus has been attenuated (weakened) to reduce the risk of serious complications.\n2. FluA (H3N2): This strain is based on the A/Wisconsin/67/2003 (H3N2) strain, which is a strain of the H3N2 subtype. The virus has been attenuated to reduce the risk of serious complications.\n3. FluB (Victoria lineage): This strain is based on the B/Brisbane/60/2008 (Victoria lineage) strain, which is a strain of the B subtype. The virus has been attenuated to reduce the risk of serious complications.\n4. FluA (Yamagata lineage): This strain is based on the A/California/7/2004 (Yamagata lineage) strain, which is a strain of the A subtype. The virus has been attenuated to reduce the risk of serious complications.\nIt's important to note that the attenuated viruses in the Fluzone Intradermal Quadrivalent vaccine are still capable of causing infection and transmission, but they are much less likely to cause serious illness than wild-type viruses. The vaccine is designed to stimulate an immune response in the body without causing the full-blown symptoms of the flu.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains a strain of the H1N1 subtype based on the A/Massachusetts/21/2007 (H1N1) strain.\n2. The vaccine also includes a strain of the H3N2 subtype based on the A/Wisconsin/67/2003 (H3N2) strain.\n3. A strain of the B subtype based on the B/Brisbane/60/2008 (Victoria lineage) strain is part of the vaccine.\n4. The vaccine contains a strain of the A subtype based on the A/California/7/2004 (Yamagata lineage) strain.\n5. The viruses in the Fluzone Intradermal Quadrivalent vaccine have been attenuated to reduce the risk of serious complications.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains a strain of the H1N1 subtype based on the A/Massachusetts/21/2007 (H1N1) strain.",
      "The vaccine also includes a strain of the H3N2 subtype based on the A/Wisconsin/67/2003 (H3N2) strain.",
      "A strain of the B subtype based on the B/Brisbane/60/2008 (Victoria lineage) strain is part of the vaccine.",
      "The vaccine contains a strain of the A subtype based on the A/California/7/2004 (Yamagata lineage) strain.",
      "The viruses in the Fluzone Intradermal Quadrivalent vaccine have been attenuated to reduce the risk of serious complications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that involves multiple genetic and environmental factors. The TNFR2 gene, also known as the tumor necrosis factor receptor superfamily member 2 gene, has been implicated in the development of SLE.\nSeveral studies have identified genetic variations in the TNFR2 gene that are associated with an increased risk of developing SLE. These variations include:\n1. TNFR2 gene expression: Studies have shown that individuals with SLE tend to have lower levels of TNFR2 gene expression in their peripheral blood mononuclear cells compared to healthy controls.\n2. TNFR2 gene promoter polymorphisms: The TNFR2 gene promoter region contains several polymorphisms, including the -1376 C/G, -1492 A/G, and -1794 G/C polymorphisms. These polymorphisms have been associated with an increased risk of developing SLE, with the -1376 C/G and -1492 A/G polymorphisms showing the strongest associations.\n3. TNFR2 gene mutations: Rare mutations in the TNFR2 gene, such as the R207H and R145Q mutations, have been identified in individuals with SLE. These mutations may lead to aberrant TNFR2 signaling and contribute to the development of SLE.\n4. TNFR2 gene copy number variations: Some studies have found that individuals with SLE tend to have increased copy numbers of the TNFR2 gene, particularly in their peripheral blood mononuclear cells.\nIt is important to note that the genetic associations between the TNFR2 gene and SLE are not absolute and may vary depending on the specific population being studied. Additionally, the genetic variations identified in TNFR2 gene are likely to interact with other genetic and environmental factors to contribute to the development of SLE.\nIn summary, the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE), and several genetic variations in the TNFR2 gene have been identified as risk factors for the development of SLE. These variations include differences in gene expression, promoter polymorph",
    "llama-2-7b-chat-hf_fact_raw": "1. Systemic Lupus Erythematosus (SLE) is genetically associated with variations in the TNFR2 gene.\n2. Individuals with SLE tend to have lower levels of TNFR2 gene expression in their peripheral blood mononuclear cells compared to healthy controls.\n3. Polymorphisms in the TNFR2 gene promoter region, including the -1376 C/G, -1492 A/G, and -1794 G/C, are associated with an increased risk of developing SLE.\n4. Rare mutations in the TNFR2 gene, such as R207H and R145Q, have been identified in individuals with SLE.\n5. Individuals with SLE may have increased copy numbers of the TNFR2 gene in their peripheral blood mononuclear cells.",
    "llama-2-7b-chat-hf_fact": [
      "Systemic Lupus Erythematosus (SLE) is genetically associated with variations in the TNFR2 gene.",
      "Individuals with SLE tend to have lower levels of TNFR2 gene expression in their peripheral blood mononuclear cells compared to healthy controls.",
      "Polymorphisms in the TNFR2 gene promoter region, including the -1376 C/G, -1492 A/G, and -1794 G/C, are associated with an increased risk of developing SLE.",
      "Rare mutations in the TNFR2 gene, such as R207H and R145Q, have been identified in individuals with SLE.",
      "Individuals with SLE may have increased copy numbers of the TNFR2 gene in their peripheral blood mononuclear cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Individuals with SLE do not typically have increased copy numbers of the TNFR2 gene in their peripheral blood mononuclear cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "I'm glad you asked! Unfortunately, there is no commercially available vaccine for peanut allergy yet, but there are ongoing research and developments in this area.\nPeanut allergy is caused by the immune system mistakenly identifying peanut proteins as harmful, leading to an immune response that can cause a range of symptoms, including hives, itching, swelling, stomach cramps, diarrhea, and difficulty breathing. Currently, the only treatment for peanut allergy is strict avoidance of peanuts and peanut products, which can be challenging and limiting.\nHowever, there are several promising areas of research that could potentially lead to the development of a vaccine for peanut allergy:\n1. Oral immunotherapy (OIT): This involves gradually introducing small amounts of peanut protein to the body over time to help build up tolerance. While OIT has shown promise in clinical trials, it's important to note that it can be risky and may not work for everyone.\n2. Epicutaneous immunotherapy (ECIT): This involves using a patch that applies a small amount of peanut protein to the skin, where it is absorbed and stimulates the immune system. ECIT has shown promise in early clinical trials and is considered a safer alternative to OIT.\n3. mRNA-based vaccines: These vaccines use a small piece of genetic material called messenger RNA (mRNA) to instruct cells to produce a specific protein. Researchers are exploring the use of mRNA-based vaccines to treat peanut allergy by inducing the body to produce a protein that can help neutralize the allergenic effects of peanuts.\n4. Gene editing technologies: Scientists are exploring the use of gene editing technologies, such as CRISPR, to modify the genes responsible for the immune system's reaction to peanuts. This could potentially lead to a more long-term and effective treatment for peanut allergy.\nWhile these approaches show promise, it's important to note that a peanut allergy vaccine is still in the experimental stages and several more years of research are needed before it could become available to the public.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no commercially available vaccine for peanut allergy.\n2. Peanut allergy is caused by the immune system mistakenly identifying peanut proteins as harmful.\n3. Oral immunotherapy (OIT) involves introducing small amounts of peanut protein to the body to build up tolerance.\n4. Epicutaneous immunotherapy (ECIT) uses a patch that applies peanut protein to the skin to stimulate the immune system.\n5. Researchers are exploring the use of mRNA-based vaccines and gene editing technologies to treat peanut allergy.",
    "llama-2-7b-chat-hf_fact": [
      "There is no commercially available vaccine for peanut allergy.",
      "Peanut allergy is caused by the immune system mistakenly identifying peanut proteins as harmful.",
      "Oral immunotherapy (OIT) involves introducing small amounts of peanut protein to the body to build up tolerance.",
      "Epicutaneous immunotherapy (ECIT) uses a patch that applies peanut protein to the skin to stimulate the immune system.",
      "Researchers are exploring the use of mRNA-based vaccines and gene editing technologies to treat peanut allergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are commercially available treatments for peanut allergy, such as Palforzia, which is an oral immunotherapy (OIT) for peanut allergy.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene, also known as the Forkhead box S (FoxS) gene, is located on chromosome 11 in mice. Specifically, it is located at position 11.03 on the chromosome, which means it is located towards the telomeric end of the chromosome (the end of the chromosome that contains the repetitive sequence called telomeres).\nThe chromosomal location of the Fxy gene is important because it helps to determine the expression patterns of the gene and its function in the body. Genes located towards the telomeric end of a chromosome tend to be expressed later in development and in specific tissues, such as the brain and spinal cord. This is likely due to the fact that these genes are not as easily accessed by transcription factors and other regulatory elements that are typically located closer to the centromere (the middle of the chromosome).\nThe Fxy gene is a member of the forkhead box (Fox) gene family, which consists of a group of transcription factors that play important roles in regulating cellular processes such as cell fate determination, differentiation, and growth. The Fxy gene is specifically involved in the regulation of neural development and patterning, and mutations in the gene have been linked to various neurological disorders, including brain malformations and cognitive impairments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on chromosome 11 in mice.\n2. The Fxy gene is specifically located at position 11.03 on chromosome 11.\n3. Genes located towards the telomeric end of a chromosome are expressed later in development and in specific tissues.\n4. The Fxy gene is a member of the forkhead box (Fox) gene family.\n5. Mutations in the Fxy gene have been linked to various neurological disorders, including brain malformations and cognitive impairments.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on chromosome 11 in mice.",
      "The Fxy gene is specifically located at position 11.03 on chromosome 11.",
      "Genes located towards the telomeric end of a chromosome are expressed later in development and in specific tissues.",
      "The Fxy gene is a member of the forkhead box (Fox) gene family.",
      "Mutations in the Fxy gene have been linked to various neurological disorders, including brain malformations and cognitive impairments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The location of a gene on a chromosome does not determine the timing of its expression during development or its tissue-specific expression.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methylation-profiling by means of &EDTA (MPE-seq) is a popular method utilized in epigenetic analysis to assess DNA methylation throughout the genome. The basic principles of MPE-seq are as follows:\n1. Sample Preparation:\nThe first step is to extract and purify DNA from the sample of interest. This involves isolating the DNA using a variety of methods, such as phenol-chloroform extraction or using a commercial DNA isolation kit. The isolated DNA is then purified using a buffer solution to remove impurities and enzymes to remove contaminants.\n2. End Repair and Adenylation:\nThe prepared DNA is then subjected to an end repair reaction, which involves treating the 3' end of the DNA molecule with a specific enzyme, DNA ligase, to form a phosphate group. This creates a single-stranded overhang that can be extended using an adenylate primer.\n3. First-Strand Synthesis:\nNext, the primed DNA is used as a template for first-strand synthesis using a reverse transcriptase enzyme. This involves synthesizing a complementary RNA molecule, called cRNA, by adding nucleotides to the 3' end of the primed DNA.\n4. Second-Strand Synthesis:\nAfter first-strand synthesis, the cRNA is used as a template for second-strand synthesis using a DNA polymerase enzyme. This involves adding nucleotides to the 5' end of the cRNA molecule to form a complementary DNA strand.\n5. Size selection:\nThe resulting DNA fragments are then separated based on their size using a size-exclusion chromatography method. This step is crucial as it helps to isolate the fragments of interest, typically in the range of 100-500 base pairs.\n6. Sequencing:\nThe purified DNA fragments are then subjected to sequencing using an Illumina platform, which produces millions of short reads that are mapped back to the reference genome. The resulting data provide a comprehensive picture of the methylation patterns across the genome.\n7. Data Analysis:\nThe final step is to analyze the sequencing data",
    "llama-2-7b-chat-hf_fact_raw": "1. Methylation-profiling by means of &EDTA (MPE-seq) is used in epigenetic analysis to assess DNA methylation throughout the genome.\n2. The first step in MPE-seq involves extracting and purifying DNA from a sample.\n3. The prepared DNA in MPE-seq is subjected to an end repair reaction using a specific enzyme, DNA ligase.\n4. First-strand synthesis in MPE-seq involves synthesizing a complementary RNA molecule using a reverse transcriptase enzyme.\n5. The purified DNA fragments in MPE-seq are sequenced using an Illumina platform.",
    "llama-2-7b-chat-hf_fact": [
      "Methylation-profiling by means of &EDTA (MPE-seq) is used in epigenetic analysis to assess DNA methylation throughout the genome.",
      "The first step in MPE-seq involves extracting and purifying DNA from a sample.",
      "The prepared DNA in MPE-seq is subjected to an end repair reaction using a specific enzyme, DNA ligase.",
      "First-strand synthesis in MPE-seq involves synthesizing a complementary RNA molecule using a reverse transcriptase enzyme.",
      "The purified DNA fragments in MPE-seq are sequenced using an Illumina platform."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Methylation-profiling by means of &EDTA (MPE-seq) is incorrect. It should be \"Methylation-profiling by means of bisulfite treatment (MBD-seq)\".\n2. TRUE\n3. FALSE [correction]: The prepared DNA in MPE-seq is subjected to an end repair reaction using a specific enzyme, but the enzyme is not necessarily DNA ligase. DNA ligase is used for ligation, not end repair.\n4. FALSE [correction]: First-strand synthesis in MPE-seq involves synthesizing a complementary DNA molecule, not RNA, using a reverse transcriptase enzyme.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Ah, an interesting question! GWAR is a fascinating and complex franchise with a rich history, and its implementation cannot be attributed to a single programming language. GWAR is a universe of interconnected stories, characters, and themes that have evolved over the decades through various mediums, including music, comics, films, and more.\nWhile it is not feasible to single out a particular programming language for GWAR's implementation, I can provide some context and insights on the technical aspects of the franchise.\nGWAR is primarily a fictional universe that has been brought to life through various forms of media, including music, films, and comics. The franchise's creators, manager, and artists have used a variety of techniques and tools to create and maintain the GWAR universe, including:\n1. Music: The band GWAR, founded in 1984, has been instrumental in popularizing the franchise through their music. The band's sound is a unique blend of heavy metal, punk, and comedy, and their albums have helped to establish the GWAR universe's tone and style.\n2. Comics: The GWAR universe has been explored in various comic book series, including the popular \"GWAR: Orgazmatron\" series. These comics have helped to expand the franchise's lore and introduce new characters and storylines.\n3. Films: GWAR has also ventured into the realm of film, with the 1995 film \"GWAR: Riplor's Return\" being a notable example. The film served as an introduction to the franchise's bizarre and humorous universe.\n4. Video games: GWAR has also proposed a video game iteration, titled \"GWAR: Eat America,\" which would allow players to immerse themselves in the franchise's universe and experience the absurdity and humor that defines GWAR.\nIn summary, while there is no single programming language responsible for implementing GWAR, the franchise's creators have leveraged a variety of techniques and tools to bring this peculiar and unique universe to life. From music and comics to films and video games, GWAR's creators have experimented with various forms of media to create an immersive and entertaining experience for fans.",
    "llama-2-7b-chat-hf_fact_raw": "1. The band GWAR was founded in 1984.\n2. The GWAR universe includes music, films, comics, and a proposed video game.\n3. GWAR's music is a blend of heavy metal, punk, and comedy.\n4. The comic book series \"GWAR: Orgazmatron\" is part of the GWAR franchise.\n5. \"GWAR: Riplor's Return\" is a film released in 1995 related to the GWAR franchise.",
    "llama-2-7b-chat-hf_fact": [
      "The band GWAR was founded in 1984.",
      "The GWAR universe includes music, films, comics, and a proposed video game.",
      "GWAR's music is a blend of heavy metal, punk, and comedy.",
      "The comic book series \"GWAR: Orgazmatron\" is part of the GWAR franchise.",
      "\"GWAR: Riplor's Return\" is a film released in 1995 related to the GWAR franchise."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no known film titled \"GWAR: Riplor's Return\" related to the GWAR franchise. It appears to be fictional or a mistake.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden, also known as masitinib, is a prescription medication that has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.\nALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually death. There is currently no cure for ALS, and existing treatments only provide temporary symptom relief and slow the progression of the disease.\nXaliproden is a tyrosine kinase inhibitor that has been shown to have neuroprotective effects in animal models of ALS. It works by blocking the action of certain enzymes that damage nerve cells, and has been shown to reduce muscle atrophy and improve motor function in mice with ALS.\nStudies in humans have also suggested that xaliproden may have potential as a treatment for ALS. In a phase II clinical trial conducted by the pharmaceutical company Masitinib Research, 107 patients with ALS were randomized to receive either xaliproden or a placebo. The results of the study showed that patients treated with xaliproden experienced a slower decline in muscle strength and function compared to those receiving the placebo.\nHowever, it's important to note that the study was small and had some limitations, so more research is needed to confirm these findings and establish the safety and efficacy of xaliproden as an ALS treatment.\nIn summary, while the current evidence suggests that xaliproden may have potential as a treatment for ALS, more research is needed to fully understand its effects and establish its place in the treatment of this disease. If you or someone you know has ALS and is considering xaliproden, it's important to speak with a healthcare professional to discuss the potential benefits and risks of this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden, also known as masitinib, is a medication that has been studied for the potential to improve prognosis of amyotrophic lateral sclerosis (ALS).\n2. ALS is a progressive neurodegenerative disease with no current cure.\n3. Xaliproden is a tyrosine kinase inhibitor with neuroprotective effects observed in animal models.\n4. A phase II clinical trial with 107 ALS patients showed that xaliproden treatment resulted in a slower decline in muscle strength and function compared to placebo.\n5. More research is needed to confirm the findings and establish the safety and efficacy of xaliproden as an ALS treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden, also known as masitinib, is a medication that has been studied for the potential to improve prognosis of amyotrophic lateral sclerosis (ALS).",
      "ALS is a progressive neurodegenerative disease with no current cure.",
      "Xaliproden is a tyrosine kinase inhibitor with neuroprotective effects observed in animal models.",
      "A phase II clinical trial with 107 ALS patients showed that xaliproden treatment resulted in a slower decline in muscle strength and function compared to placebo.",
      "More research is needed to confirm the findings and establish the safety and efficacy of xaliproden as an ALS treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden and masitinib are two different medications. Xaliproden has been studied for ALS, while masitinib is a tyrosine kinase inhibitor used for different indications.\n2. TRUE\n3. FALSE [correction]: Xaliproden is not a tyrosine kinase inhibitor; it is a compound that has been investigated for neuroprotective effects. Masitinib is the tyrosine kinase inhibitor.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a commonly used transgenic mouse line that expresses the human APP695 gene under the control of the neuron-specific enolase (NSE) promoter. The APP695 gene encodes for the amyloid precursor protein (APP), which is a key protein in the development of Alzheimer's disease (AD).\nIn terms of chromosomes, the LiPS-A3S line is a transgenic mouse line, which means that a foreign gene (in this case, the human APP695 gene) has been introduced into the mouse genome using recombinant DNA technology. The genetic modification is made on a specific chromosome, which in this case is chromosome 16.\nTo be more specific, the human APP695 gene is inserted into the mouse chromosome 16 at the distal end of the mouse chromosome 16, specifically at the location designated as chromosome band 16A12.2. This insertion results in the expression of the human APP695 gene in the mouse brain, which allows researchers to study the effects of this gene on mouse behavior and brain function.\nIt's worth noting that the LiPS-A3S line is just one of many transgenic mouse lines that have been developed to study AD and other neurodegenerative diseases. Each transgenic line has its own specific genetic modification and can be used to study different aspects of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line expresses the human APP695 gene under the control of the neuron-specific enolase (NSE) promoter.\n2. The human APP695 gene is inserted into the mouse chromosome 16.\n3. The modification is made specifically at the chromosome band 16A12.2 on mouse chromosome 16.\n4. The human APP695 gene is associated with the development of Alzheimer's disease.\n5. The LiPS-A3S line is a transgenic mouse line used to study Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line expresses the human APP695 gene under the control of the neuron-specific enolase (NSE) promoter.",
      "The human APP695 gene is inserted into the mouse chromosome 16.",
      "The modification is made specifically at the chromosome band 16A12.2 on mouse chromosome 16.",
      "The human APP695 gene is associated with the development of Alzheimer's disease.",
      "The LiPS-A3S line is a transgenic mouse line used to study Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The human APP695 gene is inserted into the mouse chromosome 12.\n3. FALSE [correction]: The modification is made specifically at the chromosome band 12A1.1 on mouse chromosome 12.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning-based tools and approaches available for predicting drug synergy. Here are some of the most notable ones:\n1. DeepSynth: Developed by the University of California, DeepSynth is a deep learning framework for predicting drug synergy. It uses a deep neural network to integrate molecular structures and bioactivity data to predict the effects of drug combinations.\n2. SynergyMiner: Developed by the University of Washington, SynergyMiner is a web-based tool that uses deep learning algorithms to predict drug synergy. It takes into account molecular structures, drug targets, and gene expression data to predict the effects of drug combinations.\n3. DrugCom: Developed by Duke University, DrugCom is a deep learning-based tool for predicting drug synergy. It uses a graph convolutional network to predict the effects of drug combinations by analyzing molecular structures and drug targets.\n4. CombinationGNN: Developed by the University of California, CombinationGNN is a graph neural network (GNN) based framework for predicting drug synergy. It models the interactions between drugs and their targets, and predicts the effects of drug combinations by aggregating the predictions of individual drugs.\n5. Drug-Related Knowledge Graph Embedding (DREAM): Developed by the University of California, DREAM is a deep learning-based tool for predicting drug synergy. It uses a knowledge graph embedding (KGE) model to integrate drug-related knowledge and predict the effects of drug combinations.\n6. Graph-based Drug Combination Prediction (GDCP): Developed by the University of Texas, GDCP is a graph-based deep learning model that predicts drug synergy by analyzing molecular structures and drug targets. It uses a graph convolutional network (GCN) to learn the representations of drugs and their targets, and predicts the effects of drug combinations.\n7. Drug Combination Predictor (DCP): Developed by the University of Illinois, DCP is a deep learning-based tool for predicting drug synergy. It uses a combination of machine learning and graph-based methods to predict the effects of drug combinations.\n8. Multi-omics Drug Combination Prediction (MODCP): Developed by the University of California",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a deep learning framework developed by the University of California for predicting drug synergy.\n2. SynergyMiner is a web-based tool developed by the University of Washington that predicts drug synergy using deep learning algorithms.\n3. DrugCom is a deep learning-based tool developed by Duke University that predicts drug synergy using a graph convolutional network.\n4. CombinationGNN is developed by the University of California and utilizes a graph neural network to predict drug synergy.\n5. Drug-Related Knowledge Graph Embedding (DREAM) is a tool developed by the University of California that uses knowledge graph embedding for predicting drug synergy effects.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a deep learning framework developed by the University of California for predicting drug synergy.",
      "SynergyMiner is a web-based tool developed by the University of Washington that predicts drug synergy using deep learning algorithms.",
      "DrugCom is a deep learning-based tool developed by Duke University that predicts drug synergy using a graph convolutional network.",
      "CombinationGNN is developed by the University of California and utilizes a graph neural network to predict drug synergy.",
      "Drug-Related Knowledge Graph Embedding (DREAM) is a tool developed by the University of California that uses knowledge graph embedding for predicting drug synergy effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DrugComb is a deep learning-based tool developed by Duke University that predicts drug synergy using a graph convolutional network.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Some popular options include:\n1. Cloud-GWAS: This is a cloud-based platform developed by the University of California, San Diego, that allows users to perform GWAS analyses on large-scale datasets with ease. Cloud-GWAS provides a user-friendly interface for uploading data, running association tests, and visualizing results.\n2. LD Hub: LD Hub is a cloud-based platform developed by the University of California, Berkeley, that provides a platform for performing GWAS analyses on large-scale datasets. LD Hub allows users to upload their data, perform association tests, and visualize results.\n3. GWAS-Cloud: GWAS-Cloud is a cloud-based platform developed by the University of Florida, that allows users to perform GWAS analyses on large-scale datasets. GWAS-Cloud provides a user-friendly interface for uploading data, running association tests, and visualizing results.\n4.OpenSNP: OpenSNP is open-source software that allows users to perform GWAS analyses on large-scale datasets. OpenSNP can be ran on any cloud computing platform such as AWS or Google cloud.\n5.MAGMA: MAGMA is a cloud-based platform developed by the University of California, Davis, that allows users to perform GWAS analyses on large-scale datasets. MAGMA provides a user-friendly interface for uploading data, running association tests, and visualizing results.\nAll of these platforms are designed to make it easier for researchers to compare GWAS results across different studies, populations, and datasets. They provide a range of tools and functionality for performing GWAS analyses, including association test, visualization, and reproducibility.\nIt's worth noting that there are also other cloud-based platforms for GWAS analysis, such as GWAS-Dimensionality Reduction (GWAS-DR), GWAS-Hidden Markov Models (GWAS-HMM), and GWAS- Liveroni (GWAS-Lvy), among others.\nIt's important to evaluate the specific requirements of your research and the features of each platform before choosing the one that best",
    "llama-2-7b-chat-hf_fact_raw": "1. Cloud-GWAS was developed by the University of California, San Diego.\n2. LD Hub was developed by the University of California, Berkeley.\n3. GWAS-Cloud was developed by the University of Florida.\n4. OpenSNP is open-source software that can be run on cloud computing platforms like AWS or Google Cloud.\n5. MAGMA was developed by the University of California, Davis.",
    "llama-2-7b-chat-hf_fact": [
      "Cloud-GWAS was developed by the University of California, San Diego.",
      "LD Hub was developed by the University of California, Berkeley.",
      "GWAS-Cloud was developed by the University of Florida.",
      "OpenSNP is open-source software that can be run on cloud computing platforms like AWS or Google Cloud.",
      "MAGMA was developed by the University of California, Davis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a bispecific antibody that has been shown to be effective in treating various types of cancer, including sarcomas. Sarcomas are a type of cancer that originates in the connective tissue of the body, such as bone, muscle, cartilage, and fat.\nCMB305 is a bispecific antibody that is designed to bind to both a cancer cell surface protein called CD30 and a immune cell surface protein called CD20. By binding to both proteins, CMB305 can stimulate an immune response against the cancer cell and trigger the destruction of the cancer cell.\nStudies have shown that CMB305 is effective in treating various types of sarcomas, including soft tissue sarcoma and bone sarcoma. In clinical trials, CMB305 has been shown to induce complete responses in some patients with advanced sarcomas, and the drug has been generally well-tolerated with manageable side effects.\nOne study published in the journal Cancer Research in 2017 found that CMB305 was effective in treating advanced soft tissue sarcomas that had progressed after previous treatment. The study included 32 patients with advanced soft tissue sarcomas, and results showed that 12 patients (38%) achieved a complete response to CMB305, and 20 patients (63%) had a partial response.\nAnother study published in the journal Oncologist in 2019 found that CMB305 was effective in treating bone sarcomas that had progressed after previous treatment. The study included 13 patients with advanced bone sarcomas, and results showed that 8 patients (62%) achieved a complete response to CMB305, and 5 patients (38%) had a partial response.\nOverall, the available data suggest that CMB305 may be a promising treatment option for patients with sarcomas, particularly those with advanced stages of the disease. However, it is important to note that CMB305 is still an experimental drug and more studies are needed to fully understand its safety and effectiveness in clinical settings.\nIn summary, CMB305 is a bispecific antibody that has shown promise in treating",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a bispecific antibody that has been effective in treating various types of cancer, including sarcomas.\n2. Sarcomas originate in the connective tissue of the body.\n3. CMB305 is designed to bind to both CD30 on cancer cells and CD20 on immune cells.\n4. A study published in Cancer Research in 2017 found that 38% of patients with advanced soft tissue sarcomas had a complete response to CMB305.\n5. Another study published in the journal Oncologist in 2019 found that 62% of patients with advanced bone sarcomas achieved a complete response to CMB305.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a bispecific antibody that has been effective in treating various types of cancer, including sarcomas.",
      "Sarcomas originate in the connective tissue of the body.",
      "CMB305 is designed to bind to both CD30 on cancer cells and CD20 on immune cells.",
      "A study published in Cancer Research in 2017 found that 38% of patients with advanced soft tissue sarcomas had a complete response to CMB305.",
      "Another study published in the journal Oncologist in 2019 found that 62% of patients with advanced bone sarcomas achieved a complete response to CMB305."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific information or references to the actual studies or data on CMB305, it is not possible to verify the accuracy of statements 1, 3, 4, and 5.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Three Prongs of the Saint, refers to a concept in mysticism and spirituality that describes the three primary aspects of a Saint or a highly evolved spiritual being. These aspects are:\n1. The Avatar: The Avatar is the physical manifestation of the Saint, often seen as a human form that is both divine and human. This aspect represents the Saint's connection to the physical world and their ability to embody the divine in a tangible form.\n2. The Buddha: The Buddha is the Saint's wisdom aspect, representing their understanding of the nature of the universe and the path to enlightenment. This aspect often reflects the Saint's knowledge and insight into the mysteries of existence, and their ability to teach and guide others along the spiritual path.\n3. The Christ: The Christ is the Saint's love aspect, representing their compassion, kindness, and selflessness. This aspect reflects the Saint's ability to embody the qualities of divine love and to radiate these qualities out into the world, inspiring others to follow the path of love and compassion.\nTogether, these three aspects of the Saint's Triad represent the full expression of a Saint's spiritual potential, and the qualities that they embody are considered to be the ultimate goals of spiritual development.\nIn terms of manifestations, the Saint's Triad can manifest in various ways depending on the individual Saint and their level of evolution. Some common ways in which these aspects may manifest include:\n* Physical manifestations: The Saint's Avatar may manifest in a physical form, such as a body with supernatural abilities or a spiritual body that is both material and immaterial. The Buddha aspect may manifest as wise teachings or instructions, while the Christ aspect may manifest as a powerful and transformative love.\n* Energetic manifestations: The Saint's Triad may also manifest as intense spiritual energies that are felt by those around them. For example, the Avatar may manifest as a powerful aura of light and energy, while the Buddha aspect may manifest as a profound sense of peace and tranquility, and the Christ aspect may manifest as a fierce and transformative love that ignites change in those around them.\n* Intuitive manifestations: The Saint's",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Title: Overexpression of LY6K: A Promising Prognostic Biomarker for Non-Small Cell Lung Cancer Patients?\nIntroduction:\nNon-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide. Despite advances in diagnostic techniques and therapeutic interventions, the prognosis for NSCLC patients remains poor, especially for those diagnosed at an advanced stage. Therefore, identifying novel prognostic biomarkers could help clinicians tailor treatment strategies and improve patient outcomes. In recent years, the immunoglobulin superfamily protein LY6K has garnered attention as a potential prognostic marker for various cancers, including NSCLC. In this response, we will delve into the current understanding of LY6K overexpression in NSCLC and its implications for patient prognosis.\nWhat is LY6K?\nLY6K (leucine-rich repeats and Ig-like domains protein 6 kinase) is an immunoglobulin superfamily protein that plays a crucial role in the regulation of adaptive immune responses. LY6K is composed of an N-terminal Ig-like domain, a centralгла ladder domain, and a C-terminal leucine-rich repeat (LRR) domain. The LRR domain is responsible for protein-protein interactions, while the Ig-like domain facilitates the binding of LY6K to its ligands. LY6K is primarily expressed on the surface of immune cells, including T cells and B cells, where it modulates immune responses by activating signaling pathways and regulating gene expression.\nLY6K Overexpression in NSCLC:\nSeveral studies have investigated the expression of LY6K in NSCLC, with varying results. A report by Ren et al. (2019) found that LY6K expression was significantly higher in NSCLC tissues compared to adjacent non-cancerous tissues. Similarly, Li et al. (2020) showed that LY6K expression was elevated in NSCLC cell lines and tumor tissues compared to normal lung tissues. Moreover, Zhang et al. (2019) found that LY6K expression",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide.\n2. The prognosis for NSCLC patients is poor, especially for those diagnosed at an advanced stage.\n3. LY6K is an immunoglobulin superfamily protein involved in the regulation of adaptive immune responses.\n4. LY6K is primarily expressed on the surface of immune cells, including T cells and B cells.\n5. Studies have found LY6K expression to be significantly higher in NSCLC tissues compared to adjacent non-cancerous tissues.",
    "llama-2-7b-chat-hf_fact": [
      "Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide.",
      "The prognosis for NSCLC patients is poor, especially for those diagnosed at an advanced stage.",
      "LY6K is an immunoglobulin superfamily protein involved in the regulation of adaptive immune responses.",
      "LY6K is primarily expressed on the surface of immune cells, including T cells and B cells.",
      "Studies have found LY6K expression to be significantly higher in NSCLC tissues compared to adjacent non-cancerous tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: LY6K is not an immunoglobulin superfamily protein; it is a member of the Ly-6 family of proteins.\n4. FALSE [correction]: LY6K is not primarily expressed on the surface of immune cells; it is primarily expressed in certain types of cancer cells, including NSCLC.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Certainly! During cytokinesis, the cell undergoes a series of complex processes to separate its duplicated daughter cells. As part of this process, various proteins undergo dephosphorylation, which plays a crucial role in the formation of the cleavage furrow and the eventually separation of the daughter cells. Here are some of the CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the cell cycle and is dephosphorylated during cytokinesis to promote the progression of the cell through this stage. Dephosphorylation of CDK1 allows for the activation of the separin protein, which is involved in the formation of the cleavage furrow.\n2. Cyclin-dependent kinase 5 (CDK5): CDK5 is another key regulator of the cell cycle and is also dephosphorylated during cytokinesis. Dephosphorylation of CDK5 allows for the activation of the scaffold protein Aurora A, which is involved in the formation of the spindle during mitosis and the separation of the daughter cells during cytokinesis.\n3. Calcium/calmodulin-dependent protein kinase II (CaMKII): CaMKII is a serine/threonine protein kinase that is involved in the regulation of synaptic plasticity and neuronal differentiation. During cytokinesis, CaMKII is dephosphorylated, which allows for the activation of the microtubule-associated protein, EB1. EB1 is involved in the formation of the cleavage furrow and the separation of the daughter cells.\n4. Protein kinase B (PKB): PKB is a key regulator of glycogen metabolism and is also involved in the insulin signaling pathway. During cytokinesis, PKB is dephosphorylated, which allows for the activation of the protein kinase D (PKD), which is involved in the formation of the cleavage furrow.\n5. Glycogen synthase kinase 3 (GSK3): GSK3 is a serine/threonine kinase",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (CDK1) is dephosphorylated during cytokinesis to promote cell progression through this stage.\n2. Cyclin-dependent kinase 5 (CDK5) is dephosphorylated during cytokinesis, allowing for the activation of Aurora A, a scaffold protein involved in spindle formation and cell separation.\n3. Calcium/calmodulin-dependent protein kinase II (CaMKII) is dephosphorylated during cytokinesis, leading to the activation of EB1, a protein involved in forming the cleavage furrow.\n4. Protein kinase B (PKB) undergoes dephosphorylation during cytokinesis, which activates protein kinase D (PKD), involved in cleavage furrow formation.\n5. Cyclin-dependent kinase 1 (CDK1) dephosphorylation activates the separin protein, which contributes to forming the cleavage furrow.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (CDK1) is dephosphorylated during cytokinesis to promote cell progression through this stage.",
      "Cyclin-dependent kinase 5 (CDK5) is dephosphorylated during cytokinesis, allowing for the activation of Aurora A, a scaffold protein involved in spindle formation and cell separation.",
      "Calcium/calmodulin-dependent protein kinase II (CaMKII) is dephosphorylated during cytokinesis, leading to the activation of EB1, a protein involved in forming the cleavage furrow.",
      "Protein kinase B (PKB) undergoes dephosphorylation during cytokinesis, which activates protein kinase D (PKD), involved in cleavage furrow formation.",
      "Cyclin-dependent kinase 1 (CDK1) dephosphorylation activates the separin protein, which contributes to forming the cleavage furrow."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Cyclin-dependent kinase 5 (CDK5) is not typically associated with cytokinesis, and Aurora A is a kinase involved in centrosome maturation and spindle assembly, not a scaffold protein.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Cyclin-dependent kinase 1 (CDK1) phosphorylation (not dephosphorylation) is involved in the activation of separase (not \"separin\"), which helps in the breakdown of cohesin and therefore the separation of sister chromatids.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a fictional drug that has gained popularity on the internet, particularly on social media platforms like Twitter and TikTok. It is often mentioned in memes and jokes, but there is no scientific evidence to support its existence as a real drug.\nThe origins of Xanamem are unclear, but it is believed to have originated as a joke or meme created by internet users. The term \"Xanamem\" is a play on words, combining the brand name of the medication Xanax (which is commonly used to treat anxiety and panic disorders) with the suffix \"-mem,\" which is often used in slang to imply a drug that has psychoactive effects.\nDespite its fictional nature, Xanamem has gained a cult following online, with many people claiming to have taken the drug or knowing someone who has. However, there is no scientific evidence to support the existence of Xanamem, and it is not listed in any medical or drug reference books.\nSome people have attempted to create their own versions of Xanamem by mixing various substances, such as energy drinks, caffeine pills, and over-the-counter medications. However, these concoctions are not safe to consume and can cause serious health problems, including overdose and death.\nIn summary, Xanamem is a fictional drug that has no basis in science or medicine. While it may be funny or intriguing to some people, it is important to remember that consuming any drug without a valid prescription from a licensed medical professional is illegal and can be dangerous. If you or someone you know is struggling with drug addiction, please seek help from a medical professional or a substance abuse treatment center.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a fictional drug popularized on social media platforms like Twitter and TikTok.\n2. Xanamem is believed to have originated as an internet joke or meme.\n3. The term \"Xanamem\" combines the brand name Xanax with the suffix \"-mem\".\n4. There is no scientific evidence to support the existence of Xanamem as a real drug.\n5. Some individuals have attempted to create their own versions of Xanamem, which can be harmful and cause health problems.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a fictional drug popularized on social media platforms like Twitter and TikTok.",
      "Xanamem is believed to have originated as an internet joke or meme.",
      "The term \"Xanamem\" combines the brand name Xanax with the suffix \"-mem\".",
      "There is no scientific evidence to support the existence of Xanamem as a real drug.",
      "Some individuals have attempted to create their own versions of Xanamem, which can be harmful and cause health problems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Hof1 and Cyk3 are two proteins that play important roles in different cellular pathways in yeast. The Hof1 protein is a transmembrane protein that is involved in the regulation of the cAMP-dependent protein kinase (PKA) signaling pathway, which is a key signaling pathway in yeast that plays a role in various cellular processes such as metabolism, stress response, and gene expression.\nThe Cyk3 protein, on the other hand, is a cytoplasmic protein that is involved in the regulation of the MAPK (mitogen-activated protein kinase) signaling pathway, which is another important signaling pathway in yeast that is involved in various cellular processes such as cell growth, differentiation, and stress response.\nThe interaction between Hof1 and Cyk3 is thought to play a crucial role in regulating the balance between the PKA and MAPK signaling pathways in yeast. Specifically, it is believed that Hof1 binds to and inhibits the activity of Cyk3, thereby reducing the activity of the MAPK signaling pathway. This can have significant consequences for cellular processes such as gene expression and stress response, as the MAPK pathway is involved in these processes and can be activated in response to various signals.\nStudies have shown that the Hof1-Cyk3 interaction is important for yeast's ability to adapt to changing environmental conditions, such as changes in nutrient availability or temperature. For example, when yeast is exposed to stressful conditions, the Hof1-Cyk3 interaction is thought to be disrupted, leading to the activation of the MAPK pathway and the induction of stress-response genes.\nIn addition to its role in stress response, the Hof1-Cyk3 interaction has also been implicated in other cellular processes such as cell growth and division. For example, it has been shown that the Hof1-Cyk3 interaction plays a role in regulating the expression of genes involved in cell cycle progression, and that disruption of the Hof1-Cyk3 interaction can lead to cell cycle arrest.\nOverall, the interaction between Hof1 and Cyk3 is a complex one that plays a crucial role in regulating multiple cellular pathways in yeast. Further research into this interaction may provide insights into the mole",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1 is a transmembrane protein involved in regulating the cAMP-dependent protein kinase signaling pathway in yeast.\n2. Cyk3 is a cytoplasmic protein involved in regulating the MAPK signaling pathway in yeast.\n3. The interaction between Hof1 and Cyk3 is believed to regulate the balance between the PKA and MAPK signaling pathways in yeast.\n4. The Hof1-Cyk3 interaction is important for yeast's ability to adapt to changing environmental conditions.\n5. Disruption of the Hof1-Cyk3 interaction can lead to cell cycle arrest in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1 is a transmembrane protein involved in regulating the cAMP-dependent protein kinase signaling pathway in yeast.",
      "Cyk3 is a cytoplasmic protein involved in regulating the MAPK signaling pathway in yeast.",
      "The interaction between Hof1 and Cyk3 is believed to regulate the balance between the PKA and MAPK signaling pathways in yeast.",
      "The Hof1-Cyk3 interaction is important for yeast's ability to adapt to changing environmental conditions.",
      "Disruption of the Hof1-Cyk3 interaction can lead to cell cycle arrest in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: These statements are very specific to molecular biology and require specialist knowledge to verify. Without access to the relevant scientific literature or expertise in this field, it is not possible to accurately determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (Tumor-Associated Chromosomal Rearrangements) are genetic alterations that are present in tumor cells and are often associated with specific types of cancer. In the case of gastric cancer, several T-UCRs have been identified as potential targets for cancer diagnosis and treatment. Here are some of the T-UCRs that have been implicated in gastric cancer:\n1. t(11;19)(q21;q12): This translocation is one of the most common T-UCRs observed in gastric cancer and involves the fusion of the ETV6 gene on chromosome 11q21 with the CIC gene on chromosome 19q12. This fusion leads to the expression of a chimeric protein that promotes cell proliferation and survival.\n2. t(6;12)(p21;q24): This translocation involves the fusion of the TGFBR2 gene on chromosome 6p21 with the CCND1 gene on chromosome 12q24. This fusion leads to the overexpression of the cyclin D1 protein, which promotes cell proliferation and is often associated with poor prognosis in gastric cancer.\n3. t(1q21;17)(q21;q23): This translocation involves the fusion of the TERT gene on chromosome 1q21 with the CYBB gene on chromosome 17q23. This fusion leads to the overexpression of the TERT protein, which is involved in the regulation of telomerase activity. High levels of TERT have been observed in many gastric cancers and are associated with poor prognosis.\n4. t(4;14)(p16;q32): This translocation involves the fusion of the TIF1 gene on chromosome 4p16 with the CDKN2A gene on chromosome 14q32. This fusion leads to the overexpression of the CDKN2A protein, which is involved in the regulation of cell cycle and apoptosis. Loss of function of the CDKN2A gene is a common event in gastric cancer and is associated with",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs are genetic alterations present in tumor cells associated with specific types of cancer.\n2. The translocation t(11;19)(q21;q12) involves the fusion of the ETV6 gene and the CIC gene and is common in gastric cancer.\n3. The translocation t(6;12)(p21;q24) involves the fusion of the TGFBR2 gene and the CCND1 gene and is associated with poor prognosis in gastric cancer.\n4. The translocation t(1q21;17)(q21;q23) leads to overexpression of the TERT protein observed in many gastric cancers.\n5. The translocation t(4;14)(p16;q32) involves the fusion of the TIF1 gene and the CDKN2A gene, with loss of function of the CDKN2A gene being common in gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs are genetic alterations present in tumor cells associated with specific types of cancer.",
      "The translocation t(11;19)(q21;q12) involves the fusion of the ETV6 gene and the CIC gene and is common in gastric cancer.",
      "The translocation t(6;12)(p21;q24) involves the fusion of the TGFBR2 gene and the CCND1 gene and is associated with poor prognosis in gastric cancer.",
      "The translocation t(1q21;17)(q21;q23) leads to overexpression of the TERT protein observed in many gastric cancers.",
      "The translocation t(4;14)(p16;q32) involves the fusion of the TIF1 gene and the CDKN2A gene, with loss of function of the CDKN2A gene being common in gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The translocation t(11;19)(q21;q12) involves the fusion of the ETV6 gene and the NTRK3 gene, which is common in congenital fibrosarcoma, not gastric cancer.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The translocation t(4;14)(p16;q32) involves the fusion of the FGFR3 gene and the IGH gene, with the overexpression of the FGFR3 gene being common in multiple myeloma, not gastric cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect various organ systems in the body. The LSI is a standardized measure that takes into account several key aspects of SLE, including the severity of symptoms, the presence of certain organs involved in the disease, and the impact of the disease on the patient's quality of life.\nDeveloped by the Lupus Foundation of America, the LSI consists of 21 items that are rated on a scale from 0 to 4, with higher scores indicating greater severity of disease. The items are grouped into three categories:\n1. Acute and chronic manifestations: This includes items related to the severity of flares, joint pain and swelling, fatigue, fever, and other symptoms.\n2. Organ involvement: This includes items related to the degree of involvement of various organs in the body, such as the skin, joints, kidneys, lungs, and nervous system.\n3. Quality of life: This includes items related to the impact of the disease on the patient's overall quality of life, including physical function, emotional well-being, and social functioning.\nThe total LSI score can range from 0 to 84, with higher scores indicating more severe disease. The LSI has been shown to be a reliable and valid measure of SLE severity, and has been used in clinical trials and research studies to assess the effectiveness of new treatments for the disease.\nIt's important to note that the LSI is not a diagnostic tool, but rather a measure of disease severity. A patient's LSI score can help healthcare providers to:\n* Identify the level of disease activity and assess the effectiveness of treatments.\n* Guide decisions regarding treatment escalation or modification.\n* Monitor disease progression and adjust treatment plans accordingly.\n* Develop a tailored treatment plan that addresses the unique needs of each patient.\nOverall, the LSI is a valuable tool for healthcare providers managing patients with systemic lupus erythematosus, as it allows for a standardized and comprehensive assessment of disease severity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease.\n2. The LSI was developed by the Lupus Foundation of America.\n3. The LSI consists of 21 items rated on a scale from 0 to 4, with higher scores indicating greater severity of disease.\n4. The total LSI score can range from 0 to 84.\n5. The LSI has been shown to be a reliable and valid measure of SLE severity.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease.",
      "The LSI was developed by the Lupus Foundation of America.",
      "The LSI consists of 21 items rated on a scale from 0 to 4, with higher scores indicating greater severity of disease.",
      "The total LSI score can range from 0 to 84.",
      "The LSI has been shown to be a reliable and valid measure of SLE severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LSI was not developed by the Lupus Foundation of America; it is not specified who developed it.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several neurodevelopmental disorders, including those caused by de novo mutations. De novo mutations are new mutations that occur spontaneously and are not inherited from either parent. Here are some of the disorders that have been linked to de novo mutations in ZSWIM6:\n1. Autism Spectrum Disorder (ASD): ZSWIM6 mutations have been identified in individuals with autism spectrum disorder (ASD), a neurodevelopmental disorder characterized by social interaction difficulties, communication impairments, and repetitive behaviors.\n2. Intellectual Disability: De novo mutations in ZSWIM6 have been found to be associated with intellectual disability, which is a spectrum of cognitive impairments that affects intellectual function, adaptive behavior, and academic achievement.\n3. Epilepsy: Some studies have reported an increased incidence of epilepsy in individuals with de novo ZSWIM6 mutations. Epilepsy is a neurological disorder characterized by recurrent seizures.\n4. Attention Deficit Hyperactivity Disorder (ADHD): Research suggests that ZSWIM6 mutations may contribute to the development of attention deficit hyperactivity disorder (ADHD), a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity.\n5. Schizophrenia: De novo ZSWIM6 mutations have been implicated in the pathogenesis of schizophrenia, a severe mental disorder characterized by hallucinations, delusions, and disorganized thinking.\n6. Bipolar Disorder: Some studies have found that de novo mutations in ZSWIM6 are associated with increased risk of bipolar disorder, a mental disorder characterized by episodes of mania or hypomania, as well as depression.\n7. Major Depressive Disorder: De novo ZSWIM6 mutations have been linked to an increased risk of major depressive disorder, a mood disorder characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities.\n8. Anxiety Disorders: De novo ZSWIM6 mutations have been associated with an increased",
    "llama-2-7b-chat-hf_fact_raw": "1. ZSWIM6 mutations have been identified in individuals with autism spectrum disorder (ASD).\n2. De novo mutations in ZSWIM6 are associated with intellectual disability.\n3. An increased incidence of epilepsy has been reported in individuals with de novo ZSWIM6 mutations.\n4. ZSWIM6 mutations may contribute to the development of attention deficit hyperactivity disorder (ADHD).\n5. De novo ZSWIM6 mutations have been implicated in the pathogenesis of schizophrenia.",
    "llama-2-7b-chat-hf_fact": [
      "ZSWIM6 mutations have been identified in individuals with autism spectrum disorder (ASD).",
      "De novo mutations in ZSWIM6 are associated with intellectual disability.",
      "An increased incidence of epilepsy has been reported in individuals with de novo ZSWIM6 mutations.",
      "ZSWIM6 mutations may contribute to the development of attention deficit hyperactivity disorder (ADHD).",
      "De novo ZSWIM6 mutations have been implicated in the pathogenesis of schizophrenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a clinical classification system used to categorize diseases based on their underlying pathological processes. The classification system was developed by Dr. Alex Koos, a Dutch psychiatrist, and it is commonly used in psychiatry to categorize psychotic disorders.\nAccording to the Koos Classification, psychotic disorders can be classified into four categories:\n1. Paranoid Type: This category includes disorders characterized by delusions of persecution, such as paranoid schizophrenia.\n2. Catatonic Type: This category includes disorders characterized by catatonia, such as catatonic schizophrenia.\n3. Disorganized Type: This category includes disorders characterized by disorganized thinking and behavior, such as disorganized schizophrenia.\n4. Mixed Type: This category includes disorders characterized by a combination of symptoms from the other three categories, such as schizophrenia with a mixed picture of delusions, hallucinations, and disorganized thinking and behavior.\nIt's worth noting that the Koos Classification is not a widely used classification system, and it has been largely superseded by newer classifications such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10). However, the Koos Classification can still be found in some psychiatric literature and is sometimes used as a historical reference or for educational purposes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to categorize diseases based on their underlying pathological processes.\n2. Dr. Alex Koos, a Dutch psychiatrist, developed the Koos Classification.\n3. The Koos Classification is commonly used in psychiatry to categorize psychotic disorders.\n4. The Koos Classification has four categories: Paranoid Type, Catatonic Type, Disorganized Type, and Mixed Type.\n5. The Koos Classification has been largely superseded by DSM-5 and ICD-10.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to categorize diseases based on their underlying pathological processes.",
      "Dr. Alex Koos, a Dutch psychiatrist, developed the Koos Classification.",
      "The Koos Classification is commonly used in psychiatry to categorize psychotic disorders.",
      "The Koos Classification has four categories: Paranoid Type, Catatonic Type, Disorganized Type, and Mixed Type.",
      "The Koos Classification has been largely superseded by DSM-5 and ICD-10."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is used to categorize vestibular schwannomas, not diseases based on their underlying pathological processes.\n2. FALSE [correction]: Dr. Koos was not a psychiatrist; he was an ear, nose, and throat doctor.\n3. FALSE [correction]: The Koos Classification is used in otolaryngology, not psychiatry.\n4. FALSE [correction]: The Koos Classification has five categories: Stage I, Stage II, Stage III, Stage IV, and Stage V, not the types listed.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme protein kinase B (PKB), also known as Akt. PKB is a key regulator of cell survival and proliferation, and AZD8601 has been shown to have a range of in vivo effects in various animal models. Here are some of the in vivo effects of AZD8601 that have been observed in various studies:\n1. Anti-tumor activity: AZD8601 has been shown to have potent anti-tumor activity in various animal models of cancer, including breast, lung, and colon cancer. It works by inhibiting the activation of PKB, which is often overexpressed in cancer cells and promotes their growth and survival. By blocking PKB activity, AZD8601 can slow down or stop the growth of cancer cells.\n2. Improved cardiovascular function: AZD8601 has been shown to improve cardiovascular function in animal models of heart failure. It works by increasing the activation of glycogen synthase kinase-3 beta (GSK-3β), which is involved in the regulation of cardiac contractility and autonomic nervous system function. By increasing GSK-3β activity, AZD8601 can improve cardiac function and reduce the severity of heart failure.\n3. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke. It works by inhibiting the activation of PKB, which can reduce the formation of toxic oligomers of amyloid-β (Aβ) in the brain, a hallmark of Alzheimer's disease. By reducing Aβ toxicity, AZD8601 can protect against neuronal death and improve cognitive function.\n4. Anti-inflammatory effects: AZD8601 has been shown to have anti-inflammatory effects in various animal models of inflammation. It works by inhibiting the activation of PKB, which can reduce the production of pro-inflammatory cytok",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of protein kinase B (PKB), also known as Akt.\n2. AZD8601 has shown anti-tumor activity in animal models of cancer, including breast, lung, and colon cancer.\n3. AZD8601 has improved cardiovascular function in animal models of heart failure.\n4. AZD8601 has neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke.\n5. AZD8601 has anti-inflammatory effects in various animal models of inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of protein kinase B (PKB), also known as Akt.",
      "AZD8601 has shown anti-tumor activity in animal models of cancer, including breast, lung, and colon cancer.",
      "AZD8601 has improved cardiovascular function in animal models of heart failure.",
      "AZD8601 has neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke.",
      "AZD8601 has anti-inflammatory effects in various animal models of inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without additional context or information about the specific drug AZD8601, it is not possible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Sahfs, also known as Shariah-compliant Halal Flip Flops, are a type of flip flop that adheres to Shariah principles and are considered halal, or permissible, under Islamic law. The creation of Sahfs involves several steps and considerations to ensure that they meet the requirements of Shariah. Here are the key steps involved in creating Sahfs:\n1. Material selection: The materials used to make the flip flop must be halal and free from any impurities. This means that the materials must meet the requirements of Shariah, which prohibits the use of intoxicants, pork, or any other substance that is not permitted in Islam.\n2. Design: The design of the flip flop must be in compliance with Shariah principles. This includes ensuring that the flip flop is modest in style and does not reveal too much skin. The design must also be aesthetically pleasing and not offensive to any religion or culture.\n3. Production process: The production process for Sahfs must be free from any unethical or unlawful activities. This means that the materials used must be sourced from legitimate and ethical suppliers, and the flip flops must be manufactured in a clean and safe environment.\n4. Certification: Sahfs must be certified by a reputable Islamic authority to ensure that they meet the requirements of Shariah. This certification process involves an assessment of the flip flop's material selection, design, and production process to ensure that they comply with Islamic principles.\n5. Packaging and labeling: The packaging and labeling of Sahfs must also comply with Shariah principles. This means that the packaging must be modest and not reveal any forbidden images or symbols. The labeling must also be clear and informative, providing the customer with accurate information about the flip flop's materials and production process.\n6. Distribution: The distribution of Sahfs must be in compliance with Shariah principles. This means that the flip flops must be sold and marketed in a responsible and ethical manner, without any unethical or unlawful activities.\n7. Service: Sahfs must provide excellent service to customers, which means that any issues or complaints must be addressed",
    "llama-2-7b-chat-hf_fact_raw": "1. Sahfs are Shariah-compliant Halal Flip Flops that adhere to Islamic law.\n2. The materials used to make Sahfs must be halal and free from any impurities prohibited in Islam.\n3. Sahfs must be designed to be modest and not reveal too much skin, complying with Shariah principles.\n4. Sahfs must be certified by a reputable Islamic authority to ensure they meet Shariah requirements.\n5. The packaging and labeling of Sahfs must also comply with Shariah principles and not reveal any forbidden images or symbols.",
    "llama-2-7b-chat-hf_fact": [
      "Sahfs are Shariah-compliant Halal Flip Flops that adhere to Islamic law.",
      "The materials used to make Sahfs must be halal and free from any impurities prohibited in Islam.",
      "Sahfs must be designed to be modest and not reveal too much skin, complying with Shariah principles.",
      "Sahfs must be certified by a reputable Islamic authority to ensure they meet Shariah requirements.",
      "The packaging and labeling of Sahfs must also comply with Shariah principles and not reveal any forbidden images or symbols."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Sahfs are footwear and do not have a requirement to cover skin, as they are not clothing. Shariah principles related to modesty apply to clothing, not footwear.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95/Discs- large/ZO-1) domain is a protein interacting domain that is found in the SATB1 transcription factor. SATB1 is aTranscription Factor that regulates gene expression in the context of stem cell pluripotency, cell fate determination, and tissue development. The PDZ domain of SATB1 is essential for its function in stem cell biology and development.\nThe PDZ domain is a small protein-binding domain that recognizes and binds to specific sequences of amino acids in target proteins. In the case of SATB1, the PDZ domain interacts with proteins involved in the regulation of gene expression, such as histones, transcription factors, and chromatin-modifying enzymes.\nThe function of the PDZ domain of SATB1 can be summarized as follows:\n1. Chromatin remodeling: The PDZ domain of SATB1 interacts with histone-modifying enzymes, such as histone acetyltransferases and histone deacetylases, to modulate chromatin structure and accessibility to transcription factors.\n2. Transcriptional activation: The PDZ domain of SATB1 interacts with transcription factors, such as c-Myc and p53, and enhances their ability to bind to DNA and activate transcription.\n3. Cell fate determination: The PDZ domain of SATB1 interacts with proteins involved in cell fate determination, such as Notch and Hes/Hey, to regulate the expression of genes involved in cell differentiation and lineage commitment.\n4. Stem cell self-renewal: The PDZ domain of SATB1 interacts with proteins involved in stem cell self-renewal, such as SOX2 and N-Myc, to regulate the maintenance and proliferation of stem cells.\nIn summary, the PDZ domain of SATB1 plays a crucial role in regulating gene expression by interacting with a variety of proteins involved in chromatin remodeling, transcriptional activation, cell fate determination, and stem cell self-renewal. The PDZ domain is a key component of the S",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein interacting domain found in SATB1 transcription factor.\n2. SATB1 regulates gene expression in the context of stem cell pluripotency, cell fate determination, and tissue development.\n3. The PDZ domain of SATB1 is involved in chromatin remodeling by interacting with histone-modifying enzymes.\n4. The PDZ domain of SATB1 enhances the ability of transcription factors, such as c-Myc and p53, to activate transcription.\n5. The PDZ domain of SATB1 interacts with proteins involved in stem cell self-renewal, such as SOX2 and N-Myc.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein interacting domain found in SATB1 transcription factor.",
      "SATB1 regulates gene expression in the context of stem cell pluripotency, cell fate determination, and tissue development.",
      "The PDZ domain of SATB1 is involved in chromatin remodeling by interacting with histone-modifying enzymes.",
      "The PDZ domain of SATB1 enhances the ability of transcription factors, such as c-Myc and p53, to activate transcription.",
      "The PDZ domain of SATB1 interacts with proteins involved in stem cell self-renewal, such as SOX2 and N-Myc."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: It is not the PDZ domain specifically, but SATB1 as a whole that enhances the ability of transcription factors like c-Myc and p53 to activate transcription.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "BLISS (Brainwriting, Listening, Imagery, Storytelling, and Systematic Looking) is a creative problem-solving technique that was developed by Dr.XX in the 1970s. The basis of BLISS is to use a combination of individual and group activities to help teams generate, evaluate, and implement new ideas. Here's a detailed explanation of the five components of the BLISS technique:\n1. Brainwriting: In this component, team members write down their ideas individually on a specific topic without any discussion or collaboration. The goal is to identify and capture any relevant ideas that come to mind, even if they seem impractical or impossible at first.\n2. Listening: After the brainwriting exercise, the team members share their ideas with each other in a structured and supportive manner. Listening is the key component of this stage, as team members are encouraged to listen actively, ask open-ended questions, and seek clarification to ensure they understand each other's ideas.\n3. Imagery: In this component, team members use visual aids such as diagrams, mind maps, or drawings to help them generate new ideas and see connections between them. The use of visual aids helps to stimulate creative thinking and improve collaboration among team members.\n4. Storytelling: This component involves using narratives and tales to explore different perspectives and potential solutions to a given problem. By sharing stories, team members can gain a deeper understanding of each other's thoughts and feelings and find connections between seemingly unrelated ideas.\n5. Systematic Looking: In the final stage, team members use a systematic approach to evaluate and prioritize the ideas generated earlier. They use tools such as simple random sampling, Pareto analysis, or other decision-making techniques to determine which ideas are most feasible, desirable, or relevant.\nOverall, the BLISS technique combines structured group activities with creative individual exercises to stimulate a diverse range of ideas and encourage collaboration among team members. By using a combination of visual, storytelling, and systematic techniques, BLISS helps teams to generate and evaluate innovative solutions to complex problems.",
    "llama-2-7b-chat-hf_fact_raw": "1. BLISS is a creative problem-solving technique developed by Dr.XX in the 1970s.\n2. The five components of BLISS are Brainwriting, Listening, Imagery, Storytelling, and Systematic Looking.\n3. In Brainwriting, team members individually write down ideas on a specific topic without discussion or collaboration.\n4. Listening involves team members sharing their ideas and listening actively to each other.\n5. Systematic Looking uses tools such as simple random sampling, Pareto analysis, or other decision-making techniques to evaluate and prioritize ideas.",
    "llama-2-7b-chat-hf_fact": [
      "BLISS is a creative problem-solving technique developed by Dr.XX in the 1970s.",
      "The five components of BLISS are Brainwriting, Listening, Imagery, Storytelling, and Systematic Looking.",
      "In Brainwriting, team members individually write down ideas on a specific topic without discussion or collaboration.",
      "Listening involves team members sharing their ideas and listening actively to each other.",
      "Systematic Looking uses tools such as simple random sampling, Pareto analysis, or other decision-making techniques to evaluate and prioritize ideas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Systematic Looking involves paying attention to the environment, identifying patterns, and looking for inspiration from other fields or industries, rather than using decision-making techniques.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with the information you requested!\nNK3R (Nuclear Receptor Subfamily 5, Group F, member 1) antagonists are a class of drugs that target the NK3 receptor, which is involved in regulating various physiological processes, including appetite, nausea, and pain. Here are three examples of NK3R antagonists:\n1. Aprepitant: Aprepitant is an NK3R antagonist that is FDA-approved for the prevention of chemotherapy-induced nausea and vomiting. It works by blocking the action of NK3 receptors in the nervous system, thereby reducing the sensitivity of the nerves to chemotherapy drugs.\n2. Netupitant: Netupitant is another NK3R antagonist that is FDA-approved for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy. It is administered orally and works by blocking the action of NK3 receptors in the gastrointestinal tract.\n3. Aloxi Keta Spray: Aloxi Keta Spray is an NK3R antagonist that is used to treat breakthrough pain in patients with cancer. It is a breath spray that is applied directly to the nostrils to deliver the drug, and it works by blocking the action of NK3 receptors in the nervous system, thus reducing the transmission of pain signals.\nI hope this information helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aprepitant is an NK3R antagonist FDA-approved for the prevention of chemotherapy-induced nausea and vomiting.\n2. Netupitant is an NK3R antagonist FDA-approved for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.\n3. Aloxi Keta Spray is an NK3R antagonist used to treat breakthrough pain in patients with cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Aprepitant is an NK3R antagonist FDA-approved for the prevention of chemotherapy-induced nausea and vomiting.",
      "Netupitant is an NK3R antagonist FDA-approved for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.",
      "Aloxi Keta Spray is an NK3R antagonist used to treat breakthrough pain in patients with cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Aprepitant is an NK1 receptor antagonist FDA-approved for the prevention of chemotherapy-induced nausea and vomiting.\n2. TRUE\n3. FALSE [correction]: Aloxi (palonosetron) is an NK1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, but it is not a spray, and it is not specifically for breakthrough pain in cancer patients. Keta Spray (ketamine nasal spray) is used for breakthrough pain, but it is not an NK3R antagonist.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986165.\nGhrelin is a hormone produced in the stomach that stimulates appetite and food intake. The ghrelin receptor is a G protein-coupled receptor that is activated by ghrelin and plays a key role in regulating appetite and metabolism. Inverse agonists of the ghrelin receptor are drugs that bind to the receptor and prevent it from activating downstream signaling pathways, resulting in decreased appetite and food intake.\nBMS-986165 is an oral, selective inverse agonist of the ghrelin receptor that was developed by Bristol-Myers Squibb (BMS) for the treatment of obesity and related metabolic disorders. In clinical trials, BMS-986165 has been shown to significantly reduce hunger and food intake in healthy subjects, as well as improve body weight and glucose tolerance in patients with obesity.\nThe first human studies of BMS-986165 were conducted in healthy volunteers, who received single-ascending dose and multiple-dose escalations of the drug. These studies demonstrated that BMS-986165 was well-tolerated and had a good pharmacokinetic profile, with the drug reaching peak plasma concentrations within 2-4 hours of dosing. BMS-986165 also showed dose-dependent reductions in hunger and food intake, as measured by a validated, digital platform, and was associated with changes in appetite-related hormone levels.\nOverall, BMS-986165 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects, and it has shown promising results in preclinical and clinical studies as a potential treatment for obesity and related metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986165 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Ghrelin is a hormone that stimulates appetite and is produced in the stomach.\n3. Bristol-Myers Squibb developed BMS-986165 for treating obesity and related metabolic disorders.\n4. Clinical trials have demonstrated that BMS-986165 can significantly reduce hunger and food intake in healthy subjects.\n5. BMS-986165 reached peak plasma concentrations within 2-4 hours of dosing in human studies.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986165 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Ghrelin is a hormone that stimulates appetite and is produced in the stomach.",
      "Bristol-Myers Squibb developed BMS-986165 for treating obesity and related metabolic disorders.",
      "Clinical trials have demonstrated that BMS-986165 can significantly reduce hunger and food intake in healthy subjects.",
      "BMS-986165 reached peak plasma concentrations within 2-4 hours of dosing in human studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora is an oral cholera vaccine that has been shown to be highly effective in preventing moderate to severe cholera in different populations and settings. The protective efficacy of Vaxchora against moderate to severe cholera has been studied in several clinical trials and real-world settings, and the results are summarized below:\n1. Clinical trials:\na. In a phase III clinical trial conducted in Bangladesh, Vaxchora was shown to provide 77.2% protection against moderate to severe cholera in adults aged 18-60 years old. The vaccine was also effective in older adults, providing 66.7% protection against moderate to severe cholera in individuals aged 61 years or older. (Source: Firestone et al., 2016)\nb. A phase II clinical trial conducted in Africa found that Vaxchora provided 57.1% protection against moderate to severe cholera in children aged 1-10 years old. (Source: Mukherjee et al., 2014)\nc. Another phase III clinical trial conducted in Africa found that Vaxchora provided 70.5% protection against moderate to severe cholera in individuals aged 1-10 years old. (Source: Griffin et al., 2016)\n2. Real-world settings:\na. A study conducted in Haiti after the 2010 cholera outbreak found that Vaxchora provided 62.5% protection against moderate to severe cholera in individuals who received the vaccine within 10 days of exposure. (Source: Mehta et al., 2016)\nb. Another study conducted in Africa found that Vaxchora provided 58.6% protection against moderate to severe cholera in individuals who received the vaccine during a cholera outbreak. (Source: Bwaka et al., 2017)\nc. A systematic review and meta-analysis of 11 studies conducted in different parts of the world found that Vaxchora provided a pooled protective efficacy of 66.6% against moderate to severe cholera",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora provided 77.2% protection against moderate to severe cholera in adults aged 18-60 years old in a phase III clinical trial in Bangladesh. (Source: Firestone et al., 2016)\n2. A phase II clinical trial in Africa showed that Vaxchora provided 57.1% protection against moderate to severe cholera in children aged 1-10 years old. (Source: Mukherjee et al., 2014)\n3. Vaxchora provided 70.5% protection against moderate to severe cholera in individuals aged 1-10 years old in another phase III clinical trial in Africa. (Source: Griffin et al., 2016)\n4. In a real-world setting study in Haiti, Vaxchora provided 62.5% protection against moderate to severe cholera if received within 10 days of exposure. (Source: Mehta et al., 2016)\n5. A systematic review and meta-analysis of 11 studies found a pooled protective efficacy of 66.6% for Vaxchora against moderate to severe cholera.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora provided 77.2% protection against moderate to severe cholera in adults aged 18-60 years old in a phase III clinical trial in Bangladesh. (Source: Firestone et al., 2016)",
      "A phase II clinical trial in Africa showed that Vaxchora provided 57.1% protection against moderate to severe cholera in children aged 1-10 years old. (Source: Mukherjee et al., 2014)",
      "Vaxchora provided 70.5% protection against moderate to severe cholera in individuals aged 1-10 years old in another phase III clinical trial in Africa. (Source: Griffin et al., 2016)",
      "In a real-world setting study in Haiti, Vaxchora provided 62.5% protection against moderate to severe cholera if received within 10 days of exposure. (Source: Mehta et al., 2016)",
      "A systematic review and meta-analysis of 11 studies found a pooled protective efficacy of 66.6% for Vaxchora against moderate to severe cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Vaxchora provided 77.2% protection against moderate to severe cholera in individuals aged 1-10 years old in another phase III clinical trial in Africa. (Source: Griffin et al., 2016)\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the Shanchol vaccine, which was approved by the US Food and Drug Administration (FDA) in 2016. Shanchol is a recombinant, bivalent vaccine that protects against both the O1 and O139 serotypes of the bacteria Vibrio cholerae, which causes cholera.\nThe Shanchol vaccine was developed by the US-based biotech company, MassBiologics, and is based on a technology that uses a small piece of the cholera bacteria's DNA to generate an immune response in the body. The vaccine is given as an injection in the upper arm, and it provides long-lasting protection against cholera infection.\nThe FDA's approval of Shanchol was based on results from a clinical trial involving over 4,000 participants in Bangladesh, India, and Haiti. The trial showed that the vaccine was effective in preventing cholera in people who were at high risk of infection, including those living in areas with high levels of cholera transmission and those who had previously been infected with the disease.\nIt's worth noting that while the Shanchol vaccine is the first cholera vaccine approved in the US, other cholera vaccines are available and have been used in other parts of the world. For example, the oral cholera vaccine (OCV) has been used in many countries, including those with high burdens of cholera, such as Bangladesh and Haiti. The OCV is a live, attenuated vaccine that is given orally and provides short-term protection against cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the Shanchol vaccine.\n2. The Shanchol vaccine was approved by the US Food and Drug Administration (FDA) in 2016.\n3. Shanchol is a recombinant, bivalent vaccine that protects against the O1 and O139 serotypes of Vibrio cholerae.\n4. The Shanchol vaccine was developed by the US-based biotech company, MassBiologics.\n5. The FDA's approval of Shanchol was based on results from a clinical trial involving over 4,000 participants in Bangladesh, India, and Haiti.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the Shanchol vaccine.",
      "The Shanchol vaccine was approved by the US Food and Drug Administration (FDA) in 2016.",
      "Shanchol is a recombinant, bivalent vaccine that protects against the O1 and O139 serotypes of Vibrio cholerae.",
      "The Shanchol vaccine was developed by the US-based biotech company, MassBiologics.",
      "The FDA's approval of Shanchol was based on results from a clinical trial involving over 4,000 participants in Bangladesh, India, and Haiti."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was the Vaxchora vaccine.\n2. TRUE\n3. FALSE [correction]: Shanchol is an inactivated, bivalent vaccine that protects against the O1 and O139 serotypes of Vibrio cholerae.\n4. FALSE [correction]: The Shanchol vaccine was developed by Shantha Biotechnics in India.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to function properly. Monogenic causes of CVID refer to those caused by a single genetic mutation or defect. In Europeans, the most common monogenic cause of CVID is mutations in the T-cell receptors (TCRs) genes.\nTCRs are proteins on the surface of T cells that recognize and bind to specific antigens presented by major histocompatibility complex (MHC) molecules on infected cells or cells from transplants. mutations in the TCR genes can lead to a deficiency in the production or function of T cells, which are essential for a proper immune response.\nThe most common TCR mutations associated with CVID in Europeans are:\n1. TCRV14 Thymic deletion: This mutation occurs in the TCRV14 gene, which codes for a protein involved in the elimination of self-reactive T cells in the thymus. Thymic deletion is a normal process that prevents autoreactive T cells from entering the circulation, where they could cause autoimmune disease.\n2. TCR delta chain rejoining: This mutation affects the gene encoding the delta chain of the TCR, which is important for T-cell signaling. This mutation can lead to impaired T-cell function and immunodeficiency.\n3. TCR gamma chain: This mutation affects the gene encoding the gamma chain of the TCR, which is also important for T-cell signaling.\nThese mutations are usually inherited in an autosomal dominant manner, meaning that a single copy of the mutated gene is enough to cause the disorder.\nIt's worth noting that other genetic mutations and environmental factors can also contribute to the development of CVID. However, mutations in the TCR genes are the most common cause of monogenic CVID in Europeans.\nIt's important to diagnose CVID accurately and early to provide appropriate treatment and management of the disorder. Genetic testing can help identify the underlying cause of CVID in individuals with suspected monogenic forms of the disorder, and this information can guide clinical management decisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to function properly.\n2. Mutations in the T-cell receptors (TCRs) genes are the most common monogenic cause of CVID in Europeans.\n3. TCRV14 thymic deletion is one of the mutations associated with CVID, occurring in the TCRV14 gene.\n4. The TCR delta chain rejoining mutation affects the gene encoding the delta chain of the TCR.\n5. Mutations in the TCR genes are usually inherited in an autosomal dominant manner.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to function properly.",
      "Mutations in the T-cell receptors (TCRs) genes are the most common monogenic cause of CVID in Europeans.",
      "TCRV14 thymic deletion is one of the mutations associated with CVID, occurring in the TCRV14 gene.",
      "The TCR delta chain rejoining mutation affects the gene encoding the delta chain of the TCR.",
      "Mutations in the TCR genes are usually inherited in an autosomal dominant manner."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the gene encoding a protein called inducible co-stimulator (ICOS) are the most common monogenic cause of CVID in Europeans.\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Mutations in the TCR genes are usually inherited in an autosomal recessive manner.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene is a key player in the pathogenesis of Systemic Lupus Erythematosus (SLE), an autoimmune disease that affects various organs and tissues throughout the body. Here's a detailed answer to your question:\nThe IFIT1 gene, also known as Interferon-Induced Transcription Factor 1, is a crucial regulator of interferon (IFN) signaling pathways. In SLE, the IFIT1 gene is mutated or dysregulated, leading to an imbalance in IFN signaling, which exacerbates autoimmune responses. Here are some key points to understand about the role of IFIT1 in SLE:\n1. IFIT1 inhibits the production of pro-inflammatory cytokines: IFIT1 negatively regulates the expression of genes involved in the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1β), which are central to the development of autoimmune diseases like SLE.\n2. IFIT1 regulates the expression of autoreactive T cells: IFIT1 can repress the expression of genes that promote the survival and activation of autoreactive T cells, which are thought to be a key component of the autoimmune response in SLE.\n3. IFIT1 and suppressor of cytokine signaling (Socs) have opposing effects: IFIT1 and Suppressor of Cytokine Signaling (Socs) are related genes that interact with each other to regulate IFN signaling pathways. While Socs inhibits the activation of JAK/STAT signaling, which is critical for the development of autoimmune diseases, IFIT1 enhances it. In SLE, the imbalance between these two genes can contribute to the overproduction of pro-inflammatory cytokines.\n4. IFIT1 mutations are associated with severe disease: Mutations in the IFIT1 gene have been linked to more severe forms of SLE, including discoid lupus and cutaneous lupus. This suggests that the gene plays a critical role in determining the disease severity.\n5. IFIT1 regul",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene, also known as Interferon-Induced Transcription Factor 1, is involved in interferon signaling pathways.\n2. Mutations or dysregulation of the IFIT1 gene can lead to an imbalance in IFN signaling in Systemic Lupus Erythematosus (SLE).\n3. IFIT1 negatively regulates the expression of genes that produce pro-inflammatory cytokines such as TNF-alpha and IL-1β.\n4. IFIT1 can repress the expression of genes that promote the survival and activation of autoreactive T cells in SLE.\n5. Mutations in the IFIT1 gene have been linked to more severe forms of SLE, including discoid lupus and cutaneous lupus.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene, also known as Interferon-Induced Transcription Factor 1, is involved in interferon signaling pathways.",
      "Mutations or dysregulation of the IFIT1 gene can lead to an imbalance in IFN signaling in Systemic Lupus Erythematosus (SLE).",
      "IFIT1 negatively regulates the expression of genes that produce pro-inflammatory cytokines such as TNF-alpha and IL-1β.",
      "IFIT1 can repress the expression of genes that promote the survival and activation of autoreactive T cells in SLE.",
      "Mutations in the IFIT1 gene have been linked to more severe forms of SLE, including discoid lupus and cutaneous lupus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and disability in patients with lateral epicondylitis, commonly known as tennis elbow. Developed by a group of physicians at the Liverpool Hospital in Australia, the LES assesses the degree of pain and impairment in the elbow, allowing healthcare providers to track the progression of the condition and monitor the effectiveness of treatment interventions.\nThe LES score is calculated by assigning weights to different elbow complaints based on their perceived impact on the patient's daily activities. The complaints are grouped into five categories:\n1. Pain: This is the most significant component of the LES, accounting for 30% of the total score. Patients rate their elbow pain on a numerical scale from 0 to 10, with higher scores indicating greater discomfort.\n2. Grip strength: This category assesses the patient's ability to generate grip force in their affected arm, which is essential for daily activities such as picking up objects or using utensils. The patient's grip strength is measured in kilograms, and a lower score indicates weaker grip strength.\n3. Elbow flexion: The patient's ability to bend their elbow is evaluated, with a lower score indicating reduced flexion.\n4. Wrist extension: The patient's ability to straighten their wrist is assessed, with a lower score indicating reduced mobility.\n5. Functional ability: This category evaluates the patient's ability to perform daily activities such as dressing, grooming, and using utensils. A lower score indicates greater impairment in these functions.\nTo calculate the LES score, the patient's scores in each of the five categories are added up, with a maximum total score of 100. A higher score indicates more severe pain and disability.\nThe LES has several advantages over other clinical assessment tools for tennis elbow. Firstly, it is simple and quick to administer, which makes it ideal for use in a clinical setting. Secondly, it takes into account the patient's subjective experience of their symptoms, which can provide valuable insights into their quality of life. Finally, the LES has good inter-rater reliability, meaning",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients with lateral epicondylitis.\n2. The LES was developed by a group of physicians at the Liverpool Hospital in Australia.\n3. The LES score is calculated by assigning weights to different elbow complaints which are grouped into five categories.\n4. Patients rate their elbow pain on a numerical scale from 0 to 10 for the LES.\n5. A higher LES score indicates more severe pain and disability.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients with lateral epicondylitis.",
      "The LES was developed by a group of physicians at the Liverpool Hospital in Australia.",
      "The LES score is calculated by assigning weights to different elbow complaints which are grouped into five categories.",
      "Patients rate their elbow pain on a numerical scale from 0 to 10 for the LES.",
      "A higher LES score indicates more severe pain and disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LES was developed by researchers at the University of Liverpool in the United Kingdom.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics project launched in 2015 by the UK government to analyze the genomes of 100,000 individuals, including those with rare and aggressive cancers such as sarcoma. The project aimed to identify new genetic mutations and variations associated with these cancers, and to develop new diagnostic and treatment approaches.\nSarcoma is a rare and diverse group of cancers that arise from the connective tissue of the body, including bone, cartilage, fat, and muscle. There are over 50 subtypes of sarcoma, each with different genetic mutations and clinical characteristics. Despite their similarities, sarcomas are often difficult to treat due to their rarity and the lack of effective targeted therapies.\nThe 100,000 Genomes Project has made significant efforts to analyze the genomes of sarcoma patients, including those with rare and aggressive subtypes. Some of the key findings and efforts from the project include:\n1. Identification of new genetic mutations: The 100,000 Genomes Project has identified new genetic mutations and variations associated with sarcoma, including those in genes previously unknown to be involved in sarcoma development.\n2. Improved diagnostic accuracy: The project has helped to improve diagnostic accuracy for sarcoma subtypes by identifying specific genetic markers associated with each subtype. This has enabled clinicians to more accurately diagnose and classify sarcoma patients.\n3. Development of personalized treatment approaches: The 100,000 Genomes Project has enabled the development of personalized treatment approaches for sarcoma patients based on the specific genetic mutations and variations identified in their tumors. This has included the use of targeted therapies and immunotherapies tailored to the specific genetic characteristics of each patient's cancer.\n4. Enhanced understanding of sarcoma biology: The project has provided new insights into the molecular biology of sarcoma, including the identification of key genes and pathways involved in sarcoma development and progression. This knowledge has the potential to lead to new therapeutic strategies and treatments for sar",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 by the UK government.\n2. The project aimed to analyze the genomes of 100,000 individuals, including those with sarcoma.\n3. Sarcoma is a rare cancer that arises from the connective tissue of the body.\n4. The 100,000 Genomes Project has identified new genetic mutations associated with sarcoma.\n5. The project has contributed to improved diagnostic accuracy and the development of personalized treatment approaches for sarcoma patients.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 by the UK government.",
      "The project aimed to analyze the genomes of 100,000 individuals, including those with sarcoma.",
      "Sarcoma is a rare cancer that arises from the connective tissue of the body.",
      "The 100,000 Genomes Project has identified new genetic mutations associated with sarcoma.",
      "The project has contributed to improved diagnostic accuracy and the development of personalized treatment approaches for sarcoma patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Protein ALEX1 is a fascinating protein that has gained significant attention in the scientific community due to its unique structure and functional properties. While it is not a well-known fact that protein ALEX1 contains armadillo repeats, I can provide you with information on the structure and function of this interesting protein.\nArmadillo repeats are a type of protein sequence motif that are found in various proteins involved in DNA binding, protein-protein interactions, and other cellular processes. They are characterized by a conserved arrangement of about 40-60 amino acids, which fold into a salt-bridge-rich, beta-sheet-rich structure resembling an armadillo's shell. Armadillo repeats are known to play a crucial role in protein-protein interactions, gene regulation, and other cellular processes.\nIn contrast, protein ALEX1 does not contain armadillo repeats. ALEX1 (Arm-fold-loop-&-stretch-domain-containing protein 1) is a novel protein identified in the human genome that lacks a well-defined structural motif. Its structure has been characterized using X-ray crystallography and NMR spectroscopy, and it is shown to consist of an irregular, elongated structure with a flattened shape. ALEX1 has been found to be involved in various cellular processes, including cell adhesion, migration, and signaling pathways.\nWhile armadillo repeats are not found in protein ALEX1, they are present in other proteins that play important roles in various biological processes. For example, the transcription factor p53 contains several armadillo repeats, which are involved in DNA binding and protein-protein interactions. Similarly, the histone fold protein HMdf contains armadillo repeats, which are involved in DNA binding and chromatin remodeling.\nIn summary, while protein ALEX1 does not contain armadillo repeats, armadillo repeats are found in other proteins involved in various cellular processes. Understanding the structure and function of these proteins can provide valuable insights into the molecular mechanisms underlying various biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.\n2. Armadillo repeats consist of a conserved arrangement of about 40-60 amino acids.\n3. Armadillo repeats fold into a beta-sheet-rich structure resembling an armadillo's shell.\n4. Protein ALEX1's structure has been characterized using X-ray crystallography and NMR spectroscopy.\n5. The transcription factor p53 contains armadillo repeats involved in DNA binding and protein-protein interactions.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats.",
      "Armadillo repeats consist of a conserved arrangement of about 40-60 amino acids.",
      "Armadillo repeats fold into a beta-sheet-rich structure resembling an armadillo's shell.",
      "Protein ALEX1's structure has been characterized using X-ray crystallography and NMR spectroscopy.",
      "The transcription factor p53 contains armadillo repeats involved in DNA binding and protein-protein interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Protein ALEX1's structure has not been fully characterized using X-ray crystallography and NMR spectroscopy.\n5. FALSE [correction]: The transcription factor p53 does not contain armadillo repeats; it contains a core domain with a specific DNA-binding motif and other domains for regulation and protein-protein interactions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with a list of enzymes that are involved in removing histone modifications. Here are some of the most common ones:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to a change in gene expression. There are several types of histone demethylases, including KDM5A, KDM5B, and JMJD2A.\n2. Histone acetyltransferases: These enzymes add acetyl groups to histone proteins, which can also affect gene expression. For example, the enzyme p300 is involved in activating gene expression by acetylating histone H3.\n3. Histone ubiquitin ligases: These enzymes remove histone proteins from chromatin by attaching a ubiquitin protein. This can result in histone degradation and changes in chromatin structure. For example, the enzyme RING1B is involved in removing histone H3 from chromatin.\n4. Histone-specific proteases: These enzymes are responsible for degrading specific histone proteins. For example, the enzyme PSMD14 is involved in degrading histone H2A.\n5. Chromatin remodeling complexes: These complexes use energy from ATP hydrolysis to move nucleosomes along DNA strands, allowing condensation of chromatin and exposure of histone tails for modification. Examples of chromatin remodeling complexes include SWI/SNF and ISW1.\n6. Histone-binding proteins: These proteins recognize and bind to specific histone modifications, allowing them to interact with other proteins that modify or remove histone modifications. For example, the protein HMGA2 binds to histone H3 and H4 and is involved in regulating chromatin structure and gene expression.\n7. Histone-deacetylase inhibitors: These drugs are used to treat cancer and other diseases by inhibiting the activity of histone deacetylases, which are enzymes that remove acetyl groups from histone proteins. Examples of histone-deacetylase inhibitors include trichostatin A and entin",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases remove methyl groups from histone proteins.\n2. Histone acetyltransferases add acetyl groups to histone proteins.\n3. Histone ubiquitin ligases attach ubiquitin to histones, leading to their degradation.\n4. Histone-specific proteases degrade specific histone proteins such as PSMD14 degrading histone H2A.\n5. Chromatin remodeling complexes such as SWI/SNF and ISW1 move nucleosomes along DNA strands.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases remove methyl groups from histone proteins.",
      "Histone acetyltransferases add acetyl groups to histone proteins.",
      "Histone ubiquitin ligases attach ubiquitin to histones, leading to their degradation.",
      "Histone-specific proteases degrade specific histone proteins such as PSMD14 degrading histone H2A.",
      "Chromatin remodeling complexes such as SWI/SNF and ISW1 move nucleosomes along DNA strands."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Histone-specific proteases do not specifically target histone proteins, and PSMD14 is not a protease that degrades histone H2A. Instead, it is involved in removing ubiquitin from histones.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Hello! I'm here to help you with your question.\nHead CT scans are a common imaging test used to diagnose and monitor various medical conditions, including brain tumors. While CT scans are generally considered safe, there is some evidence to suggest that they may increase the risk of developing a brain tumor, particularly in children and young adults.\nStudies have shown that exposure to CT scans, especially in children, can increase the risk of developing a brain tumor by up to 22%. This is because CT scans use ionizing radiation, which can damage the cells in the brain and increase the risk of cancer.\nHowever, it's important to note that the risk of developing a brain tumor from a single CT scan is relatively low. The risk increases with the number of CT scans a person has, especially in children and young adults. For example, a study published in the Journal of the National Cancer Institute found that children who had more than 10 CT scans before the age of 10 had a 2.5 times higher risk of developing a brain tumor compared to those who had fewer than 5 CT scans.\nIt's worth noting that the risk of developing a brain tumor from a CT scan is still much lower than the risk of not getting a diagnosis or treatment because of a brain tumor. Brain tumors can be life-threatening, and early detection and treatment are critical for improving outcomes.\nIf you or someone you know has a brain tumor, it's important to discuss the potential risks and benefits of head CT scans with a healthcare provider. They can help determine the best course of action based on the individual's specific situation and medical history.\nIn summary, while head CT scans may increase the risk of developing a brain tumor, especially in children and young adults, the overall risk is still relatively low. It's important to weigh the potential risks and benefits of CT scans and to discuss any concerns with a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans use ionizing radiation, which can damage cells in the brain and increase the risk of cancer.\n2. Exposure to CT scans in children can increase the risk of developing a brain tumor by up to 22%.\n3. Children who had more than 10 CT scans before the age of 10 have a 2.5 times higher risk of developing a brain tumor compared to those who had fewer than 5 CT scans.\n4. The risk of developing a brain tumor from a single CT scan is relatively low.\n5. The risk of not getting a diagnosis or treatment for a brain tumor is higher than the risk of developing a brain tumor from a CT scan.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans use ionizing radiation, which can damage cells in the brain and increase the risk of cancer.",
      "Exposure to CT scans in children can increase the risk of developing a brain tumor by up to 22%.",
      "Children who had more than 10 CT scans before the age of 10 have a 2.5 times higher risk of developing a brain tumor compared to those who had fewer than 5 CT scans.",
      "The risk of developing a brain tumor from a single CT scan is relatively low.",
      "The risk of not getting a diagnosis or treatment for a brain tumor is higher than the risk of developing a brain tumor from a CT scan."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While it is true that exposure to CT scans in children can increase the risk of developing a brain tumor, the specific percentage increase would vary and cannot be definitively stated as 22% without specific study data to support this figure.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is a transcription factor that is involved in the regulation of pluripotency in various cell types, including neurons, muscle cells, and hematopoietic cells. While Otx2 has been shown to be associated with multiple types of pluripotency, including ground state pluripotency and naïve pluripotency, its primary association is with primed pluripotency.\nPried pluripotency is a state of pluripotency that is characterized by the presence of specific transcription factors, including Otx2, Nestin, and Rex1. In this state, cells have the ability to differentiate into any cell type in the body, but they are also highly proliferative and have increased gene expression compared to naïve pluripotent cells. Pried pluripotency is thought to be a more mature form of pluripotency than naïve pluripotency, and it is often associated with the mesodermal lineage.\nOtx2 has been shown to be particularly important in the maintenance of primed pluripotency, as it regulates the expression of key pluripotency genes and promotes self-renewal in this state. For example, Otx2 has been shown to regulate the expression of the pluripotency gene Oct4, and it is required for the maintenance of stem cell self-renewal in both embryonic and adult cells.\nIn summary, Otx2 is primarily associated with primed pluripotency, a state of pluripotency characterized by the presence of specific transcription factors and increased gene expression, and it plays a key role in the maintenance of this state.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is a transcription factor involved in the regulation of pluripotency in various cell types.\n2. Otx2 is associated with multiple types of pluripotency, including ground state and naïve pluripotency, with a primary association with primed pluripotency.\n3. Primed pluripotency is characterized by the presence of specific transcription factors such as Otx2, Nestin, and Rex1.\n4. Cells in the primed pluripotent state have the ability to differentiate into any cell type in the body and are highly proliferative with increased gene expression.\n5. Otx2 is important in maintaining primed pluripotency, as it regulates the expression of key pluripotency genes like Oct4 and promotes self-renewal.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is a transcription factor involved in the regulation of pluripotency in various cell types.",
      "Otx2 is associated with multiple types of pluripotency, including ground state and naïve pluripotency, with a primary association with primed pluripotency.",
      "Primed pluripotency is characterized by the presence of specific transcription factors such as Otx2, Nestin, and Rex1.",
      "Cells in the primed pluripotent state have the ability to differentiate into any cell type in the body and are highly proliferative with increased gene expression.",
      "Otx2 is important in maintaining primed pluripotency, as it regulates the expression of key pluripotency genes like Oct4 and promotes self-renewal."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cells in the primed pluripotent state have the ability to differentiate into any cell type in the body but are considered to be more restricted in their differentiation potential compared to naïve pluripotent cells.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region is a complex and highly regulated gene cluster that contains multiple DNase I hypersensitive sites (DHS). DHS are specific regions within the genome that are highly accessible to DNase I, a enzyme that degrades nucleic acids, and are often associated with active gene regions. In the case of the murine beta globin locus, there are at least 15 DHS identified to date.\nHere are the locations and characteristics of some of the known DHS marking the murine beta globin locus region:\n1. DHS-1: Positioned at the 5' end of the beta globin gene cluster, DHS-1 is the most highly conserved and has been shown to play a role in the regulation of beta globin gene expression during erythropoiesis.\n2. DHS-2: Located approximately 10 kilobases upstream of the beta globin genes, DHS-2 is involved in the control of gene expression and is thought to play a role in the regulation of erythroid cell fate.\n3. DHS-3: Positioned at the promoter region of the beta globin gene, DHS-3 is responsible for the transcriptional activation of the gene during erythropoiesis.\n4. DHS-4: Located at the first intron of the beta globin gene, DHS-4 is involved in the splicing of the gene during mRNA processing.\n5. DHS-5: Positioned at the 3' end of the beta globin gene, DHS-5 is thought to play a role in the regulation of gene expression during erythropoiesis.\n6. DHS-6: Located at the locus control region of the beta globin gene, DHS-6 is responsible for the regulation of gene expression and is thought to play a role in the control of erythroid cell fate.\n7. DHS-7: Positioned at the proximal promoter of the beta globin gene, DHS-7 is involved in the transcriptional activation of the gene during erythropoiesis.\n8. DHS-8: Located at the distal promoter of the beta globin gene, DHS-8 is responsible for the transcription",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region contains multiple DNase I hypersensitive sites (DHS).\n2. At least 15 DHS have been identified in the murine beta globin locus to date.\n3. DHS-1 is positioned at the 5' end of the beta globin gene cluster and is highly conserved.\n4. DHS-2 is located approximately 10 kilobases upstream of the beta globin genes.\n5. DHS-3 is positioned at the promoter region of the beta globin gene and is responsible for transcriptional activation during erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region contains multiple DNase I hypersensitive sites (DHS).",
      "At least 15 DHS have been identified in the murine beta globin locus to date.",
      "DHS-1 is positioned at the 5' end of the beta globin gene cluster and is highly conserved.",
      "DHS-2 is located approximately 10 kilobases upstream of the beta globin genes.",
      "DHS-3 is positioned at the promoter region of the beta globin gene and is responsible for transcriptional activation during erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The exact number of DHS identified in the murine beta globin locus is unclear from this statement.\n3. FALSE [correction]: DHS-1 is positioned at the 5' end of the beta globin gene cluster, but its conservation status is not specified.\n4. TRUE\n5. FALSE [correction]: DHS-3 is located around 15 kilobases upstream of the beta globin genes, but its exact position and role in transcriptional activation during erythropoiesis are not specified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Certainly, here are some of the most common European influenza vaccines:\n1. GlaxoSmithKline (GSK) trivalent influenza vaccine (Fluenz): This vaccine is produced by GSK and is approved for use in the European Union (EU). It contains inactivated influenza viruses of three strains: two A strains and one B strain.\n2. Sanofi Pasteur quadrivalent influenza vaccine (Influvac): This vaccine is produced by Sanofi Pasteur and is also approved for use in the EU. It contains inactivated influenza viruses of four strains: two A strains and two B strains.\n3. Novartis influenza vaccine (Fluad): This vaccine is produced by Novartis and is approved for use in the EU. It contains inactivated influenza viruses of three strains: two A strains and one B strain, as well as a higher dose of the B strain to enhance the immune response in older adults.\n4. AstraZeneca trivalent influenza vaccine (FluMist): This vaccine is produced by AstraZeneca and is approved for use in the EU. It contains inactivated influenza viruses of three strains: two A strains and one B strain, administered through a nasal spray.\n5. Seqirus quadrivalent influenza vaccine (Flulaval): This vaccine is produced by Seqirus and is approved for use in the EU. It contains inactivated influenza viruses of four strains: two A strains and two B strains.\n6. Roche/S RA Pharmaceuticals trivalent influenza vaccine (Exemptia): This vaccine is produced by Roche/S RA Pharmaceuticals and is approved for use in the EU. It contains inactivated influenza viruses of three strains: two A strains and one B strain.\n7. Bio Farma quadrivalent influenza vaccine (Fluquin): This vaccine is produced by Bio Farma and is approved for use in the EU. It contains inactivated influenza viruses of four strains: two A",
    "llama-2-7b-chat-hf_fact_raw": "1. GlaxoSmithKline (GSK) trivalent influenza vaccine (Fluenz) is approved for use in the European Union and contains inactivated influenza viruses of three strains.\n2. Sanofi Pasteur quadrivalent influenza vaccine (Influvac) is approved for use in the European Union and contains inactivated influenza viruses of four strains.\n3. Novartis influenza vaccine (Fluad) is approved for use in the European Union and contains inactivated influenza viruses of three strains including a higher dose of the B strain.\n4. AstraZeneca trivalent influenza vaccine (FluMist) is approved for use in the European Union and is administered through a nasal spray.\n5. Seqirus quadrivalent influenza vaccine (Flulaval) is approved for use in the European Union and contains inactivated influenza viruses of four strains.",
    "llama-2-7b-chat-hf_fact": [
      "GlaxoSmithKline (GSK) trivalent influenza vaccine (Fluenz) is approved for use in the European Union and contains inactivated influenza viruses of three strains.",
      "Sanofi Pasteur quadrivalent influenza vaccine (Influvac) is approved for use in the European Union and contains inactivated influenza viruses of four strains.",
      "Novartis influenza vaccine (Fluad) is approved for use in the European Union and contains inactivated influenza viruses of three strains including a higher dose of the B strain.",
      "AstraZeneca trivalent influenza vaccine (FluMist) is approved for use in the European Union and is administered through a nasal spray.",
      "Seqirus quadrivalent influenza vaccine (Flulaval) is approved for use in the European Union and contains inactivated influenza viruses of four strains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GlaxoSmithKline (GSK) trivalent influenza vaccine (Fluenz) is approved for use in the European Union, but it is a live attenuated influenza vaccine, not inactivated.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nParamyxoviruses are a family of viruses that include the viruses that cause parainfluenza, measles, and mumps. The genome of these viruses consists of several segments of negative-sense RNA, which are oriented in a specific manner to form a circular molecule. Each segment is designated as either large (L), medium (M), or small (S), depending on its size.\nThe negative-sense RNA genome of Paramyxovirus is composed of the following segments:\n1. Large (L) segment: This segment codes for the viral RNA-dependent RNA polymerase (RdRp), which is responsible for synthesizing positive-sense RNA from the negative-sense genome during the early stages of infection.\n2. Medium (M) segment: This segment contains the genes for the non-structural proteins (NS1, NS2a, and NS2b), which play important roles in the replication and transcription of the viral genome, as well as the host cell interaction.\n3. Small (S) segment: This segment contains the genes for the structural proteins (hemagglutinin-neuraminidase (HN) and fusion (F) proteins), as well as the remained of the viral RdRp.\nThe negative-sense RNA genome of Paramyxovirus is essential for the viral replication and transcription, as it provides the template for the synthesis of the viral RNA-dependent RNA polymerase, non-structural proteins, and structural proteins. The segmented nature of the genome allows for the coordinated expression of these genes and the proper regulation of viral gene expression during infection.\nIn summary, the Paramyxovirus geneome is segmented, negative-sense RNA, containing three segments (L, M, and S) that codes for the genes necessary for viral replication and transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. Paramyxoviruses include the viruses that cause parainfluenza, measles, and mumps.\n2. The genome of Paramyxoviruses consists of several segments of negative-sense RNA.\n3. The Large (L) segment of the Paramyxovirus genome codes for the viral RNA-dependent RNA polymerase (RdRp).\n4. The Medium (M) segment contains genes for non-structural proteins that are important for viral genome replication and transcription.\n5. The Small (S) segment contains genes for structural proteins such as hemagglutinin-neuraminidase (HN) and fusion (F) proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Paramyxoviruses include the viruses that cause parainfluenza, measles, and mumps.",
      "The genome of Paramyxoviruses consists of several segments of negative-sense RNA.",
      "The Large (L) segment of the Paramyxovirus genome codes for the viral RNA-dependent RNA polymerase (RdRp).",
      "The Medium (M) segment contains genes for non-structural proteins that are important for viral genome replication and transcription.",
      "The Small (S) segment contains genes for structural proteins such as hemagglutinin-neuraminidase (HN) and fusion (F) proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The genome of Paramyxoviruses is a single linear segment of negative-sense RNA, not several segments. \n3. UNKNOWN\n4. FALSE [correction]: Paramyxoviruses do not have a segmented genome; they have a single linear genome, thus no \"Medium (M) segment\".\n5. FALSE [correction]: Paramyxoviruses have a nonsegmented genome; the structural proteins such as hemagglutinin-neuraminidase (HN) and fusion (F) proteins are encoded within the single linear RNA genome, not a \"Small (S) segment\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is a topical medication used to treat a variety of skin conditions, including:\n1. Psoriasis: Roflumilast cream has been shown to be effective in reducing the symptoms of mild to moderate psoriasis, including plaque psoriasis. It works by inhibiting the release of inflammatory mediators and reducing the inflammation that characterizes psoriasis.\n2. Atopic dermatitis: Roflumilast cream has been shown to be effective in reducing the symptoms of atopic dermatitis, including itching, redness, and dryness. It works by reducing the inflammation and itching associated with atopic dermatitis.\n3. Vitiligo : Roflumilast cream has been shown to be effective in repigmenting depigmented skin in patients with vitiligo. It works by inhibiting the release of inflammatory mediators and promoting the growth of melanocytes, the pigment-producing cells responsible for skin color.\n4. Pruritus : Roflumilast cream can be used to treat pruritus (itching) associated with a variety of skin conditions, including atopic dermatitis, psoriasis, and eczema. It works by reducing the itching and inflammation associated with these conditions.\n5. Actinic keratosis: Roflumilast cream has been shown to be effective in reducing the appearance of actinic keratosis, a common condition characterized by dry, scaly patches on the skin. It works by reducing the inflammation and itching associated with actinic keratosis.\n6. Acne: Roflumilast cream has been shown to have anti-inflammatory and antibacterial properties, making it a potential treatment for acne. However, further studies are needed to confirm its effectiveness for this purpose.\nIt is important to note that Roflumilast cream is for external use only and should not be ingested. Also, it may cause side effects such as redness, itching, and dryness at the application site. It is recommended to consult",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat mild to moderate psoriasis, including plaque psoriasis.\n2. Roflumilast cream is effective in reducing the symptoms of atopic dermatitis.\n3. Roflumilast cream can be used to repigment depigmented skin in patients with vitiligo.\n4. Roflumilast cream can be used to treat pruritus associated with various skin conditions.\n5. Roflumilast cream has been shown to be effective in reducing the appearance of actinic keratosis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat mild to moderate psoriasis, including plaque psoriasis.",
      "Roflumilast cream is effective in reducing the symptoms of atopic dermatitis.",
      "Roflumilast cream can be used to repigment depigmented skin in patients with vitiligo.",
      "Roflumilast cream can be used to treat pruritus associated with various skin conditions.",
      "Roflumilast cream has been shown to be effective in reducing the appearance of actinic keratosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Roflumilast cream is not indicated for the treatment of atopic dermatitis.\n3. FALSE [correction]: Roflumilast cream is not indicated for the treatment of vitiligo.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Here are some of the most popular ones:\n1. CrawfordLab: This tool is developed by Dr. Ian Crawford and his team at the University of Cambridge. It uses a combination of machine learning algorithms and structured bioinformatics to identify ncRNA promoters in the human genome. The tool can predict the location, orientation, and strength of ncRNA promoters, and it also provides a visualization of the predicted promoters.\n2. ncrna-promoter: This tool is developed by Dr. Anna E. V. Endelman at the University of California, San Diego. It uses a hidden Markov model (HMM) to identify ncRNA promoters in the human genome. The tool can predict the location, orientation, and strength of ncRNA promoters, and it also provides a visualization of the predicted promoters.\n3. RNApromoter: This tool is developed by Dr. Jeremy M. Berg at the University of Washington. It uses a combination of machine learning algorithms and structured bioinformatics to identify ncRNA promoters in the human genome. The tool can predict the location, orientation, and strength of ncRNA promoters, and it also provides a visualization of the predicted promoters.\n4. DeepSEA: This tool is developed by Dr. J. Michael McCracken at the University of Texas MD Anderson Cancer Center. It uses a deep learning approach to identify ncRNA promoters in the human genome. The tool can predict the location, orientation, and strength of ncRNA promoters, and it also provides a visualization of the predicted promoters.\n5. RNACore: This tool is developed by Dr. David R. Liu at the Broad Institute. It uses a combination of machine learning algorithms and structured bioinformatics to identify ncRNA promoters in the human genome. The tool can predict the location, orientation, and strength of ncRNA promoters, and it also provides a visualization of the predicted promoters.\n6. STARsplice: This tool is developed by Dr. Yibin Wu at the University of California, San Diego. It",
    "llama-2-7b-chat-hf_fact_raw": "1. CrawfordLab is a tool developed by Dr. Ian Crawford at the University of Cambridge for identifying ncRNA promoters in the human genome.\n2. Ncrna-promoter is a tool developed by Dr. Anna E. V. Endelman at the University of California, San Diego, using a hidden Markov model to identify ncRNA promoters.\n3. RNApromoter is a tool developed by Dr. Jeremy M. Berg at the University of Washington for identifying ncRNA promoters in the human genome.\n4. DeepSEA is a tool developed by Dr. J. Michael McCracken at the University of Texas MD Anderson Cancer Center that uses deep learning to identify ncRNA promoters.\n5. RNACore is a tool developed by Dr. David R. Liu at the Broad Institute for identifying ncRNA promoters in the human genome.",
    "llama-2-7b-chat-hf_fact": [
      "CrawfordLab is a tool developed by Dr. Ian Crawford at the University of Cambridge for identifying ncRNA promoters in the human genome.",
      "Ncrna-promoter is a tool developed by Dr. Anna E. V. Endelman at the University of California, San Diego, using a hidden Markov model to identify ncRNA promoters.",
      "RNApromoter is a tool developed by Dr. Jeremy M. Berg at the University of Washington for identifying ncRNA promoters in the human genome.",
      "DeepSEA is a tool developed by Dr. J. Michael McCracken at the University of Texas MD Anderson Cancer Center that uses deep learning to identify ncRNA promoters.",
      "RNACore is a tool developed by Dr. David R. Liu at the Broad Institute for identifying ncRNA promoters in the human genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Single-nucleus Whole-transcriptome Insights in Mouse brain) is a tool used to analyze the transcriptome of single neurons in the mouse brain, including those affected by glioblastoma (GBM). GBM is a type of brain cancer that is aggressive and malignant, and is the most common type of primary brain cancer.\nUsing SWIM, researchers have identified many genes that are down-regulated in GBM, including:\n1. CDKN2A: The CDKN2A gene encodes a protein called p16, which is a tumor suppressor that regulates the cell cycle and prevents cells from dividing too quickly. Loss of function mutations in CDKN2A are common in GBM, and loss of p16 expression is associated with increased cancer stem cell populations.\n2. CDKN1A: The CDKN1A gene encodes a protein called p21, which is another tumor suppressor that regulates the cell cycle and prevents cells from dividing too quickly. Loss of function mutations in CDKN1A are also common in GBM.\n3. MEN1: The MEN1 gene encodes a protein called menin, which is a transcriptional repressor that regulates the expression of many genes involved in cell growth and division. Loss of function mutations in MEN1 are associated with development of GBM.\n4. BRCA1: The BRCA1 gene encodes a protein that helps repair DNA damage. Loss of function mutations in BRCA1 are associated with development of GBM.\n5. BRCA2: The BRCA2 gene encodes a protein that helps repair DNA damage. Loss of function mutations in BRCA2 are also associated with development of GBM.\n6. PTEN: The PTEN gene encodes a protein called phosphatase and tensin homolog (PTEN), which regulates the PI3K/AKT signaling pathway and is involved in cell survival and growth. Loss of function mutations in PTEN are common in GBM.\n7. AGBL1: The AGBL1 gene encodes a protein called AGBL1, which is involved in cell adhesion and is down-regulated in GBM.\n8.",
    "llama-2-7b-chat-hf_fact_raw": "1. The CDKN2A gene is down-regulated in glioblastoma and encodes the tumor suppressor protein p16.\n2. The CDKN1A gene is down-regulated in glioblastoma and encodes the tumor suppressor protein p21.\n3. The MEN1 gene is down-regulated in glioblastoma and encodes the transcriptional repressor protein menin.\n4. The BRCA1 gene is down-regulated in glioblastoma and is associated with DNA damage repair.\n5. The PTEN gene is down-regulated in glioblastoma and encodes the protein phosphatase and tensin homolog involved in the PI3K/AKT signaling pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The CDKN2A gene is down-regulated in glioblastoma and encodes the tumor suppressor protein p16.",
      "The CDKN1A gene is down-regulated in glioblastoma and encodes the tumor suppressor protein p21.",
      "The MEN1 gene is down-regulated in glioblastoma and encodes the transcriptional repressor protein menin.",
      "The BRCA1 gene is down-regulated in glioblastoma and is associated with DNA damage repair.",
      "The PTEN gene is down-regulated in glioblastoma and encodes the protein phosphatase and tensin homolog involved in the PI3K/AKT signaling pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The CDKN1A gene encodes the tumor suppressor protein p21, but it is not specified whether it is down-regulated in glioblastoma.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Transcriptional Activation Domains (TADs). Here are some of the popular ones:\n1. TADalus: TADalus is a comprehensive package for the analysis of TADs. It provides functions for the detection, visualization, and interpretation of TADs in various types of genomic data, including ChIP-seq, RNA-seq, and DNA sequence data.\n2. TADgraph: TADgraph is an R package that focuses on the spatial analysis of TADs. It provides functions for the construction of TAD graphs, which can be used to visualize and analyze the spatial organization of TADs across the genome.\n3. TADtrack: TADtrack is an R package that provides functions for the detection and tracking of TADs in high-throughput genomic data. It can be used to identify TADs and their subregions, and to track their movements across different cell types and experimental conditions.\n4. TADMiner: TADMiner is an R package that provides a comprehensive framework for the analysis of TADs. It includes functions for the detection, visualization, and interpretation of TADs, as well as tools for the analysis of TAD-related features such as gene expression and chromatin modification profiles.\n5. TADders: TADders is an R package that provides a set of functions for the analysis of TADs in DNA sequence data. It includes tools for the detection of TADs, the analysis of their genomic annotation, and the visualization of their spatial organization.\n6. ChromCensus: ChromCensus is an R package that provides functions for the analysis of chromatin structure and gene expression. It can be used to study the organization of TADs in different regions of the genome and to identify patterns of gene expression that are associated with specific TADs.\n7. HISAT2: HISAT2 is a widely-used tool for the analysis of ChIP-seq data. It can be used to identify TADs and theirsubregions, and to study the spatial organization of chromatin modifications associated with TADs.\n8. STAR: STAR is another popular tool for the analysis of ChIP-seq data. It can be used to identify TADs and their subregions, and to study the spatial",
    "llama-2-7b-chat-hf_fact_raw": "1. TADalus is an R package developed for the analysis of Transcriptional Activation Domains (TADs).\n2. TADgraph is an R package that focuses on the spatial analysis of TADs and constructing TAD graphs.\n3. TADtrack provides functions for the detection and tracking of TADs in high-throughput genomic data.\n4. TADMiner includes functions for the detection, visualization, and interpretation of TADs.\n5. TADders is an R package designed for the analysis of TADs in DNA sequence data.",
    "llama-2-7b-chat-hf_fact": [
      "TADalus is an R package developed for the analysis of Transcriptional Activation Domains (TADs).",
      "TADgraph is an R package that focuses on the spatial analysis of TADs and constructing TAD graphs.",
      "TADtrack provides functions for the detection and tracking of TADs in high-throughput genomic data.",
      "TADMiner includes functions for the detection, visualization, and interpretation of TADs.",
      "TADders is an R package designed for the analysis of TADs in DNA sequence data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without specific knowledge about the R packages mentioned, it is difficult to accurately determine the truthfulness of the statements. It requires research or domain expertise in bioinformatics and the use of specific R packages for analyzing Transcriptional Activation Domains.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to inform you that several bioconductor tools have been developed to access bacterial regulatory networks. However, some of the most popular and widely used tools are:\n1. CRISPR-Cas Tool Suite: This tool was developed by the Broad Institute and allows users to design and predict CRISPR-Cas experiments for gene regulation. It also provides tools for analyzing and visualizing the data generated from these experiments.\n2. RegulON: This tool was developed by the University of California, San Diego and allows users to predict and analyze the regulatory interactions between transcription factors and their target genes in bacteria. RegulON uses a Bayesian Network approach to model the regulatory dynamics of bacterial gene expression.\n3. Bioneer: This tool was developed by the University of California, Berkeley and provides a framework for modeling and analyzing gene regulatory networks in bacteria. Bioneer uses a combination of machine learning algorithms and experimental data to predict regulatory interactions between transcription factors and target genes.\n4. GeneNet: This tool was developed by the University of Michigan and allows users to predict and analyze the regulatory interactions between transcription factors and target genes in bacteria. GeneNet uses a Bayesian Network approach to model the regulatory dynamics of bacterial gene expression.\n5. MeoyEst: This tool was developed by the University of California, Santa Barbara and allows users to predict the activity of bacterial regulatory elements based on their sequence. MeoyEst uses a hidden Markov model to predict the binding affinity of transcription factors to regulatory elements.\n6. Regulatory Sequence Analysis Tools (RSAT): This tool was developed by the University of California, San Diego and provides a comprehensive set of tools for analyzing and predicting the regulatory sequences of bacteria. RSAT includes tools for analyzing the sequences of promoters, terminators, and other regulatory elements, as well as tools for predicting the binding affinity of transcription factors to these elements.\n7. Transcription Analytics: This tool was developed by the University of Texas and provides a comprehensive set of tools for analyzing and predicting the regulation of gene expression in bacteria. Transcription Analytics includes tools for analyzing the sequences of promoters, terminators, and other regulatory",
    "llama-2-7b-chat-hf_fact_raw": "1. The CRISPR-Cas Tool Suite was developed by the Broad Institute.\n2. RegulON was developed by the University of California, San Diego.\n3. Bioneer was developed by the University of California, Berkeley.\n4. GeneNet was developed by the University of Michigan.\n5. MeoyEst was developed by the University of California, Santa Barbara.",
    "llama-2-7b-chat-hf_fact": [
      "The CRISPR-Cas Tool Suite was developed by the Broad Institute.",
      "RegulON was developed by the University of California, San Diego.",
      "Bioneer was developed by the University of California, Berkeley.",
      "GeneNet was developed by the University of Michigan.",
      "MeoyEst was developed by the University of California, Santa Barbara."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The CRISPR-Cas Tool Suite was developed by Jennifer Doudna and Emmanuelle Charpentier at the University of California, Berkeley.\n2. UNKNOWN\n3. FALSE [correction]: Bioneer is a biotechnology company, not a tool developed by the University of California, Berkeley.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The shikimate pathway is a metabolic pathway that is involved in the biosynthesis of aromatic amino acids, phenylalanine, tyrosine, and tryptophan, as well as other compounds such as quinates and polyamines. The end products of the shikimate pathway are:\n1. Aromatic amino acids: Phenylalanine, tyrosine, and tryptophan are the major end products of the shikimate pathway. These amino acids are important building blocks of proteins and play essential roles in various cellular processes.\n2. Quinates: Quinates are a class of compounds that are produced through the degradation of the amino acid tyrosine. They are involved in the biosynthesis of other compounds, such as flavonoids and phenolic acids.\n3. Polyamines: Polyamines are a class of compounds that are involved in various cellular processes, including cell growth and differentiation. They are produced through the degradation of the amino acid tyrosine.\n4. Other compounds: The shikimate pathway also produces other compounds, such as anthranilates, which are involved in the biosynthesis of amino acids and other compounds.\nThe shikimate pathway is a complex metabolic pathway that involves the conversion of the starting compound, chorismate, into a variety of different compounds. The pathway is found in organisms that are capable of biosynthesizing aromatic amino acids, including bacteria, fungi, and plants. The shikimate pathway is an important component of the metabolism of many organisms and plays a critical role in the biosynthesis of many compounds that are important for growth and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway is involved in the biosynthesis of the aromatic amino acids phenylalanine, tyrosine, and tryptophan.\n2. Quinates are produced through the degradation of tyrosine in the shikimate pathway.\n3. Polyamines, involved in cell growth and differentiation, are produced through the shikimate pathway.\n4. Anthranilates, which contribute to the biosynthesis of amino acids and other compounds, are products of the shikimate pathway.\n5. The shikimate pathway converts chorismate into a variety of different compounds and is found in bacteria, fungi, and plants.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway is involved in the biosynthesis of the aromatic amino acids phenylalanine, tyrosine, and tryptophan.",
      "Quinates are produced through the degradation of tyrosine in the shikimate pathway.",
      "Polyamines, involved in cell growth and differentiation, are produced through the shikimate pathway.",
      "Anthranilates, which contribute to the biosynthesis of amino acids and other compounds, are products of the shikimate pathway.",
      "The shikimate pathway converts chorismate into a variety of different compounds and is found in bacteria, fungi, and plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Quinates are produced through the degradation of the quinic acid, not tyrosine, in the shikimate pathway.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Cabergoline is a drug that is used to treat certain conditions, including Nelson's syndrome. Nelson's syndrome is a rare condition that occurs after surgical removal of a pituitary tumor. It is characterized by the excessive growth of the remaining pituitary tissue, leading to an overproduction of certain hormones, including prolactin, growth hormone, and adrenocorticotropic hormone (ACTH).\nCabergoline is a dopamine receptor agonist that is specifically used to treat hyperprolactinemia, which is an excessive production of prolactin hormone. Prolactin is a hormone produced by the pituitary gland that plays a role in lactation and breast growth during pregnancy. In Nelson's syndrome, the excessive growth of the pituitary gland leads to an overproduction of prolactin, which can cause a variety of symptoms, including hypogonadism (low sex hormone levels), galactorrhea (spontaneous milk production), and visual disturbances.\nCabergoline works by binding to dopamine receptors in the pituitary gland, which helps to reduce the production of prolactin. By reducing prolactin levels, cabergoline can help to alleviate the symptoms of Nelson's syndrome, such as hypogonadism and galactorrhea. Additionally, cabergoline may also help to improve visual disturbances associated with Nelson's syndrome, such as blurred vision and eye pain.\nIt's important to note that cabergoline is not a cure for Nelson's syndrome, and it may not completely eliminate all symptoms. However, it can help to manage the symptoms and slow down the progression of the disease. Cabergoline is usually taken as a tablet or oral solution once a week, and the dosage may need to be adjusted over time to achieve the best results.\nIn summary, cabergoline is used to treat Nelson's syndrome by reducing the production of prolactin hormone, which helps to alleviate the symptoms of the disease. While it's not a cure, cabergoline can help to manage the symptoms and slow down",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat certain conditions, including Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that occurs after surgical removal of a pituitary tumor.\n3. Cabergoline is a dopamine receptor agonist that is specifically used to treat hyperprolactinemia, an excessive production of prolactin hormone.\n4. Cabergoline works by binding to dopamine receptors in the pituitary gland, which helps to reduce the production of prolactin.\n5. Cabergoline is usually taken as a tablet or oral solution once a week.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat certain conditions, including Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that occurs after surgical removal of a pituitary tumor.",
      "Cabergoline is a dopamine receptor agonist that is specifically used to treat hyperprolactinemia, an excessive production of prolactin hormone.",
      "Cabergoline works by binding to dopamine receptors in the pituitary gland, which helps to reduce the production of prolactin.",
      "Cabergoline is usually taken as a tablet or oral solution once a week."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not used to treat Nelson's syndrome. It is used to treat hyperprolactinemia, acromegaly, and Parkinson's disease.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare and complex neurological disorder that is characterized by a range of symptoms affecting the nervous system. The main manifestations of Liebenberg syndrome include:\n1. Ataxia: This is the most common symptom of Liebenberg syndrome and refers to a loss of coordination and balance. Individuals with this condition may have difficulty walking, standing, or performing even simple movements.\n2. Spasticity: This refers to an increase in muscle tone, which can cause stiffness and rigidity in the muscles. This can lead to difficulty moving and maintaining posture.\n3. Slow and fine motor skills: Individuals with Liebenberg syndrome may experience difficulty with small, precise movements such as buttoning a shirt or tying shoelaces. They may also experience slow and unsteady movements when performing everyday tasks.\n4. Dysarthria: This is a speech disorder that can cause slurred or slow speech, and difficulty articulating words.\n5. Dysphagia: This is difficulty swallowing, which can lead to malnutrition and dehydration.\n6. Seizures: Some individuals with Liebenberg syndrome may experience seizures, which can be caused by changes in brain activity.\n7. Cognitive impairment: Some individuals with Liebenberg syndrome may experience cognitive impairment, including difficulty with memory, attention, and decision-making.\n8. Vision problems: Some individuals with Liebenberg syndrome may experience blurry vision, double vision, or other visual disturbances.\n9. Hearing loss: Some individuals with Liebenberg syndrome may experience hearing loss or difficulty hearing.\n10. Emotional changes: Individuals with Liebenberg syndrome may experience emotional changes, including depression, anxiety, and mood swings.\nIt is important to note that the symptoms of Liebenberg syndrome can vary in severity and may progress over time. A proper diagnosis can only be made by a qualified medical professional through a comprehensive evaluation of the individual's symptoms and medical history.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ataxia is the most common symptom of Liebenberg syndrome.\n2. Spasticity in Liebenberg syndrome causes stiffness and rigidity in muscles.\n3. Individuals with Liebenberg syndrome may experience difficulty with small, precise movements.\n4. Dysarthria in Liebenberg syndrome can cause slurred or slow speech.\n5. Dysphagia, or difficulty swallowing, can occur in individuals with Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Ataxia is the most common symptom of Liebenberg syndrome.",
      "Spasticity in Liebenberg syndrome causes stiffness and rigidity in muscles.",
      "Individuals with Liebenberg syndrome may experience difficulty with small, precise movements.",
      "Dysarthria in Liebenberg syndrome can cause slurred or slow speech.",
      "Dysphagia, or difficulty swallowing, can occur in individuals with Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Certainly, I'd be happy to help! Bioavailable MPS1 kinase inhibitors are a class of drugs that inhibit the activity of the enzyme MPS1, which is involved in various cellular processes, including cell signaling and DNA replication. Here are some orally bioavailable MPS1 kinase inhibitors that are currently being investigated for various therapeutic applications:\n1. Conservasin: Conservasin is a small molecule inhibitor of MPS1 that was identified through a high-throughput screening assay. It has been shown to inhibit MPS1 with a Ki value of 77 nM and exhibits potent activity against various cancer cell lines, including those with mutations in the MPS1 gene.\n2. EIP-001: EIP-001 is a potent and selective orally bioavailable MPS1 kinase inhibitor that has shown activity against various types of cancer, including pancreatic, colorectal, and lung cancers. It has also been shown to inhibit the growth of cancer stem cells and has promising anti-tumor activity in preclinical studies.\n3. GDC-0980: GDC-0980 is a highly selective and potent orally bioavailable MPS1 kinase inhibitor that has shown activity against various types of cancer, including breast, lung, and pancreatic cancers. It has also been shown to inhibit the growth of cancer stem cells and has promising anti-tumor activity in preclinical studies.\n4. GS-9973: GS-9973 is a small molecule inhibitor of MPS1 that has shown activity against various types of cancer, including lung, breast, and ovarian cancers. It has also been shown to inhibit the growth of cancer stem cells and has promising anti-tumor activity in preclinical studies.\n5. MEDI3553: MEDI3553 is a highly selective and potent orally bioavailable MPS1 kinase inhibitor that has shown activity against various types of cancer, including breast, lung, and pancreatic cancers. It has also been shown to inhibit",
    "llama-2-7b-chat-hf_fact_raw": "1. Conservasin is an orally bioavailable MPS1 kinase inhibitor with a Ki value of 77 nM.\n2. EIP-001 is an orally bioavailable MPS1 kinase inhibitor that has been investigated for its activity against pancreatic, colorectal, and lung cancers.\n3. GDC-0980 is an orally bioavailable MPS1 kinase inhibitor with activity against breast, lung, and pancreatic cancers in preclinical studies.\n4. GS-9973 is an orally bioavailable MPS1 kinase inhibitor that has been shown to inhibit the growth of cancer cells in various cancers including lung, breast, and ovarian.\n5. MEDI3553 is an orally bioavailable MPS1 kinase inhibitor active against types of cancer such as breast, lung, and pancreatic.",
    "llama-2-7b-chat-hf_fact": [
      "Conservasin is an orally bioavailable MPS1 kinase inhibitor with a Ki value of 77 nM.",
      "EIP-001 is an orally bioavailable MPS1 kinase inhibitor that has been investigated for its activity against pancreatic, colorectal, and lung cancers.",
      "GDC-0980 is an orally bioavailable MPS1 kinase inhibitor with activity against breast, lung, and pancreatic cancers in preclinical studies.",
      "GS-9973 is an orally bioavailable MPS1 kinase inhibitor that has been shown to inhibit the growth of cancer cells in various cancers including lung, breast, and ovarian.",
      "MEDI3553 is an orally bioavailable MPS1 kinase inhibitor active against types of cancer such as breast, lung, and pancreatic."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab is a medication that is used to treat certain autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.\nGolimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor, which works by blocking the action of TNF-alpha, a protein that is involved in the inflammation and immune system. By blocking the action of TNF-alpha, golimumab can help to reduce the symptoms of autoimmune diseases, such as joint pain and swelling, fatigue, and loss of function.\nWhile golimumab has been studied in clinical trials for the treatment of various autoimmune diseases, there is no evidence to suggest that it is effective for the treatment of diabetes. In fact, golimumab has been shown to increase the risk of infections, including serious bacterial, fungal, and viral infections, which could potentially be harmful for people with diabetes.\nIf you have diabetes and are looking for effective treatment options, it is important to work with your healthcare provider to develop a comprehensive treatment plan that includes lifestyle modifications, such as a healthy diet and regular physical activity, as well as medications that are approved by the FDA for the treatment of diabetes. These may include metformin, sulfonylureas, thiazolidinediones, and insulin, among others.\nIn summary, golimumab is not approved by the FDA for the treatment of diabetes, and it is not a recommended treatment option for this condition. If you have diabetes and are looking for effective treatment options, it is important to work with your healthcare provider to develop a comprehensive treatment plan that includes approved medications and lifestyle modifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. The U.S. Food and Drug Administration has not approved golimumab for the treatment of diabetes.\n3. Golimumab is a tumor necrosis factor-alpha inhibitor, which blocks the action of TNF-alpha involved in inflammation and the immune system.\n4. Clinical trials have not shown golimumab to be effective in treating diabetes.\n5. Golimumab has been shown to increase the risk of serious infections.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "The U.S. Food and Drug Administration has not approved golimumab for the treatment of diabetes.",
      "Golimumab is a tumor necrosis factor-alpha inhibitor, which blocks the action of TNF-alpha involved in inflammation and the immune system.",
      "Clinical trials have not shown golimumab to be effective in treating diabetes.",
      "Golimumab has been shown to increase the risk of serious infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by an autosomal recessive gene mutation. Progeria is a rare genetic disorder that affects approximately 1 in 4 million children worldwide. It is characterized by accelerated aging, which leads to physical deformities, growth failure, and a shorter lifespan.\nThe mutation responsible for Progeria is a point mutation in the LMNA gene, which codes for the lamin A/C protein. This protein is an essential component of the nuclear lamina, a network of filaments that provides structural support to the nucleus and regulates various cellular processes. The mutation leads to a deficiency of functional lamin A/C, which disrupts the normal functioning of the nuclear lamina and causes the characteristic signs and symptoms of Progeria.\nThe autosomal recessive inheritance pattern of Progeria means that a child must inherit two copies of the mutated LMNA gene, one from each parent, in order to develop the disorder. If a child inherits only one mutated copy of the gene, they will be a carrier of Progeria but are unlikely to develop the disorder themselves.\nUnderstanding the genetic basis of Progeria has important implications for diagnosis, treatment, and future research. Studies of Progeria have provided valuable insights into the molecular mechanisms of aging and age-related diseases, and have identified potential therapeutic targets for the treatment of Progeria and other age-related disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by an autosomal recessive gene mutation.\n2. The disorder affects approximately 1 in 4 million children worldwide.\n3. Progeria is characterized by accelerated aging, physical deformities, growth failure, and a shorter lifespan.\n4. The mutation responsible for Progeria is a point mutation in the LMNA gene.\n5. A child must inherit two copies of the mutated LMNA gene, one from each parent, to develop the disorder.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by an autosomal recessive gene mutation.",
      "The disorder affects approximately 1 in 4 million children worldwide.",
      "Progeria is characterized by accelerated aging, physical deformities, growth failure, and a shorter lifespan.",
      "The mutation responsible for Progeria is a point mutation in the LMNA gene.",
      "A child must inherit two copies of the mutated LMNA gene, one from each parent, to develop the disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is caused by an autosomal dominant gene mutation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: A child does not need to inherit two copies of the mutated LMNA gene, one mutated gene is enough to develop the disorder.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The 12q14 and 12q24 regions on chromosome 12 are known to be implicated in various genetic disorders and conditions. Here are some common variants associated with these regions:\n12q14:\n1. Beta-thalassemia: Variants in the HBB gene on 12q14 are associated with beta-thalassemia, an inherited blood disorder characterized by reduced or absent production of hemoglobin.\n2. Hutterite syndrome: Hutterite syndrome is a rare genetic disorder caused by variants in the TPAN gene on 12q14. It is characterized by intellectual disability, growth delays, and distinctive facial features.\n3. Nova Scotia gene: The Nova Scotia gene, also known as the HLA-B*37 gene, is located on 12q14 and is associated with an increased risk of certain autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis.\n4. Schizophrenia: Some studies have suggested that variants in the DRD2 gene on 12q14 may be associated with an increased risk of schizophrenia.\n12q24:\n1. Diabetes: Variants in the KCNJ11 gene on 12q24 have been associated with an increased risk of type 2 diabetes.\n2. Prostate cancer: Variants in the BRCA1 and BRCA2 genes on 12q24 have been associated with an increased risk of prostate cancer.\n3. Breast cancer: Some studies have suggested that variants in the BRCA2 gene on 12q24 may be associated with an increased risk of breast cancer.\n4. Ovarian cancer: Variants in the BRCA1 and BRCA2 genes on 12q24 have been associated with an increased risk of ovarian cancer.\n5. Cardiovascular disease: Variants in the NPR1 gene on 12q24 have been associated with an increased risk of cardiovascular disease.\n6. Loeys-Dietz syndrome: Variants in the TGFA gene on 12q24 have been associated with",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants in the HBB gene on 12q14 are associated with beta-thalassemia, a blood disorder.\n2. Hutterite syndrome is caused by variants in the TPAN gene on 12q14 and is characterized by intellectual disability and growth delays.\n3. The HLA-B*37 gene on 12q14, also known as the Nova Scotia gene, is associated with an increased risk of autoimmune disorders like multiple sclerosis and rheumatoid arthritis.\n4. Variants in the KCNJ11 gene on 12q24 have been associated with an increased risk of type 2 diabetes.\n5. Variants in the BRCA1 and BRCA2 genes on 12q24 have been associated with an increased risk of prostate, breast, and ovarian cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Variants in the HBB gene on 12q14 are associated with beta-thalassemia, a blood disorder.",
      "Hutterite syndrome is caused by variants in the TPAN gene on 12q14 and is characterized by intellectual disability and growth delays.",
      "The HLA-B*37 gene on 12q14, also known as the Nova Scotia gene, is associated with an increased risk of autoimmune disorders like multiple sclerosis and rheumatoid arthritis.",
      "Variants in the KCNJ11 gene on 12q24 have been associated with an increased risk of type 2 diabetes.",
      "Variants in the BRCA1 and BRCA2 genes on 12q24 have been associated with an increased risk of prostate, breast, and ovarian cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hutterite syndrome is caused by variants in the SLC6A4 gene on 17q11 and is characterized by intellectual disability and growth delays.\n3. FALSE [correction]: The HLA-B*57 gene, not the HLA-B*37 gene, is associated with an increased risk of autoimmune disorders like multiple sclerosis and rheumatoid arthritis.\n4. FALSE [correction]: Variants in the KCNJ11 gene on 11p15 have been associated with an increased risk of type 2 diabetes.\n5. FALSE [correction]: Variants in the BRCA1 and BRCA2 genes on 17q21 and 13q13 respectively have been associated with an increased risk of breast and ovarian cancers, but not specifically prostate cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating various cellular processes, including cell migration, differentiation, and survival. There are four known members of the Roundabout receptor family: Robo1, Robo2, Robo3, and Robo4. Each of these receptors has different ligands that bind to them and initiate downstream signaling pathways. Here are the known ligands of each Roundabout receptor:\n1. Robo1:\nThe primary ligand for Robo1 is slit (Slit), a secreted protein that is expressed in the nervous system. Slit is secreted by neurons and binds to Robo1 on the surface of adjacent cells, initiating signaling pathways that regulate neuronal migration and axon guidance. In addition to Slit, Robo1 also binds to other ligands, including roundabout (Rbt), a protein that is expressed in the developing nervous system, and neuroligin (Neu), which is enriched in neural synapses.\n2. Robo2:\nThe main ligand for Robo2 is epidermal growth factor repeats (EGFR), which is a transmembrane receptor that is overexpressed in many human cancers. EGFR binds to Robo2 on the surface of cancer cells, leading to activation of downstream signaling pathways that promote cell proliferation and migration. Other ligands that bind to Robo2 include betilakto (Be), a protein that is expressed in the embryonic immune system, and LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5), which is involved in regulating stem cell maintenance and proliferation.\n3. Robo3:\nThe primary ligand for Robo3 is Rho-associated protein kinase (Rock), a serine/threonine kinase that regulates various cellular processes, including cell migration and differentiation. Rock binds to Robo3 on the surface of cells and activates downstream signaling pathways that regulate cell adhesion and contractility. In addition to Rock, Robo3 also binds to other ligands, including growth factors, such as fibroblast growth factor (",
    "llama-2-7b-chat-hf_fact_raw": "1. The primary ligand for Robo1 is slit (Slit), a protein secreted by neurons.\n2. Robo1 can also bind to roundabout (Rbt) and neuroligin (Neu).\n3. The main ligand for Robo2 is epidermal growth factor repeats (EGFR).\n4. Robo2 also binds to betilakto (Be) and LGR5.\n5. The primary ligand for Robo3 is Rho-associated protein kinase (Rock).",
    "llama-2-7b-chat-hf_fact": [
      "The primary ligand for Robo1 is slit (Slit), a protein secreted by neurons.",
      "Robo1 can also bind to roundabout (Rbt) and neuroligin (Neu).",
      "The main ligand for Robo2 is epidermal growth factor repeats (EGFR).",
      "Robo2 also binds to betilakto (Be) and LGR5.",
      "The primary ligand for Robo3 is Rho-associated protein kinase (Rock)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Robo1 does not bind to roundabout (Rbt) and neuroligin (Neu), as these are not known ligands for Robo1.\n3. FALSE [correction]: The main ligand for Robo2 is not epidermal growth factor repeats (EGFR), it is also slit (Slit) protein\n4. UNKNOWN\n5. FALSE [correction]: The primary ligand for Robo3 is not Rho-associated protein kinase (Rock), but instead is also slit (Slit) protein.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I (Transcription Factor II-I) is a general transcription factor that plays a crucial role in the regulation of gene expression in various cell types, including stem cells. While TFII-I is not specifically known to be involved in megakaryopoiesis, a subfield of hematopoiesis that deals with the development of platelets, it is possible that TFII-I may have some indirect role in this process.\nMegakaryopoiesis is a complex process that involves the coordinated regulation of multiple transcription factors, including those within the TFII family. TFII-I is one of the core components of the basal transcription complex and plays a crucial role in the initiation of transcription by RNA polymerase II (RNAPII) (1). Given its role in the basal transcription machinery, it is likely that TFII-I also plays a role in the regulation of genes involved in megakaryopoiesis, although the exact nature of this involvement is currently unknown.\nSeveral studies have shown that TFII-I is required for the proper differentiation of hematopoietic stem cells, including megakaryocytes (2, 3). TFII-I has been shown to be involved in the regulation of genes involved in the differentiation of hematopoietic stem cells, including those involved in the megakaryocyte lineage (4). Additionally, TFII-I has been shown to be a key regulator of the expression of genes involved in platelet function and hemostasis (5).\nWhile TFII-I is not directly involved in megakaryopoiesis, its role in regulating the expression of genes involved in the process suggests that it may have an indirect role in the development and function of platelets. Further research is needed to fully elucidate the role of TFII-I in megakaryopoiesis and its potential as a therapeutic target for the treatment of platelet disorders.\nIn summary, while TFII-I is not specifically known to be involved in megakaryopoiesis, it is likely that it plays an indirect role in the regulation of genes involved in the process, and further research is needed to fully understand its involvement in",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I stands for Transcription Factor II-I.\n2. TFII-I is a general transcription factor that plays a role in regulating gene expression in various cell types, including stem cells.\n3. TFII-I is part of the basal transcription complex and helps initiate transcription by RNA polymerase II (RNAPII).\n4. TFII-I has been shown to be required for the proper differentiation of hematopoietic stem cells, including megakaryocytes.\n5. TFII-I regulates the expression of genes involved in platelet function and hemostasis.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I stands for Transcription Factor II-I.",
      "TFII-I is a general transcription factor that plays a role in regulating gene expression in various cell types, including stem cells.",
      "TFII-I is part of the basal transcription complex and helps initiate transcription by RNA polymerase II (RNAPII).",
      "TFII-I has been shown to be required for the proper differentiation of hematopoietic stem cells, including megakaryocytes.",
      "TFII-I regulates the expression of genes involved in platelet function and hemostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Atenolol, which is the brand name for an antidepressant drug called tenormin, is metabolized by CYP2D6 on its way out of the body. CYP2D6 is a wonderfully crucial drug metabolic enzyme that helps your liver metabolize many drugs. It is chiefly responsible for converting these drugs into inactive forms that can be excreted from the body.\nAtenolol is one of the many drugs metabolized by the CYP2D6 enzyme. Studies have shown that around 30 to 40% of atenolol is metabolized by CYP2D6. This means that if you have a variant of CYP2D6 that is less efficient, you may have lower levels of atenolol in your body, which could affect how well it works for you.\nIt is important to note that atenolol also has other pathways of metabolism. About 60% of atenolol is metabolized by CYP3A4, another important metabolic enzyme. However, CYP2D6 is the primary enzyme involved in the metabolism of atenolol.\nCYP2D6 plays a crucial role in the metabolism of many drugs, including atenolol. Knowing whether a drug is primarily metabolized by CYP2D6 or other enzymes can help healthcare providers tailor treatment plans to individual patients based on their unique genetic profiles.\nThe information you provided about CYP2D6 is informative, You asked if atenolol is metabolized by CYP2D6. I answered your question by providing detailed information about CYP2D6 and its role in atenolol metabolism. Remember that genetic variations in CYP2D6 can affect how well atenolol works for individual patients, so it is essential to consult with a healthcare professional before making any changes to your treatment plan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. CYP2D6 is a drug metabolic enzyme in the liver responsible for converting drugs into inactive forms.\n3. Approximately 30 to 40% of atenolol is metabolized by CYP2D6.\n4. Atenolol also has other pathways of metabolism, with about 60% being metabolized by CYP3A4.\n5. Genetic variations in CYP2D6 can affect the levels of atenolol in the body and its effectiveness.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "CYP2D6 is a drug metabolic enzyme in the liver responsible for converting drugs into inactive forms.",
      "Approximately 30 to 40% of atenolol is metabolized by CYP2D6.",
      "Atenolol also has other pathways of metabolism, with about 60% being metabolized by CYP3A4.",
      "Genetic variations in CYP2D6 can affect the levels of atenolol in the body and its effectiveness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by CYP2D6; it is primarily excreted unchanged by the kidneys.\n2. TRUE\n3. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, this percentage is incorrect.\n4. FALSE [correction]: Atenolol is not metabolized by CYP3A4; it is excreted unchanged by the kidneys.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Certainly! ExpansionHunter is a popular software tool used for finding and installing font expansion files for the Adobe InDesign software. Here are some versions of ExpansionHunter that you might be interested in:\n1. ExpansionHunter 1.0: This is the original version of ExpansionHunter, which was first released in 2013. It allows users to search and install font expansion files for InDesign, and it includes a user-friendly interface for searching and installing fonts.\n2. ExpansionHunter 2.0: Released in 2015, this version of ExpansionHunter includes several new features, including improved search functionality, a new user interface, and support for multiple operating systems.\n3. ExpansionHunter Pro: This is an enhanced version of ExpansionHunter that includes additional features such as the ability to create and manage custom font sets, import and export font lists, and access to a larger database of font expansion files.\n4. ExpansionHunter Cloud: This is a cloud-based version of ExpansionHunter that allows users to access and install font expansion files from anywhere, without the need to download or install any software.\n5. ExpansionHunter for InDesign: This is a version of ExpansionHunter specifically designed for use with Adobe InDesign. It includes a user-friendly interface for searching and installing font expansion files, and it integrates seamlessly with InDesign.\n6. ExpansionHunter CS6: This is an updated version of ExpansionHunter that is compatible with Adobe InDesign CS6 and later versions. It includes all the features of the previous versions, as well as some new enhancements such as improved search functionality and better compatibility with InDesign.\n7. ExpansionHunter for Mac: This is a version of ExpansionHunter that is specifically designed for use on Mac computers. It includes all the features of the Windows version, as well as some exclusive features for Mac users.\n8. ExpansionHunter for Windows: This is the standard version of ExpansionHunter that is designed for use on Windows computers. It includes all the features of the Mac version, as well as some exclusive features for Windows users.\n9. ExpansionHunter Portable: This is a portable version of ExpansionHunter that allows users to take their font expansion files",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was first released in 2013.\n2. ExpansionHunter 2.0 was released in 2015.\n3. ExpansionHunter Pro includes the ability to create and manage custom font sets.\n4. ExpansionHunter Cloud is a cloud-based version of the software.\n5. ExpansionHunter CS6 is compatible with Adobe InDesign CS6 and later versions.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was first released in 2013.",
      "ExpansionHunter 2.0 was released in 2015.",
      "ExpansionHunter Pro includes the ability to create and manage custom font sets.",
      "ExpansionHunter Cloud is a cloud-based version of the software.",
      "ExpansionHunter CS6 is compatible with Adobe InDesign CS6 and later versions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: ExpansionHunter Pro is a software for detecting repeat expansions in genomic data, not for managing custom font sets.\n4. UNKNOWN\n5. FALSE [correction]: ExpansionHunter is a bioinformatics tool, not related to Adobe InDesign compatibility.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain with thrombospondin type 1 repeats 18) is a protein that plays a crucial role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) activity. Here's a detailed answer to the user's question:\nAdamts18 is a secreted glycoprotein that belongs to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin type 1 repeat) family of proteins. It is primarily expressed in the endothelium, and its expression is known to be regulated by various hormones, growth factors, and inflammatory mediators. Adamts18 has been shown to play a key role in the regulation of hormone receptor signaling, particularly in the context of ER signaling.\nERs are a subfamily of nuclear receptors that play a crucial role in the regulation of various physiological processes, including cell proliferation, differentiation, and apoptosis. In the case of estrogen, there are three subtypes of ERs (ERα, ERβ, and ERγ), each with distinct functions and tissue distributions. Estrogen binding to ERs triggers a cascade of intracellular signaling events that ultimately lead to changes in gene expression, cell growth, and differentiation.\nAdamts18 has been shown to modulate ER signaling by interacting with the ER protein in a number of ways. Firstly, Adamts18 has been shown to interact with the ER protein directly, via its extracellular domain, and promote ER-mediated gene transcription. This interaction between Adamts18 and the ER protein is thought to be mediated by the formation of a stable complex between the two proteins, which allows for the enhancement of ER-mediated signaling.\nSecondly, Adamts18 has been shown to modulate the activity of ER by inhibiting its degradation. ER is a rapidly degraded protein in response to estrogen withdrawal, and this degradation is thought to play a key role in the termination of estrogen signaling. Adamts18 has been shown to inhibit the ubiquitination and degradation of ER,",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protein that plays a crucial role in the regulation of estrogen receptor (ER) activity.\n2. Adamts18 is a secreted glycoprotein that belongs to the ADAMTS family of proteins.\n3. Adamts18 is primarily expressed in the endothelium.\n4. Estrogen receptors have three subtypes: ERα, ERβ, and ERγ, each with distinct functions and tissue distributions.\n5. Adamts18 can interact directly with the ER protein and promote ER-mediated gene transcription.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protein that plays a crucial role in the regulation of estrogen receptor (ER) activity.",
      "Adamts18 is a secreted glycoprotein that belongs to the ADAMTS family of proteins.",
      "Adamts18 is primarily expressed in the endothelium.",
      "Estrogen receptors have three subtypes: ERα, ERβ, and ERγ, each with distinct functions and tissue distributions.",
      "Adamts18 can interact directly with the ER protein and promote ER-mediated gene transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Adamts18 is a protein that plays a crucial role in eye and heart development, not in the regulation of estrogen receptor (ER) activity.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Estrogen receptors have two main subtypes: ERα and ERβ. There is no ERγ subtype.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a highly selective and potent inhibitor of the enzyme diacylglycerol acyltransferase 1 (DGA1), which plays a key role in the regulation of lipid metabolism. The mode of action of thiazovivin can be broken down into several main steps:\n1. Inhibition of DGA1: Thiazovivin binds to DGA1 with high affinity and specificity, thereby inhibiting its enzymatic activity. DGA1 is responsible for catalyzing the transfer of acyl groups from diacylglycerols to a variety of acceptor substrates, such as phosphatidic acid, lysophosphatidic acid, and glycerol-3-phosphate. By inhibiting DGA1, thiazovivin reduces the amount of acyl-CoA available for the synthesis of triacylglycerols (TAgs), which are the major constituents of lipid-rich tissues such as adipose tissue.\n2. Reduction of triacylglycerol (TAG) synthesis: With reduced DGA1 activity, there is a decrease in the conversion of diacylglycerols to TAGs, resulting in lower levels of TAGs in the liver and other tissues. TAGs are the primary lipid species used for energy storage in the body, and their synthesis is tightly regulated by a variety of hormones and substrate availability.\n3. Activation of lipolytic enzymes: Thiazovivin has been shown to activate the lipolytic enzyme ATGL (adenylate cyclase-activating polymerizing trombose 8-like protein), leading to increased lipolysis in adipose tissue. Lipolysis is the breakdown of stored lipids in adipose tissue, releasing free fatty acids and glycerol into the bloodstream.\n4. Increased glucose uptake: Thiazovivin has been shown to activate the glucose transporter 4 (GLUT4), leading to increased glucose uptake in adipose tissue and skeletal muscle. Increased gl",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an inhibitor of the enzyme diacylglycerol acyltransferase 1 (DGA1).\n2. DGA1 is responsible for catalyzing the transfer of acyl groups from diacylglycerols to various acceptor substrates.\n3. Inhibiting DGA1 reduces the amount of acyl-CoA available for the synthesis of triacylglycerols (TAGs).\n4. Thiazovivin activation of ATGL leads to increased lipolysis in adipose tissue.\n5. Thiazovivin activation of GLUT4 leads to increased glucose uptake in adipose tissue and skeletal muscle.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an inhibitor of the enzyme diacylglycerol acyltransferase 1 (DGA1).",
      "DGA1 is responsible for catalyzing the transfer of acyl groups from diacylglycerols to various acceptor substrates.",
      "Inhibiting DGA1 reduces the amount of acyl-CoA available for the synthesis of triacylglycerols (TAGs).",
      "Thiazovivin activation of ATGL leads to increased lipolysis in adipose tissue.",
      "Thiazovivin activation of GLUT4 leads to increased glucose uptake in adipose tissue and skeletal muscle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the enzyme diacylglycerol acyltransferase 1 (DGA1), it is a small molecule inhibitor of Rho-associated kinase (ROCK).\n2. TRUE\n3. FALSE [correction]: Inhibiting DGA1 reduces the amount of triacylglycerols (TAGs) synthesized, not acyl-CoA. Acyl-CoA is a substrate used in the synthesis of TAGs.\n4. FALSE [correction]: Thiazovivin does not activate ATGL, it inhibits ROCK which can indirectly affect lipolysis.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  }
]